0001999371-24-004138.txt : 20240328 0001999371-24-004138.hdr.sgml : 20240328 20240328171554 ACCESSION NUMBER: 0001999371-24-004138 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NANOPHASE TECHNOLOGIES Corp CENTRAL INDEX KEY: 0000883107 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 363687863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22333 FILM NUMBER: 24800389 BUSINESS ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 BUSINESS PHONE: 6303231200 MAIL ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 FORMER COMPANY: FORMER CONFORMED NAME: NANOPHASE TECHNOLOGIES CORPORATION DATE OF NAME CHANGE: 19970305 10-K 1 nanx-10k_123123.htm ANNUAL REPORT
false 2023 FY --12-31 0000883107 http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member 0000883107 2023-01-01 2023-12-31 0000883107 2023-06-30 0000883107 2024-03-28 0000883107 2023-12-31 0000883107 2022-12-31 0000883107 2022-01-01 2022-12-31 0000883107 us-gaap:ProductMember 2023-01-01 2023-12-31 0000883107 us-gaap:ProductMember 2022-01-01 2022-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-12-31 0000883107 us-gaap:PreferredStockMember 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-12-31 0000883107 2021-12-31 0000883107 us-gaap:PreferredStockMember 2022-12-31 0000883107 us-gaap:CommonStockMember 2022-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000883107 us-gaap:RetainedEarningsMember 2022-12-31 0000883107 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0000883107 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000883107 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000883107 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0000883107 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000883107 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000883107 us-gaap:PreferredStockMember 2023-12-31 0000883107 us-gaap:CommonStockMember 2023-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000883107 us-gaap:RetainedEarningsMember 2023-12-31 0000883107 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2022-12-31 0000883107 us-gaap:EquipmentMember srt:MinimumMember 2023-12-31 0000883107 us-gaap:EquipmentMember srt:MaximumMember 2023-12-31 0000883107 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2023-12-31 0000883107 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2023-12-31 0000883107 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember srt:MinimumMember 2023-12-31 0000883107 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember srt:MaximumMember 2023-12-31 0000883107 nanx:MedicalDiagnosticsApplicationCustomerMember 2023-12-31 0000883107 nanx:PersonalCareIngredientCustomerMember 2023-12-31 0000883107 us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000883107 us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2023-01-01 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2022-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-01-01 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2022-12-31 0000883107 nanx:BeachcorpLLCMember 2023-01-01 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2022-12-31 0000883107 nanx:BeachcorpLLCOneMember 2023-01-01 2023-12-31 0000883107 nanx:BeachcorpLLCOneMember 2023-12-31 0000883107 nanx:BeachcorpLLCOneMember 2022-12-31 0000883107 nanx:StrandlerLLCMember 2023-01-01 2023-12-31 0000883107 nanx:StrandlerLLCMember 2023-12-31 0000883107 nanx:StrandlerLLCMember 2022-12-31 0000883107 nanx:StrandlerLLCOneMember 2023-01-01 2023-12-31 0000883107 nanx:StrandlerLLCOneMember 2023-12-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-01 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2023-01-01 2023-12-31 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2018-11-15 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2018-11-15 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember srt:MinimumMember 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BeachcorpLLCMember 2018-11-15 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2020-09-08 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2020-12-23 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BeachcorpLLCMember 2020-12-22 2020-12-23 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2021-04-21 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BeachcorpLLCMember 2021-04-20 2021-04-21 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2021-04-20 2021-04-21 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2021-04-21 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2021-04-20 2021-04-21 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2018-04-21 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2023-11-12 2023-11-13 0000883107 nanx:BusinessLoanAgreementMember nanx:InventoryFacilityMember nanx:BeachcorpLLCMember 2021-04-21 0000883107 nanx:BusinessLoanAgreementMember nanx:InventoryFacilityMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember nanx:ReplacementPromissoryNoteMember nanx:BeachcorpLLCMember 2023-11-13 0000883107 nanx:BusinessLoanAgreementMember nanx:ReplacementPromissoryNoteMember nanx:BeachcorpLLCMember 2023-11-12 2023-11-13 0000883107 nanx:StrandlerLLCMember nanx:TermLoanMember 2022-01-27 2022-01-28 0000883107 nanx:StrandlerLLCMember nanx:TermLoanMember 2023-11-12 2023-11-13 0000883107 nanx:BridgeNoteMember nanx:StrandlerLLCMember 2023-11-13 0000883107 nanx:BridgeNoteMember nanx:StrandlerLLCMember 2023-11-12 2023-11-13 0000883107 nanx:BusinessLoanAgreementMember nanx:StrandlerLLCAndBeachcorpLLCMember us-gaap:SubsequentEventMember 2024-02-29 2024-03-01 0000883107 nanx:BusinessLoanAgreementMember nanx:StrandlerLLCAndBeachcorpLLCMember 2023-12-30 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2022-01-01 2022-12-31 0000883107 nanx:StrandlerLLCMember 2022-01-01 2022-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000883107 us-gaap:OfficeEquipmentMember 2023-12-31 0000883107 us-gaap:OfficeEquipmentMember 2022-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000883107 us-gaap:ConstructionInProgressMember 2023-12-31 0000883107 us-gaap:ConstructionInProgressMember 2022-12-31 0000883107 nanx:JanuaryThroughMayMember 2023-12-31 0000883107 nanx:JuneThroughDecemberMember 2023-12-31 0000883107 us-gaap:TaxYear2023Member 2023-01-01 2023-12-31 0000883107 nanx:Expiring2023To2037Member 2023-12-31 0000883107 us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0000883107 us-gaap:GeneralBusinessMember 2023-12-31 0000883107 us-gaap:TaxYear2018Member 2023-12-31 0000883107 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0000883107 us-gaap:StateAndLocalJurisdictionMember 2023-01-01 2023-12-31 0000883107 us-gaap:SubsequentEventMember nanx:SeriesXPreferredStockMember 2024-02-29 2024-03-01 0000883107 us-gaap:SubsequentEventMember nanx:SeriesXPreferredStockMember 2024-03-01 0000883107 nanx:PriorToEquityCompensationPlan2019Member 2023-01-01 2023-12-31 0000883107 nanx:EquityCompensationPlan2019Member 2023-01-01 2023-12-31 0000883107 nanx:EquityCompensationPlan2010Member 2023-01-01 2023-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2023-12-31 0000883107 nanx:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-12-31 0000883107 nanx:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-12-31 0000883107 nanx:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-12-31 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-12-31 0000883107 nanx:CustomerOneMember 2023-12-31 0000883107 nanx:CustomerOneMember 2022-12-31 0000883107 nanx:CustomerTwoMember 2023-12-31 0000883107 nanx:CustomerTwoMember 2022-12-31 0000883107 nanx:CustomerThreeMember 2023-12-31 0000883107 nanx:CustomerThreeMember 2022-12-31 0000883107 us-gaap:SupplyCommitmentMember 2023-12-31 0000883107 us-gaap:NonUsMember 2023-01-01 2023-12-31 0000883107 us-gaap:NonUsMember 2022-01-01 2022-12-31 0000883107 nanx:SolesenceMember 2023-01-01 2023-12-31 0000883107 nanx:SolesenceMember 2022-01-01 2022-12-31 0000883107 nanx:PersonalCareIngredientsMember 2023-01-01 2023-12-31 0000883107 nanx:PersonalCareIngredientsMember 2022-01-01 2022-12-31 0000883107 nanx:AdvancedMaterialsMember 2023-01-01 2023-12-31 0000883107 nanx:AdvancedMaterialsMember 2022-01-01 2022-12-31 0000883107 us-gaap:SubsequentEventMember 2024-03-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

or

 

☐  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM_____ TO_____

 

COMMISSION FILE NUMBER 000-22333 

 

NANOPHASE TECHNOLOGIES CORPORATION

(Exact name of registrant as specified in its charter) 

 

Delaware 36-3687863
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)  

 

1319 Marquette Drive, Romeoville, Illinois 60446  

(Address of principal executive offices) (zip code)

 

Registrant’s telephone number, including area code: (630) 771-6708

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act: 

Common Stock, par value $.01 per share

 

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The aggregate market value of the registrant’s voting stock held by non-affiliates of the registrant based upon the last reported sale price of the registrant’s common stock on June 30, 2023 was $23,412,675 as of such date.

 

The number of shares outstanding of the registrant’s common stock, par value $.01, as of March 28, 2024 was 54,801,834.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

 

 

 

 

  PART I  
Item 1.  General 2
  Company Background 2
  Solésence Beauty Science Business 2
  Personal Care Ingredients Business 3
  Advanced Materials Business 3
  Sources and Availability of Raw Materials 3
  Markets and Distribution 4
  Research and Development 4
  Competitive Advantage 5
  Manufacturing Operations 5
  Intellectual Property and Proprietary Rights 5
  Competition 6
  Governmental Regulations, Including Climate Change 6
  Employees 6
  Backlog 7
  Business Segment and Geographical Information 7
  Key Customers 7
  Forward-Looking Statements 7
  Investor Information 8
Item 1A. Risk Factors 8
Item 1B. Unresolved Staff Comments 8
Item 1C. Cybersecurity 8
Item 2. Properties 8
Item 3. Legal Proceedings 9
Item 4. Mine Safety Disclosures 9
     
  PART II  
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 10
Item 6. Selected Financial Data 10
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 10
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 15
Item 8. Financial Statements and Supplementary Data 15
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 15
Item 9A. Controls and Procedures 15
Item 9B. Other Information 16
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 16
     
  PART III  
     
Item 10. Directors, Executive Officers and Corporate Governance 16
Item 11. Executive Compensation 19
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 22
Item 13. Certain Relationships and Related Transactions, and Director Independence 23
Item 14. Principal Accounting Fees and Services 24
     
  PART IV  
     
Item 15. Exhibits and Financial Statement Schedules 24
Item 16. Form 10-K Summary 25

 

1

 

 

 PART I

 

Item 1. General

 

Company Background

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”), along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is a leading innovator in minerals-based and scientifically-driven health care solutions across beauty and life science categories, protecting skin from environmental aggressors and aiding in medical diagnostics. Skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy, with additional revenue being generated from other legacy advanced materials applications. The Company was incorporated in Illinois on November 25, 1989 and became a Delaware corporation during November 1997. Our common stock trades on the OTCQB marketplace under the symbol NANX. We have development and application laboratories, and manufacturing capacity in three locations in the Chicago, Illinois area.

 

Leveraging a platform of integrated patented and proprietary technologies, we create products with unique performance to enhance end-consumers’ health and well-being. We offer soup-to-nuts production, from engineered materials, formulation development, and finished product development, to commercial manufacturing and packaging capabilities. Our expertise in materials engineering allows us to effectively coat and disperse materials on a nano and “non-nano” scale for use in a variety of markets in skin health, including for use in sunscreens as Active Pharmaceutical Ingredients (“APIs”) and as fully developed prestige skin care products, marketed and sold through our Solésence beauty science subsidiary.  We believe that we have developed technological advantages with respect to our APIs sold for use as ingredients, while our Solésence beauty science technologies lead to enhanced efficacy and aesthetics in our finished products, which have received broad acceptance in the marketplace. Due to the enhanced efficacy and aesthetic qualities offered by our proprietary technology platform, Solésence finished products satisfy growing consumer demands around “clean” and inclusive beauty. Solésence beauty science also benefits from the Company’s vertical integration with each product’s key active ingredient that delivers its point-of-difference. This vertical integration helps us to improve efficiency and avoid potential major supply chain challenges while also addressing ongoing sustainability efforts.  

 

Polymerase Chain Reaction (“PCR”) testing for various viruses, most notably SARS-CoV-2 (“COVID-19”), has become a critical use of our technology in the life science space. We believe that our deep expertise in materials science has created advantages that enable performance in certain tests that may not be achievable through other materials. Outside of life science, we continue to sell advanced materials for use in legacy applications, all of which, along with medical diagnostics, currently fall into the advanced materials product category.    

 

Given our technological position, in addition to the historical market acceptance of our APIs for use in skin health products and sunscreens, rapidly growing sales for our suite of Solésence® finished products, and the expanded use of our diagnostic materials in aiding the fight to curb the spread of COVID-19 and other viruses, in 2021 we announced that we reoriented our Company strategy. We continue to see unprecedented demand in both beauty science, for our APIs and finished products, and life science areas. The markets for both have shown an appetite for what we are producing, and management believes that this growth is happening now due to a confluence of our technology, market conditions that favor what we produce, and our expanded expertise in these areas.  

 

Nanophase, primarily through Solésence, now partners with brands to develop, manufacture, and market products and ingredients that enhance lives through healthy skin. We are focusing our combined business-, ingredient-, and product-development capabilities on products with unique performance in this area. While we will continue to produce and sell materials to our other advanced materials customers, it is not our strategic focus. We may develop additional technologies, or find unique applications outside of our core markets in the future, but to maximize the use of our resources today, we plan on expanding efforts in areas where we have proven we can deliver innovation and growth.

 

Solésence Beauty Science Business

 

In 2020, Solésence beauty science finished products surpassed our personal care ingredients business in terms of total revenue, and since 2021, Solésence beauty science more than doubled our revenue from personal care ingredients. We believe that Solésence offers the greatest growth potential of any group of products in any market in the Company’s history. Our volumes are continuing to grow, limited mainly by our capacity. We expect our Solésence volume, based on 2024 shipments and customer orders in-hand, to exceed full year 2023 volume.  

 

The extent to which we grow will be dependent upon our ability to effectively expand our capabilities during 2024. As a result, we plan to continue investments in facilities and equipment as well as in human resources, in 2024 and beyond. We are prioritizing facilities expansion, and capital investment in this business to allow for continued growth, and increased profitability.  

 

2

 

 

During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense™ Technology — which has become the cornerstone of our new product development in our Solésence business, with first revenue recognized during 2017. We now offer a suite of three technologies under our Active Stress Defense™ platform, each of which offers a distinct market advantage in terms of performance, aesthetics, and/or “clean” positioning in UV and environmental protection, with flexible formulas that allow for adoption by a range of brands with different market positions. We continue to develop and expand our in-house formulating capability, through which we have created, and now sold, more than 250 SKUs of fully formulated finished cosmetics products in markets focused on skin health, with the majority in prestige beauty. Products developed and sold by our Solésence beauty science subsidiary are all produced under the requirements of current Good Manufacturing Standards (“cGMP”), as enforced by the U.S. Food and Drug Administration (“FDA”), which enables us to leverage the expertise we developed in the manufacture of personal care ingredients. Although our Solésence products are fully formulated for consumer use, we do not sell directly to consumers or distribute products to consumers under the Solésence® brand through intermediaries or resellers. Instead, we sell our Solésence® products to brand partners as market-ready products, as customized white label products, or as custom-developed products, in each case, for sale or distribution to consumers under our customers’ brand names. In 2022, Solésence (through Nanophase, as its parent company) was granted site clearance by Australia’s Therapeutic Goods Administration (“TGA”) for the full finished product manufacture of creams, lotions, sprays, sticks and all topical sunscreen forms. TGA site clearance is legally required for brands to market Solésence-made products as primary sunscreens in Australia. Our initial focus continues to be on establishing a footprint with both new and existing Solésence brand partners, to enable the sale of our patented skin health products as primary sunscreens. Also in 2022, Nanophase was granted a patent in Korea for the Kleair™ technology used exclusively in Solésence products. Shortly thereafter, Solésence Beauty Science received two industry accolades. In July at Cosmoprof North America, Solésence was awarded the Cosmopack Award for best Formulation for its product Multi-Cultural Magic SPF 50+ Featuring Kleair™ technology, acknowledging the Company’s technology, formulation and marketing know-how. In September, Solésence was awarded the Cosmetics & Toiletries Allē Award for Most Significant Active Ingredient in Sun/Light Protection for Kleair™ technology, a further acknowledgement of the company’s technology know-how, as well as a recognition for the Company in the areas of innovation and impact. In early 2023, Solésence was named number 2 on Fast Company’s Most Innovative Beauty Businesses list. This is a prestigious award that recognizes the impact we have on the industry we serve and the lives of the people who use our products. In July of 2023, Solésence was again awarded the Cosmopack Award for best Formulation, this time for its product Natural Glow Face Oil SPF 40+ featuring Kleair™ and Bloom™ technology, recognizing our continued innovative approach to formulation and product development. In 2023, Solésence also won the 2023 BeautyMatter NEXT Award for Best Contract Manufacturer and was a winner of the 22nd Chicago Innovation Awards. Most recently, Solésence’s market-ready product Soft Glow SPF 50+ won the 2024 Cosmetics & Toiletries Allē Awards Best in Finished Formula-Prestige Category, spotlighting the ingenuity and creativity of our formulas. 

 

Personal Care Ingredients Business

 

Prior to 2020, our largest line of business had been the manufacture and sale of APIs in the skin health and sun care markets, which we deliver to customers through strategic partnerships. We continue to manufacture and supply hundreds of metric tons of surface engineered zinc oxide and titanium dioxide to our customers annually, and these are used by major global consumer products companies for sunscreens and skin health-focused personal care products. We produce these products using proprietary coating and dispersion technologies that comply with the requirements of cGMP and are classified as Active Pharmaceutical Ingredients, or APIs, by the FDA. We believe we have opportunities for growth in API sales in 2024.

 

Advanced Materials Business

 

Our third line of business has been the manufacture and sale of advanced nanoparticle materials, including a material used in life science applications to enhance the performance of PCR test methods. We continue to service other profitable markets where we have had a degree of success in the past, including applications in food packaging, coatings and optical polishing, but our strategic focus and related future development is in the area of improving the health for all human beings, and any related applications that may be created as we work to develop future materials to satisfy this growing area.

 

Sources and Availability of Raw Materials

 

Most of the raw materials we use are readily commercially available. In some cases, we rely on sole-source processors of materials that utilize an array of worldwide sources for the raw materials that they process to our specifications. However, we require very high purity zinc for our personal care applications that have occasionally seen shortages in prior years. Although we currently believe we have developed adequate commercial relationships to supply the necessary raw materials for our business which are not readily commercially available, our business is subject to the pricing and availability of certain raw materials.

 

Some of the raw materials that are critical to the production of our products and parts that are critical to the operation of our equipment are sourced from single suppliers, suppliers from China and Korea, and in some cases, a single supplier from China. However, we do not knowingly source any materials from the Xinjiang region of China. Since 2022 we continue to monitor delays in shipping exports from China and Korea. Despite the Russian invasion of Ukraine, we do not anticipate any directly related supply disruptions as we do not knowingly source any materials directly from either country. Additionally, we could be disrupted by conditions unrelated to our business operations or that are beyond our control, including but not limited to international trade restrictions and conditions related to epidemics. We typically maintain no less than one month’s supply of raw materials and parts that are sourced from sole suppliers and make efforts to identify additional suppliers who may be able to provide such raw materials or parts. The Company is actively taking steps to reduce the number of singularly sourced raw materials.

 

3

 

 

Markets and Distribution

 

Solésence Beauty Science Business

 

We partner with brands on a global basis to develop, manufacture and market products that enhance lives through healthy skin. These products are fully-formulated solutions built around proprietary Solésence technologies, which are designed to improve skin health for all human beings, and are aligned with consumer demand for “clean” and inclusive beauty products that enhance skin health. Solésence clients, or brand partners, are positioned in skin care, makeup/cosmetics, and sun care markets, with the majority of our partners operating in the prestige beauty segment with retail, direct-to-consumer, and/or omnichannel strategies. This represents a move downstream from our previous position — one of providing ingredients to manufacturers — to offering finished products that we believe offer a clear and distinct market advantage relative to both aesthetics and performance. With our first Solésence beauty science product revenue recognized during 2017, we had our first material amounts of Solésence product revenue in 2018, and saw significant expansion in these sales through 2023. Solésence brand partners have experienced strong growth as our products have seen broad acceptance from retailers, adoption by consumers, and recognition by third-party media outlets through awards and accolades. We expect our Solésence beauty science business to enhance both our degree of control of the business development cycle, and to further enable our ability to grow rapidly.  

 

Personal Care Ingredients Business

 

In addition to serving strategic partners in diverse markets and geographic locations, we will continue to devote significant resources to maintaining and growing our relationship with BASF Corporation (“BASF”), the largest customer in our personal care ingredients line of business. This has been a successful relationship that we expect will contribute to our future growth. BASF, which describes itself as the world’s leading chemical company with annual revenue of approximately $79 billion, is a “globally leading supplier of sustainable high-performance ingredients for the personal care industry,” with recognized brands, significant revenue, and a broad sales network. BASF is primarily responsible for the business development cycle and maintains the direct customer relationships. We have a long-term exclusive relationship with BASF, primarily to provide nano-scale specific zinc oxide-based products made to specific specifications to be used as ingredients in personal care cosmetics, with sunscreens and daily wear products being the dominant applications.  

 

On August 9, 2022 BASF filed a complaint in the Superior Court of New Jersey. The New Jersey Complaint claims that Nanophase breached the parties’ 1999 Zinc Oxide Supply Agreement. For additional information about the complaint see Item 3. Legal proceedings.

 

Advanced Materials Business

 

Our technologies for engineering and manufacturing life science materials and other nanomaterials, and our understanding of how to make nano-scale and other advanced materials exhibit desirable performance characteristics in various media, have resulted in commercial materials solutions that we believe offer superior performance in many applications. Medical diagnostics, which we view as being a life science application, was the largest market for our advanced materials business from 2020 through 2023, and we expect this to be true for the foreseeable future. This is a key area of focus in advanced materials in terms of new business development.  Our legacy markets for advanced materials include architectural coatings, surface treatment (polishing), plastics additives, textiles applications, and others. As advanced materials markets continue to develop and grow, we believe that customers’ preferred delivery formats will often be dispersed and/or coated nanomaterials for life science applications. We believe we are well-positioned with our platform of integrated commercial nanomaterial technologies to respond to this demand, although outside of life science areas, we are currently not actively developing new business in this area.   

 

Research and Development

 

Most of our research and development over the past few years has been directly related to Solésence beauty science product and personal care ingredient applications development. We endeavor to either meet specific customer needs or to develop applications solutions to address unmet needs in a particular market where we believe our materials will offer a distinct performance advantage. Our efforts in research and development, cosmetic formulating, process engineering and advanced engineering groups are focused in three major areas: 1) application development for our products; 2) creating or obtaining additional core materials technologies and/or materials that have the capability to serve multiple beauty or life science markets; and 3) continuing to improve our core technologies to improve manufacturing operations and reduce costs.

 

Our total research and development expense, which includes all expenses relating to our technology and advanced engineering groups, during the years ended December 31, 2023 and 2022, was $3.8 million and $3.0 million, respectively. This represents our share of these expenses only and does not take into account amounts spent by any of our customers in support of new product development. Our future success will depend in large part upon our ability to develop products which bring a high degree of value to our customers’ products. Through the two-year period ended December 31, 2023, we had cumulative research and development expenses of approximately $6.8 million and no related cumulative capital expenditures on equipment and leasehold improvements.

 

4

 

 

Competitive Advantage

 

In our Solésence beauty science business, our Active Stress Defense™ platform of proprietary technologies – which includes Kleair™ – offers unique skin health benefits through performance-related and aesthetic advantages in environmental protection skin health products, including in UVA/UVB, pollution and HEV (blue) light protection. These technologies expand access to healthy skin by improving both the product experience across the full range of skin tones while also leveraging a unique versatility that enables a variety of novel formats to reach the full range of product preferences and lifestyles. By combining our market awareness, proprietary dispersion capabilities and formulation know-how, our Solésence products enable our brand partners to expand the range of products within skin care and color cosmetics categories that can include sun and environmental protection, and their products consequently fill a unique market segment which drives the growing demand for our Solésence products.

 

In our personal care ingredients business, we believe that targeted collaborations with our long-standing customers in the ingredients space will enable them to have a competitive advantage which will sustain and/or grow their market share in the sunscreen API market. Both the Solesence® beauty science business and the personal care ingredients business have been positively impacted by the growing interest among consumers for mineral-based sunscreens, which management sees as a validation of the Company strategy.

 

In our advanced materials business, we have created an integrated platform of commercial nanomaterial technologies that are patented, patent-pending or proprietary, and result in products that see end use in a variety of applications, including use in enhancing the performance of PCR testing for various viruses, including COVID-19. These technologies revolve around our two distinct manufacturing process (PVS – Plasma Vapor Synthesis and NAS – NanoArc® Synthesis) and are designed to deliver nano-, non-nano and advanced-materials solutions for a targeted market or a specific customer application. Our platform provides flexibility and capability to engineer nanomaterials that meet a customer’s performance requirements and delivers our nanomaterial solutions in a readily usable format. Our technologies are scalable and robust, having allowed us to produce up to several hundred metric tons in this segment annually.

 

Manufacturing Operations  

 

We currently have manufacturing capacity based in three locations in the Chicago area. At two of these facilities, we are able to develop and supply engineered materials and bulk finished goods in quantities ranging from grams to metric tons. Our two existing facilities are registered under the ISO 9001, American National Standard, Quality Management System Requirements, and ISO 14001, American National Standard, Environmental Management System Requirements.  We are compliant with cGMP for products under U.S. Food and Drug Administration (“FDA”) regulation, applying to the manufacture of APIs and OTC Finished Dosage Form materials (primarily used in sun protection). Our third facility, our newest and also in the Chicago area, is now registered under the ISO 9001, American National Standard, Quality Management System Requirements, and ISO 14001, American National Standard, Environmental Management System Requirements.  It is also compliant with cGMP for products under FDA regulation, applying to the manufacture of APIs and OTC Finished Dosage Form materials (primarily used in sun protection). We have registered some of the chemicals we ship to customers in Europe pursuant to the European Chemical Agency’s regulations issued to date pertaining to Registration Evaluation and Authorization of Chemicals (“REACH”). Currently, we have registered Zinc Oxide, Aluminum Oxide, Iron Oxide and Octyltrimethoxysilane under REACH.

 

Our operations employ a cellular, team-based manufacturing approach, where workers operate in work “cells,” under a lean manufacturing environment to continuously advance and improve production capabilities. We have also developed a highly flexible workforce that has been cross trained to allow it to be employed broadly across our manufacturing processes. Beginning in late 2019, we also began to employ a significant number of temporary operators to assist us in supporting the production of our Solésence products.  Our manufacturing approach, targeted engineering actions, and capital investment have resulted in continuing process innovations and improvements that have reduced the variable manufacturing cost significantly over the past several years, while increasing our capacity to meet demand.

 

We are committed to a Lean Six Sigma manufacturing approach, to the extent possible given a certain measure of irregular demand, where we are able to reduce excess labor and manage the lowest practical inventory and supply levels in order to minimize working capital demands. This approach complements two of our major operational goals - (1) to increase output without adding unnecessarily to existing equipment and (2) to continually reduce production costs while consistently producing high quality products.   

 

Intellectual Property and Proprietary Rights

 

We rely on a combination of patent, trademark, copyright, trade secret and other intellectual property laws, nondisclosure agreements and other protective measures to protect our intellectual property. In addition to obtaining patent and trademarks based on our inventions and products, we may also license certain third-party patents from time-to-time to expand our technology base.

 

As of the date of this filing, we own 10 U.S. patents and 8 pending U.S. patent applications. We also own 56 foreign patents and patent applications consisting of 35 issued or allowed foreign patents and 21 pending foreign patent applications. All of the pending and owned foreign patents are counterparts to domestic filings covering our platform of nanotechnologies and surface treatments.

 

5

 

 

Competition

 

Within each of our targeted markets and product applications, we face potential competition from contract manufacturers and developers, advanced materials and chemical companies, and suppliers of traditional materials. In many markets, the actual or potential competitors are larger and more diversified than we are; however, we believe we focus on market segments and opportunities where our materials and related technologies are superior to those of our competitors, often due to our abilities to produce highly engineered ingredients to meet specific performance requirements, develop advanced material solutions for customers’ specific applications, and in the case of Solésence, finished products that impart the benefits of minerals-based products with superior tactile, visual, and performance characteristics. 

 

With respect to traditional suppliers, we may compete against lower priced traditional materials for certain customer applications. In some product or process applications the benefits of using advanced materials do not always justify a process change or outweigh their frequently higher costs. 

 

We believe that our material technologies and manufacturing platforms are strong. We believe we are well-positioned with our platform of integrated commercial materials technologies and track record of technology improvement and evolution.

 

In addition to competition in the advanced materials and related markets, our Solésence beauty science subsidiary faces competition from a wide variety of offerings in the field of skin care. Our Solésence products compete with existing solutions as well as new solutions from various sources, including other product developers and manufacturers who seek to serve skin care brands and integrated brands who also manufacture their own products in-house, and we must differentiate our value proposition in order to gain traction in this marketplace. The complexities of sunscreen regulation and the nuances of the development and manufacture of sunscreen products present a barrier for brands with integrated manufacturing in other skin care and cosmetics areas. Still, several Solésence customers have internal development and manufacturing capabilities that are similar to the capabilities of Solésence, and can serve as indirect competition to our products and services. We believe that our Solésence beauty science technology and our expertise in the nuances of formulating products that contain UV protection, coupled with our expanding capability to produce novel formats, will allow us to become a competitive player in this market on a sustainable basis. 

 

Governmental Regulations, Including Climate Change

 

The manufacture and use of certain of the products that contain Active Pharmaceutical Ingredients are subject to governmental regulations. As a result, we are required to adhere to the cGMP requirements of the FDA and similar regulations that include testing, control and documentation requirements enforced by periodic inspections. We also comply with the European Chemical Agency’s regulations issued to date pertaining to the chemicals we have registered under REACH. In early 2022, we were granted site clearance by Australia’s TGA for the full finished product manufacture of creams, lotions, sprays, sticks and all topical sunscreen forms. TGA site clearance is legally required for brands to market Solésence-made products as primary sunscreens in Australia. Our initial focus will be on establishing a footprint with both new and existing Solésence brand partners, to enable the sale of our patented skin health products as primary sunscreens.

 

We are committed to environmental health and safety (“EH&S”). We believe we comply with all applicable exposure limit standards issued by the United States Department of Labor’s Occupational Health and Safety Administration (“OSHA”). Because nanotechnology remains an emerging and evolving science, there are no currently required, measurements or personal protective equipment available that are specific to nanoparticle safety. Accordingly, we rely on general chemical safety and process safety requirements to identify safe personal protective equipment and appropriate handling protocols. We believe that we have taken a leadership position on EH&S in our operations and have internal and external review and monitoring of our practices.

 

In addition, our facilities and operations are subject to the plant and laboratory safety requirements of various environmental and occupational safety and health laws. We believe we are in compliance with all such laws and regulations, and to date, those regulations have not materially restricted or impeded operations. Further, we believe our processes to be highly efficient, generating very low levels of waste and emissions. For this reason, we do not view issues surrounding climate change and any currently foreseeable related regulations as materially impacting our business and financial statements, beyond any inestimable impact on the macro-economic environment. 

 

We have taken a responsible, proactive approach to EH&S by implementing appropriate procedures and processes to have our facilities registered under ISO 14001, American National Standard, Environmental Management System Requirements. We are also involved with leading industry groups that are defining nanomaterial standards and protocols. These currently include the ASTM International Committee on Nanotechnology, and the US TAG to ISO TC 229 Nanotechnology committee managed by the American National Standards Institute committee (ANSI). We also participate in FDA reviews relative to cosmetic and applicable drug applications. We have a full-time, advanced degreed professional, along with a supporting staff, who spend a significant amount of time managing governmental regulation compliance and EH&S. We believe that our Company has an exemplary safety record.

 

Employees

 

On December 31, 2023, we had a total of 79 full-time employees, 12 of whom hold advanced degrees. Additionally, we have a number of temporary, and temporary-to-permanent employees, typically 65 to 85 on a demand-driven basis, and a number of contractors with specific industry experience that have become a part of our talent pool. We have no collective bargaining agreements and believe that we have a strong relationship with our employees, whom management believes represent the strength of our Company.

 

6

 

 

Backlog

 

We do not believe that a backlog as of any particular date is indicative of future results. Our sales are primarily pursuant to purchase orders for delivery of our Solésence formulated products, personal care ingredients, and advanced materials. We have some agreements that give customers the right to purchase a specific quantity of ingredients during a specified time period. These agreements, however, do not obligate the customers to purchase any minimum quantity of such ingredients. The quantities actually purchased by the customer, as well as the shipment schedules, are frequently revised during the agreement term to reflect changes in the customer’s needs. For these reasons we do not believe that such agreements are meaningful for determining backlog amounts.

 

Business Segment and Geographical Information

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. See Note 13 to the accompanying Financial Statements for additional information.

 

Key Customers

 

A limited number of key customers account for a substantial portion of our commercial revenue, and aside from our largest customer, and our medical diagnostics customer, we are seeing the composition of these key customers change with the growth we are experiencing within our Solésence beauty science subsidiary, which has grown to exceed Personal Care Ingredients and Advanced Materials combined.  For 2023, total Solésence revenue amounted to $25.2M or 68% of total revenue compared to $23.1M, or 62% for 2022.  In particular, revenue from four customers across all business areas, our largest customer in personal care applications (BASF) and three of our Solésence customers, constituted approximately 25%, 17%, 15%, and 7%, respectively, of our 2023 total revenue.

 

As our Solésence products continue to represent more of our total revenues, we expect to see a number of smaller (sub-10% of revenue) customers represent a more significant portion of our total revenue. We have experienced this in 2023 and 2022 and expect it to continue in 2024 and beyond. Many of our customers are significantly larger than we are and, therefore, may be able to exert a high degree of influence over us. While our agreements with BASF are long-term agreements, they may be terminated by BASF under certain circumstances with reasonable notice and do not provide any guarantees that BASF will buy our products. The loss of one of our largest customers or the failure to attract new customers could have a material adverse effect on our business, results of operations and financial condition. To reduce the impact of having a high concentration of sales to a limited number of customers, we have pursued new customers through our market focused business model, and particularly through our Solésence beauty science subsidiary. To the extent we are successful in both adding a large number of customers through this model, and maintaining or expanding our existing partners, we believe we will be able to best manage the risks associated with customer concentration.

 

Forward-Looking Statements

 

We want to provide investors with more meaningful and useful information. As a result, this Annual Report on Form 10-K (the “Form 10-K”) contains certain “forward-looking statements”, as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements reflect our current expectations of the future results of our operations, performance and achievements. Forward-looking statements are covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We have tried, wherever possible, to identify these statements by using words such as “anticipates”, “believes”, “estimates”, “expects”, “plans”, “intends” and similar expressions. These statements reflect management’s current beliefs and are based on information now available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies that could cause our actual results, performance or achievements in 2024 and beyond to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and factors include, without limitation: our ability to be consistently profitable despite the losses we have incurred since our incorporation; a decision by a customer to cancel a purchase order or supply agreement in light of our dependence on a limited number of key customers; the terms of our supply agreements with BASF which could trigger a requirement to transfer technology and/or sell equipment to that customer; our potential inability to obtain working capital when needed on acceptable terms or at all; our ability to obtain materials at costs we can pass through to our customers, including high purity zinc, and other items impacted by supply chain pressures; uncertain demand for, and acceptance of, our Solésence products, and our advanced materials; our manufacturing capacity and product mix flexibility in light of customer demand; our limited marketing experience, including with our suite of Solésence products; changes in development and distribution relationships; the impact of competitive products and technologies; our dependence on patents and protection of proprietary information; our ability to maintain an appropriate electronic trading venue for our securities; the impact of any potential new governmental regulations, especially any new governmental regulations focusing on the processing, handling, storage or sale of nanomaterials, that could be difficult to respond to or costly to comply with; business interruptions due to unexpected events or public health crises, including viral pandemics such as COVID-19; and the resolution of litigation or other legal proceedings in which we may become involved. In addition, our forward-looking statements could be affected by general industry and market conditions and growth rates. Readers of this Form 10-K should not place undue reliance on any forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

 

7

 

 

Investor Information

 

We are subject to the informational requirements of the Exchange Act and, accordingly, file periodic reports, proxy statements and other information with the Securities and Exchange Commission (the “SEC”). Such reports, proxy statements and other information may be obtained by visiting the Public Reference Room of the SEC at 100 F Street, N.E., Washington, DC 20549 or by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically.

 

Financial and other information may also be accessed at our website. The address is www.nanophase.com. We make available, free of charge, copies of our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after filing such material electronically with, or otherwise furnishing it to, the SEC, and intend to make all such reports and amendments to reports available free of charge on our website. We have included our website address throughout this Form 10-K as textual references only. The information contained on, or accessible through, our website is not incorporated into this Form 10-K.

 

Item 1A. Risk Factors

 

Not required for a smaller reporting company.

 

Item 1B. Unresolved Staff Comments

 

Not required for a smaller reporting company.

 

Item 1C. Cybersecurity

 

Risk Assessment and Strategy

 

The Company regularly evaluates cybersecurity risk from computer viruses and more sophisticated and targeted cyber-related attacks such as ransomware, as well as cybersecurity failures resulting from human error and technological errors.

 

Our overall strategy in combatting known cybersecurity risks includes a variety of individual tactics, including:

 

·The use of antivirus software, virtual private networks, email security, as well as other software to prevent and detect data intrusions.
·The deployment of updates and patches as they are available and maintaining the current versions of major software to reduce the exposure to vulnerabilities.
·If necessary, the use of third-party security experts if and when an incident is detected.

 

We are not aware of having experienced any material cybersecurity incidents. We are not aware of any existent cybersecurity threats that would materially affect, or are reasonably likely to materially affect, our business strategy, results of operations or financial conditions.

 

Management Oversight

 

Day-to-day management of cybersecurity threats is conducted by our information technology consultant which is charged with identifying and reporting threats to senior management.

 

Board Oversight

 

The Board of Directors is responsible for oversight of management’s efforts to eliminate cybersecurity risks.

 

Item 2. Properties

 

We operate three facilities in the Chicago suburbs - a 36,000 square-foot production, research and headquarters facility in Romeoville, Illinois, a 20,000 square-foot production facility in Burr Ridge, Illinois and a 260,000 square-foot production and warehouse facility in Bolingbrook, Illinois.

 

Our manufacturing operations in Burr Ridge are registered under ISO 9001, and we believe that our manufacturing operations are within the cGMP requirements of the FDA for products that require such compliance. This facility is also registered under ISO 14001 which is the international standard for environmental management. The Burr Ridge site is registered with the FDA for API manufacturing.

 

The Romeoville facility houses our headquarters, advanced engineering, manufacturing (including particle coating, particle dispersion and pilot-scale manufacturing), and research and development with three applications development and formulating laboratories. The Romeoville facility has a quality control laboratory designed for the dual purposes of validating operations to cGMP and ISO standards and production process control. This laboratory is equipped to handle many routine analytical and in-process techniques that are currently required. All Romeoville manufacturing processes are registered under ISO 9001, ISO 22716 and ISO 14001, and we believe that the particle coating processes used for our ingredients and fully formulated sunscreens and cosmetic products for personal care are in compliance with the cGMP requirements of the FDA. The Romeoville site is registered with the FDA for API manufacturing, manufacturing, and packaging.

 

The Bolingbrook facility houses our warehousing operations, sunscreen lotions manufacturing, filling and assembly of our Solésence® products and additional quality control spaces.  The Bolingbrook facility is registered with the FDA for OTC drug manufacturing and packaging, site is registered under ISO 9001, ISO 22716 and ISO 14001.

 

We lease our Romeoville, Burr Ridge and Bolingbrook facilities. During October 2016 we entered into an amendment to our Industrial Lease Agreement for the facility in Romeoville, Illinois, which, among other things, extended the term of such lease through December 31, 2024. On March 14, 2017, we entered into a new Building Lease for the Burr Ridge facility that began in September 2017, and after exercising the final lease extension, it now ends in September 2024.  During December 2021, we entered into a Standard Form Industrial Lease for a new facility in Bolingbrook, Illinois, which, among other things, will end in May of 2032, with options to extend this lease at market rent for each of three concurrent five-year periods.

 

With the addition of our new Bolingbrook space, we believe that our leased facilities will provide sufficient capacity to fulfill current known customer demand as well as allow for the creation of substantial additional space to enable expansion of key production processes. We believe we will be able to expand certain operations, and consolidate others, to support additional growth in an economically efficient manner. We believe that our capital expenditures made in 2023, and projected for 2024, will support currently anticipated demand from existing and expected customers through 2024 and into 2025. Management continues to spend considerable time determining how best to optimize our facilities to maximize growth over the next few years. Our actual future capacity requirements will depend on many factors, including new and potential customer acceptance of our current and potential engineered materials, applications and products, both expected and currently unplanned growth from existing customers, continued progress in our research and development activities and product testing programs and the magnitude of these activities and programs.

 

8

 

 

Item 3. Legal Proceedings

 

On August 31, 2022, counsel for Nanophase Technologies Corporation (“Nanophase”) received a letter from lawyers representing BASF Corporation (“BASF”) stating that BASF had filed a complaint against Nanophase in the Superior Court of New Jersey (“SCNJ”) on August 9, 2022 (the “New Jersey Complaint”) and that Nanophase’s registered agent for service of process had been served with the New Jersey Complaint on August 11, 2022. The August 31, 2022 letter from BASF’s lawyers was Nanophase’s first notice of the New Jersey Complaint.

 

The New Jersey Complaint claims that Nanophase breached the Zinc Oxide Supply Agreement dated as of September 16, 1999 between Nanophase and BASF, as assignee, as amended through January 1, 2019 (the “Agreement”). The New Jersey Complaint specifically alleges that Nanophase breached the exclusivity provision of the Agreement by selling zinc oxide to entities other than BASF, including sales to Nanophase’s subsidiary Solésence, LLC (“Solésence”), in markets designated as being in the field of use (the “Field”) under the Agreement. The New Jersey Complaint also relatedly alleges that Nanophase breached the capacity and inventory provisions of the Agreement. In addition, the New Jersey Complaint alleges claims for unjust enrichment and violation of the duty of good faith and fair dealing. The New Jersey Complaint seeks an unspecified amount of damages, a permanent injunction, counsel fees, and litigation expenses. The New Jersey Complaint is not seeking termination of the Agreement.

 

Management believes that the allegations of BASF’s New Jersey Complaint are without merit and are unsupported by the terms of the Agreement and governing law. On September 8, 2022, Nanophase filed a Motion to Dismiss (“MTD”) the New Jersey Complaint with the SCNJ, arguing that BASF’s claims in its New Jersey Complaint are not supported by the terms of the Agreement. Following completion of briefing and a hearing on the MTD, the SCNJ denied Nanophase’s MTD on February 10, 2023, finding that under the “liberality” standards of New Jersey procedure, the allegations of BASF’s complaint were “sufficient to survive” the MTD. The SCNJ specifically noted that it did not consider whether BASF could prove its claims. Thereafter, on February 28, 2023, Nanophase answered BASF’s New Jersey Complaint, denying all wrongdoing and, as mandated by New Jersey procedural requirements, filed two counterclaims: (1) a request for a declaration that contrary to BASF’s views, the exclusivity provision of the Agreement does not apply to all products containing zinc oxide as an ingredient for uses designated under the Agreement nor does the exclusivity provision prohibit Nanophase’s sales of Solésence products containing zinc oxide as an ingredient; and (2) a claim that BASF had breached its obligations under the Agreement to buy from Nanophase at least 70% of BASF’s zinc oxide requirements for use in the Field. On April 17, 2023, BASF moved to dismiss Nanophase’s counterclaims, arguing that the declaratory judgment claim duplicated BASF’s claim for Nanophase’s alleged breach of contract and Nanophase’s claim for BASF’s breach of its zinc oxide purchase requirements was procedurally insufficient. Following briefing and a hearing on October 6, 2023, the SCNJ: (1) denied BASF’s motion to dismiss Nanophase’s declaratory judgment counterclaim, finding that it did not duplicate BASF’s breach of contract claim and that BASF’s litigating its claim would not provide Nanophase with complete relief as to the exclusivity issues raised in the counterclaim; and (2) granted BASF’s motion to dismiss Nanophase’s claim for BASF’s breach of its zinc oxide purchase requirements on procedural grounds. On October 31, 2023, BASF filed its answer to Nanophase’s declaratory judgment counterclaim, denying the counterclaim. Discovery in the New Jersey litigation is ongoing.

 

On September 7, 2022, Nanophase filed a Complaint for Declaratory Judgment against BASF in the Circuit Court of Cook County, Illinois (the “Illinois Complaint”). The Illinois Complaint asked the court for a declaration similar to that subsequently sought in Nansphase’s counterclaim in the New Jersey litigation. On November 3, 2022, BASF moved to dismiss Nanophase’s Illinois Complaint, arguing that it duplicates the New Jersey litigation. Following briefing and a hearing, the Illinois court granted BASF’s motion on procedural grounds on March 16, 2023.

 

Given our view, we have decided that it is not appropriate to record a contingent liability relating to these actions at this time.

 

Nanophase intends to continue negotiating with BASF in good faith to resolve these issues. In the event that an acceptable solution is not reached, and litigation proceeds, the ultimate resolution cannot now be determined with certainty.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

9

 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information; Holders; Dividends

 

Our common stock is traded under the symbol “NANX” on the OTCQB marketplace, operated by OTC Markets Group. The following table sets forth, for the periods indicated, the range of high and low sale prices for our common stock on the OTCQB marketplace:

 

    High     Low  
Fiscal year ended December 31, 2023:                
First Quarter   $ 1.79     $ 1.08  
Second Quarter     1.45       0.50  
Third Quarter     1.40       0.88  
Fourth Quarter     1.00       0.55  
Fiscal year ended December 31, 2022:                
First Quarter   $ 4.42     $ 2.04  
Second Quarter     3.45       2.51  
Third Quarter     3.25       2.32  
Fourth Quarter     2.50       1.12  

 

On March 27, 2024, the last reported sale price of our common stock was $0.72 per share, and there were 121 holders of record of our common stock.

 

We have never declared or paid any cash dividends on our common stock and do not currently anticipate paying any cash dividends or other distributions on our common stock in the foreseeable future. We intend instead to retain any future earnings for reinvestment in our business. Any future determination to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements and such other factors deemed relevant by our Board of Directors. Our Business Loan Agreements with Beachcorp, LLC (“Beachcorp”), Strandler, LLC (“Strandler”), and Libertyville Bank and Trust Company (“Libertyville”), dated as of November 19, 2018, January 28, 2022, and December 21, 2021 respectively, require us to obtain the written consent of the lender prior to paying any cash dividends on our common stock. 

 

Item 6. [Reserved]

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis should be read in conjunction with risks discussed in the financial statements and related notes thereto appearing elsewhere in this Form 10-K. When used in the following discussions, the words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and contingencies that could cause actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. See the “Forward Looking Statements” section in Part 1, Item 1, of this Form 10-K.

 

Overview

 

Nanophase is a health-oriented, science-driven company, which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused on various beauty- and life-science markets. Our primary skin health products are fully developed prestige skin care formulations with mineral-based UV protection, marketed and sold through our Solésence beauty science subsidiary, enabled by our proprietary Active Pharmaceutical Ingredients (“APIs”), which are also marketed as APIs for sale to manufacturers of other types of skin health products, including sunscreens and daily care products.  In terms of the balance of our life sciences focus, we have seen continued demand for our medical diagnostics ingredients, which are used in testing for various viruses, most notably COVID-19.  Additionally, we continue to sell products in legacy markets including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, currently fall into the advanced materials product category.  

 

Critical Accounting Estimates

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.

 

10

 

 

Other critical estimates include the allowance for doubtful accounts applied against our receivables balance as well as an inventory reserve. In the determination of a reserve to apply toward receivables, management considered provisions in FASB ASC 326 & ASC 450-20-25 regarding the recognition of loss contingencies and applied a reserve balance against gross receivables to arrive at the net reported balance. Under the guidance referenced above, management judgmentally applied an estimate of the portion of gross receivables for which loss is both probable and can be reasonably estimated and accrued a loss contingency by a charge to income. A bad debt reserve of $225,000 and $139,000 was applied to gross receivables for 2023 and 2022, respectively. Particularly with respect to customers of our Solésence beauty science subsidiary, it can be difficult to estimate collectability. We frequently require significant deposits from customers before ordering materials and scheduling production. This serves as a good indicator of the customer’s wherewithal to pay for the balance of the product when shipped. In cases where it is difficult to establish creditworthiness, we require payment of the full amount before we ship. Notwithstanding these credit security measures, we frequently find that pay cycles get extended for reasons that can be outside of our control. The nature of the business is that there are many product launches, often by smaller or start-up companies, that may not result in initial commercial success. This has resulted in extensions of payment terms, but collectability has ultimately occurred in most cases. As our Solésence beauty science subsidiary grows, we will monitor this closely and adjust estimates as necessary.

 

Management also monitors the value of inventory for the effects of aging, obsolescence, and seasonality. Consistent with the provisions in FASB ASC 330-10-35, we adjust inventory valuation upon management’s determination that the net realizable value of our inventory, which applies the average cost method, is lower than its historic cost. In the application of this policy in 2023, management deemed a portion of inventory will likely experience such an impairment and elected to apply a $677,000 inventory reserve in anticipation. Some of the materials in question are nearing expiration and therefore more difficult to sell, some represent soon-to-be obsolete products, and some are raw materials that we no longer use regularly.

 

Certain assumptions are necessary to assess the impact of risks and uncertainties on the financial information, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. Any changes in those plans or assumptions could have a material impact on our liquidity and financial condition. While we have seen costs continue to increase on an inflationary basis as we enter 2024, it is our belief that we will be able to offset much of this cost as we gain greater production efficiencies and seek to increase our pricing where possible. 

 

Results of Operations

 

Years Ended December 31, 2023 and 2022

 

Total revenue decreased to $37,297,000 in 2023, compared to $37,317,000 in 2022. A substantial majority of our revenue for each year is from our largest customers, in particular, sales to our largest customer in skin care and sunscreen applications, finished skin health products marketed through our Solésence beauty science subsidiary. Product revenue, the primary component of our total revenue, decreased to $36,641,000 in 2023, compared to $36,731,000 in 2022. This slight decrease was due to a decrease in revenue from our personal care business and a medical diagnostics materials customer (within our advanced materials business). 

 

Current Significant Customers

 

   2023   2022 
Largest Personal Care Customer   25%   30%
Solésence Customer - 1   17%   17%
Solésence Customer - 2   15%   15%
Significant Customer Total   57%   62%

 

11

 

 

Cost of revenue generally includes costs associated with commercial production and customer development arrangements. Cost of revenue increased to $29,472,000 in 2023, compared to $28,957,000 in 2022. The increase in cost of revenue was primarily driven by the higher management costs related to the production processes. Lower-than-expected volume in the fourth quarter of 2023, write-downs of obsolete inventory, reduction in contract revenue (which generally has little direct cost associated with it), and changes in product mix, added to relative increases in cost of revenue. All of these factors contributed to a reduction of overall gross margin percentage by 1% when compared to 2022. We expect to continue new materials development and dispersion technologies for personal care applications and for our formulated Solésence products during 2024 and beyond, as part of our business model. At current revenue levels we have generated a positive gross margin, though margins can be impeded by the cyclicality of our demand, often leading to the Company not having enough revenue to efficiently absorb manufacturing overhead that is required to work with current customers and expected future customers. We believe that our current fixed manufacturing cost structure is sufficient to support higher levels of revenue volume. The extent to which margins grow, as a percentage of total revenue, will be dependent upon revenue mix, revenue volume, our ability to cut costs and pass commodity market-driven raw materials increases on to customers, and the speed and efficiency with which we are able to scale up production for our Solésence products. We expect that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow. We expect to continue to focus on reducing controllable variable product manufacturing costs, with potential variability related to the commodity metals markets and cost and wage inflation but may or may not realize gross margin percentage growth through 2024 and beyond, dependent upon the factors discussed above.

 

Research and development expense, which includes all expenses relating to the technology and advanced engineering groups, primarily consists of costs associated with the development or acquisition of new finished product formulations for skin care, new product applications for our skin care ingredients, advancement of our medical diagnostics ingredient knowledge, and the cost of enhancing our manufacturing processes. This includes legal fees related to intellectual property development, protection, and maintenance. As an example, we are currently focusing the bulk of our resources on developing new product formulations, and related new technologies, as we expand marketing and sales efforts relating to our Solésence products. This work has led to several new products and additional potential new products. Our efforts in research and development, cosmetic formulating, process engineering and advanced engineering groups are focused in three major areas: 1) application development for our products; 2) creating or obtaining additional core materials technologies and/or materials that have the capability to serve multiple skin health-related markets; and 3) continuing to improve our core technologies to improve manufacturing operations and reduce costs.

 

Research and development expense increased to $3,837,000 in 2023, compared to $3,037,000 in 2022. The primary reasons for this were increases in compensation expense and headcount, outside testing, and materials charges associated with the development and launch of our Solésence line of personal care products and related capabilities. We expect expenses for research and development to continue to increase depending on growth in our Solésence line of products, and related technologies. This expense growth will be dependent upon the success we have in developing new products, which adds significantly to outside testing fees to both enhance product development and comply with regulatory requirements.

 

Selling, general and administrative expense decreased to $7,534,000 in 2023, compared to $7,581,000 in 2022. The net decrease was largely attributed to a decrease in professional services. We expect 2024 expenses in this area to be slightly lower, even if growth continues as planned due to expected decreased legal costs.  We will be expanding parts of our administrative functions, including related staffing additions.  The extent to which this increase occurs will be dependent upon growth.

 

Interest expense increased to $838,000 in 2023, compared to $382,000 in 2022, due to higher interest rates in 2023 and increased usage of the debt facilities. The interest expense for 2023 and 2022 related to interest paid relating to our revolving lines of credit for working capital funding, and finance leases and term loans supporting some of our equipment.

 

In Company-wide operations, we believe inflation has not had a material effect on our operations or financial position for 2023, although we have seen increases in our costs. We expect supplier price increases and wage and benefit inflation, both of which represent a significant component of our costs of operations, may have a material effect on our operations and financial position in 2024 and beyond. We will apply our best efforts to pass through cost increases to our customers. If we are unable to pass through any increases due to contractual limitations or conditions in our markets specifically, this could reduce margins and net income.

 

Liquidity and Capital Resources

 

Cash, cash proceeds and use of cash for 2023 and 2022 were:

 

   For the year ended December 31, 
   2023   2022 
Total cash  $1,722,000   $2,186,000 
Cash used in operating activities   (2,006,000)   (1,650,000)
Net cash used in investing activities   (1,051,000)   (2,823,000)
Net cash provided by financing activities   2,593,000    6,002,000 

 

The $354,000 year-over-year increase in cash used in operating activities for the year ended December 31, 2023 was mainly due to the Company incurring $4,390,000 in net loss in 2023 compared to $2,623,000 in net income in 2022. Cash capital expenditures amounted to approximately $1,051,000 and $2,823,000 for the years ended December 31, 2023 and 2022, respectively. We did not dispose of or sell any assets during 2023 or 2022.

 

The Company maintains a credit agreement with Libertyville to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. As of December 31, 2023 there was no outstanding borrowings on this line of credit. This credit agreement has a maturity of December 22, 2024.

 

12

 

 

On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500,000 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000,000 to $2,750,000.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750,000 to $4,000,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000,000 to $6,000,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500,000 to $1,000,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022.

 

On January 28, 2022, to support the working capital demands created by the commercial growth of the Company and its wholly owned subsidiary, Solésence, LLC, the Company entered into (i) an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement, (ii) a Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, (iii) a Business Loan Agreement (the “New Revolving Loan Agreement” and together with the A&R Loan Agreement and the New Term Loan Agreement, the “Loan Agreements”) with Beachcorp, LLC, and (iv) three promissory notes in order to evidence the loans pursuant to the Loan Agreements (the “Notes”). Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors.

 

The Loan Agreements changed the terms of both the Company’s asset-based revolving loan facility (the “A/R Revolver Facility”) and the secured advance (the “Term Loan”, which was assigned from Beachcorp, LLC to Strandler, LLC) under the Master Agreement and provide a new asset-based revolving loan facility based on inventory (the “Inventory Facility”). The maximum borrowing amount under the A/R Revolver Facility increases from $6,000,000 to $8,000,000, with a borrowing base consisting of qualified accounts receivable of the Company. The maximum borrowing amount under the Inventory Facility is $4,000,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The Loan Agreements also extended the date for which all principal and accrued interest under the A&R Revolver Facility and the Term Loan are due from March 31, 2023 and March 31, 2022, respectively, to March 31, 2024, which was also the maturity date for the Inventory Facility. The Loan Agreements reduce interest on outstanding borrowings under the A/R Revolver Facility and the Term Loan from the prime rate plus 2% and 5.25% per year, to a floating rate equal to the prime rate plus 0.75%, which is also the interest rate for borrowings under the Inventory Facility. The amount of the Term Loan remains $1,000,000. The A/R Revolver Facility, the Inventory Facility and the Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s revolving line of credit with Libertyville Bank & Trust. 

 

On November 13, 2023 to support working capital demands the Company entered into (i) a new Promissory Note (“Bridge Note”) with Strandler, LLC,. The maximum borrowing amount under the Bridge Note is $2,000,000. The interest rate for the Bridge Note is at the prime rate plus 0.75%, and it matures on May 13, 2024, and (ii) amendments to the Loan Agreements increasing increasing the principal amount of the Inventory Facility to $5,200,000 and extending the maturity date under the Loan Agreement to March 31, 2025.

 

On December 31, 2023, the balance on the Term Loan was $1,000,000, the balance on the A/R Revolver Facility was $2,810,000, the balance on the Inventory Facility was $5,000,000, and the balance on the Bridge Note was $2,000,000. On December 31, 2022, the balance on the Term Loan was $1,000,000, the balance on the A/R Revolver Facility was $4,282,000, and the balance on the Inventory Facility was $3,000,000.

 

On March 1, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”), between the Company and Strandler, LLC (“Strandler”).

 

Pursuant to the Purchase Agreement, the Company issued to Strandler 15,000 shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”) at a purchase price per share of $400, for total consideration of $6,000,000, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”).

 

13

 

 

Under the Purchase Agreement, the Company granted Strandler customary registration rights with respect to shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), it may receive in connection with any conversion of Series X Preferred Stock into Common Stock, as described below. For so long as any amount of Preferred Stock is outstanding, the Purchase Agreement also (i) prevents the Company from paying any dividend on any shares of the Company’s capital stock (other than dividends consisting solely of Common Stock or rights to purchase Common Stock), (ii) prevents the Company from repurchasing any Common Stock, and (iii) subject to certain permitted exceptions, restricts the Company’s ability to permit any lien or other encumbrance on Company assets.

 

At any time and from time to time, in whole or in part, following the Company properly filing an amendment (the “Certificate Amendment”) to its Certificate of Incorporation to increase the number of authorized shares of its Common Stock from 60,000,000 to 95,000,000, each share of Series X Preferred Stock is convertible, at the option of the holder, into 1,000 shares of Common Stock at no additional cost. If the Company has not properly filed, upon shareholder approval, the Certificate Amendment on or before August 1, 2024, then each share of Series X Preferred Stock will be redeemable at the holder’s option, in whole or in part, without penalty or premium, at a redemption price equal to $420 per share (each, a “Redemption”). If the Company fails to fully pay any Redemption within five days of receiving notice, all unpaid amounts will bear interest at a rate of 10% per annum. In addition, in the event of a Change in Control (as defined in the Certificate of Designations) of the Company, each share of the Series X Preferred Stock is redeemable at the option of the holder, without penalty or premium, at a redemption price equal to $420 per share. Upon any conversion of Preferred Stock into Common Stock by Strandler, Strandler is required to hold the Common Stock received in the conversion for a period of 12 months.

 

Holders of Series X Preferred Stock (i) are not entitled to receive dividends, subject to customary anti-dilution protections, (ii) have no voting rights, and (iii)receive a liquidation preference of $400 per share. The Series X Preferred Stock ranks senior in right of payment to all securities designated as junior securities, including Common Stock.

 

In connection with the Company’s entry into the Purchase Agreement, the Company also entered into (i) a Second Amendment to Business Loan Agreement (the “Term Loan Agreement Amendment”) with Strandler, LLC, (ii) a Second Amendment to Business Loan Agreement (the “A&R Loan Agreement Amendment”) with Beachcorp, LLC, which is also an affiliate of our controlling shareholder, Bradford T. Whitmore (“Beachcorp”), and (iii) a Second Amendment to Business Loan Agreement with Beachcorp (the “Revolving Loan Agreement Amendment” and together with the Term Loan Agreement Amendment and the A&R Term Loan Agreement Amendment, the “Loan Agreement Amendments”). The Loan Agreement Amendments extend the maturity date under each respective loan agreement from March 31, 2025 to October 1, 2025.

 

For more information regarding the New Business Loan Agreement, see Note 3 to our Financial Statements referred to in Part II, Item 8 of this Annual Report on Form 10-K. 

 

Our actual future capital requirements in 2024 and beyond will depend on many factors, including customer acceptance of our current and potential finished Solésence  products, APIs sold as ingredients in to the skin health markets, medical diagnostics ingredients, and other engineered materials, applications, and products, continued progress in research and development activities and product testing programs, the magnitude of these activities and programs, and the costs necessary to increase and expand our manufacturing capabilities and to market and sell these products and ingredients. Other important issues that will drive future capital requirements will be the development of new markets and new customers as well as the potential for significant unplanned growth with existing customers. Depending on the success of certain projects, we expect that capital spending relating to currently known capital needs for 2024 will be between $1 million and $5 million, to be funded by profit from operations, our existing loans and lines of credit, and possible new financing. If those projects are delayed or ultimately prove unsuccessful, or if we fail to be able to support the additional cost of funding them in the near term, we expect our capital expenditures may fall below the lower end of the range. Similarly, substantial success in business development projects may cause the actual 2024 capital investment to exceed the top of this range.

 

The Company currently has two areas within its strategic plan that will result in material cash requirements that could have an impact on operations. We have several operating leases (see note 6 to the financial statements) for our facilities that require us to increase our cash outlays for facilities expenses significantly beginning in 2022. The 260,000 square foot facility we leased in December 2021 exceeds our current needs for space considerably. We consequently have sublet a portion of the facility on shorter term leases. We are growing rapidly and continue to expect significant growth going forward. We will also consolidate some of our facilities to mitigate costs. Our view was that a lack of space would have hindered our ability to continue to grow, as well as making it difficult to satisfy existing customer demands on a timely basis if we couldn’t expand our production footprint. We have estimated our future growth through a combination of industry experience, customer feedback, market intelligence, and our successful history in commercializing new products. Sales of our Solésence products have roughly tripled between 2019 and 2021, increased by 27% in 2022, and increased by 9% in 2023 to reach $25 million annually. We expect this growth to continue, albeit at less than a multiple of each year’s sales going forward. Many of these estimates are qualitative in nature, but are informed by experience. If we were to not grow more than incrementally in 2024, we would need to re-evaluate our expansion strategy in light of the increases in our facilities costs that extend for as much as ten years into the future. Similarly, our capital spending plan for 2024 will amount to between $1 million and $5 million. We expect our capital spending to increase further in 2025 and 2026. At December 31, 2023, our commitments to equipment suppliers relate mainly to the $1 million of construction in progress, much of which reflects deposits on to-be-delivered equipment. We estimate the unpaid committed capital relating to capital spending to be less than $1 million as of December 31, 2023.

 

We have federal net operating loss carryforwards for tax purposes of approximately $50 million on December 31, 2023. We have section 179 carryforwards of approximately $0.2M at December 31, 2023. Because the Company may experience “ownership changes” within the meaning of the U.S. Internal Revenue Code (“IRC”) in connection with any future equity offerings, future utilization of this carryforward may be subject to certain limitations as defined by the IRC. If not utilized, $44 million of this loss carryforward will expire between 2024 and 2037. Given changes to the IRC, net operating loss carryforwards generated after January 1, 2018 do not expire, therefore, $5.6 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $21.3 million on December 31, 2023. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2042.

 

14

 

 

As a result of the annual limitation and uncertainty as to the amount of future taxable income that will be earned prior to the expiration of the carryforward, we have concluded that it is likely that some portion of this carryforward will expire before ultimately becoming available to reduce income tax liabilities.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for a smaller reporting company.

 

Item 8. Financial Statements and Supplementary Data

 

The financial statements, with the report of independent auditors, listed in Item 15 appear on pages F-1 through F-21 of this Form 10-K.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures. We are responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports filed by us under the Exchange Act is: (a) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and (b) accumulated and communicated to our management, including our principal executive and principal financial officer, to allow timely decisions regarding required disclosures. It should be noted that in designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and that our management necessarily was required to apply its judgment regarding the design of our disclosure controls and procedures. As of the end of the period covered by this report, we conducted an evaluation, under the supervision (and with the participation) of our management, including our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer (which roles are currently filled by the same person), concluded that our disclosure controls and procedures were effective at reaching that level of reasonable assurance.

 

Management’s Annual Report on Internal Control Over Financial Reporting. Management is responsible for the preparation, integrity and fair presentation of the financial statements and Notes to the financial statements. Management is also responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed under the supervision of the Company’s principal executive officer and principal financial officer in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company’s internal control over financial reporting includes those policies and procedures that:

 

  (i) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets of the Company;
  (ii) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
  (iii) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria established in Internal Control–Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

 

15

 

 

Based on our assessment and those criteria, our management, including our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer) (which roles are currently filled by the same person), believes that the Company maintained effective internal control over financial reporting as of December 31, 2023.

 

Changes in Internal Control over Financial Reporting. The Company’s management, including the Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), confirm that there was no change in the Company’s internal control over financial reporting during the quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Form 10-K.

 

Item 9B. Other Information

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not applicable.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

DIRECTORS

 

Set forth below is certain information regarding the directors of the Company.

 

Name   Age   Position with Company   Director Since   Term Expires   Class
R. Janet Whitmore   69   Chair of the Board of Directors   2003   2025   I
                     
Laura M. Beres   39   Director   2020   2025   I
                     

Mark E. Miller 

  

60 

  

Director 

  

2023 

  

2024 

  

III 

                     
Jess A. Jankowski   58   President, Chief Executive Officer, Chief Financial Officer, and Director   2009   2024   III

 

Ms. Whitmore joined the board in November 2003. She is a former director of Silverleaf Resorts, Inc., where she served as Chair of the Compensation Committee and as a member of the Audit Committee. She is also a former director of Epoch Biosciences, a supplier of proprietary products used to accelerate genomic analysis. Ms. Whitmore is Founder of Benton Consulting, LLC, which specializes in business development and processes. From 1976 through 1999, Ms. Whitmore held numerous engineering and finance positions at Mobil Corporation, including Mobil’s Chief Financial Analyst and Controller of Mobil’s Global Petrochemicals Division. Ms. Whitmore holds a B.S. degree in Chemical Engineering from Purdue University and an M.B.A. from Lewis University. We believe that Ms. Whitmore’s combination of global financial, engineering, and management expertise makes her a valuable member of our Board of Directors. Ms. Whitmore is the sister of Bradford T. Whitmore, and herself beneficially owned approximately 3% of the outstanding shares of our common stock as of October 20, 2023. Mr. Whitmore, together with his affiliate Grace Investments, LP., beneficially owned approximately 63% of the outstanding shares of our common stock as of October 20, 2023. He is also the manager of Beachcorp, LLC and Strandler, LLC.  The Company has entered into loan agreements with both Beachcorp, LLC, and Strandler, LLC.

 

Ms. Beres has served as a director of the Company since October, 2020.  She has spent her career in corporate strategy and operations in retail and consumer industries, transforming programs and building new organizational and market-facing capabilities.  Ms. Beres currently serves as the VP Merchandising, Strategy & Growth at Ulta Beauty, having previously served as the VP, Enterprise Transformation.  Previously, she has worked at Deloitte Consulting, advising primarily on growth and transformation strategies in Consumer-Packaged Goods, with additional leadership roles in the CMO practice, developing and executing strategies on large global accounts. Ms. Beres started her career working in the financial services, focused on small and middle market companies, with responsibilities including commercial lending and credit evaluation, and credit transaction negotiation.  She earned her M.B.A. from The University of Chicago Booth School of Business and has a B.S. in Finance and B.A. in Oboe Performance from Butler University.  Ms. Beres has also served on Associate and Auxiliary Boards for non-profit organizations in Chicago, as well as the Board of Directors for Chicago Youth Symphony Orchestras.  We believe that Ms. Beres’ broad strategic experience in CPG, and specific experience with cosmetics, along with her strong financial background makes her a valuable member of our Board of Directors.

 

16

 

 

Mr. Miller has served as a director of the Company since July, 2023. He has spent most of his career in leadership and operations roles in chemical manufacturing companies in the personal care and pharmaceutical industries. Mr. Miller most recently was the President and Chief Operating Officer at Nagase Specialty Materials, where he led the Nagase Specialty Materials NA organization. Previously, he has worked at Business Performance Consultancy as a Principal and in Executive roles at Lonza and BASF. He earned his JD from the University of Illinois Chicago, M.B.A. from the University of Illinois Urbana-Champaign, and has a BBA in Business Administration from the University of Notre Dame. We believe that Mr. Miller’s broad strategic experience in personal care chemical manufacturing along with his strong executive leadership background makes him a valuable member of our Board of Directors.

 

Mr. Jankowski joined the Board in February 2009. He has served as the Company’s President and Chief Executive Officer since that time. Mr. Jankowski also served as the Company’s principal financial officer and principal accounting officer from November 2017 until March 2018, and again from April 2019 through the current time. After joining the Company in 1995, Mr. Jankowski held offices including Vice President of Finance, Chief Financial Officer, Secretary, Treasurer and Controller. Prior to joining the Company, he served as Controller for two building and public works contractors in the Chicago area, during which time he had significant business development responsibilities. He began his career working for Kemper Financial Services. Mr. Jankowski holds a B.S. from Northern Illinois University and an M.B.A. from Loyola University. He was appointed to serve on the board of directors of the Northern Illinois Technology Foundation, an economic development and technology transfer entity that is part of Northern Illinois University (2009-2018). Mr. Jankowski was also appointed to serve on the Due Diligence Team of the State’s Invest Illinois Venture Fund (2011-2015). He also served on the TechAmerica Midwest Board (2008-2012). Mr. Jankowski was also appointed to serve on the Romeoville Economic Development Commission (2004-2010). He has also served on the advisory board of NITECH (Formerly WESTEC), an Illinois Technology Enterprise Center focusing on the commercialization of advanced manufacturing technologies (2003-2008). Mr. Jankowski has served on the Advisory Board of the Nanobusiness Commercialization Association since 2009. We believe that Mr. Jankowski’s long-term and intimate experience with the Company’s operations and business development process, his financial and management expertise, and his extensive industry relationships, make him a valuable member of our Board of Directors.

 

Meetings of the Board and Committees During the year ended December 31, 2023, the Board of Directors (“BOD”) held twenty one meetings. All directors attended all meetings of the BOD and related committee meetings in 2023 with the exception of one committee meeting where Ms. Beres was absent.

 

Committees of the Board of Directors -- The Board of Directors has established an Audit and Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee. Each operates in accordance with its charter (available on our website www.nanophase.com under the “Investor Relations” section). The current members of the Audit and Finance Committee are Ms. Whitmore (Chair), Ms. Beres, and Mr. Miller. The members of the Compensation Committee are Ms. Whitmore (Chair), Ms. Beres, and Mr. Miller. The members of the Nominating and Corporate Governance Committee are Ms. Whitmore (Chair), Ms. Beres, and Mr. Miller.

 

The Audit and Finance Committee generally has responsibility for retaining the Company’s independent public auditors, reviewing the plan and scope of the accountants’ annual audit, reviewing the Company’s internal control functions and financial management policies, reviewing and approving all related party transactions, and reporting to the Board of Directors regarding all of the foregoing. The Audit and Finance Committee held five meetings during 2023. The Board of Directors has determined that Ms. Whitmore is an “audit committee financial expert” as described in applicable SEC rules.   The Board of Directors has not determined affirmatively that Ms. Whitmore is independent under the Nasdaq Stock Market rules, but such rules are inapplicable to the Company because the Company is no longer listed on Nasdaq.

 

The Compensation Committee generally has responsibility for establishing executive officer and key employee compensation, reviewing, and establishing the Company’s executive compensation, evaluating our Outside Director compensation, and reporting to the Board of Directors regarding the foregoing. The Compensation Committee also has responsibility for administering the 2019 Equity Compensation Plan (the “2019 Equity Plan”), determining the number of options, if any, to be granted to the Company’s employees and consultants pursuant to the 2019 Equity Plan, and reporting to the Board of Directors regarding the foregoing. Regarding most compensation matters, including executive compensation, our management provides recommendations to the Compensation Committee; however, the Compensation Committee does not delegate any of its functions to others in setting compensation. The Compensation Committee does not currently utilize external consultants in executive or director compensation matters. The Compensation Committee held two meetings during 2023. Each member of the Compensation Committee is a “non-employee director” as defined in Rule 16b-3 under the Exchange Act and is an “Outside Director” as defined by the regulations under Section 162(m) of the Internal Revenue Code.

 

The Nominating and Corporate Governance Committee generally has responsibility for evaluating and nominating candidates to serve on the Board of Directors, and for establishing and reviewing our Corporate Governance Principles. The Nominating and Corporate Governance Committee held two meetings during 2023.

 

17

 

 

The Board of Directors considers its role in risk oversight to focus primarily on evaluating risk at the entity and strategic levels, with management primarily responsible for managing day-to-day risk factors and presenting summary materials for those positions to the Board of Directors. Consistent with this philosophy, the Board of Directors has no formal policy as to whether the roles of Chief Executive Officer and board Chair should be segregated or combined. The Board of Directors considers the circumstances of the Company and makes a determination as to the appropriate leadership structure for the Company at that time. As of the time of this filing, the positions of CEO and Board Chair are held by two individuals – Ms. Whitmore serves as Chair and Mr. Jankowski serves as CEO. Ms. Whitmore brings extensive experience in corporate leadership from her own working experience and from a number of boards on which she has served in the past, and Mr. Jankowski is expected to benefit from that experience. The Board of Directors believes this to be the most appropriate structure for the Company at this time. Under our Corporate Governance Principles, in the event that the Chair of the Board is not an Outside Director, the Board will elect a lead independent director, who will have the responsibility to schedule and prepare agendas for meetings of the Outside Directors, communicate with the CEO, disseminate information to the rest of the Board and raise issues with management on behalf of the Outside Directors when appropriate. The Board evaluates its leadership structure on an ongoing basis and may change it as circumstances warrant.

 

The Board of Directors does not have a stated policy regarding diversity, although pursuant to our Corporate Governance Principles, diversity is one factor that the Nominating and Corporate Governance Committee considers when recommending directors for stockholder approval. The Board seeks experienced individuals for service who bring extensive experience in leadership, operations, finance, and engineering, particularly in areas directly applicable to the Company or its intended future endeavors.

 

EXECUTIVE OFFICERS

 

Set forth below is certain information regarding the executive officers of the Company as of the date of this Form 10-K who are not identified above as directors.

 

Name   Age   Position
Kevin Cureton   62   Chief Operating Officer

 

Mr. Cureton joined the Company in November 2012 as Vice President of Sales, Marketing and Business Development. Effective January 1, 2018, Mr. Cureton was named Chief Commercial Officer, and became the Company’s Chief Operating Officer in December 2019. His chemical industry experience has spanned more than twenty years, the majority of which has been in the personal care industry, including twelve years at AMCOL International Corporation, where he served as the founder and Managing Director of its skin care and dermatology technology business. Prior to AMCOL, he made significant contributions at Air Products, Borden, and other entities. Mr. Cureton holds a Bachelor of Science in chemical engineering from Carnegie Mellon University and an M.B.A. from the University of Chicago Booth School of Business.

 

The Board of Directors elects executive officers and such executive officers, subject to the terms of their employment agreements, serve at the discretion of the Board of Directors. Messrs. Jankowski and Cureton each have employment agreements with the Company. See Item 11 below. There are no family relationships among any of the directors or officers of the Company.

 

DELINQUENT SECTION 16(a) REPORTS

 

Section 16 of the Exchange Act requires the Company’s officers (as defined under Section 16), directors and persons who beneficially own greater than 10% of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Based solely on a review of the forms we have received, we believe that during 2023 all Section 16 filing requirements applicable to our officers, directors and 10% beneficial owners were complied with by such persons, with the exception of one late Form 4 filing by Mr. Cureton.

 

CODE OF ETHICS

 

We have adopted a Code of Business Conduct and Ethics (“Code of Ethics”) that applies to, among others, our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Ethics is posted on our Internet website www.nanophase.com under the “Investor Relations” section. In the event that we make any amendment to, or grant any waiver from, a provision of the Code of Ethics that requires disclosure under applicable SEC rules, we intend to disclose such amendment or waiver on our website. 

 

18

 

 

 Item 11. Executive Compensation

 

SUMMARY COMPENSATION TABLE

 

The following table sets forth a summary of the compensation for each of our named executive officers in U.S. dollars for the years ended December 31, 2023 and 2022.

 

Name and Principal Position   Year     Salary
($)		     Bonus
($) (1)		     Option
Awards
($) (2)		     All
Other Compensation
($) (3)		     Total
($)		  
Jess Jankowski     2023     $ 341,409     $ —     $ 5,521     $ 27,919     $ 374,849  
Chief Executive Officer     2022     $ 336,240     $ —     $ 68,898     $ 27,317     $ 418,725  
Kevin Cureton     2023     $ 294,492     $ —     $ 5,521     $ 22,704     $ 322,687  
Chief Operating Officer     2022     $ 290,000     $ —     $ 68,898     $ 23,414     $ 368,582  

 

(1) Any amounts earned during 2023 and 2022 would typically have been paid in early-to-mid 2024 and 2023, respectively. Bonus compensation is driven by Company performance against its goals as ultimately determined by the Compensation Committee of the Board of Directors (“Compensation Committee”). A set of Company-level objectives is created at the beginning of the year, focusing on total revenue, revenue growth, particular sources of revenue growth, business development achievements, cash flows and related targets, as well as a small discretionary component designed to capture items not specifically listed. Each measure has varying levels of achievement, which is reflected in the aggregate bonus measurement. The resulting bonus calculation is then applied to each individual’s bonus potential as a percentage of salary. Performance milestones were not achieved in 2023 or 2022 and related bonuses will not be paid.     
(2) The amounts in this column represent the aggregate grant date fair value of awards granted in 2023 and 2022 in accordance with FASB ASC Topic 718. See Note 10 of the notes to our financial statements contained elsewhere in this Form 10-K for a discussion of all assumptions made by us in determining the FASB ASC Topic 718 values.
(3) The amounts in this column represent 401(k) match (total for executive officers of $14,585 during 2023 and $14,839 during 2022), and the value of the Company portion of the health and life insurance including employer HSA contributions. Health insurance benefits are the same for all employees. Life insurance is provided to all employees in the amount of the employee’s annual base salary, capped at a maximum of $150,000.
   

Employment Agreements

 

Effective as of August 12, 2009, we entered into an employment agreement with Jess Jankowski in connection with his services as President and Chief Executive Officer. No term has been assigned to Mr. Jankowski’s employment agreement.

 

Pursuant to the terms of his employment agreement, Mr. Jankowski will receive an annual base salary of not less than $275,000. In addition, Mr. Jankowski will be eligible for discretionary bonuses for services to be performed as an executive officer of the Company based on performance and achieving milestones approved by our Board of Directors (the “Board”).

 

Mr. Jankowski will be eligible for such stock options and other equity compensation as the Board deems appropriate, subject to the provisions of the 2019 Equity Compensation Plan. Mr. Jankowski will also be entitled to the employee benefits made available by us generally to all of our other executive officers, subject to the terms and conditions of our employee benefit plan in effect from time to time.

 

In the event Mr. Jankowski’s employment is terminated other than for “cause” (as such term is defined in the employment agreement), Mr. Jankowski will receive a sum equal to Mr. Jankowski’s base salary in effect at the time of termination for 52 full weeks after the effective date of termination, payable in proportionate amounts on our regular pay cycle for professional employees, provided that Mr. Jankowski signs, without subsequent revocation, a separation agreement and release in a form acceptable to us. In addition, all stock options granted to Mr. Jankowski prior to termination will become fully vested and exercisable in accordance with the applicable option grant agreement and the 2019 Equity Compensation. If he is terminated for cause, or if he resigns as an employee of the Company, Mr. Jankowski will not be entitled to any severance or other benefits accruing after the term of the employment agreement and such rights will be forfeited immediately upon the end of such term.

 

19

 

 

If, within two years after the occurrence of a change in control, as defined in his employment agreement, Mr. Jankowski’s employment is terminated other than for cause, his responsibilities or annual compensation are materially reduced without his prior consent, or we cease to be publicly held (each, a “Trigger”), then, subject to Mr. Jankowski signing, without subsequently revoking, a separation agreement and release in a form acceptable to us, Mr. Jankowski will receive a sum equal to his base salary for 104 full weeks after the date the Trigger occurs. In addition, all stock options granted to Mr. Jankowski prior to the Trigger will become fully vested and exercisable in accordance with the applicable option grant agreement and the 2019 Equity Compensation Plan. 

 

 Effective as of November 28, 2012, we entered into an employment agreement with Mr. Kevin Cureton providing for an annual base salary of not less than $190,000. No term has been assigned to Mr. Cureton’s employment agreement. If Mr. Cureton is terminated other than for “cause” (as such term is defined in Mr. Cureton’s employment agreement), then, subject to Mr. Cureton signing, without revoking, a separation agreement and release in a form acceptable to us, Mr. Cureton will receive severance benefits in an amount equal to Mr. Cureton’s base salary for 26 weeks. In addition, all stock options granted to Mr. Cureton prior to termination will become fully vested and exercisable in connection with the applicable option grant agreement and the 2019 Equity Compensation Plan. A signing bonus of $25,000 was paid upon Mr. Cureton’s acceptance of employment.

 

OUTSTANDING EQUITY AWARDS AT YEAR-END

 

The following table sets forth information regarding each unexercised option held by each of our named executive officers as of December 31, 2023.

 

    Option Awards      Stock Awards  
Name   Number of Securities Underlying Unexercised Options (#) Exercisable     Number of Securities Underlying Unexercised Options (#) Unexercisable     Option Exercise Price ($)     Option Expiration Date     Number
of Shares of
Stock
That Have
Not
Vested
(#)		     Market Value of Shares of Stock That Have Not Vested ($)  
Jess Jankowski                                      
    67,450     -0-     $ 0.52     02/13/24              
    81,000     -0-     $ 0.44     02/18/25              
    69,000     -0-     $ 0.42     02/23/26              
    81,000     -0-     $ 0.68     02/21/27              
    90,000     -0-     $ 0.82     05/23/28              
    16,500     -0-     $ 0.51     05/22/29              
    90,000     -0-     $ 0.45     06/18/27              
    60,000     30,000 (1)    $ 4.17     12/28/28              
    24,000     48,000 (2)    $ 1.17     12/20/29              
    -0-     12,600 (3)   $ 0.61     12/27/30     —     —  
                             
Kevin Cureton                                      
    25,000     -0-     $ 0.52     02/13/24              
    50,000     -0-     $ 0.44     02/18/25              
    43,500     -0-     $ 0.42     02/23/26              
    50,000     -0-     $ 0.68     02/21/27              
    80,000     -0-     $ 0.82     05/23/28              
    16,500     -0-     $ 0.51     05/22/29              
    90,000     -0-     $ 0.45     06/18/27              
    60,000     30,000 (1)    $ 4.17     12/28/28              
    24,000     48,000 (2)    $ 1.17     12/20/29              
    -0-     12,600 (3)    $ 0.61     12/27/30     —     —  

  

(1) These grants expiring December 28, 2028 vest in three equal installments on December 28, 2022, 2023, and 2024.
(2) These grants expiring December 20, 2029 vest in three equal installments on December 20, 2023, 2024, and 2025.
(3) These grants expiring December 27, 2030 vest in three equal installments on December 27, 2024, 2025, and 2026.

 

20

 

 

POTENTIAL PAYMENT UPON TERMINATION OR CHANGE IN CONTROL

 

Severance Benefits. Please see discussion of severance benefits under “Employment Agreements” above.

 

Change in Control. Upon a change in control, the 2019 Equity Compensation Plan provides that: (1) vesting under all outstanding stock options will automatically accelerate and each option will become fully exercisable; (2) the restrictions and conditions on all outstanding restricted shares shall immediately lapse; and (3) the holders of performance shares will receive a payment in settlement of the performance shares, in an amount determined by the Compensation Committee, based on the target payment for the performance period and the portion of the performance period that precedes the change in control. If the Company is not the surviving entity, the successor is required to assume all unexercised options.

 

Payments. The following table quantifies the estimated payments that would be made in each covered circumstance to the following named executive officers:

 

 Name   Termination By Company Without
Cause (1)(4)		     Change In
Control (2)(4)		     Involuntary
Termination In Connection With
or
Following a
Change In
Control (3)(4)		  
Jess Jankowski   $ 341,000     $ -0-     $ 682,000  
Kevin Cureton   $ 147,000     $ -0-     $ 147,000  

 

  (1) This amount represents the severance benefits that would be received under the executive officer’s employment agreement as described had the executive officer been terminated by the Company without cause on December 31, 2023, including the value of any stock options that would have accelerated vesting in connection with such termination.

 

  (2) This amount represents an estimate of the value that would have been received under the 2019 Equity Compensation Plan had a change in control occurred as of December 31, 2023, and the executive officers benefited from an acceleration of vesting in the 2019 Equity Compensation Plan awards, as described above.

 

  (3)

This amount represents an estimate of the payments and value (including acceleration of vesting of equity-based awards) that would have been received by the executive officers had the executive officers been terminated by the Company without cause on December 31, 2023 in connection with a change in control on this date. 

     
  (4) In all three columns, for purposes of calculating the value of the acceleration of vesting of equity-based awards relating to a change in control on December 31, 2023, the closing price of our common stock as of December 31, 2023, was used. The amount represents the difference between the exercise price of any unvested options and $0.60.

 

DIRECTOR COMPENSATION

 

Upon first being elected to the Board of Directors, each director of the Company who is not an employee or consultant of the Company (an “Outside Director”) is granted stock options to purchase shares of common stock at the closing price as of the date of issuance (the fair market value). This initial option grant to an Outside Director typically vests over three years, though may accelerate upon termination from the Board of Directors.

 

In 2023, we paid quarterly compensation to the Chairman of the Board of Directors, for an annual total of $24,000. Our other two then Outside Directors, Ms. Beres and Dr. Siegel (who retired during 2023) were each paid quarterly compensation for an annual total of $18,000. Outside Director Mr. Miller was paid compensation totaling $8,120 during 2023. This compensation was made solely for services performed by each in their capacities as directors.

 

During the fourth quarter of 2023, we granted our Outside Directors stock options totaling 37,800 shares under the 2019 Equity Plan, as follows: the Chairman of the Board of Directors received stock options to purchase 12,600 shares of our common stock, while the other two of the then Outside Directors received stock options to purchase 12,600 shares of our common stock. Our current Outside Directors had the following shares of our common stock underlying stock options (both vested and unvested) outstanding as of December 31, 2022: Ms. Whitmore: 93,267 shares; Ms. Beres: 52,600 shares; and Mr. Miller: 22,600 shares.

 

        In 2005, we adopted, and our stockholders approved, the 2005 Non-Employee Director Restricted Stock Plan (the “Director Restricted Stock Plan”) which reserved 150,000 shares of our common stock to be issued to Outside Directors in the form of restricted shares. In 2005, no awards were made under the Director Restricted Stock Plan. In 2005, we also adopted the Non-Employee Director Deferred Compensation Plan (the “Director Deferred Compensation Plan”) which permits an Outside Director to defer the receipt of director fees until separation from service or the Company undergoes a change in control. We amended the Director Restricted Stock Plan in 2005 to permit an Outside Director to defer receipt of restricted stock granted under it. The deferred restricted shares are accounted for under the Director Deferred Compensation Plan and issued upon separation from service or the Company’s change in control. Under the Director Deferred Compensation Plan, the deferred fees that would have been paid in cash are deemed invested in 5-year U.S. Treasury Bonds during the deferral period. The accumulated hypothetical earnings are paid following the Outside Director’s separation from service or the Company’s change in control. The deferred fees that would have been paid as restricted shares are deemed invested in our common stock during the deferral period. The Director Deferred Compensation Plan is an unfunded, nonqualified deferred compensation arrangement. In 2009, all Outside Directors elected to defer receipts of all of the restricted shares they became entitled to under the Director Restricted Stock Plan, which was consolidated into the 2010 Equity Plan. In November 2019, the 2010 Equity Plan was consolidated in to the 2019 Equity Compensation Plan.

 

21

 

 

All Outside Directors are reimbursed for their reasonable out-of-pocket expenses incurred in attending board and committee meetings. 

 

    2023 Outside Director Compensation  
Name    Fees Earned
or Paid in
Cash
($)		     Option Awards ($) (1)     Total ($)  
R. Janet Whitmore   $ 24,000     $ 5,521     $ 29,521  
Laura M. Beres   $ 18,000     $ 5,521     $ 23,521  
Dr. Richard Siegel   $ 18,000     $ -0-     $ 18,000  
Mark E. Miller   $ 8,120     $ 15,719     $ 23,839  

 

  (1) The amounts in this column represent the aggregate grant date fair value of awards granted in 2023 in accordance with FASB ASC Topic 718. See Note 10 of the notes to our financial statements contained elsewhere in this Form 10-K for a discussion of all assumptions made by us in determining the FASB ASC Topic 718 values.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLAN

 

The following table gives information about our common stock that may be issued upon the exercise of options and rights under our 2019 Equity Compensation Plan (the “2019 Equity Plan”) and our 2010 Equity Compensation Plan (the “2010 Equity Plan”) on December 31, 2023. The 2019 Equity Plan replaced the 2010 Equity Plan.

 

   (a)  

(b) 

    (c) 
             
Plan Category   Number of securities to be issued upon exercise of outstanding options, warrants and rights    Weighted - average exercise price of outstanding options, warrants and rights   Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 
Plans Approved by Shareholders   3,526,000   $1.22    451,000 
Plans Not Approved by Shareholders   None   $—      None 

 

22

 

 

SECURITY OWNERSHIP OF MANAGEMENT 

AND PRINCIPAL STOCKHOLDERS

 

The following table sets forth, as of March 28, 2024 certain information with respect to the beneficial ownership of our common stock by (1) each person known by us to own beneficially more than 5% of the outstanding shares of common stock, (2) each of our directors, (3) each of our named executive officers and (4) all of our named executive officers and directors as a group. There were 54,801,834 shares of common stock outstanding as of March 28, 2024.

 

Name  Number of
Shares
Beneficially Owned (1)		   Percent of
Shares Beneficially Owned		 
Bradford T. Whitmore   34,884,596 (2)   63.75%
R. Janet Whitmore   1,705,978(3)   3.43%
Jess A. Jankowski   638,950(4)   1.27%
Kevin Cureton   539,821(5)   1.08%
Beres, Laura M   25,000(6)   * 
Miller, Mark E   -0-(7)   * 
All current executive officers and directors as a group (5 persons)   2,909,749(8)   5.74%

 

*Denotes beneficial ownership of less than one percent.

 

Unless otherwise indicated below, the person’s address is the same as the address for the Company.

 

  (1) Beneficial ownership is determined in accordance with the rules of the SEC. Unless otherwise indicated below, the persons in the above table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them.

 

  (2) Includes 601,410 shares of common stock held by Grace Investments, Ltd., and 30,458,322 shares held by Bradford T. Whitmore, as well as 51,454 shares held by his daughter.  Mr. Whitmore is a general partner of Grace Investments, Ltd.  In such capacities, Mr. Whitmore shares voting and investment power with respect to the shares of common stock held by the Grace Investments, Ltd..  This information is based on information reported on a Form 4 filed on December 15, 2022 with the SEC. The address of the stockholder is 5215 Old Orchard Road, Illinois 60077.

   

  (3) Includes Ms. Whitmore’s 60,666 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 26, 2024.

 

  (4) Includes Mr. Jankowski’s 578,950 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 26, 2024, as well as 1,000 shares held by his spouse.

 

  (5) Includes Mr. Cureton’s 439,000 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 26, 2024.

 

  (6)

Includes Ms. Beres’ 25,000 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 26, 2024.

 

  (7)

Includes Mr. Miller’s 0 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 26, 2024.

 

  (8) Includes all current executive officers and directors as a group’s 1,103,616 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 26, 2024.

 

 Item 13. Certain Relationships and Related Transactions, and Director Independence

 

We have engaged in a series of debt and equity transactions with Bradford T. Whitmore since January 1, 2020. One of these was for debt with a conversion provision that resulted in the issuance of common shares in May, 2021. Together with his affiliates Grace Brothers, Ltd., Grace Investments, Ltd., Mr. Whitmore beneficially owned approximately 64% of the outstanding shares of our common stock as of March 26, 2024. Mr. Whitmore is the brother of R. Janet Whitmore, who has been the Chair of the Board of Directors since November 19, 2019 and one of our directors since 2003, and who is also a stockholder. Through his affiliates Beachcorp, LLC and Strandler, LLC, Mr. Whitmore is also a substantial lender to the Company under the Business Loan Agreement, dated November 16, 2018 (see Note 3 to our financial statements included in this Annual Report on Form 10-K).

 

23

 

 

 Director Independence. The Board of Directors has determined that the following Company directors are “independent” as that term is defined in the rules and regulations of the SEC and the Nasdaq Stock Market: Ms. Beres and Mr. Miller. Though we are no longer listed on Nasdaq, our Board of Directors used the Nasdaq listing standards in making its independence determinations. Under the Nasdaq Stock Market rules, the Company would qualify as a “controlled company” because of the direct and indirect ownership of Bradford T. Whitmore. As a controlled company, the Company would be exempt from the requirements under those rules to have a majority of independent directors, to have an independent compensation committee, or to have independent director oversight of director nominations.

 

The Board of Directors has established an Audit and Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee (the “Standing Committees”). Ms. Whitmore, Ms. Beres, and Mr. Miller are members of the Standing Committees, and Ms. Whitmore serves as Chair of each committee.

 

Item 14. Principal Accounting Fees and Services

 

Audit Fees. The aggregate amount billed by our principal accountant, RSM US LLP (“RSM”), for audit services performed for the fiscal years ended December 31, 2023 and 2022 was approximately $263,000 and $237,000 respectively. Audit services include the auditing of financial statements and quarterly reviews.

 

 Audit Related Fees. There were $26,000 and $0 in audit related fees billed by RSM for the years ended December 31, 2023 and 2022, respectively, which may include costs incurred for reviews of registration statements, assistance with Staff comment letters, and consultation on various accounting matters in support of our financial statements.

 

 Tax Fees. There were no fees billed by our principal accountant for tax related services for the fiscal years ended December 31, 2023 and 2022.

 

All Other Fees. Other than those fees described above, during the fiscal years ended December 31, 2023 and 2022, there were no other fees billed for services performed by our principal accountant.

 

All of the fees described above were approved by our Audit and Finance Committee.

 

Audit and Finance Committee Pre-Approval Policies and Procedures. Our Audit and Finance Committee pre-approves the audit and non-audit services performed by RSM, our principal accountants, in order to assure that the provision of such services does not impair RSM’s independence. Unless a type of service to be provided by RSM has received general pre-approval, it will require specific pre-approval by the Audit and Finance Committee. In addition, any proposed services exceeding pre-approval cost levels or budgeted amounts will require specific pre-approval by the Audit and Finance Committee.

 

The term of any pre-approval is 12 months from the date of pre-approval, unless the Audit and Finance Committee specifically provides for a different period. The Audit and Finance Committee will periodically revise the list of pre-approved services, based on subsequent determinations, and has delegated pre-approval authority to the Chairman of the Audit and Finance Committee. In the event the Chairman exercises such delegated authority, he shall report such pre-approval decisions to the Audit and Finance Committee at its next scheduled meeting. The Audit and Finance Committee does not delegate its responsibilities to pre-approve services performed by the independent auditor to management.

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a) The following documents are filed as part of this Form 10-K:

 

  1. The following financial statements of the Company, with the report of independent registered public accounting firm, are filed as part of this Form 10-K:

 

Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2023 and 2022
Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022
Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022
Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022

 

Notes to Consolidated Financial Statements

 

  2. A list of exhibits required to be filed as part of this Form 10-K is set forth in the Exhibit Index beginning on page E-1 of this Form 10-K, and is incorporated herein by reference.


 

24

 


 

Item 16. Form 10-K Summary

 

NONE. 

 

25

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

  Page
   
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 49) F-2
   
Consolidated Balance Sheets as of December 31, 2023 and 2022 F-4
   
Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 F-5
   
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023 and 2022 F-6
   
Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 F-7
   
Notes to the Consolidated Financial Statements F-8

  

F-1

 

   

Report of Independent Registered Public Accounting Firm

 

 

To the Stockholders and the Board of Directors of Nanophase Technologies Corporation

 

 

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Nanophase Technologies Corporation and its subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

F-2

 

 

Contingencies

 

The Company has contingent liabilities related to litigation and claims that arise in the normal course of business. The Company accrues for contingent liabilities when management determines it is probable that a liability has been incurred and the amount can be reasonably estimated. This determination requires significant judgment by management.

 

As described in Notes 12 and 14 to the financial statements, the Company has exclusive supply agreements with BASF Corporation (BASF), its largest customer, and in 2022, BASF filed a complaint against the Company alleging that it had breached the supply agreement. Discovery in that litigation is ongoing. Management believes at this time that the allegations of BASF’s complaint are without merit and are unsupported by the terms of the agreement and governing law. Certain counterclaims and appeals have occurred and legal proceedings are ongoing. A contingent liability was not recorded as of December 31, 2023, and an estimated range of possible losses is not disclosed in the financial statements, as management has determined an unfavorable outcome is not probable nor is a range of loss reasonably estimable at this time.

 

In assessing whether the Company should accrue a liability in its financial statements as a result of the lawsuit, as well as evaluating what other risks and uncertainties may exist, the Company considered various factors, including the legal and factual circumstances of the case, the trial records, the current status of the proceedings, applicable law and the views of legal counsel. While the Company believes that the ultimate resolution of this matter will not have a material impact on the Company’s financial statements, the outcome of litigation is inherently uncertain and the final resolution of this matter may result in expense or business consequences to the Company in excess of management’s expectations.

 

We identified this potential contingent liability and disclosure related to the BASF litigation as a critical audit matter because evaluating the likelihood of potential outcomes of the BASF lawsuit involves significant judgment by management. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the Company’s assertion that a loss from this litigation is not probable and reasonably estimable as of December 31, 2023.

 

Our audit procedures related to the potential contingent liability and disclosure of the BASF lawsuit included the following, among others:

 

●We held discussions with management to determine the status of the case and to understand the basis for the Company’s conclusion that the loss from the case is not probable and reasonably estimable as of December 31, 2023.

 

●We performed tests of details on legal expense accounts, including inspection of third-party invoices for legal services incurred.

 

●We obtained and evaluated an audit response letter directly from the Company’s external counsel involved in the case confirming the facts and circumstances of the proceedings, and to consider any professional judgments on the outcome of the matter.

 

●We evaluated the accuracy and completeness of the Company’s disclosures in the December 31, 2023 financial statements by comparing the disclosures to the legal letters from external counsel and analysis of the case.

 

●We performed subsequent event inquiries of management and external counsel to reasonably coincide with the date of our report.

 

/s/ RSM US LLP

 

We have served as the Company’s auditor since 2001.

 

Milwaukee, Wisconsin

March 28, 2024

 

F-3

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED BALANCE SHEETS

 

           
   As of December 31, 
   2023   2022 
   (in thousands except share and
per share data)		 
ASSETS        
Current assets:          
Cash  $1,722   $2,186 
Trade accounts receivable   3,692    4,873 
Allowance for Credit Losses   (225)   (139)
    Trade accounts receivable, net   3,467    4,734 
Inventories, net   10,031    8,839 
Prepaid expenses and other current assets   1,082    866 
Total current assets   16,302    16,625 
           
Equipment and leasehold improvements, net   8,668    7,949 
Operating leases, right of use   7,907    8,978 
Other assets, net   4    6 
Total assets  $32,881   $33,558 
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities:          
Line of credit – accounts receivable, related party  $2,810   $4,282 
Current portion of debt, related party   2,000    —   
Current portion of operating lease obligations   1,297    —   
Accounts payable   6,260    6,363 
Current portion of deferred revenue   2,353    2,167 
Accrued expenses   869    1,023 
Total current liabilities   15,589    13,835 
           
Long-term portion of operating lease obligations   9,152    9,823 
Long-term line of credit – inventory, related party   5,000    3,000 
Long-term debt, related party   1,000    1,000 
Long-term portion of deferred revenue   —      21 
Asset retirement obligations   238    230 
Total long-term liabilities   15,390    14,074 
           
Contingent liabilities   —      —   
Stockholders’ equity:          
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding   —      —   
Common stock, $.01 par value, 60,000,000 shares authorized; 49,627,254 and 49,320,680 shares issued and outstanding on December 31, 2023 and December 31, 2022, respectively   496    493 
Additional paid-in capital   106,069    105,226 
Accumulated deficit   (104,663)   (100,070)
Total stockholders’ equity   1,902    5,649 
Total liabilities and stockholders’ equity  $32,881   $33,558 

 

 (See accompanying Notes to Consolidated Financial Statements)

 

F-4

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

           
   Years ended December 31, 
   2023   2022 
   (in thousands except share and
per share data)		 
Revenue:        
Product revenue  $36,641   $36,731 
Other revenue   656    586 
Total revenue   37,297    37,317 
           
Operating expense:          
Cost of revenue   29,472    28,957 
Gross profit   7,825    8,360 
           
Research and development expense   3,837    3,037 
Selling, general and administrative expense   7,534    7,581 
Loss from operations   (3,546)   (2,258)
Interest expense   (838)   (382)
Loss before provision (benefit) for income taxes   (4,384)   (2,640)
Provision (benefit) for income taxes   6    (17)
           
Net loss  $(4,390)  $(2,623)
           
Net loss per share-basic  $(0.09)  $(0.05)
           
Weighted average number of basic common shares outstanding   49,556,305    49,117,000 
           
Net loss per share-diluted  $(0.09)  $(0.05)
           
Weighted average number of diluted common shares outstanding   49,556,305    49,117,000 

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-5

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 (in thousands except share data)

 

                                          
    Preferred Stock    Common Stock    Additional
Paid-in
Capital		    Accumulated     
Description   Shares    Amount    Shares    Amount    Capital    Deficit     Total 
Balance on December 31, 2021   —     $—      48,893,573   $489   $104,423   $(97,447)  $7,465 
Issuances of shares and stock option exercises   —      —      427,107   $4   $178    —      182 
Stock-based compensation   —      —      —      —      625    —      625 
Net loss for the year ended December 31, 2022   —      —      —      —      —      (2,623)   (2,623)
Balance on December 31, 2022   —     $—      49,320,680   $493   $105,226   $(100,070)  $5,649 
Cumulative effect of accounting changes related to expected credit losses   —      —      —      —      —      (203)   (203)
Issuances of shares and stock option exercises   —      —      306,574    3    151    —      154 
Stock-based compensation   —      —      —      —      773    —      773 
Rights offering expense   —      —      —      —      (81)   —      (81)
Net loss for the year ended December 31, 2023   —      —      —      —      —      (4,390)   (4,390)
Balance on December 31, 2023   —     $—      49,627,254   $496   $106,069   $(104,663)  $1,902 

  

(See accompanying Notes to Consolidated Financial Statements)

 

F-6

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

           
   Years Ended December 31, 
   2023   2022 
   (in thousands) 
Operating activities:          
Net loss:  $(4,390)  $(2,623)
     Adjustments to reconcile net loss to cash used in operating activities:          
     Depreciation and amortization   742    567 
     Share-based compensation   773    625 
     Changes in assets and liabilities related to operations:          
     Trade accounts receivable   1,064    (797)
     Inventories   (1,192)   (2,744)
     Prepaid expenses and other assets   (216)   44 
     Accounts payable   (503)   1,826 
     Deferred revenue   165    744 
     Accrued expenses   (146)   77 
     Net changes in right-of-use assets and lease liabilities – operating   1,697    631 
Net cash used in operating activities   (2,006)   (1,650)
           
Investing activities:          
Acquisition of equipment and leasehold improvements   (1,051)   (2,823)
Net cash used in investing activities   (1,051)   (2,823)
           
Financing activities:          
Principal payment on finance leases   —      (111)
(Payments) proceeds to line of credit – accounts receivable, related party   (1,472)   2,931
Proceeds from line of credit – inventory, related party   2,000    3,000 
Payments to term loans, related party   (1,346)   —   
Proceeds from term loans, related party   3,338    —   
Proceeds from exercise of stock options   73    182 
Net cash provided by financing activities   2,593    6,002 
(Decrease) increase in cash   (464)   1,529 
Cash at beginning of period   2,186    657 
Cash at end of period  $1,722   $2,186 
           
Supplemental cash flow information:          
Cash paid for interest  $752   $333 
           
Supplemental non-cash investing and financing activity:          
Accounts payable incurred for the purchase of equipment and leasehold improvements  $400   $971 
Right-of-use asset obtained in exchange for a lease liability   182    —   

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-7

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(In thousands, except share and per share data or as otherwise noted herein)

 

(1) Description of Business

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably COVID-19, has become a critical use of our technology.  Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category.   

 

 We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.    

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 

 

The Company recorded a net loss and negative cash flow from operations in 2023.  In addition, the company outstanding debt increased which left little borrowing capacity available. In early March 2024 the company completed an equity financing providing an additional $6 million in funds. For additional information see Note 9. Management believes that current liquidity and available borrowing capacity are sufficient to fund operations and there is not substantial doubt regarding the Company's ability to continue as a going concern.

 

 

(2) Summary of Significant Accounting Policies

 

Use of Estimates and Risks and Uncertainties

 

The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.

 

F-8

 

 

Cash

 

The Cash balance on December 31, 2023 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.

 

 Trade Accounts Receivable

 

Trade accounts receivable are carried at original invoice amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.

 

On January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.

 

This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.

 Allowance for Credit Losses

   2023   2022 
Balance, beginning  $139   $0 
Change in credit loss   86    139 
Balance, ending  $225   $139 

 

 

Inventories

 

Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.

 

Equipment and Leasehold Improvements

 

Equipment is stated at cost and is being depreciated over its estimated useful life (3-20 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (3-7 years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (7-10 years) using the straight-line method.

 

Long Lived Assets

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented. 

 

Deferred Revenue

 

The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $2,353 in deferred revenue reported in 2023, 97% related to prepayments received from certain customers per Company policy, and the remaining 3% related to prepayments from a product development agreement with a personal care ingredient customer.

 

F-9

 

 

Asset Retirement Obligations

 

In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, Asset Retirement Obligations, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.

 

Activity in the asset retirement obligation account for the years ended December 31, is as follows:

 

   2023   2022 
Balance, beginning  $230   $222 
Accretion of liability due to passage of time   8    8 
Amortization of asset due to passage of time   —      —   
Balance, ending  $238   $230 

 

Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

Our financial instruments include cash, cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.

 

There were no financial instruments adjusted to fair value on December 31, 2023 and 2022.

 

Product Revenue

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2023 no volume rebates were recorded because the customers did not meet required volumes. In 2022 the company recorded $557 in volume rebates as a reduction in revenue.

 

As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer.

 

Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows:

 

   Accounts Receivable   Contract Assets   Contract Liabilities 
2021  $3,937   $179   $1,444 
2022   4,734    —      2,188 
2023   3,467    —      2,353 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $2,084 and $667 for the years ended December 31, 2023, and 2022, respectively. 

 

F-10

 

 

Other Revenue

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $656 and $217 for the years ended December 31, 2023 and 2022, respectively.

 

Research and Development Expenses

 

Research and development expenses are recognized as expense when incurred.

 

Income Taxes

 

We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2023, and 2022, we had no liability for unrecognized tax benefits.

 

Earnings Per Share

 

Options to purchase approximately 889,000 shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period.  Options to purchase approximately 2,051,000 shares of common stock that were outstanding as of December 31, 2022 were not included in the computation of earnings per share for the year ended December 31, 2022.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

             
   Years Ended December 31, 
   2023   2022 
Numerator: (in Thousands)        
Net loss  $(4,390)  $(2,623)
           
Denominator:          
Weighted average number of basic common shares outstanding   49,556,305    49,117,000 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   —      —   
Weighted average number of diluted common shares outstanding   49,556,305    49,117,000 
           
Basic earnings per common share:          
Net loss per share – basic  $(0.09)  $(0.05)
Diluted earnings per common share:          
Net loss per share – diluted  $(0.09)  $(0.05)

 

F-11

 

 

Recently Adopted Pronouncements

 

 In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. 

 

On January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.

 

This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.

 

Recently Issued Pronouncements

 

 On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, Improvements to Income Tax Disclosures, applies to all entities subject to income taxes. This new requirement will be effective for Nanophase Technologies for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.

 

(3) Related Party Notes and Lines of Credit

 

Notes and lines of credit consist of the following:

 

       As of December 31, 
       2023   2022 
   Rate   Available  

Outstanding 

Balance 

   Available  

Outstanding 

Balance 

 
Libertyville Bank & Trust (1)   9.50%  $30   $—     $30   $—   
Libertyville Bank & Trust (2)   9.50%   500    —      500    —   
Beachcorp, LLC (3) (4)   9.25%   3,298    2,810    4,392    4,282 
Beachcorp, LLC (3) (5)   9.25%   5,200    5,000    4,000    3,000 
Strandler, LLC   (3) (6)   9.25%   1,000    1,000    1,000    1,000 
Strandler, LLC  (7)   9.25%   2,000    2,000    n/a    n/a 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.

 

F-12

 

 
2)The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Interest on drawn balances was at the prime rate plus 1%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2024. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000 to $2,750.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750 to $4,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000 to $6,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500 to $1,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.

 

4)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On November 13, 2023 the Company entered into a First Amendment to the A&R Loan Agreement extending the maturity of the A/R Revolver Facility to March 31, 2025.

 

5)On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024. On November 13, 2023 the company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%, and it now matures on March 31, 2025.

 

6)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On November 13, 2023 the Company entered into the First Amendment To the New Term Loan Agreement with Strandler, LLC, which extended the maturity of the New Term Loan Agreement to March 31, 2025.

 

7)On November 13, 2023 the Company entered into a new Promissory Note (“Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is $2,000. The interest rate for the Bridge Note is at the prime rate plus 0.75%, and it matures on May 13, 2024.

 

As part of the March 1, 2024 Securities Purchase Agreement the maturity dates of the Term Loan, A/R Revolver Facility and Inventory Facility were extended to October 1, 2025 from March 31, 2025. No other changes were made to the debt agreements. 

 

The Company classifies the line of credit – accounts receivable as current because we are required to pay back the borrowings as cash is received from our customers. The company’s remaining debt is presented within the Consolidated Balance Sheet as of December 31, 2023, and 2022 in accordance with the maturity dates in the financing agreements. 

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank & Trust. 

 

Related party interest expense consists of the following:

 

   Twelve Months Ended December 31, 
   2023   2022 
Interest expense, related parties  $770   $356 

 

Accrued interest consists of the following:

 

   As of December 31, 
   2023   2022 
Accrued interest expense, related parties  $81   $49 

 

Outstanding balances associated with related parties are as follows:

 

   As of December 31, 
   2023   2022 
Beachcorp, LLC  $7,810   $7,282 
Strandler, LLC   3,000    1,000 

 

(4) Inventories  

 

Inventories consist of the following:

 

            
   As of December 31, 
   2023   2022 
Raw materials  $8,524   $7,298 
Finished goods   2,184    2,041 
Inventory reserve   (677)   (500) 
      Total Inventories, net   10,031    8,839 

 

(5)

 

Equipment and Leasehold Improvements

 

Equipment and leasehold improvements consist of the following:  

Equipment and leasehold improvements consist of the following:  

   As of December 31, 
   2023   2022 
Machinery and equipment  $23,339   $19,899 
Office equipment   1,014    1,014 
Office furniture   126    110 
Leasehold improvements   5,157    5,140 
Construction in progress   931    2,952 
    30,567    29,115 
Less: Accumulated depreciation and amortization   (21,899)   (21,166)
   $8,668   $7,949 

 

Depreciation expense was $732 and $557, for the years ended December 31, 2023 and 2022, respectively.

 

F-13

 

 

(6) Lease Commitments

 

The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. During the first calendar year of our newly leased building, we have subleased a portion of the unused floorspace on a temporary basis. This sublease may convert to a month-to-month lease upon expiration.

 

As of December 31, 2023, the right-of-use (ROU) asset had a balance of $7,907 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $1,297 and $9,152, respectively. These amounts are included in the “Current portion of operating lease obligations” and “Long-term portion of operating lease obligations” line items of these consolidated financial statements. As of December 31, 2022, the ROU asset had a balance of $8,978 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $0 and $9,823, respectively.  The $0 in current lease liability stems from expected payments from the lessor of the Bolingbrook facility reimbursing the Company for tenant improvement allowances in the amount of $1,957 over the subsequent twelve months. As a result, the total lease liability was reduced by the expected payment, and the net effect of reimbursements received, and cash paid for leases in 2023 results in net lease payments of $97. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

 

The office leases contain variable lease payments which consist primarily of taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to combine lease and non-lease components for building leases.

 

Quantitative information regarding the Company’s leases is as follows:

 

   Twelve Months Ended December 31, 2023   Twelve Months Ended December 31, 2022 
Components of lease cost          
Finance lease cost components:          
Amortization of finance lease assets  $—     $33 
Interest on finance lease liabilities   —      4 
Total finance lease costs   —      37 
Operating lease cost components:          
Operating lease cost   1,881    2,068 
Variable lease cost   581    536 
Short-term lease cost   112    138 
Sub-lease income   (786)   (689)
Total operating lease costs   1,788    2,053 
Total lease cost  $1,788   $2,090 

 

Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022:

 

    2023     2022  
Cash paid for amounts included in the measurement of lease liabilities:            
Operating cash outflow from operating leases   $ 172     $ 1,433  
                 
Lease liabilities arising from obtaining right-of-use assets   $ 182     $ 12  
Early termination of operating lease     —       73  
Reduction in right of use asset due to remeasurement     —       (1,793 )
Reduction in lease liability due to remeasurement     —       (1,898 )
Weighted-average remaining lease term-operating leases (in years)     7.9       9.6  
Weighted-average discount rate-operating leases     7.1 %     7.6 %

  

F-14

 

 

The future maturities of the Company’s operating leases as of December 31, 2023 are as follows:

 

2024   $1,968 
2025    1,483 
2026    1,481 
2027    1,520 
2028    1,549 
Thereafter    5,613 
Total payments   $13,614 
Less amounts representing interest    (3,165)
Total minimum payments required   $10,449 

 

Nanophase Technologies subleases a portion of a leased industrial building that is used primarily for the storage of furniture, equipment and displays used for retail sales. The arrangement is not with a related party.

 

Payments received by the Company for this sublease are comprised of two components, which include base rent and Common Area Maintenance (CAM) charges. While the base rent is fixed, the CAM charges are indexed directly to the Master Lease and are expected to be adjusted periodically as actual costs are incurred. However, the executed sublease agreement specifically itemizes these costs with a provision that informs the sublessee that the CAM charges will be adjusted (up or down) based on actual amounts once this information becomes known. As such, the nature of the charges is more closely representative of a fixed payment (an “in-substance fixed” charge) with the adjustments occurring simply to “true up” the listed CAM charges once actual charges from the head lessor become known. As sublessor, Nanophase Technologies has elected the practical expedient to not separate lease and nonlease components in disclosing future undiscounted cashflows and treats the combined components as a single lease component.

 

The sublease arrangement automatically renews following expiration of the initial term on May 31, 2025, with a one-year notice required to terminate the lease. As of the issuance of these financial statements the sublessee has not yet provided notice of their intent to renew or terminate said arrangement.

 

The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance.

 

Months        
   For the Year 
Months  2024   2025 
January - May  $124,015   $128,640 
June - December   173,621    — 
           
Total  $297,636   $128,640 

 

 

(7) Accrued Expenses

 

Accrued expenses consist of the following:

 

           
    As of December 31,  
    2023     2022  
Accrued payroll and related expenses   $ 255     $ 288  
Accrued accounts payable     128       403  
Tenant security deposit / advance rent     —       61  
Other     486       271  
 Total   $ 869     $ 1,023  

 

(8)Income Taxes

 

Our net income tax provision, including both current and deferred, related to U.S. federal and state income taxes, is $6. Our current federal and deferred tax expenses are zero.

 

F-15

 

 

A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows:

 

   2023   2022 
Income tax credit at statutory rates  $(921)  $(551)
Over/Under Accrual of Income Taxes   (3)   (17)
Nondeductible Expenses   23    —   
Record Tax Credits   (118)   —   
Permanent tax deduction stock options exercised   (63)   (273)
State income tax, net of federal benefits   (165)   (124)
Expiration of NOL & credits   1,492    1,149 
Effect of change in deferred tax rate   45    69 
Expiration of stock options   60    75 
Other   —      2 
Change in valuation allowance   (344)   (347)
   $6    (17)

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

 

         
   As of December 31, 
   2023   2022 
Deferred tax liabilities:          
  Excess tax depreciation  $(477)   (253)
ASC 892 Operating Lease Asset   (1,975)    —   
     Total deferred tax liabilities   (2,452)   (253)
           
Deferred tax assets:          
  Net operating loss carryforwards  $12,020   $13,416 
  179 Carryforwards   245    117 
  163(j) Business interest limitation carryforwards   302    98 
  Deferred revenue   —      202 
  Inventory and other allowances   239    177 
  Excess (tax) book depreciation   —      —   
  Excess (tax) book amortization   60    59 
  174 research & experimental expenditures   902    480 
  Share-based compensation   530    394 
  Tax Credits   118    —   
ASC 892 Operating Lease Liability    2,610   —   
  Other accrued costs   13    238 
     Total deferred tax assets   17,039    15,181 
           
  Less: Valuation allowance   (14,587)   (14,928)
Deferred income taxes  $—     $—   

 

The valuation allowance decreased approximately $0.3 million and $0.3 million for the years ended December 31, 2023 and 2022, respectively (net of approximately $7.1 million and $5.5 million for the years ended December 31, 2023 and 2022, respectively, for expiring net operating loss carryforwards and credits) due principally to the change in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and our public offering of common stock, may subject us to annual limitations on the utilization of our net operating loss carryforward. As of December 31, 2023, it has been determined that we are not subject to annual limitations on the utilization of our net operating loss carryforward.

 

We have federal net operating loss carryforwards for tax purposes of approximately $50 million on December 31, 2023. $44 million expire between 2024 and 2037. We have section 179 carryforwards of approximately $0.2M at December 31, 2023. All net operating loss carryforwards generated after January 1, 2018 do not expire. Therefore, $5.6 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $21.3 million on December 31, 2023. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2039.

 

F-16

 

 

(9) 

Capital Stock 

 

As of December 31, 2023, and 2022, we had 24,088 authorized but unissued shares of preferred stock.

 

Pursuant to the Securities Purchase Agreement executed on March 1, 2024, the Company issued to Strandler 15,000 shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”)at a purchase price per share of $400, for total consideration of $6,000,000, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”).

 

(10) Stock Options and Stock Grants

 

We have entered into stock option agreements with certain officers, employees and directors. The stock options granted prior to the adoption of the 2019 Equity Compensation Plan (the “2019 Plan”) on November 19, 2019 generally expire ten years from the date of grant. Future options to be granted under the 2019 Plan will expire seven years from the date of grant.

 

Employee Stock Options

 

We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. 

 

         
  

Years ended  

December 31, 

 
   2023   2022 
Share-based compensation expense  $773   $625 
Remaining unrecognized compensation expense  $1,118    1,732 
Remaining weighted average-period, expense recognition (years)   1.8    2.5 

 

We use the Black-Scholes option pricing model to determine the fair value of stock-based compensation. The Black-Scholes model requires us to make several assumptions, including the estimated length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of our common stock price over the expected term, and estimated forfeitures. Expected price volatility is based on the daily market rate changes of our stock. The active shares granted prior to fiscal 2020 had a contractual life of 10 years as dictated by the 2010 Plan. The Black-Scholes model also requires a risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of the grant, and the dividend yield on our common stock, which is assumed to be zero since we do not pay dividends and have no current plans to do so in the future. Changes in these assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related expense recognized on the statement of operations. We recognize stock-based compensation expense on a straight-line basis over the requisite service period. 

 

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

 

   Years Ended December 31, 
   2023   2022 
Weighted-average risk-free interest rates:   3.8%   3.5%
           
Dividend yield:   0%   0%
           
Weighted-average expected life (years) of the option:   4    5 
           
Weighted-average expected stock price volatility:   93%   116%
           
Weighted-average fair value of the options granted:  $0.50   $0.97 

  

F-17

 

 

Additional disclosures for options granted for all years presented:

 

   Years Ended December 31, 
   2023   2022 
Vesting period (years) of shares granted in period   3    3 
           
Contractual life (years) of shares granted in period   7    7 
           
Estimated forfeitures   8%   4%

 

The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023:

 

                Weighted        
          Weighted     Average     Aggregate  
          Average     Remaining     Intrinsic  
    Shares     Exercise Price     Contractual     Value  
Options   (Rounded)     per Share     Term (Years)     (000s)  
Outstanding on January 1, 2023     3,443,661     $ 1.33       4.9       1,230  
                                 
Granted     668,200     $ 0.68                  
Exercised     (294,074 )   $ 0.50                  
Forfeited or expired     (291,821 )   $ 1.92                  
                                 
Outstanding on December 31, 2023     3,525,966     $ 1.22       4.2     $ 160  
Exercisable on December 31, 2023     2,334,458     $ 1.15       3.2     $ 160  
                                 
Shares available for grant     450,900                          

 

The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 on the last business day for the year ended December 31, 2023.

 

         
  

Years ended  

December 31, 

 
   2023   2022 
Shares exercised   294,074    414,455 
Total intrinsic value  $195   $942 
Cash received  $154   $182 

 

Based on our election of the “with and without” approach, no realized tax benefits from stock options were recognized for the years ended December 31, 2023 and 2022.

 

 

(11) 401(k) Profit-Sharing Plan

 

We have a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. Contributions made in 2023 and 2022 aggregated to $191 and $153, respectively.

 

F-18

 

 

(12) Significant Customers

 

We had three significant customers for the year ended December 31, 2023.

 

       For the years ended 
       December 31, 
Customer #   Product Category  2023   2022 
1   Personal Care Ingredients   25%   30%
2   Solésence®   17%   17%
3   Solésence®   15%   15%
               
    Total   57%   62%

 

 Accounts receivable balances for these three customers were approximately:

 

       For the years ended
December 31,		 
Customer #   Product Category  2023   2022 
1   Personal Care Ingredients  $—     $1,082 
2   Solésence®   1,288    438 
3   Solésence®   864    683 
               
    Total  $2,152   $2,202 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.

 

F-19

 

  

(13) Business Segmentation and Geographical Distribution

 

Revenue from international sources approximated $2,918 and $1,971 for the years ended December 31, 2023 and 2022, respectively. As part of our revenue from international sources, we recognized approximately $1,664 and $1,236 in product revenue from German companies, in the aggregate, for the years ended December 31, 2023 and 2022, respectively.

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues for 2023 and 2022 by category are as follows:

 

  

For the years ended  

December 31 

 
Product Category  2023   2022 
Solésence  $25,211   $23,111 
Personal Care Ingredients   9,277    11,121 
Advanced Materials   2,809    3,085 
Total Sales  $37,297   $37,317 

 

(14) Commitments and Contingencies 

 

On August 9, 2022, BASF filed a complaint against Nanophase in New Jersey state court (the “New Jersey Complaint”), alleging that Nanophase had breached the 1999 Zinc Oxide Supply Agreement (the “Agreement”). BASF alleges several issues, the one having the biggest potential impact on Nanophase being a claim that our sales through Solésence violate the exclusivity provision of the Agreement. BASF seeks an unspecified amount of damages, a permanent injunction enjoining sales to any party (other than BASF) of a broad range of zinc oxide products that BASF contends are within the scope of the exclusivity provision, counsel fees and litigation expenses. On September 7, 2022, Nanophase filed a Complaint for Declaratory Judgement in Illinois state court (the “Illinois Complaint”), asking for a declaration that contrary to BASF’s allegation, the exclusivity provision of the Agreement does not apply to all products containing zinc oxide as an ingredient for uses designated under the Agreement, nor does the exclusivity provision prohibit Nanophase’s sales of Solésence products containing zinc oxide as an ingredient. Both companies filed Motions to Dismiss (MTD) the other’s respective complaint. Nanophase’s MTD BASF’s New Jersey Complaint was denied on procedural grounds on February 10, 2023, with the New Jersey court superficially noting that it did not consider whether BASF could prove its claims. On February 28, 2023, Nanophase filed its answer to BASF’s New Jersey Complaint, denying all wrongdoing and, as mandated by New Jersey procedural requirements, counterclaims including a request for a declaration similar to that Nanophase sought in its Illinois Complaint and a claim alleging that BASF had breached its obligations under the Agreement to buy from Nanophase at least 70% of BASF’s zinc oxide requirements for use in the Field under the Agreement. BASF subsequently moved to dismiss Nanophase’s counterclaims, arguing that the declaratory judgment claim duplicated BASF’s claim for Nanophase’s alleged breach of contract and Nanophase’s claim for BASF’s breach of the zinc oxide purchase requirement was procedurally insufficient. On October 6, 2023, the New Jersey court: denied BASF’s motion to dismiss Nanophase’s declaratory judgment claim, finding that it did not duplicate BASF’s breach of contract claim and that litigating that claim would not provide Nanophase with complete relief as to the exclusivity issues raised in the counterclaim; and granted BASF’s motion to dismiss Nanophase’s claim for BASF’s breach of its zinc oxide purchase requirement on procedural grounds. On March 16, 2023, the Illinois court granted BASF’s MTD Nanophase’s Illinois Complaint, finding it duplicative of the New Jersey litigation. Discovery in the New Jersy litigation is ongoing. Management believes at this time that the allegations of BASF’s complaint are without merit and are unsupported by the terms of the Agreement and governing law. Per ASC 450 for the period ending December 31, 2023, an estimated contingent loss was not recorded, and an estimated range of loss is not disclosed as the outcome is not probable at this time and nor is a range of loss estimable.   

    

F-20

 

 

(15) Subsequent Event

 

On March 1, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”), between the Company and Strandler, LLC (“Strandler”).

 

Pursuant to the Purchase Agreement, the Company issued to Strandler 15,000 shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”) at a purchase price per share of $400, for total consideration of $6,000,000, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”).

 

Under the Purchase Agreement, the Company granted Strandler customary registration rights with respect to shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), it may receive in connection with any conversion of Series X Preferred Stock into Common Stock, as described below. For so long as any amount of Preferred Stock is outstanding, the Purchase Agreement also (i) prevents the Company from paying any dividend on any shares of the Company’s capital stock (other than dividends consisting solely of Common Stock or rights to purchase Common Stock), (ii) prevents the Company from repurchasing any Common Stock, and (iii) subject to certain permitted exceptions, restricts the Company’s ability to permit any lien or other encumbrance on Company assets.

 

At any time and from time to time, in whole or in part, following the Company properly filing an amendment (the “Certificate Amendment”) to its Certificate of Incorporation to increase the number of authorized shares of its Common Stock from 60,000,000 to 95,000,000, each share of Series X Preferred Stock is convertible, at the option of the holder, into 1,000 shares of Common Stock at no additional cost. If the Company has not properly filed, upon shareholder approval, the Certificate Amendment on or before August 1, 2024, then each share of Series X Preferred Stock will be redeemable at the holder’s option, in whole or in part, without penalty or premium, at a redemption price equal to $420 per share (each, a “Redemption”). If the Company fails to fully pay any Redemption within five days of receiving notice, all unpaid amounts will bear interest at a rate of 10% per annum. In addition, in the event of a Change in Control (as defined in the Certificate of Designations) of the Company, each share of the Series X Preferred Stock is redeemable at the option of the holder, without penalty or premium, at a redemption price equal to $420 per share. Upon any conversion of Preferred Stock into Common Stock by Strandler, Strandler is required to hold the Common Stock received in the conversion for a period of 12 months.

 

Holders of Series X Preferred Stock (i) are not entitled to receive dividends, subject to customary anti-dilution protections, (ii) have no voting rights, and (iii)receive a liquidation preference of $400 per share. The Series X Preferred Stock ranks senior in right of payment to all securities designated as junior securities, including Common Stock.

 

In connection with the Company’s entry into the Purchase Agreement, the Company also entered into (i) a Second Amendment to Business Loan Agreement (the “Term Loan Agreement Amendment”) with Strandler, LLC, (ii) a Second Amendment to Business Loan Agreement (the “A&R Loan Agreement Amendment”) with Beachcorp, LLC, which is also an affiliate of our controlling shareholder, Bradford T. Whitmore (“Beachcorp”), and (iii) a Second Amendment to Business Loan Agreement with Beachcorp (the “Revolving Loan Agreement Amendment” and together with the Term Loan Agreement Amendment and the A&R Term Loan Agreement Amendment, the “Loan Agreement Amendments”). The Loan Agreement Amendments extend the maturity date under each respective loan agreement from March 31, 2025 to October 1, 2025.

 

F-21

 

 

EXHIBIT INDEX

 

Exhibit
Number

 

2.1 Plan and Agreement of Merger dated as of November 25, 1997 by and between the Company and its Illinois predecessor, incorporated by reference to Exhibit 2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1997 (the “1997 10-K”), SEC File No. 000-22333.

 

3(i).1 Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the 1997 10-K, SEC File No. 000-22333.

 

3(i).2 First Amendment to the Certificate of Incorporation of the Company dated July 27, 2006, incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed July 27, 2006, SEC File No. 000-22333.

   

3(i).3 Second Amendment to the Certificate of Incorporation of the Company dated August 23, 2010, incorporated by reference to Exhibit A of the Company’s Definitive Proxy Statement on Schedule 14A filed July 9, 2010, SEC File No. 000-22333.

 

3(i).4 Third Amendment to the Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed August 29, 2016.

 

3(i).5 Fourth Amendment to the Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed November 22, 2019.

 

3(i).6 Fifth Amendment to the Certificate of Incorporation of the Company.

 

3(ii).1 By-Laws of the Company, incorporated by reference to Exhibit 3.2 to the 1997 10-K, SEC File No. 000-22333.

 

4.1 Specimen stock certificate representing common stock, incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1/A filed November 4, 1997 (File No. 333-36937) (the “Form S-1/A”).

 

4.2 Form of Warrants, incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1 filed October 1, 1997 (File No. 333-36937) (the “IPO S-1”).

 

4.3 Certificate of Designations of Series A Junior Participating Preferred Stock, incorporated by reference to Exhibit 4.4 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1998, SEC File No. 000-22333.

 

4.4 Stock Purchase Agreement dated August 25, 2006 between the Company and Rohm and Haas Electronic Materials CMP Holdings, Inc., incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed August 28, 2006, SEC File No. 000-22333.

 

4.5 Registration Rights Agreement dated August 25, 2006 between the Company and Rohm and Haas Electronic Materials CMP Holdings, Inc., incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K filed August 28, 2006, SEC File No. 000-22333.

 

4.6 Common Stock Purchase Agreement, dated February 10, 2016, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed February 10, 2016.

 

4.7 Common Stock Purchase Agreement, dated December 19, 2017, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed December 21, 2017.

 

4.8 Common Stock Purchase Agreement, dated May 13, 2019, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q filed May 15, 2019

 

4.9 Securities Purchase Agreement, dated November 13, 2019, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q filed November 14, 2019.

 

4.10 Commercial Security Agreement, dated November 20, 2019, between the Company, Solésence, LLC and Bradford T. Whitmore, incorporated by reference to Exhibit 4.2 of the Company’s Quarterly Report on Form 10-Q filed November 14, 2019.

 

E-1

 

 

4.11 Certification of Designation of Series X Preferred Stock, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed March 5, 2024, EC File No. 000-22333.
   
10.1 Industrial Building Lease dated September 15, 2004 between the Company and the Village of Burr Ridge, incorporated by reference to Exhibit 10.32 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004 (the “2004 10-K”), SEC File No. 000- 22333.

 

10.2 Industrial Building Lease Agreement between Centerpoint Properties Trust (formerly CP Financing Trust) and the Company, dated June 15, 2000, incorporated by reference to Exhibit 10.23 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2000 (the “2000 10-K”), SEC File No. 000-22333.

 

10.3 Lease Amendment effective October 1, 2005 between the Company and Centerpoint Properties Trust, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed October 20, 2005, SEC File No. 000-22333.

 

10.4 Second Amendment to Industrial Lease Agreement, dated as of November 13, 2014 between the Company and MLRP 1319 Marquette LLC, successor-in-interest to Centerpoint Properties Trust, incorporated by reference to Exhibit 10.4 to the Company’s Annual Report on Form 10- K for the year ended December 31, 2014.

 

10.5 Third Amendment to Industrial Lease Agreement, entered into on October 17, 2016 and effective October 1, 2016, by and between the Company and 1319 Marquette, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 19, 2016.

 

10.6 Mutual Cooperation Agreement entered into on January 17, 2012, by and among the Company, C.I. Kasei Co., Ltd. and CIK NanoTek Corporation, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed January 20, 2012, SEC File No. 000-22333.

 

10.7 Trademark Ownership Assignment Agreement, dated March 31, 2012, between the Company and CIK NanoTek Corporation, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 4, 2012, SEC File No 000-22333.

 

10.8 Memorandum on the Payment of Royalty, dated March 31, 2012, between the Company and CIK NanoTek Corporation, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed April 4, 2012, SEC File No 000-22333.

 

10.9 Supply Agreement between the Company and Schering-Plough HealthCare Products, Inc. dated as of March 15, 1997, incorporated by reference to Exhibit 10.17 to the Form S-1/A.

 

10.10* Zinc Oxide Supply Agreement dated as of September 16, 1999 between the Company and BASF Corporation, as assignee, incorporated by reference to Exhibit 10.22 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1999, SEC File No. 000-22333.

 

10.11* Amendment No. 1 to Zinc Oxide Supply Agreement dated as of January, 2001 between the Company and BASF Corporation, incorporated by reference to Exhibit 10.24 to the 2000 10-K, SEC File No. 000-22333.

 

10.12 Amendment No. 2. to Zinc Oxide Supply Agreement dated as of March 17, 2003 between the Company and BASF Corporation, incorporated by reference to Exhibit 10.26 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2002 (the “2002 10-K”), SEC File No. 000-22333.

 

10.13* Amendment No. 3 to Zinc Oxide Supply Agreement entered into on December 12, 2012, between the Company and BASF Corporation, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed December 6, 2012, SEC File No. 000-22333.

 

10.14*

Amendment No. 4 to Zinc Oxide Supply Agreement, dated as of January 1, 2019 and entered into on March 11, 2019, between the Company and BASF Corporation, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed May 15, 2019. 

 

E-2

 

 

10.15 Z-COTE HP-2 Brand Supply Agreement dated May 15, 2006 between the Company and BASF Corporation, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed June 20, 2006, SEC File No. 000-22333.

 

10.16* Amended and Restated Cooperation Agreement dated August 25, 2006 between the Company and Rohm and Haas Electronic Materials CMP Inc., incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed August 28, 2006, SEC File No. 000-22333.

 

10.17 Supply Agreement effective as of March 23, 2009, between the Company and Rohm and Haas Electronic Materials CMP Inc., incorporated by reference to Exhibit 10.56 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, SEC File No. 000-22333.

 

10.18* Distributor Agreement dated October 24, 2005 between Johnson Matthey Catalog Company, Inc., d/b/a ALFA AESAR and the Company, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed November 1, 2005, SEC File No. 000-22333.

 

10.19* Supply Agreement dated March 3, 2006 between Roche Diagnostics GmbH and the Company, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed March 9, 2006, SEC File No. 000-22333.

 

10.20* First Amendment to the Supply Agreement entered into on November 19, 2014 between the Company and Roche Diagnostics GmbH, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 25, 2014.

 

10.21* Second Amendment to the Supply Agreement, entered into on November 21, 2016, between the Company and Roche Diagnostics GmbH, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 28, 2016.
   
10.22* Third Amendment to the Supply Agreement, entered into on February 3, 2023, between the Company and Roche Diagnostics GmbH.

 

10.23 Joint Development Agreement dated March 23, 2004 between the Company and Altana Chemie AG, incorporated by reference to Exhibit 10.29 to the 2003 10-K, SEC File No. 000-22333.

 

10.24* Agreement dated July 7, 2008 between the Company and Altana Chemie GmbH, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed July 18, 2008, SEC File No. 000-22333.

 

10.25* Settlement and Termination Agreement, dated August 20, 2010, between the Company and Altana Chemie GmbH, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 25, 2010, SEC File No. 000-22333.

 

10.26* Supply Agreement, dated as of March 31, 2016, between the Company and Ester Solutions Company, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 6, 2016.

 

10.27 First Amendment to Supply Agreement, dated May 21, 2018, by and between Nanophase Technologies Corporation and Hallstar Ester Solutions Corporation (formerly known as Ester Solutions Company), incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 25, 2018.

 

10.28 Joint Development Agreement, dated as of July 31, 2019, between the Company and Sumitomo Corporation of Americas, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 2, 2019.

 

10.29 Joint Development & Supply Agreement, dated December 12, 2016, by and between Solésence, LLC and Colorescience Inc., incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 24, 2018.

 

10.30 Amended and Restated Joint Development & Supply Agreement, executed by Solésence, LLC on May 18, 2018, by and between Solésence, LLC and Colorescience Inc., incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 24, 2018.

 

 10.31

Promissory Note, dated March 4, 2015, granted by the Company in favor of Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed March 10, 2015. 

 

E-3

 

 

10.32

Commercial Security Agreement, dated March 4, 2015, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed March 10, 2015.

 

10.33 

Change in Terms Agreement, dated March 4, 2016, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed March 10, 2016. 

 

10.34 Change in Terms Agreement, dated February 14, 2017, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.32 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

 

10.35 Promissory Note, executed by the Company on March 26, 2018, granted by the Company in favor of Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

10.36 Commercial Security Agreement, executed by the Company on March 26, 2018, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.35 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

10.37 Business Loan Agreement, executed by the Company on March 22, 2019, between the Company and Libertyville Bank and Trust Company, incorporated by reference to the Exhibit 10.32 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

 

10.38 Change in Terms Agreement, executed by the Company on March 22, 2019, between the Company and Libertyville Bank and Trust Company, incorporated by reference to the Exhibit 10.33 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

 

10.39 Business Loan Agreement, dated November 16, 2018, between the Company and Beachcorp, LLC, incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed November 19, 2018.

 

10.40 Promissory Note, dated November 19, 2018, made by the Company and payable to the order of Beachcorp, LLC to evidence a term loan in the original principal amount of up to $500,000, incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed November 19, 2018.

 

10.41 Promissory Note, dated November 19, 2018, made by the Company and payable to the order of Beachcorp, LLC to evidence revolving borrowings in a principal amount of up to $2,000,000, incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed November 19, 2018.

 

10.42 First Amendment to Business Loan Agreement, dated March 23, 2020, between the Company and Beachcorp, LLC, incorporated by reference to the Company’s Annual Report on Form 10-K filed March 30, 2020.

 

10.43 Fourth Amendment to Business Loan Agreement, dated April 21, 2021, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 21, 2021.

 

10.44 Business Loan Agreement, dated January 28, 2022, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

10.45 Business Loan Agreement, dated January 28, 2022, between the Company and Strandler, LLC, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

10.46 Amended and Restated Business Loan Agreement, dated January 28, 2022, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

10.47

Replacement Promissory Note, dated January 28, 2022, made by the Company and payable to the order of Beachcorp, LLC to evidence revolving borrowings in a principal amount of up to $8,000,000, incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed February 2, 2022. 

 

E-4

 

 

10.48 Promissory Note, dated January 28, 2022, made by the Company and payable to the order of Strandler, LLC to evidence a term loan in the original principal amount of up to $1,000,000, incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

10.49 Promissory Note, dated January 28, 2022, made by the Company and payable to the order of Beachcorp, LLC to evidence revolving borrowings in a principal amount of up to $4,000,000, incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed February 2, 2022.
   
10.50 First Amendment to Amended and Restated Business Loan Agreement with Beachcorp, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.51 Replacement Promissory Note with Beachcorp,LLC, incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.52 First Amendment to Business Loan Agreement with Beachcorp, LLC, incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.53 First Amendment to Business Loan Agreement with Strandler, LLC, incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.54 Promissory Note with Strandler, LLC, incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.55 Securities Purchase Agreement with Strandler, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed March 5, 2024, EC File No. 000-22333.
   
10.56 Second Amendment to Business Loan Agreement with Strandler, LLC, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed March 5, 2024, EC File No. 000-22333.
   
10.57 Second Amendment to Amended and Restated Business Loan Agreement with Beachcorp, LLC, incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed March 5, 2024, EC File No. 000-22333.
   
10.58 Second Admendment to Business Loan Agreement with Beachcorp, LLC, incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed March 5, 2024, EC File No. 000-22333.

 

10.59 Employment Agreement effective August 12, 2009 between the Company and Jess Jankowski, incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, SEC File No. 000-22333. +

 

10.60

Employment Agreement dated November 28, 2012, between the Company and Kevin Cureton, incorporated by reference to Exhibit 10.36 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, SEC File No. 000-22333. +  

 

10.61 Nanophase Technologies Corporation 2004 Equity Compensation Plan (“2004 Equity Plan”), incorporated by reference to Exhibit 4 to the Company’s Registration Statement on Form S-8 (File No. 333-119466). +

 

10.62 2008 Long-Term Cash Incentive Plan, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed July 25, 2008, SEC File No. 000-22333.+

 

10.63 Nanophase Technologies Corporation 2010 Equity Compensation Plan, as amended, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 29, 2016.+

 

10.64 Form of Stock Option Award Agreement under the 2010 Equity Compensation Plan, incorporated by reference to Exhibit 10.47 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.+

 

10.65 Nanophase Technologies Corporation 2019 Equity Compensation Plan, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 22, 2019.+

 

10.66 Building Lease, dated as of September 15, 2010, between the Company and the Village of Burr Ridge, incorporated by reference to Exhibit 10.50 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

 

E-5

 

 

10.67 Building Lease, dated as of March 13, 2017, between the Company and the Village of Burr Ridge, incorporated by reference to Exhibit 10.51 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

 

10.68* Know-How License Agreement, executed by the Company on June 26, 2017, between the Company and Eminess Technologies, Inc., incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed June 29, 2017.

 

10.70 Technology Development Agreement, executed by the Company on June 26, 2017, between the Company and Eminess Technologies, Inc., incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed June 29, 2017.

 

10.71* Exclusive Supply Agreement, effective April 1, 2021, between Solesence, LLC and Ilia Beauty, Inc., incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed June 14, 2021.

 

10.72* Lease, effective December 1, 2021, between the Company and FR JH 10, LLC, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed December 9, 2021.

 

21.1

Subsidiary of the Company. (filed herewith) 

 

23.1 Consent of RSM US LLP. (filed herewith)

 

31.1 Certification of the Chief Executive Officer (principal executive officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act. (filed herewith)

 

31.2 Certification of the Chief Financial Officer (principal financial officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act. (filed herewith)

 

32 Certification of the Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) pursuant to 18 U.S.C. Section 1350. (filed herewith)

 

101 The following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, formatted in XBRL (Extensible Business Reporting Language): (1) the Balance Sheets, (2) the Statements of Operations, (3) the Statements of Cash Flows, (4) the Statements of Stockholders’ Equity, and (5) the Notes to the Financial Statements.

 

* Confidentiality previously granted for portions of this agreement.

 

+ Indicates management contracts or compensatory plans or arrangements.

 

E-6

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 28th day of March, 2024.

 

  NANOPHASE TECHNOLOGIES CORPORATION
       
    By: /s/ Jess A. Jankowski
      Jess A. Jankowski
      President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on the 28th day of March, 2024.

 

Signature   Title
     
/s/ Jess A. Jankowski   President, Chief Executive Officer (principal executive officer,
Jess A. Jankowski   principal financial officer, and principal accounting officer) and Director
     
/s/ R. Janet Whitmore   Chair of the Board of Directors
R. Janet Whitmore    
     
/s/ Laura M. Beres   Director
Laura M. Beres    
     
/s/ Mark E. Miller   Director
Mark E. Miller    

 

 

 EX-21.1 2 ex21-1.htm SUBSIDIARY OF THE COMPANY
 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

 

 

EXHIBIT 21.1

 

SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION

(as of December 31, 2023)

 

  Name Jurisdiction of Formation
     
  Solésence, LLC Delaware

 

 

 EX-23.1 3 ex23-1.htm CONSENT OF RSM US LLP.
 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

 

 

EXHIBIT 23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

We consent to the incorporation by reference in the Registration Statements (No. 333-53445, No. 333-74170, No. 333-119466, No. 333-150765, No. 333-187649, and No. 333-255357) on Form S-8 and Registration Statements (No. 333-90326, No. 333-116224, No. 333-140461, and No. 333-163363) on Form S-3 of Nanophase Technologies Corporation of our report dated March 28, 2024, relating to the consolidated financial statements of Nanophase Technologies Corporation, appearing in this Annual Report on Form 10-K of Nanophase Technologies Corporation for the year ended December 31, 2023.

 

/s/ RSM US LLP

 

Milwaukee, Wisconsin

March 28, 2024

 

 

 EX-31.1 4 ex31-1.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

 

 

EXHIBIT 31.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO

RULES 13A-14(A) AND 15D-14(A) UNDER THE EXCHANGE ACT

 

I, Jess A. Jankowski, certify that:

 

1.        I have reviewed this annual report on Form 10-K of Nanophase Technologies Corporation;

 

2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)       Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)       Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)       Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)      Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a)       All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 28, 2024    
     
  /s/ JESS A. JANKOWSKI
    Jess A. Jankowski
    President and Chief Executive Officer
    (Principal Executive Officer)

 

 

 EX-31.2 5 ex31-2.htm CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

 

 

EXHIBIT 31.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO 

RULES 13A-14(A) AND 15D-14(A) UNDER THE EXCHANGE ACT

 

I, Jess Jankowski, certify that:

 

1.        I have reviewed this annual report on Form 10-K of Nanophase Technologies Corporation;

 

2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)        Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)        Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)        Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)       Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a)        All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)        Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 28, 2024    
     
  /s/ JESS A. JANKOWSKI
    Jess A. Jankowski
    President, Chief Executive Officer, and Chief Financial Officer
   

(Principal Financial Officer) 

 

 

 EX-32 6 ex32.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

 

 

Exhibit 32

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

 

In connection with this annual report of Nanophase Technologies Corporation (the “Company”) on Form 10-K for the year ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jess A. Jankowski, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

1.             The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.             The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 28, 2024    
     
  /s/ JESS A. JANKOWSKI
    Jess A. Jankowski
    President, Chief Executive Officer, and Chief Financial Officer

 

 

 EX-101.SCH 7 nanx-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Related Party Notes and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Equipment and Leasehold Improvements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Lease Commitments link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stock Options and Stock Grants link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 401(k) Profit-Sharing Plan link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Significant Customers link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Business Segmentation and Geographical Distribution link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Related Party Notes and Lines of Credit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equipment and Leasehold Improvements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Lease Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stock Options and Stock Grants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Significant Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Business Segmentation and Geographical Distribution (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Allowance for Credit Losses (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Notes and lines of credit consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Related Party Notes and Lines of Credit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Inventories consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Equipment and leasehold improvements consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Equipment and Leasehold Improvements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Quantitative information regarding the Company’s leases is as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022: (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - The future maturities of the Company’s operating leases as of December 31, 2023 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance. (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Lease Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Accrued expenses consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Capital Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Additional disclosures for options granted for all years presented: (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023: (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Stock Options and Stock Grants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - 401(k) Profit-Sharing Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - We had three significant customers for the year ended December 31, 2023. (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Accounts receivable balances for these three customers were approximately: (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Significant Customers (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - The revenues for 2023 and 2022 by category are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Subsequent Event (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 nanx-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 nanx-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 nanx-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Product and Service [Axis] Product [Member] Product and Service, Other [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption, Adjustment [Member] Long-Lived Tangible Asset [Axis] Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Leasehold Improvements [Member] Other Capitalized Property Plant and Equipment [Member] Customer [Axis] Medical Diagnostics Application Customer [Member] Personal Care Ingredient Customer [Member] Timing of Transfer of Good or Service [Axis] Transferred over Time [Member] Credit Facility [Axis] Libertyville Bank and Trust [Member] Libertyville Bank and Trust One [Member] Beachcorp, LLC [Member] Beachcorp, LLC One [Member] Strandler, LLC [Member] Strandler LLC One [Member] Short-Term Debt, Type [Axis] Letter of Credit [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Business Loan Agreement [Member] Term Loan [Member] Counterparty Name [Axis] Revolving Credit Facility [Member] Term Loan and the Revolver Facility [Member] Inventory Facility [Member] Replacement Promissory Note [Member] Related Party, Type [Axis] Bridge Note [Member] Strandler, LLC and Beachcorp, LLC [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Machinery and Equipment [Member] Office Equipment [Member] Furniture and Fixtures [Member] Construction in Progress [Member] Lease Contractual Term [Axis] January - May [Member] June - December [Member] Tax Period [Axis] Tax Year 2023 [Member] Expiring2023 To2037 [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] Tax Credit Carryforward [Axis] General Business Tax Credit Carryforward [Member] Tax Year 2018 [Member] State and Local Jurisdiction [Member] Class of Stock [Axis] Series X Preferred Stock [Member] Plan Name [Axis] Prior to Equity Compensation Plan 2019 [Member] Equity Compensation Plan 2019 [Member] Equity Compensation Plan 2010 [Member] Award Type [Axis] Share-Based Payment Arrangement, Option [Member] Customer One [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer Two [Member] Customer Three [Member] Customers One Through Three [Member] Supply Commitment [Axis] Supply Commitment [Member] Geographical [Axis] Non-US [Member] Solesence [Member] Personal Care ingredients [Member] Advanced Materials [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash Trade accounts receivable Allowance for Credit Losses     Trade accounts receivable, net Inventories, net Prepaid expenses and other current assets Total current assets Equipment and leasehold improvements, net Operating leases, right of use Other assets, net Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Line of credit – accounts receivable, related party Current portion of debt, related party Current portion of operating lease obligations Accounts payable Current portion of deferred revenue Accrued expenses Total current liabilities Long-term portion of operating lease obligations Long-term line of credit – inventory, related party Long-term debt, related party Long-term portion of deferred revenue Asset retirement obligations Total long-term liabilities Contingent liabilities Stockholders’ equity: Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding Common stock, $.01 par value, 60,000,000 shares authorized; 49,627,254 and 49,320,680 shares issued and outstanding on December 31, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Statement [Table] Statement [Line Items] Revenue: Total revenue Operating expense: Cost of revenue Gross profit Research and development expense Selling, general and administrative expense Loss from operations Interest expense Loss before provision (benefit) for income taxes Provision (benefit) for income taxes Net loss Net loss per share-basic Weighted average number of basic common shares outstanding Net loss per share-diluted Weighted average number of diluted common shares outstanding Beginning balance Beginning balance (in shares) Cumulative effect of accounting changes related to expected credit losses Issuances of shares and stock option exercises Issuances of shares and stock option exercises (in shares) Stock-based compensation Rights offering expense Net loss Ending balance Ending balance (in shares) Statement of Cash Flows [Abstract] Operating activities: Net loss:      Adjustments to reconcile net loss to cash used in operating activities:      Depreciation and amortization      Share-based compensation      Changes in assets and liabilities related to operations:      Trade accounts receivable      Inventories      Prepaid expenses and other assets      Accounts payable      Deferred revenue      Accrued expenses      Net changes in right-of-use assets and lease liabilities – operating Net cash used in operating activities Investing activities: Acquisition of equipment and leasehold improvements Net cash used in investing activities Financing activities: Principal payment on finance leases (Payments) proceeds to line of credit – accounts receivable, related party Proceeds from line of credit – inventory, related party Payments to term loans, related party Proceeds from term loans, related party Proceeds from exercise of stock options Net cash provided by financing activities (Decrease) increase in cash Cash at beginning of period Cash at end of period Supplemental cash flow information: Cash paid for interest Supplemental non-cash investing and financing activity: Accounts payable incurred for the purchase of equipment and leasehold improvements Right-of-use asset obtained in exchange for a lease liability Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Debt Disclosure [Abstract] Related Party Notes and Lines of Credit Inventory Disclosure [Abstract] Inventories Property, Plant and Equipment [Abstract] Equipment and Leasehold Improvements Lease Commitments Lease Commitments Payables and Accruals [Abstract] Accrued Expenses Income Tax Disclosure [Abstract] Income Taxes Equity [Abstract] Capital Stock Share-Based Payment Arrangement [Abstract] Stock Options and Stock Grants Retirement Benefits [Abstract] 401(k) Profit-Sharing Plan Risks and Uncertainties [Abstract] Significant Customers Segment Reporting [Abstract] Business Segmentation and Geographical Distribution Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Event Use of Estimates and Risks and Uncertainties Cash Trade Accounts Receivable Inventories Equipment and Leasehold Improvements Long Lived Assets Deferred Revenue Asset Retirement Obligations Financial Instruments Product Revenue Other Revenue Research and Development Expenses Income Taxes Earnings Per Share Recently Adopted Pronouncements Recently Issued Pronouncements Allowance for Credit Losses Activity in the asset retirement obligation account for the years ended December 31, is as follows: Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows: Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: Notes and lines of credit consist of the following: Schedule of Related Parties Inventories consist of the following: Equipment and leasehold improvements consist of the following: Quantitative information regarding the Company’s leases is as follows: Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022: The future maturities of the Company’s operating leases as of December 31, 2023 are as follows: The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance. Accrued expenses consist of the following: A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following: We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: Additional disclosures for options granted for all years presented: The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023: The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 We had three significant customers for the year ended December 31, 2023. Accounts receivable balances for these three customers were approximately: The revenues for 2023 and 2022 by category are as follows: Balance, beginning Change in credit loss Balance, ending Balance, beginning Accretion of liability due to passage of time Amortization of asset due to passage of time Balance, ending Accounts receivable, net Contract assets Contract liabilities Numerator: (in Thousands) Denominator: Weighted average additional shares assuming conversion of in-the-money stock options to common shares Weighted average number of diluted common shares outstanding Basic earnings per common share: Net loss per share – basic Diluted earnings per common share: Net loss per share – diluted Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Accounting Standards Update [Extensible Enumeration] Retained earnings Equipment leasehold improvements and leased assets useful life Deferred revenue Percentage of prepayments Volume Rebates Revenue recognized in the reporting period included in contract liability balance at beginning of period Revenue Anti-dilutive pptions excluded from computation of earnings per share Line of Credit Facility [Table] Line of Credit Facility [Line Items] Line of Credit Facility, Commitment Fee Percentage Available Line of Credit Facility, Maximum Borrowing Capacity Letter of credit and related promissory note Debt Instrument, Description of Variable Rate Basis Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Maturity Date Line of Credit Facility, Expiration Date Line of Credit Percentage of Eligible inventory Interest expense related party Accrued interest expense, related parties Outstanding balances associated with related partie Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Raw materials Finished goods Inventory reserve       Total Inventories, net Property plant and equipment,gross Less: Accumulated depreciation and amortization Property, Plant and Equipment, Net, Total Depreciation expense Quantitative Information Regarding Companys Leases Is As Follows Components of lease cost Finance lease cost components: Amortization of finance lease assets Interest on finance lease liabilities Total finance lease costs Operating lease cost components: Operating lease cost Variable lease cost Short-term lease cost Sub-lease income Total operating lease costs Total lease cost Supplemental Cash Flow Information Related To Leases Is As Follows For Years Ended December 31 2023 And 2022 Operating cash outflow from operating leases Lease liabilities arising from obtaining right-of-use assets Early termination of operating lease Reduction in right of use asset due to remeasurement Reduction in lease liability due to remeasurement Weighted-average remaining lease term-operating leases (in years) Weighted-average discount rate-operating leases 2024 2025 2026 2027 2028 Thereafter Total payments Less amounts representing interest Total minimum payments required Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] 2024 2025 Tenant improvement allowances Operating lease payment net Accrued payroll and related expenses Accrued accounts payable Tenant security deposit / advance rent Other  Total Income tax credit at statutory rates Over/Under Accrual of Income Taxes Nondeductible Expenses Record Tax Credits Permanent tax deduction stock options exercised State income tax, net of federal benefits Expiration of NOL & credits Effect of change in deferred tax rate Expiration of stock options Other Change in valuation allowance   Deferred tax liabilities:   Excess tax depreciation ASC 892 Operating Lease Asset      Total deferred tax liabilities Deferred tax assets:   Net operating loss carryforwards   179 Carryforwards   163(j) Business interest limitation carryforwards   Deferred revenue   Inventory and other allowances   Excess (tax) book depreciation   Excess (tax) book amortization   174 research & experimental expenditures   Share-based compensation   Tax Credits ASC 892 Operating Lease Liability   Other accrued costs      Total deferred tax assets   Less: Valuation allowance Deferred income taxes Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Income tax provision Increase (decrease) in valuation allowance Valuation allowance, net operating loss carryforwards and credits Net operating loss carryforwards Operating loss carryforwards expiration period start Operating loss carryforwards expiration period end Carryforwards Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock, shares authorized Number of shares issued Price per share Consideration from sale of shares Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based compensation expense Remaining unrecognized compensation expense Remaining weighted average-period, expense recognition (years) Weighted-average risk-free interest rates Dividend yield Weighted-average expected life (years) of the option Weighted-average expected stock price volatility Weighted-average fair value of the options granted Vesting period (years) of shares granted in period Contractual life (years) of shares granted in period Estimated forfeitures Shares Outstanding, Beginning Shares Outstanding Beginning, (per share) Weighted Average Remaining Contractual Term, Outstanding, end Shares Outstanding (Intrinsic value) Granted Granted (per share) Exercised Exercised (per share) Forfeited or expired Forfeited or expired (per share) Shares Outstanding, Beginning Shares Outstanding Beginning, (per share) Weighted Average Remaining Contractual Term, Outstanding, end Shares Outstanding (Intrinsic value) Shares Exercisable Shares Exercisable, (per share) Shares Exercisable (years) Shares Exercisable (Intrinsic value) Shares available for grant Closing stock share price Shares exercised Total intrinsic value Cash received Shares based compensation payment award expiration period Defined contribution plan, cost Concentration Risk [Table] Concentration Risk [Line Items] Revenue from customers Total Supply Commitment [Table] Supply Commitment [Line Items] Equipment sale - net book value Equipment sale- original book value Revenue from External Customers by Products and Services [Table] Revenue from External Customer [Line Items] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues Subsequent Event [Table] Subsequent Event [Line Items] Common stock, authorized for conversion of preferred stock Shares issued upon conversion per share Conversion price Interest rate Liquidation preference The element represents advanced materials member. The element represents customer one member. The element represents customer three member. The element represents customer two member. The element represents equipment sale original book value of equipment and upgrades. The element represents solesence member. The element represents personal care ingredients member. The element represents line of credit percentage of eligible inventory. The element represents equipment sale net book value equipment. The element represents business loan agreement member. The element represents beachcorp l l c member. The element represents libertyville bank and trust member. The element represents libertyville bank and trust one member. Beachcorp, LLC One. The element represents strandler l l c member. Inventory Facility. Early termination of operating lease amount. Bridge Note. The element represents percentage of prepayments. The element represents personal care ingredient customer member. The element represents other revenue policy text block. The element represents recently issued pronouncements policies text block. The element represents leases text block. Total finance lease costs. The element represents operating lease cost components abstract. The element represents finance lease cost components abstract. The element represents summary of supplemental cash flow information related to leases table text block. The element represents reduction in right of use asset due to remeasurement. The element represents reduction in lease liability due to remeasurement. The element represents customer net volume rebate payable. The element represents tenant security deposit. The element represents nondeductible expenses. The element represents overunder accrual of income taxes. The element represents expiring2023 to2037 member. The element represents operating loss carryforwards expiration year start. The element represents operating loss carryforwards expiration year end. Equity Compensation Plan 2019 [Member] Equity Compensation Plan 2010 [Member] The element represents additional disclosures for options granted table text block. The element represents share based compensation arrangement by share based payment award award contractual life. The element represents share based compensation arrangement by share based payment award fair value assumptions fortfeiture rate. The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1. The element represents share based compensation arrangement by share based payment award options outstanding intrinsic valu1. The element represents stock options recognized table text block. The element represents contract with customer account receivables table text block. The element represents expiration of nol credits. The element represents strandler l l c one member. The element represents term loan member. The element represents term loan and the revolver facility member. The element represents related party interest expense. The element represents proceeds from related party term loan. The element represents payments to term loans related party. The element represents medical diagnostics application customer. Replacement Promissory Note [Member] Net operating lease payments. Series X Preferred Stock [Member] If the Company fails to fully pay any Redemption within five days of receiving notice, all unpaid amounts will bear interest at specified rate per annum. The maximum number of common shares permitted to be issued by an entity's charter and bylaws for conversion of preferred stock. Strandler, LLC and Beachcorp, LLC [Member] Prior to Equity Compensation Plan 2019 [Member] Volume rebates recognized as a reduction in revenue. January - May [Member] June - December [Member] Customers One Through Three [Member] Amount of deferred tax liability attributable to taxable temporary differences from operating lease asset. Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liability. Total operating lease costs. Accounting Standards Update 2016-13 [Member] Accounts Receivable, Allowance for Credit Loss, Current Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Interest Expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Stockholders' Equity, Other Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Payments to Term Loans Related Party Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Leases [Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Inventory Valuation Reserves Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Lease Costs Finance Sublease Income Lease Costs Operating Lease, Cost Reduction in Right of Use Asset Due To Remeasurement Reduction in Lease Liability Due To Remeasurement Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessor, Operating Lease, Payment to be Received, Year One Lessor, Operating Lease, Payment to be Received, Year Two Effective Income Tax Rate Reconciliation, Tax Credit, Amount Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities Operating Lease Asset Deferred Tax Liabilities, Gross Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price EX-101.PRE 11 nanx-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 28, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 000-22333    
Entity Registrant Name NANOPHASE TECHNOLOGIES CORPORATION    
Entity Central Index Key 0000883107    
Entity Tax Identification Number 36-3687863    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1319 Marquette Drive    
Entity Address, City or Town Romeoville    
Entity Address, State or Province IL    
Entity Address, Postal Zip Code 60446    
City Area Code (630)    
Local Phone Number 771-6708    
Title of 12(b) Security Common Stock, par value $.01 per share    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 23,412,675
Entity Common Stock, Shares Outstanding   54,801,834  
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 49    
Auditor Name RSM US LLP    
Auditor Location Milwaukee, Wisconsin    
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash $ 1,722 $ 2,186
Trade accounts receivable 3,692 4,873
Allowance for Credit Losses (225) (139)
    Trade accounts receivable, net 3,467 4,734
Inventories, net 10,031 8,839
Prepaid expenses and other current assets 1,082 866
Total current assets 16,302 16,625
Equipment and leasehold improvements, net 8,668 7,949
Operating leases, right of use 7,907 8,978
Other assets, net 4 6
Total assets 32,881 33,558
Current liabilities:    
Line of credit – accounts receivable, related party 2,810 4,282
Current portion of debt, related party 2,000
Current portion of operating lease obligations 1,297 0
Accounts payable 6,260 6,363
Current portion of deferred revenue 2,353 2,167
Accrued expenses 869 1,023
Total current liabilities 15,589 13,835
Long-term portion of operating lease obligations 9,152 9,823
Long-term line of credit – inventory, related party 5,000 3,000
Long-term debt, related party 1,000 1,000
Long-term portion of deferred revenue 21
Asset retirement obligations 238 230
Total long-term liabilities 15,390 14,074
Contingent liabilities
Stockholders’ equity:    
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding
Common stock, $.01 par value, 60,000,000 shares authorized; 49,627,254 and 49,320,680 shares issued and outstanding on December 31, 2023 and December 31, 2022, respectively 496 493
Additional paid-in capital 106,069 105,226
Accumulated deficit (104,663) (100,070)
Total stockholders’ equity 1,902 5,649
Total liabilities and stockholders’ equity $ 32,881 $ 33,558
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized 24,088 24,088
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized 60,000,000 60,000,000
Common stock, issued 49,627,254 49,320,680
Common stock, outstanding 49,627,254 49,320,680
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue:    
Total revenue $ 37,297 $ 37,317
Operating expense:    
Cost of revenue 29,472 28,957
Gross profit 7,825 8,360
Research and development expense 3,837 3,037
Selling, general and administrative expense 7,534 7,581
Loss from operations (3,546) (2,258)
Interest expense (838) (382)
Loss before provision (benefit) for income taxes (4,384) (2,640)
Provision (benefit) for income taxes 6 (17)
Net loss $ (4,390) $ (2,623)
Net loss per share-basic $ (0.09) $ (0.05)
Weighted average number of basic common shares outstanding 49,556,305 49,117,000
Net loss per share-diluted $ (0.09) $ (0.05)
Weighted average number of diluted common shares outstanding 49,556,305 49,117,000
Product [Member]    
Revenue:    
Total revenue $ 36,641 $ 36,731
Product and Service, Other [Member]    
Revenue:    
Total revenue $ 656 $ 586
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance at Dec. 31, 2021 $ 489 $ 104,423 $ (97,447) $ 7,465
Beginning balance (in shares) at Dec. 31, 2021 48,893,573      
Issuances of shares and stock option exercises $ 4 178 182
Issuances of shares and stock option exercises (in shares) 427,107      
Stock-based compensation 625 625
Net loss (2,623) (2,623)
Ending balance at Dec. 31, 2022 $ 493 105,226 (100,070) 5,649
Ending balance (in shares) at Dec. 31, 2022 49,320,680      
Cumulative effect of accounting changes related to expected credit losses (203) (203)
Issuances of shares and stock option exercises $ 3 151 154
Issuances of shares and stock option exercises (in shares) 306,574      
Stock-based compensation 773 773
Rights offering expense (81) (81)
Net loss (4,390) (4,390)
Ending balance at Dec. 31, 2023 $ 496 $ 106,069 $ (104,663) $ 1,902
Ending balance (in shares) at Dec. 31, 2023 49,627,254      
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating activities:    
Net loss: $ (4,390) $ (2,623)
     Adjustments to reconcile net loss to cash used in operating activities:    
     Depreciation and amortization 742 567
     Share-based compensation 773 625
     Changes in assets and liabilities related to operations:    
     Trade accounts receivable 1,064 (797)
     Inventories (1,192) (2,744)
     Prepaid expenses and other assets (216) 44
     Accounts payable (503) 1,826
     Deferred revenue 165 744
     Accrued expenses (146) 77
     Net changes in right-of-use assets and lease liabilities – operating 1,697 631
Net cash used in operating activities (2,006) (1,650)
Investing activities:    
Acquisition of equipment and leasehold improvements (1,051) (2,823)
Net cash used in investing activities (1,051) (2,823)
Financing activities:    
Principal payment on finance leases (111)
(Payments) proceeds to line of credit – accounts receivable, related party (1,472) 2,931
Proceeds from line of credit – inventory, related party 2,000 3,000
Payments to term loans, related party (1,346)
Proceeds from term loans, related party 3,338
Proceeds from exercise of stock options 73 182
Net cash provided by financing activities 2,593 6,002
(Decrease) increase in cash (464) 1,529
Cash at beginning of period 2,186 657
Cash at end of period 1,722 2,186
Supplemental cash flow information:    
Cash paid for interest 752 333
Supplemental non-cash investing and financing activity:    
Accounts payable incurred for the purchase of equipment and leasehold improvements 400 971
Right-of-use asset obtained in exchange for a lease liability $ 182
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Description of Business
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

 

(1) Description of Business

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably COVID-19, has become a critical use of our technology.  Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category.   

 

 We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.    

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 

 

The Company recorded a net loss and negative cash flow from operations in 2023.  In addition, the company outstanding debt increased which left little borrowing capacity available. In early March 2024 the company completed an equity financing providing an additional $6 million in funds. For additional information see Note 9. Management believes that current liquidity and available borrowing capacity are sufficient to fund operations and there is not substantial doubt regarding the Company's ability to continue as a going concern.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

 

(2) Summary of Significant Accounting Policies

 

Use of Estimates and Risks and Uncertainties

 

The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.

 

Cash

 

The Cash balance on December 31, 2023 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.

 

 Trade Accounts Receivable

 

Trade accounts receivable are carried at original invoice amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.

 

On January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.

 

This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.

 Allowance for Credit Losses

   2023   2022 
Balance, beginning  $139   $0 
Change in credit loss   86    139 
Balance, ending  $225   $139 

 

 

Inventories

 

Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.

 

Equipment and Leasehold Improvements

 

Equipment is stated at cost and is being depreciated over its estimated useful life (3-20 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (3-7 years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (7-10 years) using the straight-line method.

 

Long Lived Assets

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented. 

 

Deferred Revenue

 

The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $2,353 in deferred revenue reported in 2023, 97% related to prepayments received from certain customers per Company policy, and the remaining 3% related to prepayments from a product development agreement with a personal care ingredient customer.

 

Asset Retirement Obligations

 

In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, Asset Retirement Obligations, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.

 

Activity in the asset retirement obligation account for the years ended December 31, is as follows:

 

   2023   2022 
Balance, beginning  $230   $222 
Accretion of liability due to passage of time   8    8 
Amortization of asset due to passage of time   —      —   
Balance, ending  $238   $230 

 

Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

Our financial instruments include cash, cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.

 

There were no financial instruments adjusted to fair value on December 31, 2023 and 2022.

 

Product Revenue

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2023 no volume rebates were recorded because the customers did not meet required volumes. In 2022 the company recorded $557 in volume rebates as a reduction in revenue.

 

As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer.

 

Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows:

 

   Accounts Receivable   Contract Assets   Contract Liabilities 
2021  $3,937   $179   $1,444 
2022   4,734    —      2,188 
2023   3,467    —      2,353 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $2,084 and $667 for the years ended December 31, 2023, and 2022, respectively. 

 

Other Revenue

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $656 and $217 for the years ended December 31, 2023 and 2022, respectively.

 

Research and Development Expenses

 

Research and development expenses are recognized as expense when incurred.

 

Income Taxes

 

We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2023, and 2022, we had no liability for unrecognized tax benefits.

 

Earnings Per Share

 

Options to purchase approximately 889,000 shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period.  Options to purchase approximately 2,051,000 shares of common stock that were outstanding as of December 31, 2022 were not included in the computation of earnings per share for the year ended December 31, 2022.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

             
   Years Ended December 31, 
   2023   2022 
Numerator: (in Thousands)        
Net loss  $(4,390)  $(2,623)
           
Denominator:          
Weighted average number of basic common shares outstanding   49,556,305    49,117,000 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   —      —   
Weighted average number of diluted common shares outstanding   49,556,305    49,117,000 
           
Basic earnings per common share:          
Net loss per share – basic  $(0.09)  $(0.05)
Diluted earnings per common share:          
Net loss per share – diluted  $(0.09)  $(0.05)

 

Recently Adopted Pronouncements

 

 In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. 

 

On January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.

 

This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.

 

Recently Issued Pronouncements

 

 On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, Improvements to Income Tax Disclosures, applies to all entities subject to income taxes. This new requirement will be effective for Nanophase Technologies for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Related Party Notes and Lines of Credit
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Related Party Notes and Lines of Credit

 

(3) Related Party Notes and Lines of Credit

 

Notes and lines of credit consist of the following:

 

       As of December 31, 
       2023   2022 
   Rate   Available  

Outstanding 

Balance 

   Available  

Outstanding 

Balance 

 
Libertyville Bank & Trust (1)   9.50%  $30   $—     $30   $—   
Libertyville Bank & Trust (2)   9.50%   500    —      500    —   
Beachcorp, LLC (3) (4)   9.25%   3,298    2,810    4,392    4,282 
Beachcorp, LLC (3) (5)   9.25%   5,200    5,000    4,000    3,000 
Strandler, LLC   (3) (6)   9.25%   1,000    1,000    1,000    1,000 
Strandler, LLC  (7)   9.25%   2,000    2,000    n/a    n/a 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.

 

2)The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Interest on drawn balances was at the prime rate plus 1%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2024. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000 to $2,750.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750 to $4,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000 to $6,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500 to $1,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.

 

4)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On November 13, 2023 the Company entered into a First Amendment to the A&R Loan Agreement extending the maturity of the A/R Revolver Facility to March 31, 2025.

 

5)On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024. On November 13, 2023 the company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%, and it now matures on March 31, 2025.

 

6)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On November 13, 2023 the Company entered into the First Amendment To the New Term Loan Agreement with Strandler, LLC, which extended the maturity of the New Term Loan Agreement to March 31, 2025.

 

7)On November 13, 2023 the Company entered into a new Promissory Note (“Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is $2,000. The interest rate for the Bridge Note is at the prime rate plus 0.75%, and it matures on May 13, 2024.

 

As part of the March 1, 2024 Securities Purchase Agreement the maturity dates of the Term Loan, A/R Revolver Facility and Inventory Facility were extended to October 1, 2025 from March 31, 2025. No other changes were made to the debt agreements. 

 

The Company classifies the line of credit – accounts receivable as current because we are required to pay back the borrowings as cash is received from our customers. The company’s remaining debt is presented within the Consolidated Balance Sheet as of December 31, 2023, and 2022 in accordance with the maturity dates in the financing agreements. 

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank & Trust. 

 

Related party interest expense consists of the following:

 

   Twelve Months Ended December 31, 
   2023   2022 
Interest expense, related parties  $770   $356 

 

Accrued interest consists of the following:

 

   As of December 31, 
   2023   2022 
Accrued interest expense, related parties  $81   $49 

 

Outstanding balances associated with related parties are as follows:

 

   As of December 31, 
   2023   2022 
Beachcorp, LLC  $7,810   $7,282 
Strandler, LLC   3,000    1,000 
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Inventories
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Inventories

 

(4) Inventories  

 

Inventories consist of the following:

 

            
   As of December 31, 
   2023   2022 
Raw materials  $8,524   $7,298 
Finished goods   2,184    2,041 
Inventory reserve   (677)   (500) 
      Total Inventories, net   10,031    8,839 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Equipment and Leasehold Improvements
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Equipment and Leasehold Improvements

 

(5)

 

Equipment and Leasehold Improvements

 

Equipment and leasehold improvements consist of the following:  

Equipment and leasehold improvements consist of the following:  

   As of December 31, 
   2023   2022 
Machinery and equipment  $23,339   $19,899 
Office equipment   1,014    1,014 
Office furniture   126    110 
Leasehold improvements   5,157    5,140 
Construction in progress   931    2,952 
    30,567    29,115 
Less: Accumulated depreciation and amortization   (21,899)   (21,166)
   $8,668   $7,949 

 

Depreciation expense was $732 and $557, for the years ended December 31, 2023 and 2022, respectively.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Lease Commitments
 12 Months Ended
Dec. 31, 2023
Lease Commitments  
Lease Commitments

 

(6) Lease Commitments

 

The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. During the first calendar year of our newly leased building, we have subleased a portion of the unused floorspace on a temporary basis. This sublease may convert to a month-to-month lease upon expiration.

 

As of December 31, 2023, the right-of-use (ROU) asset had a balance of $7,907 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $1,297 and $9,152, respectively. These amounts are included in the “Current portion of operating lease obligations” and “Long-term portion of operating lease obligations” line items of these consolidated financial statements. As of December 31, 2022, the ROU asset had a balance of $8,978 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $0 and $9,823, respectively.  The $0 in current lease liability stems from expected payments from the lessor of the Bolingbrook facility reimbursing the Company for tenant improvement allowances in the amount of $1,957 over the subsequent twelve months. As a result, the total lease liability was reduced by the expected payment, and the net effect of reimbursements received, and cash paid for leases in 2023 results in net lease payments of $97. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

 

The office leases contain variable lease payments which consist primarily of taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to combine lease and non-lease components for building leases.

 

Quantitative information regarding the Company’s leases is as follows:

 

   Twelve Months Ended December 31, 2023   Twelve Months Ended December 31, 2022 
Components of lease cost          
Finance lease cost components:          
Amortization of finance lease assets  $—     $33 
Interest on finance lease liabilities   —      4 
Total finance lease costs   —      37 
Operating lease cost components:          
Operating lease cost   1,881    2,068 
Variable lease cost   581    536 
Short-term lease cost   112    138 
Sub-lease income   (786)   (689)
Total operating lease costs   1,788    2,053 
Total lease cost  $1,788   $2,090 

 

Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022:

 

    2023     2022  
Cash paid for amounts included in the measurement of lease liabilities:            
Operating cash outflow from operating leases   $ 172     $ 1,433  
                 
Lease liabilities arising from obtaining right-of-use assets   $ 182     $ 12  
Early termination of operating lease     —       73  
Reduction in right of use asset due to remeasurement     —       (1,793 )
Reduction in lease liability due to remeasurement     —       (1,898 )
Weighted-average remaining lease term-operating leases (in years)     7.9       9.6  
Weighted-average discount rate-operating leases     7.1 %     7.6 %

  

The future maturities of the Company’s operating leases as of December 31, 2023 are as follows:

 

2024   $1,968 
2025    1,483 
2026    1,481 
2027    1,520 
2028    1,549 
Thereafter    5,613 
Total payments   $13,614 
Less amounts representing interest    (3,165)
Total minimum payments required   $10,449 

 

Nanophase Technologies subleases a portion of a leased industrial building that is used primarily for the storage of furniture, equipment and displays used for retail sales. The arrangement is not with a related party.

 

Payments received by the Company for this sublease are comprised of two components, which include base rent and Common Area Maintenance (CAM) charges. While the base rent is fixed, the CAM charges are indexed directly to the Master Lease and are expected to be adjusted periodically as actual costs are incurred. However, the executed sublease agreement specifically itemizes these costs with a provision that informs the sublessee that the CAM charges will be adjusted (up or down) based on actual amounts once this information becomes known. As such, the nature of the charges is more closely representative of a fixed payment (an “in-substance fixed” charge) with the adjustments occurring simply to “true up” the listed CAM charges once actual charges from the head lessor become known. As sublessor, Nanophase Technologies has elected the practical expedient to not separate lease and nonlease components in disclosing future undiscounted cashflows and treats the combined components as a single lease component.

 

The sublease arrangement automatically renews following expiration of the initial term on May 31, 2025, with a one-year notice required to terminate the lease. As of the issuance of these financial statements the sublessee has not yet provided notice of their intent to renew or terminate said arrangement.

 

The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance.

 

Months        
   For the Year 
Months  2024   2025 
January - May  $124,015   $128,640 
June - December   173,621    — 
           
Total  $297,636   $128,640 

 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Accrued Expenses

 

(7) Accrued Expenses

 

Accrued expenses consist of the following:

 

           
    As of December 31,  
    2023     2022  
Accrued payroll and related expenses   $ 255     $ 288  
Accrued accounts payable     128       403  
Tenant security deposit / advance rent     —       61  
Other     486       271  
 Total   $ 869     $ 1,023  
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

 

(8)Income Taxes

 

Our net income tax provision, including both current and deferred, related to U.S. federal and state income taxes, is $6. Our current federal and deferred tax expenses are zero.

 

A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows:

 

   2023   2022 
Income tax credit at statutory rates  $(921)  $(551)
Over/Under Accrual of Income Taxes   (3)   (17)
Nondeductible Expenses   23    —   
Record Tax Credits   (118)   —   
Permanent tax deduction stock options exercised   (63)   (273)
State income tax, net of federal benefits   (165)   (124)
Expiration of NOL & credits   1,492    1,149 
Effect of change in deferred tax rate   45    69 
Expiration of stock options   60    75 
Other   —      2 
Change in valuation allowance   (344)   (347)
   $6    (17)

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

 

         
   As of December 31, 
   2023   2022 
Deferred tax liabilities:          
  Excess tax depreciation  $(477)   (253)
ASC 892 Operating Lease Asset   (1,975)    —   
     Total deferred tax liabilities   (2,452)   (253)
           
Deferred tax assets:          
  Net operating loss carryforwards  $12,020   $13,416 
  179 Carryforwards   245    117 
  163(j) Business interest limitation carryforwards   302    98 
  Deferred revenue   —      202 
  Inventory and other allowances   239    177 
  Excess (tax) book depreciation   —      —   
  Excess (tax) book amortization   60    59 
  174 research & experimental expenditures   902    480 
  Share-based compensation   530    394 
  Tax Credits   118    —   
ASC 892 Operating Lease Liability    2,610   —   
  Other accrued costs   13    238 
     Total deferred tax assets   17,039    15,181 
           
  Less: Valuation allowance   (14,587)   (14,928)
Deferred income taxes  $—     $—   

 

The valuation allowance decreased approximately $0.3 million and $0.3 million for the years ended December 31, 2023 and 2022, respectively (net of approximately $7.1 million and $5.5 million for the years ended December 31, 2023 and 2022, respectively, for expiring net operating loss carryforwards and credits) due principally to the change in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and our public offering of common stock, may subject us to annual limitations on the utilization of our net operating loss carryforward. As of December 31, 2023, it has been determined that we are not subject to annual limitations on the utilization of our net operating loss carryforward.

 

We have federal net operating loss carryforwards for tax purposes of approximately $50 million on December 31, 2023. $44 million expire between 2024 and 2037. We have section 179 carryforwards of approximately $0.2M at December 31, 2023. All net operating loss carryforwards generated after January 1, 2018 do not expire. Therefore, $5.6 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $21.3 million on December 31, 2023. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2039.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Capital Stock
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Capital Stock

 

(9) 

Capital Stock 

 

As of December 31, 2023, and 2022, we had 24,088 authorized but unissued shares of preferred stock.

 

Pursuant to the Securities Purchase Agreement executed on March 1, 2024, the Company issued to Strandler 15,000 shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”)at a purchase price per share of $400, for total consideration of $6,000,000, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”).
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Stock Options and Stock Grants
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock Options and Stock Grants

 

(10) Stock Options and Stock Grants

 

We have entered into stock option agreements with certain officers, employees and directors. The stock options granted prior to the adoption of the 2019 Equity Compensation Plan (the “2019 Plan”) on November 19, 2019 generally expire ten years from the date of grant. Future options to be granted under the 2019 Plan will expire seven years from the date of grant.

 

Employee Stock Options

 

We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. 

 

         
  

Years ended  

December 31, 

 
   2023   2022 
Share-based compensation expense  $773   $625 
Remaining unrecognized compensation expense  $1,118    1,732 
Remaining weighted average-period, expense recognition (years)   1.8    2.5 

 

We use the Black-Scholes option pricing model to determine the fair value of stock-based compensation. The Black-Scholes model requires us to make several assumptions, including the estimated length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of our common stock price over the expected term, and estimated forfeitures. Expected price volatility is based on the daily market rate changes of our stock. The active shares granted prior to fiscal 2020 had a contractual life of 10 years as dictated by the 2010 Plan. The Black-Scholes model also requires a risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of the grant, and the dividend yield on our common stock, which is assumed to be zero since we do not pay dividends and have no current plans to do so in the future. Changes in these assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related expense recognized on the statement of operations. We recognize stock-based compensation expense on a straight-line basis over the requisite service period. 

 

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

 

   Years Ended December 31, 
   2023   2022 
Weighted-average risk-free interest rates:   3.8%   3.5%
           
Dividend yield:   0%   0%
           
Weighted-average expected life (years) of the option:   4    5 
           
Weighted-average expected stock price volatility:   93%   116%
           
Weighted-average fair value of the options granted:  $0.50   $0.97 

  

Additional disclosures for options granted for all years presented:

 

   Years Ended December 31, 
   2023   2022 
Vesting period (years) of shares granted in period   3    3 
           
Contractual life (years) of shares granted in period   7    7 
           
Estimated forfeitures   8%   4%

 

The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023:

 

                Weighted        
          Weighted     Average     Aggregate  
          Average     Remaining     Intrinsic  
    Shares     Exercise Price     Contractual     Value  
Options   (Rounded)     per Share     Term (Years)     (000s)  
Outstanding on January 1, 2023     3,443,661     $ 1.33       4.9       1,230  
                                 
Granted     668,200     $ 0.68                  
Exercised     (294,074 )   $ 0.50                  
Forfeited or expired     (291,821 )   $ 1.92                  
                                 
Outstanding on December 31, 2023     3,525,966     $ 1.22       4.2     $ 160  
Exercisable on December 31, 2023     2,334,458     $ 1.15       3.2     $ 160  
                                 
Shares available for grant     450,900                          

 

The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 on the last business day for the year ended December 31, 2023.

 

         
  

Years ended  

December 31, 

 
   2023   2022 
Shares exercised   294,074    414,455 
Total intrinsic value  $195   $942 
Cash received  $154   $182 

 

Based on our election of the “with and without” approach, no realized tax benefits from stock options were recognized for the years ended December 31, 2023 and 2022.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.1
401(k) Profit-Sharing Plan
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
401(k) Profit-Sharing Plan

 

(11) 401(k) Profit-Sharing Plan

 

We have a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. Contributions made in 2023 and 2022 aggregated to $191 and $153, respectively.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Significant Customers
 12 Months Ended
Dec. 31, 2023
Risks and Uncertainties [Abstract]  
Significant Customers

 

(12) Significant Customers

 

We had three significant customers for the year ended December 31, 2023.

 

       For the years ended 
       December 31, 
Customer #   Product Category  2023   2022 
1   Personal Care Ingredients   25%   30%
2   Solésence®   17%   17%
3   Solésence®   15%   15%
               
    Total   57%   62%

 

 Accounts receivable balances for these three customers were approximately:

 

       For the years ended
December 31,		 
Customer #   Product Category  2023   2022 
1   Personal Care Ingredients  $—     $1,082 
2   Solésence®   1,288    438 
3   Solésence®   864    683 
               
    Total  $2,152   $2,202 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Business Segmentation and Geographical Distribution
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Business Segmentation and Geographical Distribution

  

(13) Business Segmentation and Geographical Distribution

 

Revenue from international sources approximated $2,918 and $1,971 for the years ended December 31, 2023 and 2022, respectively. As part of our revenue from international sources, we recognized approximately $1,664 and $1,236 in product revenue from German companies, in the aggregate, for the years ended December 31, 2023 and 2022, respectively.

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues for 2023 and 2022 by category are as follows:

 

  

For the years ended  

December 31 

 
Product Category  2023   2022 
Solésence  $25,211   $23,111 
Personal Care Ingredients   9,277    11,121 
Advanced Materials   2,809    3,085 
Total Sales  $37,297   $37,317 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

 

(14) Commitments and Contingencies 

 

On August 9, 2022, BASF filed a complaint against Nanophase in New Jersey state court (the “New Jersey Complaint”), alleging that Nanophase had breached the 1999 Zinc Oxide Supply Agreement (the “Agreement”). BASF alleges several issues, the one having the biggest potential impact on Nanophase being a claim that our sales through Solésence violate the exclusivity provision of the Agreement. BASF seeks an unspecified amount of damages, a permanent injunction enjoining sales to any party (other than BASF) of a broad range of zinc oxide products that BASF contends are within the scope of the exclusivity provision, counsel fees and litigation expenses. On September 7, 2022, Nanophase filed a Complaint for Declaratory Judgement in Illinois state court (the “Illinois Complaint”), asking for a declaration that contrary to BASF’s allegation, the exclusivity provision of the Agreement does not apply to all products containing zinc oxide as an ingredient for uses designated under the Agreement, nor does the exclusivity provision prohibit Nanophase’s sales of Solésence products containing zinc oxide as an ingredient. Both companies filed Motions to Dismiss (MTD) the other’s respective complaint. Nanophase’s MTD BASF’s New Jersey Complaint was denied on procedural grounds on February 10, 2023, with the New Jersey court superficially noting that it did not consider whether BASF could prove its claims. On February 28, 2023, Nanophase filed its answer to BASF’s New Jersey Complaint, denying all wrongdoing and, as mandated by New Jersey procedural requirements, counterclaims including a request for a declaration similar to that Nanophase sought in its Illinois Complaint and a claim alleging that BASF had breached its obligations under the Agreement to buy from Nanophase at least 70% of BASF’s zinc oxide requirements for use in the Field under the Agreement. BASF subsequently moved to dismiss Nanophase’s counterclaims, arguing that the declaratory judgment claim duplicated BASF’s claim for Nanophase’s alleged breach of contract and Nanophase’s claim for BASF’s breach of the zinc oxide purchase requirement was procedurally insufficient. On October 6, 2023, the New Jersey court: denied BASF’s motion to dismiss Nanophase’s declaratory judgment claim, finding that it did not duplicate BASF’s breach of contract claim and that litigating that claim would not provide Nanophase with complete relief as to the exclusivity issues raised in the counterclaim; and granted BASF’s motion to dismiss Nanophase’s claim for BASF’s breach of its zinc oxide purchase requirement on procedural grounds. On March 16, 2023, the Illinois court granted BASF’s MTD Nanophase’s Illinois Complaint, finding it duplicative of the New Jersey litigation. Discovery in the New Jersy litigation is ongoing. Management believes at this time that the allegations of BASF’s complaint are without merit and are unsupported by the terms of the Agreement and governing law. Per ASC 450 for the period ending December 31, 2023, an estimated contingent loss was not recorded, and an estimated range of loss is not disclosed as the outcome is not probable at this time and nor is a range of loss estimable.   
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Subsequent Event
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Event

 

(15) Subsequent Event

 

On March 1, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”), between the Company and Strandler, LLC (“Strandler”).

 

Pursuant to the Purchase Agreement, the Company issued to Strandler 15,000 shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”) at a purchase price per share of $400, for total consideration of $6,000,000, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”).

 

Under the Purchase Agreement, the Company granted Strandler customary registration rights with respect to shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), it may receive in connection with any conversion of Series X Preferred Stock into Common Stock, as described below. For so long as any amount of Preferred Stock is outstanding, the Purchase Agreement also (i) prevents the Company from paying any dividend on any shares of the Company’s capital stock (other than dividends consisting solely of Common Stock or rights to purchase Common Stock), (ii) prevents the Company from repurchasing any Common Stock, and (iii) subject to certain permitted exceptions, restricts the Company’s ability to permit any lien or other encumbrance on Company assets.

 

At any time and from time to time, in whole or in part, following the Company properly filing an amendment (the “Certificate Amendment”) to its Certificate of Incorporation to increase the number of authorized shares of its Common Stock from 60,000,000 to 95,000,000, each share of Series X Preferred Stock is convertible, at the option of the holder, into 1,000 shares of Common Stock at no additional cost. If the Company has not properly filed, upon shareholder approval, the Certificate Amendment on or before August 1, 2024, then each share of Series X Preferred Stock will be redeemable at the holder’s option, in whole or in part, without penalty or premium, at a redemption price equal to $420 per share (each, a “Redemption”). If the Company fails to fully pay any Redemption within five days of receiving notice, all unpaid amounts will bear interest at a rate of 10% per annum. In addition, in the event of a Change in Control (as defined in the Certificate of Designations) of the Company, each share of the Series X Preferred Stock is redeemable at the option of the holder, without penalty or premium, at a redemption price equal to $420 per share. Upon any conversion of Preferred Stock into Common Stock by Strandler, Strandler is required to hold the Common Stock received in the conversion for a period of 12 months.

 

Holders of Series X Preferred Stock (i) are not entitled to receive dividends, subject to customary anti-dilution protections, (ii) have no voting rights, and (iii)receive a liquidation preference of $400 per share. The Series X Preferred Stock ranks senior in right of payment to all securities designated as junior securities, including Common Stock.

 

In connection with the Company’s entry into the Purchase Agreement, the Company also entered into (i) a Second Amendment to Business Loan Agreement (the “Term Loan Agreement Amendment”) with Strandler, LLC, (ii) a Second Amendment to Business Loan Agreement (the “A&R Loan Agreement Amendment”) with Beachcorp, LLC, which is also an affiliate of our controlling shareholder, Bradford T. Whitmore (“Beachcorp”), and (iii) a Second Amendment to Business Loan Agreement with Beachcorp (the “Revolving Loan Agreement Amendment” and together with the Term Loan Agreement Amendment and the A&R Term Loan Agreement Amendment, the “Loan Agreement Amendments”). The Loan Agreement Amendments extend the maturity date under each respective loan agreement from March 31, 2025 to October 1, 2025.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Use of Estimates and Risks and Uncertainties

Use of Estimates and Risks and Uncertainties

 

The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.
Cash

Cash

 

The Cash balance on December 31, 2023 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.
Trade Accounts Receivable

 Trade Accounts Receivable

 

Trade accounts receivable are carried at original invoice amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.

 

On January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.

 

This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.

 Allowance for Credit Losses

   2023   2022 
Balance, beginning  $139   $0 
Change in credit loss   86    139 
Balance, ending  $225   $139 

 
Inventories

Inventories

 

Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.
Equipment and Leasehold Improvements

Equipment and Leasehold Improvements

 

Equipment is stated at cost and is being depreciated over its estimated useful life (3-20 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (3-7 years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (7-10 years) using the straight-line method.
Long Lived Assets

Long Lived Assets

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented. 
Deferred Revenue

Deferred Revenue

 

The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $2,353 in deferred revenue reported in 2023, 97% related to prepayments received from certain customers per Company policy, and the remaining 3% related to prepayments from a product development agreement with a personal care ingredient customer.
Asset Retirement Obligations

Asset Retirement Obligations

 

In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, Asset Retirement Obligations, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.

 

Activity in the asset retirement obligation account for the years ended December 31, is as follows:

 

   2023   2022 
Balance, beginning  $230   $222 
Accretion of liability due to passage of time   8    8 
Amortization of asset due to passage of time   —      —   
Balance, ending  $238   $230 
Financial Instruments

Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

Our financial instruments include cash, cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.

 

There were no financial instruments adjusted to fair value on December 31, 2023 and 2022.
Product Revenue

Product Revenue

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2023 no volume rebates were recorded because the customers did not meet required volumes. In 2022 the company recorded $557 in volume rebates as a reduction in revenue.

 

As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer.

 

Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows:

 

   Accounts Receivable   Contract Assets   Contract Liabilities 
2021  $3,937   $179   $1,444 
2022   4,734    —      2,188 
2023   3,467    —      2,353 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $2,084 and $667 for the years ended December 31, 2023, and 2022, respectively. 
Other Revenue

Other Revenue

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $656 and $217 for the years ended December 31, 2023 and 2022, respectively.
Research and Development Expenses

Research and Development Expenses

 

Research and development expenses are recognized as expense when incurred.
Income Taxes

Income Taxes

 

We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2023, and 2022, we had no liability for unrecognized tax benefits.
Earnings Per Share

Earnings Per Share

 

Options to purchase approximately 889,000 shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period.  Options to purchase approximately 2,051,000 shares of common stock that were outstanding as of December 31, 2022 were not included in the computation of earnings per share for the year ended December 31, 2022.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

             
   Years Ended December 31, 
   2023   2022 
Numerator: (in Thousands)        
Net loss  $(4,390)  $(2,623)
           
Denominator:          
Weighted average number of basic common shares outstanding   49,556,305    49,117,000 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   —      —   
Weighted average number of diluted common shares outstanding   49,556,305    49,117,000 
           
Basic earnings per common share:          
Net loss per share – basic  $(0.09)  $(0.05)
Diluted earnings per common share:          
Net loss per share – diluted  $(0.09)  $(0.05)
Recently Adopted Pronouncements

Recently Adopted Pronouncements

 

 In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. 

 

On January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.

 

This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.
Recently Issued Pronouncements

Recently Issued Pronouncements

 

 On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, Improvements to Income Tax Disclosures, applies to all entities subject to income taxes. This new requirement will be effective for Nanophase Technologies for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Allowance for Credit Losses

 Allowance for Credit Losses

   2023   2022 
Balance, beginning  $139   $0 
Change in credit loss   86    139 
Balance, ending  $225   $139 
Activity in the asset retirement obligation account for the years ended December 31, is as follows:

Activity in the asset retirement obligation account for the years ended December 31, is as follows:

 

   2023   2022 
Balance, beginning  $230   $222 
Accretion of liability due to passage of time   8    8 
Amortization of asset due to passage of time   —      —   
Balance, ending  $238   $230 
Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows:

Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows:

 

   Accounts Receivable   Contract Assets   Contract Liabilities 
2021  $3,937   $179   $1,444 
2022   4,734    —      2,188 
2023   3,467    —      2,353 
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

             
   Years Ended December 31, 
   2023   2022 
Numerator: (in Thousands)        
Net loss  $(4,390)  $(2,623)
           
Denominator:          
Weighted average number of basic common shares outstanding   49,556,305    49,117,000 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   —      —   
Weighted average number of diluted common shares outstanding   49,556,305    49,117,000 
           
Basic earnings per common share:          
Net loss per share – basic  $(0.09)  $(0.05)
Diluted earnings per common share:          
Net loss per share – diluted  $(0.09)  $(0.05)
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Related Party Notes and Lines of Credit (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Notes and lines of credit consist of the following:

Notes and lines of credit consist of the following:

 

       As of December 31, 
       2023   2022 
   Rate   Available  

Outstanding 

Balance 

   Available  

Outstanding 

Balance 

 
Libertyville Bank & Trust (1)   9.50%  $30   $—     $30   $—   
Libertyville Bank & Trust (2)   9.50%   500    —      500    —   
Beachcorp, LLC (3) (4)   9.25%   3,298    2,810    4,392    4,282 
Beachcorp, LLC (3) (5)   9.25%   5,200    5,000    4,000    3,000 
Strandler, LLC   (3) (6)   9.25%   1,000    1,000    1,000    1,000 
Strandler, LLC  (7)   9.25%   2,000    2,000    n/a    n/a 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.

 

2)The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Interest on drawn balances was at the prime rate plus 1%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2024. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000 to $2,750.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750 to $4,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000 to $6,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500 to $1,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.

 

4)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On November 13, 2023 the Company entered into a First Amendment to the A&R Loan Agreement extending the maturity of the A/R Revolver Facility to March 31, 2025.

 

5)On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024. On November 13, 2023 the company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%, and it now matures on March 31, 2025.

 

6)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On November 13, 2023 the Company entered into the First Amendment To the New Term Loan Agreement with Strandler, LLC, which extended the maturity of the New Term Loan Agreement to March 31, 2025.

 

7)On November 13, 2023 the Company entered into a new Promissory Note (“Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is $2,000. The interest rate for the Bridge Note is at the prime rate plus 0.75%, and it matures on May 13, 2024.
Schedule of Related Parties

Related party interest expense consists of the following:

 

   Twelve Months Ended December 31, 
   2023   2022 
Interest expense, related parties  $770   $356 

 

Accrued interest consists of the following:

 

   As of December 31, 
   2023   2022 
Accrued interest expense, related parties  $81   $49 

 

Outstanding balances associated with related parties are as follows:

 

   As of December 31, 
   2023   2022 
Beachcorp, LLC  $7,810   $7,282 
Strandler, LLC   3,000    1,000 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Inventories (Tables)
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Inventories consist of the following:

Inventories consist of the following:

 

            
   As of December 31, 
   2023   2022 
Raw materials  $8,524   $7,298 
Finished goods   2,184    2,041 
Inventory reserve   (677)   (500) 
      Total Inventories, net   10,031    8,839 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Equipment and Leasehold Improvements (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Equipment and leasehold improvements consist of the following:

Equipment and leasehold improvements consist of the following:  

   As of December 31, 
   2023   2022 
Machinery and equipment  $23,339   $19,899 
Office equipment   1,014    1,014 
Office furniture   126    110 
Leasehold improvements   5,157    5,140 
Construction in progress   931    2,952 
    30,567    29,115 
Less: Accumulated depreciation and amortization   (21,899)   (21,166)
   $8,668   $7,949 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Lease Commitments (Tables)
 12 Months Ended
Dec. 31, 2023
Lease Commitments  
Quantitative information regarding the Company’s leases is as follows:

Quantitative information regarding the Company’s leases is as follows:

 

   Twelve Months Ended December 31, 2023   Twelve Months Ended December 31, 2022 
Components of lease cost          
Finance lease cost components:          
Amortization of finance lease assets  $—     $33 
Interest on finance lease liabilities   —      4 
Total finance lease costs   —      37 
Operating lease cost components:          
Operating lease cost   1,881    2,068 
Variable lease cost   581    536 
Short-term lease cost   112    138 
Sub-lease income   (786)   (689)
Total operating lease costs   1,788    2,053 
Total lease cost  $1,788   $2,090 
Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022:

Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022:

 

    2023     2022  
Cash paid for amounts included in the measurement of lease liabilities:            
Operating cash outflow from operating leases   $ 172     $ 1,433  
                 
Lease liabilities arising from obtaining right-of-use assets   $ 182     $ 12  
Early termination of operating lease     —       73  
Reduction in right of use asset due to remeasurement     —       (1,793 )
Reduction in lease liability due to remeasurement     —       (1,898 )
Weighted-average remaining lease term-operating leases (in years)     7.9       9.6  
Weighted-average discount rate-operating leases     7.1 %     7.6 %
The future maturities of the Company’s operating leases as of December 31, 2023 are as follows:

The future maturities of the Company’s operating leases as of December 31, 2023 are as follows:

 

2024   $1,968 
2025    1,483 
2026    1,481 
2027    1,520 
2028    1,549 
Thereafter    5,613 
Total payments   $13,614 
Less amounts representing interest    (3,165)
Total minimum payments required   $10,449 
The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance.

The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance.

 

Months        
   For the Year 
Months  2024   2025 
January - May  $124,015   $128,640 
June - December   173,621    — 
           
Total  $297,636   $128,640 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Accrued expenses consist of the following:

Accrued expenses consist of the following:

 

           
    As of December 31,  
    2023     2022  
Accrued payroll and related expenses   $ 255     $ 288  
Accrued accounts payable     128       403  
Tenant security deposit / advance rent     —       61  
Other     486       271  
 Total   $ 869     $ 1,023  
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows:

A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows:

 

   2023   2022 
Income tax credit at statutory rates  $(921)  $(551)
Over/Under Accrual of Income Taxes   (3)   (17)
Nondeductible Expenses   23    —   
Record Tax Credits   (118)   —   
Permanent tax deduction stock options exercised   (63)   (273)
State income tax, net of federal benefits   (165)   (124)
Expiration of NOL & credits   1,492    1,149 
Effect of change in deferred tax rate   45    69 
Expiration of stock options   60    75 
Other   —      2 
Change in valuation allowance   (344)   (347)
   $6    (17)
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

 

         
   As of December 31, 
   2023   2022 
Deferred tax liabilities:          
  Excess tax depreciation  $(477)   (253)
ASC 892 Operating Lease Asset   (1,975)    —   
     Total deferred tax liabilities   (2,452)   (253)
           
Deferred tax assets:          
  Net operating loss carryforwards  $12,020   $13,416 
  179 Carryforwards   245    117 
  163(j) Business interest limitation carryforwards   302    98 
  Deferred revenue   —      202 
  Inventory and other allowances   239    177 
  Excess (tax) book depreciation   —      —   
  Excess (tax) book amortization   60    59 
  174 research & experimental expenditures   902    480 
  Share-based compensation   530    394 
  Tax Credits   118    —   
ASC 892 Operating Lease Liability    2,610   —   
  Other accrued costs   13    238 
     Total deferred tax assets   17,039    15,181 
           
  Less: Valuation allowance   (14,587)   (14,928)
Deferred income taxes  $—     $—   
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Stock Options and Stock Grants (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest.

We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. 

 

         
  

Years ended  

December 31, 

 
   2023   2022 
Share-based compensation expense  $773   $625 
Remaining unrecognized compensation expense  $1,118    1,732 
Remaining weighted average-period, expense recognition (years)   1.8    2.5 
The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

 

   Years Ended December 31, 
   2023   2022 
Weighted-average risk-free interest rates:   3.8%   3.5%
           
Dividend yield:   0%   0%
           
Weighted-average expected life (years) of the option:   4    5 
           
Weighted-average expected stock price volatility:   93%   116%
           
Weighted-average fair value of the options granted:  $0.50   $0.97 
Additional disclosures for options granted for all years presented:

Additional disclosures for options granted for all years presented:

 

   Years Ended December 31, 
   2023   2022 
Vesting period (years) of shares granted in period   3    3 
           
Contractual life (years) of shares granted in period   7    7 
           
Estimated forfeitures   8%   4%
The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023:

The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023:

 

                Weighted        
          Weighted     Average     Aggregate  
          Average     Remaining     Intrinsic  
    Shares     Exercise Price     Contractual     Value  
Options   (Rounded)     per Share     Term (Years)     (000s)  
Outstanding on January 1, 2023     3,443,661     $ 1.33       4.9       1,230  
                                 
Granted     668,200     $ 0.68                  
Exercised     (294,074 )   $ 0.50                  
Forfeited or expired     (291,821 )   $ 1.92                  
                                 
Outstanding on December 31, 2023     3,525,966     $ 1.22       4.2     $ 160  
Exercisable on December 31, 2023     2,334,458     $ 1.15       3.2     $ 160  
                                 
Shares available for grant     450,900                          
The aggregate intrinsic value in the table above is based on our closing stock price of $0.60

The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 on the last business day for the year ended December 31, 2023.

 

         
  

Years ended  

December 31, 

 
   2023   2022 
Shares exercised   294,074    414,455 
Total intrinsic value  $195   $942 
Cash received  $154   $182 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Significant Customers (Tables)
 12 Months Ended
Dec. 31, 2023
Risks and Uncertainties [Abstract]  
We had three significant customers for the year ended December 31, 2023.

We had three significant customers for the year ended December 31, 2023.

 

       For the years ended 
       December 31, 
Customer #   Product Category  2023   2022 
1   Personal Care Ingredients   25%   30%
2   Solésence®   17%   17%
3   Solésence®   15%   15%
               
    Total   57%   62%
Accounts receivable balances for these three customers were approximately:

 Accounts receivable balances for these three customers were approximately:

 

       For the years ended
December 31,		 
Customer #   Product Category  2023   2022 
1   Personal Care Ingredients  $—     $1,082 
2   Solésence®   1,288    438 
3   Solésence®   864    683 
               
    Total  $2,152   $2,202 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Business Segmentation and Geographical Distribution (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
The revenues for 2023 and 2022 by category are as follows:

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues for 2023 and 2022 by category are as follows:

 

  

For the years ended  

December 31 

 
Product Category  2023   2022 
Solésence  $25,211   $23,111 
Personal Care Ingredients   9,277    11,121 
Advanced Materials   2,809    3,085 
Total Sales  $37,297   $37,317 
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Allowance for Credit Losses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Balance, beginning $ 139 $ 0
Change in credit loss 86 139
Balance, ending $ 225 $ 139
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Balance, beginning $ 230 $ 222
Accretion of liability due to passage of time 8 8
Amortization of asset due to passage of time
Balance, ending $ 238 $ 230
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows: (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Accounts receivable, net $ 3,467 $ 4,734 $ 3,937
Contract assets     179
Contract liabilities $ 2,353 $ 2,188 $ 1,444
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Numerator: (in Thousands)    
Net loss $ (4,390) $ (2,623)
Denominator:    
Weighted average number of basic common shares outstanding 49,556,305 49,117,000
Weighted average additional shares assuming conversion of in-the-money stock options to common shares
Weighted average number of diluted common shares outstanding 49,556,305 49,117,000
Basic earnings per common share:    
Net loss per share – basic $ (0.09) $ (0.05)
Diluted earnings per common share:    
Net loss per share – diluted $ (0.09) $ (0.05)
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Accounting Standards Update [Extensible Enumeration]   Accounting Standards Update 2016-13 [Member]
Retained earnings $ 104,663 $ 100,070
Deferred revenue 2,353  
Volume Rebates   557
Revenue recognized in the reporting period included in contract liability balance at beginning of period 2,084 667
Revenue $ 37,297 $ 37,317
Anti-dilutive pptions excluded from computation of earnings per share 889,000 2,051,000
Transferred over Time [Member]    
Property, Plant and Equipment [Line Items]    
Revenue $ 656 $ 217
Medical Diagnostics Application Customer [Member]    
Property, Plant and Equipment [Line Items]    
Percentage of prepayments 97.00%  
Personal Care Ingredient Customer [Member]    
Property, Plant and Equipment [Line Items]    
Percentage of prepayments 3.00%  
Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 3 years  
Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 20 years  
Leasehold Improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 3 years  
Leasehold Improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 7 years  
Other Capitalized Property Plant and Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 7 years  
Other Capitalized Property Plant and Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 10 years  
Cumulative Effect, Period of Adoption, Adjustment [Member]    
Property, Plant and Equipment [Line Items]    
Retained earnings   $ 203
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Notes and lines of credit consist of the following: (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Nov. 13, 2023
Jan. 28, 2022
Apr. 21, 2021
Dec. 23, 2020
Nov. 16, 2018
Jul. 31, 2014
Dec. 31, 2023
Dec. 31, 2022
Sep. 08, 2020
Apr. 21, 2018
Letter of Credit [Member]                    
Line of Credit Facility [Line Items]                    
Letter of credit and related promissory note           $ 30        
Debt Instrument, Description of Variable Rate Basis           prime rate prime rate      
Debt Instrument, Basis Spread on Variable Rate           1.00% 1.00%      
Libertyville Bank and Trust [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Commitment Fee Percentage [1]             9.50%      
Available             $ 30 [1] $ 30    
Line of Credit Facility, Maximum Borrowing Capacity [1]                
Libertyville Bank and Trust One [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Commitment Fee Percentage [2]             9.50%      
Available [2]             $ 500 500    
Line of Credit Facility, Maximum Borrowing Capacity                
Beachcorp, LLC [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Commitment Fee Percentage [3],[4]             9.25%      
Available [3],[4]             $ 3,298 4,392    
Line of Credit Facility, Maximum Borrowing Capacity [3],[4]             $ 2,810 4,282    
Beachcorp, LLC One [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Commitment Fee Percentage [4],[5]             9.25%      
Available [4],[5]             $ 5,200 4,000    
Line of Credit Facility, Maximum Borrowing Capacity [4],[5]             $ 5,000 3,000    
Strandler, LLC [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Commitment Fee Percentage [4],[6]             9.25%      
Available [4],[6]             $ 1,000 1,000    
Line of Credit Facility, Maximum Borrowing Capacity [4],[6]             $ 1,000 $ 1,000    
Strandler LLC One [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Commitment Fee Percentage [7]             9.25%      
Available [7]             $ 2,000      
Line of Credit Facility, Maximum Borrowing Capacity [7]             $ 2,000      
Term Loan [Member] | Strandler, LLC [Member]                    
Line of Credit Facility [Line Items]                    
Debt Instrument, Description of Variable Rate Basis   prime rate                
Debt Instrument, Basis Spread on Variable Rate   0.75%                
Line of Credit Facility, Expiration Date Mar. 31, 2025 Mar. 31, 2024                
Term Loan [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Maximum Borrowing Capacity     $ 1,000   $ 500          
Debt Instrument, Interest Rate, Stated Percentage         8.25%          
Debt Instrument, Maturity Date         Dec. 31, 2020          
Line of Credit Facility, Expiration Date     Mar. 31, 2022              
Revolving Credit Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Maximum Borrowing Capacity   $ 8,000 $ 6,000 $ 4,000 $ 2,000       $ 2,750 $ 6,000
Debt Instrument, Description of Variable Rate Basis         prime rate          
Debt Instrument, Basis Spread on Variable Rate         3.00%          
Line of Credit Facility, Expiration Date Mar. 31, 2025 Mar. 31, 2024 Mar. 31, 2023   Mar. 31, 2020          
Revolving Credit Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member] | Minimum [Member]                    
Line of Credit Facility [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage         8.25%          
Term Loan and the Revolver Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                    
Line of Credit Facility [Line Items]                    
Debt Instrument, Description of Variable Rate Basis   prime rate prime rate              
Debt Instrument, Basis Spread on Variable Rate   0.75% 2.00%              
Debt Instrument, Maturity Date       Mar. 31, 2022 Mar. 31, 2021          
Inventory Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Maximum Borrowing Capacity     $ 4,000              
Debt Instrument, Description of Variable Rate Basis   prime rate                
Debt Instrument, Basis Spread on Variable Rate   0.75%                
Line of Credit Facility, Expiration Date   Mar. 31, 2024                
Line of Credit Percentage of Eligible inventory   50.00%                
Replacement Promissory Note [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Maximum Borrowing Capacity $ 5,200                  
Debt Instrument, Description of Variable Rate Basis prime rate                  
Debt Instrument, Basis Spread on Variable Rate 0.75%                  
Line of Credit Facility, Expiration Date Mar. 31, 2025                  
Line of Credit Percentage of Eligible inventory 55.00%                  
Bridge Note [Member] | Strandler, LLC [Member]                    
Line of Credit Facility [Line Items]                    
Line of Credit Facility, Maximum Borrowing Capacity $ 2,000                  
Debt Instrument, Description of Variable Rate Basis prime rate                  
Debt Instrument, Basis Spread on Variable Rate 0.75%                  
Line of Credit Facility, Expiration Date May 13, 2024                  
[1] Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.
[2] The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Interest on drawn balances was at the prime rate plus 1%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2024. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.
[3] On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On November 13, 2023 the Company entered into a First Amendment to the A&R Loan Agreement extending the maturity of the A/R Revolver Facility to March 31, 2025.
[4] On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000 to $2,750.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750 to $4,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000 to $6,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500 to $1,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.
[5] On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024. On November 13, 2023 the company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%, and it now matures on March 31, 2025.
[6] On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On November 13, 2023 the Company entered into the First Amendment To the New Term Loan Agreement with Strandler, LLC, which extended the maturity of the New Term Loan Agreement to March 31, 2025.
[7] On November 13, 2023 the Company entered into a new Promissory Note (“Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is $2,000. The interest rate for the Bridge Note is at the prime rate plus 0.75%, and it matures on May 13, 2024.
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Related Parties (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Line of Credit Facility [Line Items]    
Interest expense related party $ 770 $ 356
Accrued interest expense, related parties 81 49
Beachcorp, LLC [Member]    
Line of Credit Facility [Line Items]    
Outstanding balances associated with related partie 7,810 7,282
Strandler, LLC [Member]    
Line of Credit Facility [Line Items]    
Outstanding balances associated with related partie $ 3,000 $ 1,000
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Related Party Notes and Lines of Credit (Details Narrative) - Business Loan Agreement [Member] - Strandler, LLC and Beachcorp, LLC [Member]
Mar. 01, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Line of Credit Facility, Expiration Date   Mar. 31, 2025
Subsequent Event [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Line of Credit Facility, Expiration Date Oct. 01, 2025  
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Inventories consist of the following: (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 8,524 $ 7,298
Finished goods 2,184 2,041
Inventory reserve (677) (500)
      Total Inventories, net $ 10,031 $ 8,839
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Equipment and leasehold improvements consist of the following: (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross $ 30,567 $ 29,115
Less: Accumulated depreciation and amortization (21,899) (21,166)
Property, Plant and Equipment, Net, Total 8,668 7,949
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 23,339 19,899
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 1,014 1,014
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 126 110
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 5,157 5,140
Construction in Progress [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross $ 931 $ 2,952
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Equipment and Leasehold Improvements (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 732 $ 557
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Quantitative information regarding the Company’s leases is as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Finance lease cost components:    
Amortization of finance lease assets $ 33
Interest on finance lease liabilities 4
Total finance lease costs 37
Operating lease cost components:    
Operating lease cost 1,881 2,068
Variable lease cost 581 536
Short-term lease cost 112 138
Sub-lease income (786) (689)
Total operating lease costs 1,788 2,053
Total lease cost $ 1,788 $ 2,090
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Lease Commitments    
Operating cash outflow from operating leases $ 172 $ 1,433
Lease liabilities arising from obtaining right-of-use assets $ 182 12
Early termination of operating lease   73
Reduction in right of use asset due to remeasurement   (1,793)
Reduction in lease liability due to remeasurement   $ (1,898)
Weighted-average remaining lease term-operating leases (in years) 7 years 10 months 24 days 9 years 7 months 6 days
Weighted-average discount rate-operating leases 7.10% 7.60%
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.1
The future maturities of the Company’s operating leases as of December 31, 2023 are as follows: (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Lease Commitments  
2024 $ 1,968
2025 1,483
2026 1,481
2027 1,520
2028 1,549
Thereafter 5,613
Total payments 13,614
Less amounts representing interest (3,165)
Total minimum payments required $ 10,449
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.1
The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance. (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Lessee, Lease, Description [Line Items]  
2024 $ 297,636
2025 128,640
January - May [Member]  
Lessee, Lease, Description [Line Items]  
2024 124,015
2025 128,640
June - December [Member]  
Lessee, Lease, Description [Line Items]  
2024 173,621
2025
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Lease Commitments (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Lease Commitments    
Operating leases, right of use $ 7,907 $ 8,978
Current portion of operating lease obligations 1,297 0
Long-term portion of operating lease obligations 9,152 $ 9,823
Tenant improvement allowances 1,957  
Operating lease payment net $ 97  
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Accrued expenses consist of the following: (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued payroll and related expenses $ 255 $ 288
Accrued accounts payable 128 403
Tenant security deposit / advance rent 61
Other 486 271
 Total $ 869 $ 1,023
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.1
A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Income tax credit at statutory rates $ (921) $ (551)
Over/Under Accrual of Income Taxes (3) (17)
Nondeductible Expenses 23
Record Tax Credits (118)
Permanent tax deduction stock options exercised (63) (273)
State income tax, net of federal benefits (165) (124)
Expiration of NOL & credits 1,492 1,149
Effect of change in deferred tax rate 45 69
Expiration of stock options 60 75
Other 2
Change in valuation allowance (344) (347)
  $ 6 $ (17)
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred tax liabilities:    
  Excess tax depreciation $ (477) $ (253)
ASC 892 Operating Lease Asset (1,975)
     Total deferred tax liabilities (2,452) (253)
Deferred tax assets:    
  Net operating loss carryforwards 12,020 13,416
  179 Carryforwards 245 117
  163(j) Business interest limitation carryforwards 302 98
  Deferred revenue 202
  Inventory and other allowances 239 177
  Excess (tax) book depreciation
  Excess (tax) book amortization 60 59
  174 research & experimental expenditures 902 480
  Share-based compensation 530 394
  Tax Credits 118
ASC 892 Operating Lease Liability 2,610
  Other accrued costs 13 238
     Total deferred tax assets 17,039 15,181
  Less: Valuation allowance (14,587) (14,928)
Deferred income taxes
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating Loss Carryforwards [Line Items]    
Income tax provision $ 6 $ (17)
Increase (decrease) in valuation allowance 300 300
Valuation allowance, net operating loss carryforwards and credits 7,100 $ 5,500
Net operating loss carryforwards 50,000  
General Business Tax Credit Carryforward [Member]    
Operating Loss Carryforwards [Line Items]    
Carryforwards $ 200  
Domestic Tax Authority [Member]    
Operating Loss Carryforwards [Line Items]    
Operating loss carryforwards expiration period start 2024  
Operating loss carryforwards expiration period end 2037  
State and Local Jurisdiction [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards $ 21,300  
Operating loss carryforwards expiration period start 2029  
Operating loss carryforwards expiration period end 2039  
Tax Year 2023 [Member]    
Operating Loss Carryforwards [Line Items]    
Income tax provision $ 6  
Expiring2023 To2037 [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards 44,000  
Tax Year 2018 [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards $ 5,600  
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Capital Stock (Details Narrative) - USD ($)
Mar. 01, 2024
Dec. 31, 2023
Dec. 31, 2022
Class of Stock [Line Items]      
Preferred stock, shares authorized   24,088 24,088
Subsequent Event [Member] | Series X Preferred Stock [Member]      
Class of Stock [Line Items]      
Number of shares issued 15,000    
Price per share $ 400    
Consideration from sale of shares $ 6,000,000    
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.1
We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Share-based compensation expense $ 773 $ 625
Remaining unrecognized compensation expense $ 1,118 $ 1,732
Remaining weighted average-period, expense recognition (years) 1 year 9 months 18 days 2 years 6 months
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.1
The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]    
Weighted-average risk-free interest rates 3.80% 3.50%
Dividend yield 0.00% 0.00%
Weighted-average expected life (years) of the option 4 years 5 years
Weighted-average expected stock price volatility 93.00% 116.00%
Weighted-average fair value of the options granted $ 0.50 $ 0.97
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Additional disclosures for options granted for all years presented: (Details) - Share-Based Payment Arrangement, Option [Member]
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Vesting period (years) of shares granted in period 3 years 3 years
Contractual life (years) of shares granted in period 7 years 7 years
Estimated forfeitures 8.00% 4.00%
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.1
The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023: (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Shares Outstanding, Beginning 3,443,661
Shares Outstanding Beginning, (per share) | $ / shares $ 1.33
Weighted Average Remaining Contractual Term, Outstanding, end 4 years 10 months 24 days
Shares Outstanding (Intrinsic value) | $ $ 1,230
Granted 668,200
Granted (per share) | $ / shares $ 0.68
Exercised (294,074)
Exercised (per share) | $ / shares $ 0.50
Forfeited or expired (291,821)
Forfeited or expired (per share) | $ / shares $ 1.92
Shares Outstanding, Beginning 3,525,966
Shares Outstanding Beginning, (per share) | $ / shares $ 1.22
Weighted Average Remaining Contractual Term, Outstanding, end 4 years 2 months 12 days
Shares Outstanding (Intrinsic value) | $ $ 160
Shares Exercisable 2,334,458
Shares Exercisable, (per share) | $ / shares $ 1.15
Shares Exercisable (years) 3 years 2 months 12 days
Shares Exercisable (Intrinsic value) | $ $ 160
Shares available for grant 450,900
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.1
The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Shares exercised 294,074  
Cash received $ 73 $ 182
Share-Based Payment Arrangement, Option [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Closing stock share price $ 0.60  
Shares exercised 294,074 414,455
Total intrinsic value $ 195 $ 942
Cash received $ 154 $ 182
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.24.1
Stock Options and Stock Grants (Details Narrative)
 12 Months Ended
Dec. 31, 2023
Prior to Equity Compensation Plan 2019 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Shares based compensation payment award expiration period 10 years
Equity Compensation Plan 2019 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Shares based compensation payment award expiration period 7 years
Equity Compensation Plan 2010 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Shares based compensation payment award expiration period 10 years
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.24.1
401(k) Profit-Sharing Plan (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Retirement Benefits [Abstract]    
Defined contribution plan, cost $ 191 $ 153
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.24.1
We had three significant customers for the year ended December 31, 2023. (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Customer One [Member]    
Concentration Risk [Line Items]    
Revenue from customers 25.00% 30.00%
Customer Two [Member]    
Concentration Risk [Line Items]    
Revenue from customers 17.00% 17.00%
Customer Three [Member]    
Concentration Risk [Line Items]    
Revenue from customers 15.00% 15.00%
Customers One Through Three [Member]    
Concentration Risk [Line Items]    
Revenue from customers 57.00% 62.00%
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.24.1
Accounts receivable balances for these three customers were approximately: (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Total $ 2,152 $ 2,202
Customer One [Member]    
Total 1,082
Customer Two [Member]    
Total 1,288 438
Customer Three [Member]    
Total $ 864 $ 683
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.24.1
Significant Customers (Details Narrative) - Supply Commitment [Member]
Dec. 31, 2023
Supply Commitment [Line Items]  
Equipment sale - net book value 115.00%
Equipment sale- original book value 30.00%
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.24.1
The revenues for 2023 and 2022 by category are as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue from External Customer [Line Items]    
Total revenue $ 37,297 $ 37,317
Solesence [Member]    
Revenue from External Customer [Line Items]    
Total revenue 25,211 23,111
Personal Care ingredients [Member]    
Revenue from External Customer [Line Items]    
Total revenue 9,277 11,121
Advanced Materials [Member]    
Revenue from External Customer [Line Items]    
Total revenue $ 2,809 $ 3,085
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.24.1
Business Segmentation and Geographical Distribution (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues $ 1,664 $ 1,236
Non-US [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues $ 2,918 $ 1,971
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.24.1
Subsequent Event (Details Narrative)
Mar. 01, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Subsequent Event [Line Items]      
Common stock, par value (in dollars per share) | $ / shares   $ 0.01 $ 0.01
Common stock, authorized | shares   60,000,000 60,000,000
Business Loan Agreement [Member] | Strandler, LLC and Beachcorp, LLC [Member]      
Subsequent Event [Line Items]      
Line of Credit Facility, Expiration Date   Mar. 31, 2025  
Subsequent Event [Member]      
Subsequent Event [Line Items]      
Common stock, par value (in dollars per share) | $ / shares $ 0.01    
Common stock, authorized | shares 60,000,000    
Subsequent Event [Member] | Business Loan Agreement [Member] | Strandler, LLC and Beachcorp, LLC [Member]      
Subsequent Event [Line Items]      
Line of Credit Facility, Expiration Date Oct. 01, 2025    
Subsequent Event [Member] | Series X Preferred Stock [Member]      
Subsequent Event [Line Items]      
Number of shares issued | shares 15,000    
Price per share | $ / shares $ 400    
Consideration from sale of shares | $ $ 6,000,000    
Common stock, authorized for conversion of preferred stock | shares 95,000,000    
Shares issued upon conversion per share | shares 1,000    
Conversion price | $ / shares $ 420    
Interest rate 0.10    
Liquidation preference | $ / shares $ 400    
EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 81 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 144 315 1 true 62 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://nanophase.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://nanophase.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://nanophase.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://nanophase.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - Description of Business Sheet http://nanophase.com/role/DescriptionOfBusiness Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Related Party Notes and Lines of Credit Notes http://nanophase.com/role/RelatedPartyNotesAndLinesOfCredit Related Party Notes and Lines of Credit Notes 9 false false R10.htm 00000010 - Disclosure - Inventories Sheet http://nanophase.com/role/Inventories Inventories Notes 10 false false R11.htm 00000011 - Disclosure - Equipment and Leasehold Improvements Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovements Equipment and Leasehold Improvements Notes 11 false false R12.htm 00000012 - Disclosure - Lease Commitments Sheet http://nanophase.com/role/LeaseCommitments Lease Commitments Notes 12 false false R13.htm 00000013 - Disclosure - Accrued Expenses Sheet http://nanophase.com/role/AccruedExpenses Accrued Expenses Notes 13 false false R14.htm 00000014 - Disclosure - Income Taxes Sheet http://nanophase.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 00000015 - Disclosure - Capital Stock Sheet http://nanophase.com/role/CapitalStock Capital Stock Notes 15 false false R16.htm 00000016 - Disclosure - Stock Options and Stock Grants Sheet http://nanophase.com/role/StockOptionsAndStockGrants Stock Options and Stock Grants Notes 16 false false R17.htm 00000017 - Disclosure - 401(k) Profit-Sharing Plan Sheet http://nanophase.com/role/KProfit-sharingPlan 401(k) Profit-Sharing Plan Notes 17 false false R18.htm 00000018 - Disclosure - Significant Customers Sheet http://nanophase.com/role/SignificantCustomers Significant Customers Notes 18 false false R19.htm 00000019 - Disclosure - Business Segmentation and Geographical Distribution Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution Business Segmentation and Geographical Distribution Notes 19 false false R20.htm 00000020 - Disclosure - Commitments and Contingencies Sheet http://nanophase.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 00000021 - Disclosure - Subsequent Event Sheet http://nanophase.com/role/SubsequentEvent Subsequent Event Notes 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://nanophase.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://nanophase.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Related Party Notes and Lines of Credit (Tables) Notes http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditTables Related Party Notes and Lines of Credit (Tables) Tables http://nanophase.com/role/RelatedPartyNotesAndLinesOfCredit 24 false false R25.htm 00000025 - Disclosure - Inventories (Tables) Sheet http://nanophase.com/role/InventoriesTables Inventories (Tables) Tables http://nanophase.com/role/Inventories 25 false false R26.htm 00000026 - Disclosure - Equipment and Leasehold Improvements (Tables) Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables Equipment and Leasehold Improvements (Tables) Tables http://nanophase.com/role/EquipmentAndLeaseholdImprovements 26 false false R27.htm 00000027 - Disclosure - Lease Commitments (Tables) Sheet http://nanophase.com/role/LeaseCommitmentsTables Lease Commitments (Tables) Tables http://nanophase.com/role/LeaseCommitments 27 false false R28.htm 00000028 - Disclosure - Accrued Expenses (Tables) Sheet http://nanophase.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://nanophase.com/role/AccruedExpenses 28 false false R29.htm 00000029 - Disclosure - Income Taxes (Tables) Sheet http://nanophase.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://nanophase.com/role/IncomeTaxes 29 false false R30.htm 00000030 - Disclosure - Stock Options and Stock Grants (Tables) Sheet http://nanophase.com/role/StockOptionsAndStockGrantsTables Stock Options and Stock Grants (Tables) Tables http://nanophase.com/role/StockOptionsAndStockGrants 30 false false R31.htm 00000031 - Disclosure - Significant Customers (Tables) Sheet http://nanophase.com/role/SignificantCustomersTables Significant Customers (Tables) Tables http://nanophase.com/role/SignificantCustomers 31 false false R32.htm 00000032 - Disclosure - Business Segmentation and Geographical Distribution (Tables) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables Business Segmentation and Geographical Distribution (Tables) Tables http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution 32 false false R33.htm 00000033 - Disclosure - Allowance for Credit Losses (Details) Sheet http://nanophase.com/role/AllowanceForCreditLossesDetails Allowance for Credit Losses (Details) Details 33 false false R34.htm 00000034 - Disclosure - Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details) Sheet http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details) Details 34 false false R35.htm 00000035 - Disclosure - Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows: (Details) Sheet http://nanophase.com/role/ContractBalancesForYearsEndedDecember3120232022And2021AreAsFollowsDetails Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows: (Details) Details 35 false false R36.htm 00000036 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) Sheet http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) Details 36 false false R37.htm 00000037 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables 37 false false R38.htm 00000038 - Disclosure - Notes and lines of credit consist of the following: (Details) Notes http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails Notes and lines of credit consist of the following: (Details) Details 38 false false R39.htm 00000039 - Disclosure - Schedule of Related Parties (Details) Sheet http://nanophase.com/role/ScheduleOfRelatedPartiesDetails Schedule of Related Parties (Details) Details 39 false false R40.htm 00000040 - Disclosure - Related Party Notes and Lines of Credit (Details Narrative) Notes http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative Related Party Notes and Lines of Credit (Details Narrative) Details http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditTables 40 false false R41.htm 00000041 - Disclosure - Inventories consist of the following: (Details) Sheet http://nanophase.com/role/InventoriesConsistOfFollowingDetails Inventories consist of the following: (Details) Details 41 false false R42.htm 00000042 - Disclosure - Equipment and leasehold improvements consist of the following: (Details) Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails Equipment and leasehold improvements consist of the following: (Details) Details 42 false false R43.htm 00000043 - Disclosure - Equipment and Leasehold Improvements (Details Narrative) Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative Equipment and Leasehold Improvements (Details Narrative) Details http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables 43 false false R44.htm 00000044 - Disclosure - Quantitative information regarding the Company???s leases is as follows: (Details) Sheet http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails Quantitative information regarding the Company???s leases is as follows: (Details) Details 44 false false R45.htm 00000045 - Disclosure - Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022: (Details) Sheet http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312023And2022Details Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022: (Details) Details 45 false false R46.htm 00000046 - Disclosure - The future maturities of the Company???s operating leases as of December 31, 2023 are as follows: (Details) Sheet http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails The future maturities of the Company???s operating leases as of December 31, 2023 are as follows: (Details) Details 46 false false R47.htm 00000047 - Disclosure - The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance. (Details) Sheet http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance. (Details) Details 47 false false R48.htm 00000048 - Disclosure - Lease Commitments (Details Narrative) Sheet http://nanophase.com/role/LeaseCommitmentsDetailsNarrative Lease Commitments (Details Narrative) Details http://nanophase.com/role/LeaseCommitmentsTables 48 false false R49.htm 00000049 - Disclosure - Accrued expenses consist of the following: (Details) Sheet http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails Accrued expenses consist of the following: (Details) Details 49 false false R50.htm 00000050 - Disclosure - A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows: (Details) Sheet http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows: (Details) Details 50 false false R51.htm 00000051 - Disclosure - Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details) Sheet http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details) Details 51 false false R52.htm 00000052 - Disclosure - Income Taxes (Details Narrative) Sheet http://nanophase.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://nanophase.com/role/IncomeTaxesTables 52 false false R53.htm 00000053 - Disclosure - Capital Stock (Details Narrative) Sheet http://nanophase.com/role/CapitalStockDetailsNarrative Capital Stock (Details Narrative) Details http://nanophase.com/role/CapitalStock 53 false false R54.htm 00000054 - Disclosure - We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) Sheet http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) Details 54 false false R55.htm 00000055 - Disclosure - The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details) Sheet http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details) Details 55 false false R56.htm 00000056 - Disclosure - Additional disclosures for options granted for all years presented: (Details) Sheet http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails Additional disclosures for options granted for all years presented: (Details) Details 56 false false R57.htm 00000057 - Disclosure - The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023: (Details) Sheet http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023: (Details) Details 57 false false R58.htm 00000058 - Disclosure - The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 (Details) Sheet http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 (Details) Details 58 false false R59.htm 00000059 - Disclosure - Stock Options and Stock Grants (Details Narrative) Sheet http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative Stock Options and Stock Grants (Details Narrative) Details http://nanophase.com/role/StockOptionsAndStockGrantsTables 59 false false R60.htm 00000060 - Disclosure - 401(k) Profit-Sharing Plan (Details Narrative) Sheet http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative 401(k) Profit-Sharing Plan (Details Narrative) Details http://nanophase.com/role/KProfit-sharingPlan 60 false false R61.htm 00000061 - Disclosure - We had three significant customers for the year ended December 31, 2023. (Details) Sheet http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details We had three significant customers for the year ended December 31, 2023. (Details) Details 61 false false R62.htm 00000062 - Disclosure - Accounts receivable balances for these three customers were approximately: (Details) Sheet http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails Accounts receivable balances for these three customers were approximately: (Details) Details 62 false false R63.htm 00000063 - Disclosure - Significant Customers (Details Narrative) Sheet http://nanophase.com/role/SignificantCustomersDetailsNarrative Significant Customers (Details Narrative) Details http://nanophase.com/role/SignificantCustomersTables 63 false false R64.htm 00000064 - Disclosure - The revenues for 2023 and 2022 by category are as follows: (Details) Sheet http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails The revenues for 2023 and 2022 by category are as follows: (Details) Details 64 false false R65.htm 00000065 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative Business Segmentation and Geographical Distribution (Details Narrative) Details http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables 65 false false R66.htm 00000066 - Disclosure - Subsequent Event (Details Narrative) Sheet http://nanophase.com/role/SubsequentEventDetailsNarrative Subsequent Event (Details Narrative) Details http://nanophase.com/role/SubsequentEvent 66 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate - nanx-10k_123123.htm 27 nanx-10k_123123.htm nanx-20231231.xsd nanx-20231231_cal.xml nanx-20231231_def.xml nanx-20231231_lab.xml nanx-20231231_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 86 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nanx-10k_123123.htm": { "nsprefix": "nanx", "nsuri": "http://nanophase.com/20231231", "dts": { "inline": { "local": [ "nanx-10k_123123.htm" ] }, "schema": { "local": [ "nanx-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "nanx-20231231_cal.xml" ] }, "definitionLink": { "local": [ "nanx-20231231_def.xml" ] }, "labelLink": { "local": [ "nanx-20231231_lab.xml" ] }, "presentationLink": { "local": [ "nanx-20231231_pre.xml" ] } }, "keyStandard": 279, "keyCustom": 36, "axisStandard": 24, "axisCustom": 0, "memberStandard": 30, "memberCustom": 29, "hidden": { "total": 71, "http://fasb.org/us-gaap/2023": 59, "http://nanophase.com/20231231": 7, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 144, "entityCount": 1, "segmentCount": 62, "elementCount": 519, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 635, "http://xbrl.sec.gov/dei/2023": 34 }, "report": { "R1": { "role": "http://nanophase.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R2": { "role": "http://nanophase.com/role/ConsolidatedBalanceSheets", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R3": { "role": "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R4": { "role": "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R5": { "role": "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R6": { "role": "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R7": { "role": "http://nanophase.com/role/DescriptionOfBusiness", "longName": "00000007 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R8": { "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R9": { "role": "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCredit", "longName": "00000009 - Disclosure - Related Party Notes and Lines of Credit", "shortName": "Related Party Notes and Lines of Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R10": { "role": "http://nanophase.com/role/Inventories", "longName": "00000010 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R11": { "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovements", "longName": "00000011 - Disclosure - Equipment and Leasehold Improvements", "shortName": "Equipment and Leasehold Improvements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R12": { "role": "http://nanophase.com/role/LeaseCommitments", "longName": "00000012 - Disclosure - Lease Commitments", "shortName": "Lease Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "nanx:LeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "nanx:LeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R13": { "role": "http://nanophase.com/role/AccruedExpenses", "longName": "00000013 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R14": { "role": "http://nanophase.com/role/IncomeTaxes", "longName": "00000014 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R15": { "role": "http://nanophase.com/role/CapitalStock", "longName": "00000015 - Disclosure - Capital Stock", "shortName": "Capital Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R16": { "role": "http://nanophase.com/role/StockOptionsAndStockGrants", "longName": "00000016 - Disclosure - Stock Options and Stock Grants", "shortName": "Stock Options and Stock Grants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R17": { "role": "http://nanophase.com/role/KProfit-sharingPlan", "longName": "00000017 - Disclosure - 401(k) Profit-Sharing Plan", "shortName": "401(k) Profit-Sharing Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R18": { "role": "http://nanophase.com/role/SignificantCustomers", "longName": "00000018 - Disclosure - Significant Customers", "shortName": "Significant Customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R19": { "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution", "longName": "00000019 - Disclosure - Business Segmentation and Geographical Distribution", "shortName": "Business Segmentation and Geographical Distribution", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R20": { "role": "http://nanophase.com/role/CommitmentsAndContingencies", "longName": "00000020 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R21": { "role": "http://nanophase.com/role/SubsequentEvent", "longName": "00000021 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R22": { "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000022 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R23": { "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R24": { "role": "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditTables", "longName": "00000024 - Disclosure - Related Party Notes and Lines of Credit (Tables)", "shortName": "Related Party Notes and Lines of Credit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R25": { "role": "http://nanophase.com/role/InventoriesTables", "longName": "00000025 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R26": { "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables", "longName": "00000026 - Disclosure - Equipment and Leasehold Improvements (Tables)", "shortName": "Equipment and Leasehold Improvements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R27": { "role": "http://nanophase.com/role/LeaseCommitmentsTables", "longName": "00000027 - Disclosure - Lease Commitments (Tables)", "shortName": "Lease Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R28": { "role": "http://nanophase.com/role/AccruedExpensesTables", "longName": "00000028 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R29": { "role": "http://nanophase.com/role/IncomeTaxesTables", "longName": "00000029 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R30": { "role": "http://nanophase.com/role/StockOptionsAndStockGrantsTables", "longName": "00000030 - Disclosure - Stock Options and Stock Grants (Tables)", "shortName": "Stock Options and Stock Grants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R31": { "role": "http://nanophase.com/role/SignificantCustomersTables", "longName": "00000031 - Disclosure - Significant Customers (Tables)", "shortName": "Significant Customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R32": { "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables", "longName": "00000032 - Disclosure - Business Segmentation and Geographical Distribution (Tables)", "shortName": "Business Segmentation and Geographical Distribution (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R33": { "role": "http://nanophase.com/role/AllowanceForCreditLossesDetails", "longName": "00000033 - Disclosure - Allowance for Credit Losses (Details)", "shortName": "Allowance for Credit Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R34": { "role": "http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails", "longName": "00000034 - Disclosure - Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details)", "shortName": "Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AssetRetirementObligationsNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:AssetRetirementObligationsNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "us-gaap:AssetRetirementObligationsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R35": { "role": "http://nanophase.com/role/ContractBalancesForYearsEndedDecember3120232022And2021AreAsFollowsDetails", "longName": "00000035 - Disclosure - Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows: (Details)", "shortName": "Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R36": { "role": "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails", "longName": "00000036 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details)", "shortName": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000037 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R38": { "role": "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "longName": "00000038 - Disclosure - Notes and lines of credit consist of the following: (Details)", "shortName": "Notes and lines of credit consist of the following: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2014-07-31_us-gaap_LetterOfCreditMember", "name": "us-gaap:ShortTermBorrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2014-07-31_us-gaap_LetterOfCreditMember", "name": "us-gaap:ShortTermBorrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R39": { "role": "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails", "longName": "00000039 - Disclosure - Schedule of Related Parties (Details)", "shortName": "Schedule of Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "nanx:RelatedPartyInterestExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "nanx:RelatedPartyInterestExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R40": { "role": "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "longName": "00000040 - Disclosure - Related Party Notes and Lines of Credit (Details Narrative)", "shortName": "Related Party Notes and Lines of Credit (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2023-12-302023-12-31_custom_BusinessLoanAgreementMember_custom_StrandlerLLCAndBeachcorpLLCMember", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://nanophase.com/role/InventoriesConsistOfFollowingDetails", "longName": "00000041 - Disclosure - Inventories consist of the following: (Details)", "shortName": "Inventories consist of the following: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R42": { "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "longName": "00000042 - Disclosure - Equipment and leasehold improvements consist of the following: (Details)", "shortName": "Equipment and leasehold improvements consist of the following: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R43": { "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative", "longName": "00000043 - Disclosure - Equipment and Leasehold Improvements (Details Narrative)", "shortName": "Equipment and Leasehold Improvements (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R44": { "role": "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails", "longName": "00000044 - Disclosure - Quantitative information regarding the Company\u2019s leases is as follows: (Details)", "shortName": "Quantitative information regarding the Company\u2019s leases is as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R45": { "role": "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312023And2022Details", "longName": "00000045 - Disclosure - Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022: (Details)", "shortName": "Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "nanx:SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "nanx:SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R46": { "role": "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails", "longName": "00000046 - Disclosure - The future maturities of the Company\u2019s operating leases as of December 31, 2023 are as follows: (Details)", "shortName": "The future maturities of the Company\u2019s operating leases as of December 31, 2023 are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R47": { "role": "http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details", "longName": "00000047 - Disclosure - The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance. (Details)", "shortName": "The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R48": { "role": "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative", "longName": "00000048 - Disclosure - Lease Commitments (Details Narrative)", "shortName": "Lease Commitments (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:TenantImprovements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "nanx:LeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R49": { "role": "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails", "longName": "00000049 - Disclosure - Accrued expenses consist of the following: (Details)", "shortName": "Accrued expenses consist of the following: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R50": { "role": "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails", "longName": "00000050 - Disclosure - A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows: (Details)", "shortName": "A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R51": { "role": "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails", "longName": "00000051 - Disclosure - Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details)", "shortName": "Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R52": { "role": "http://nanophase.com/role/IncomeTaxesDetailsNarrative", "longName": "00000052 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R53": { "role": "http://nanophase.com/role/CapitalStockDetailsNarrative", "longName": "00000053 - Disclosure - Capital Stock (Details Narrative)", "shortName": "Capital Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details", "longName": "00000054 - Disclosure - We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details)", "shortName": "We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:StockOptionPlanExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:StockOptionPlanExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R55": { "role": "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails", "longName": "00000055 - Disclosure - The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details)", "shortName": "The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R56": { "role": "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "longName": "00000056 - Disclosure - Additional disclosures for options granted for all years presented: (Details)", "shortName": "Additional disclosures for options granted for all years presented: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "nanx:AdditionalDisclosuresForOptionsGrantedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "nanx:AdditionalDisclosuresForOptionsGrantedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R57": { "role": "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details", "longName": "00000057 - Disclosure - The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023: (Details)", "shortName": "The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R58": { "role": "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details", "longName": "00000058 - Disclosure - The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 (Details)", "shortName": "The aggregate intrinsic value in the table above is based on our closing stock price of $0.60 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "p", "nanx:StockOptionsRecognizedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R59": { "role": "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "longName": "00000059 - Disclosure - Stock Options and Stock Grants (Details Narrative)", "shortName": "Stock Options and Stock Grants (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_PriorToEquityCompensationPlan2019Member", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_PriorToEquityCompensationPlan2019Member", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R60": { "role": "http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative", "longName": "00000060 - Disclosure - 401(k) Profit-Sharing Plan (Details Narrative)", "shortName": "401(k) Profit-Sharing Plan (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R61": { "role": "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details", "longName": "00000061 - Disclosure - We had three significant customers for the year ended December 31, 2023. (Details)", "shortName": "We had three significant customers for the year ended December 31, 2023. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R62": { "role": "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "longName": "00000062 - Disclosure - Accounts receivable balances for these three customers were approximately: (Details)", "shortName": "Accounts receivable balances for these three customers were approximately: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "nanx:ContractWithCustomerAccountReceivablesTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "nanx:ContractWithCustomerAccountReceivablesTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R63": { "role": "http://nanophase.com/role/SignificantCustomersDetailsNarrative", "longName": "00000063 - Disclosure - Significant Customers (Details Narrative)", "shortName": "Significant Customers (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_SupplyCommitmentMember", "name": "nanx:EquipmentSaleNetBookValueEquipment", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_SupplyCommitmentMember", "name": "nanx:EquipmentSaleNetBookValueEquipment", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R64": { "role": "http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails", "longName": "00000064 - Disclosure - The revenues for 2023 and 2022 by category are as follows: (Details)", "shortName": "The revenues for 2023 and 2022 by category are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_SolesenceMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } }, "R65": { "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "longName": "00000065 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative)", "shortName": "Business Segmentation and Geographical Distribution (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_ProductMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_ProductMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true, "unique": true } }, "R66": { "role": "http://nanophase.com/role/SubsequentEventDetailsNarrative", "longName": "00000066 - Disclosure - Subsequent Event (Details Narrative)", "shortName": "Subsequent Event (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-01_us-gaap_SubsequentEventMember", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10k_123123.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdateExtensibleList", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Extensible Enumeration]", "documentation": "Indicates amendment to accounting standards." } } }, "auth_ref": [ "r149", "r150", "r151", "r152", "r153", "r196", "r197", "r198", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r274", "r392", "r393", "r394", "r413", "r414", "r420", "r421", "r422", "r428", "r429", "r430", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r454", "r455", "r456", "r457", "r465", "r466", "r468", "r469", "r470", "r488", "r489", "r490", "r491", "r492", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r740" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r19" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18", "r684" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Allowance for Credit Losses", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r744" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade accounts receivable", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r166", "r251", "r252", "r664" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/ContractBalancesForYearsEndedDecember3120232022And2021AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Trade accounts receivable, net", "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r251", "r252" ] }, "us-gaap_AccretionExpenseIncludingAssetRetirementObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionExpenseIncludingAssetRetirementObligations", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of asset due to passage of time", "documentation": "Amount of accretion expense, which includes, but is not limited to, accretion expense from asset retirement obligations, environmental remediation obligations, and other contingencies." } } }, "auth_ref": [ "r745" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails", "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r48", "r160", "r525" ] }, "nanx_AdditionalDisclosuresForOptionsGrantedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20231231", "localname": "AdditionalDisclosuresForOptionsGrantedTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "Additional disclosures for options granted for all years presented:", "documentation": "The element represents additional disclosures for options granted table text block." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r86", "r684", "r812" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r392", "r393", "r394", "r559", "r737", "r738", "r739", "r788", "r814" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r60", "r61", "r358" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Rights offering expense", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r10", "r116" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "auth_ref": [] }, "nanx_AdvancedMaterialsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "AdvancedMaterialsMember", "presentation": [ "http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Advanced Materials [Member]", "documentation": "The element represents advanced materials member." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/AllowanceForCreditLossesDetails", "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Allowance for Credit Losses", "periodStartLabel": "Balance, beginning", "periodEndLabel": "Balance, ending", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r167", "r255", "r270" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "presentation": [ "http://nanophase.com/role/AllowanceForCreditLossesDetails" ], "lang": { "en-us": { "role": { "label": "Change in credit loss", "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r744" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r712" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive pptions excluded from computation of earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r219" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r423" ] }, "us-gaap_AssetRetirementObligationAccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationAccretionExpense", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Accretion of liability due to passage of time", "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability." } } }, "auth_ref": [ "r276", "r277" ] }, "us-gaap_AssetRetirementObligationsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationsNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails", "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Asset retirement obligations", "periodStartLabel": "Balance, beginning", "periodEndLabel": "Balance, ending", "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r746" ] }, "us-gaap_AssetRetirementObligationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationsPolicy", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Asset Retirement Obligations", "documentation": "Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset." } } }, "auth_ref": [ "r275" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r123", "r162", "r188", "r228", "r237", "r242", "r259", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r424", "r426", "r453", "r518", "r596", "r684", "r697", "r751", "r752", "r796" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r155", "r170", "r188", "r259", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r424", "r426", "r453", "r684", "r751", "r752", "r796" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r712" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r709", "r711", "r712" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r709", "r711", "r712" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r709", "r711", "r712" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387" ] }, "nanx_BeachcorpLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "BeachcorpLLCMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Beachcorp, LLC [Member]", "documentation": "The element represents beachcorp l l c member." } } }, "auth_ref": [] }, "nanx_BeachcorpLLCOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "BeachcorpLLCOneMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Beachcorp, LLC One [Member]", "documentation": "Beachcorp, LLC One." } } }, "auth_ref": [] }, "nanx_BridgeNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "BridgeNoteMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Bridge Note [Member]", "documentation": "Bridge Note." } } }, "auth_ref": [] }, "nanx_BusinessLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "BusinessLoanAgreementMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business Loan Agreement [Member]", "documentation": "The element represents business loan agreement member." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable incurred for the purchase of equipment and leasehold improvements", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r29", "r158", "r662" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r30" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r29", "r101", "r184" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "(Decrease) increase in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r101" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental non-cash investing and financing activity:" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r148", "r163", "r164", "r165", "r188", "r210", "r214", "r216", "r218", "r222", "r223", "r259", "r284", "r286", "r287", "r288", "r291", "r292", "r307", "r308", "r312", "r315", "r323", "r453", "r553", "r554", "r555", "r556", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r584", "r605", "r623", "r638", "r639", "r640", "r641", "r642", "r719", "r734", "r741" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r163", "r164", "r165", "r222", "r307", "r308", "r310", "r312", "r315", "r321", "r323", "r553", "r554", "r555", "r556", "r674", "r719", "r734" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r423" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contingent liabilities", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r26", "r72", "r519", "r583" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r110", "r278", "r279", "r646", "r748" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r687", "r688", "r689", "r691", "r692", "r693", "r694", "r737", "r738", "r788", "r811", "r814" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r85" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r85", "r584" ] }, "nanx_CommonStockSharesAuthorizedForConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://nanophase.com/20231231", "localname": "CommonStockSharesAuthorizedForConversionOfPreferredStock", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized for conversion of preferred stock", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws for conversion of preferred stock." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r85" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r85", "r584", "r602", "r814", "r815" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $.01 par value, 60,000,000 shares authorized; 49,627,254 and 49,320,680 shares issued and outstanding on December 31, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r85", "r521", "r684" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r37", "r39", "r67", "r68", "r250", "r645" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r37", "r39", "r67", "r68", "r250", "r550", "r645" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r37", "r39", "r67", "r68", "r250", "r645", "r723" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/SignificantCustomers" ], "lang": { "en-us": { "role": { "label": "Significant Customers", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r105" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r645" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Revenue from customers", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r37", "r39", "r67", "r68", "r250" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r36", "r37", "r39", "r40", "r67", "r122", "r645" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r37", "r39", "r67", "r68", "r250", "r645" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "nanx_ContractWithCustomerAccountReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20231231", "localname": "ContractWithCustomerAccountReceivablesTableTextBlock", "presentation": [ "http://nanophase.com/role/SignificantCustomersTables" ], "lang": { "en-us": { "role": { "label": "Accounts receivable balances for these three customers were approximately:", "documentation": "The element represents contract with customer account receivables table text block." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows:", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r755" ] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ContractBalancesForYearsEndedDecember3120232022And2021AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Contract assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r325", "r327", "r339" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ContractBalancesForYearsEndedDecember3120232022And2021AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r325", "r326", "r339" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue recognized in the reporting period included in contract liability balance at beginning of period", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r340" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "crdr": "debit", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current." } } }, "auth_ref": [ "r325", "r328", "r339" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued upon conversion per share", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r16", "r54", "r84", "r114", "r318" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenue", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r98", "r502" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r190", "r191", "r295", "r310", "r495", "r665", "r667" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "auth_ref": [ "r151", "r195", "r201", "r207", "r263", "r269", "r392", "r393", "r394", "r413", "r414", "r431", "r432", "r433", "r435", "r436", "r437", "r442", "r445", "r447", "r448", "r490" ] }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "auth_ref": [ "r151", "r195", "r201", "r207", "r263", "r269", "r392", "r393", "r394", "r413", "r414", "r431", "r432", "r433", "r435", "r436", "r437", "r442", "r445", "r447", "r448", "r490" ] }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r151", "r195", "r201", "r207", "r263", "r269", "r392", "r393", "r394", "r413", "r414", "r431", "r432", "r433", "r435", "r436", "r437", "r442", "r445", "r447", "r448", "r490" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r38", "r250" ] }, "nanx_CustomerNetVolumeRebatePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "CustomerNetVolumeRebatePayable", "crdr": "credit", "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Accrued accounts payable", "documentation": "The element represents customer net volume rebate payable." } } }, "auth_ref": [] }, "nanx_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "CustomerOneMember", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "The element represents customer one member." } } }, "auth_ref": [] }, "nanx_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "CustomerThreeMember", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "documentation": "The element represents customer three member." } } }, "auth_ref": [] }, "nanx_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "CustomerTwoMember", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "The element represents customer two member." } } }, "auth_ref": [] }, "nanx_CustomersOneThroughThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "CustomersOneThroughThreeMember", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Customers One Through Three [Member]", "documentation": "Customers One Through Three [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCredit" ], "lang": { "en-us": { "role": { "label": "Related Party Notes and Lines of Credit", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r111", "r186", "r293", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Description of Variable Rate Basis", "documentation": "Description of reference rate used for variable rate of debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r24", "r294" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r145", "r673", "r789" ] }, "us-gaap_DeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncome", "crdr": "credit", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r720", "r808", "r810" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r82", "r83", "r125", "r407" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r727" ] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term portion of deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r728" ] }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsDeferredIncome", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income." } } }, "auth_ref": [ "r66", "r787" ] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Excess (tax) book amortization", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r408" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Inventory and other allowances", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r66", "r787" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income taxes", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r786" ] }, "nanx_DeferredTaxAssetsOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "DeferredTaxAssetsOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "ASC 892 Operating Lease Liability", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liability." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r66", "r787" ] }, "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOtherTaxCarryforwards", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "179 Carryforwards", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other." } } }, "auth_ref": [ "r66", "r787" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Excess (tax) book depreciation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credits", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r65", "r66", "r787" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "163(j) Business interest limitation carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards." } } }, "auth_ref": [ "r65", "r66", "r787" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "174 research & experimental expenditures", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r65", "r66", "r787" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Other accrued costs", "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances." } } }, "auth_ref": [ "r66", "r787" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r66", "r787" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less:\u00a0Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r409" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "nanx_DeferredTaxLiabilitiesOperatingLeaseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "DeferredTaxLiabilitiesOperatingLeaseAsset", "crdr": "credit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "ASC 892 Operating Lease Asset", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease asset.", "label": "Deferred Tax Liabilities Operating Lease Asset" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Excess tax depreciation", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r66", "r787" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan, cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r354" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r47" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r6", "r232" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables" ], "lang": { "en-us": { "role": { "label": "The revenues for 2023 and 2022 by category are as follows:", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r756" ] }, "nanx_DisclosureLeaseCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanophase.com/20231231", "localname": "DisclosureLeaseCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Lease Commitments", "verboseLabel": "Quantitative Information Regarding Companys Leases Is As Follows", "terseLabel": "Supplemental Cash Flow Information Related To Leases Is As Follows For Years Ended December 31 2023 And 2022" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrants" ], "lang": { "en-us": { "role": { "label": "Stock Options and Stock Grants", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r356", "r361", "r388", "r389", "r391", "r681" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r711" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r709", "r711", "r712" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r709", "r711", "r712", "r714" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r710" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r698" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r711" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r711" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r713" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r701" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "nanx_EarlyTerminationOfOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "EarlyTerminationOfOperatingLease", "crdr": "credit", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312023And2022Details" ], "lang": { "en-us": { "role": { "label": "Early termination of operating lease", "documentation": "Early termination of operating lease amount." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Net loss per share-basic", "verboseLabel": "Net loss per share \u2013 basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r179", "r199", "r200", "r201", "r202", "r203", "r208", "r210", "r216", "r217", "r218", "r220", "r448", "r449", "r515", "r529", "r670" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Basic earnings per common share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Net loss per share-diluted", "verboseLabel": "Net loss per share \u2013 diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r179", "r199", "r200", "r201", "r202", "r203", "r210", "r216", "r217", "r218", "r220", "r448", "r449", "r515", "r529", "r670" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Diluted earnings per common share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r34", "r35" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Permanent tax deduction stock options exercised", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r721", "r784" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Accrued payroll and related expenses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Remaining weighted average-period, expense recognition (years)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r390" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense", "crdr": "debit", "presentation": [ "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Remaining unrecognized compensation expense", "documentation": "The amount of plan compensation cost recognized during the period." } } }, "auth_ref": [ "r62" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r704" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r700" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r700" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r718" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r700" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r715" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r712" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r700" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r700" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r700" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r700" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r716" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "nanx_EquipmentSaleNetBookValueEquipment": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20231231", "localname": "EquipmentSaleNetBookValueEquipment", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment sale - net book value", "documentation": "The element represents equipment sale net book value equipment." } } }, "auth_ref": [] }, "nanx_EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20231231", "localname": "EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment sale- original book value", "documentation": "The element represents equipment sale original book value of equipment and upgrades." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "nanx_EquityCompensationPlan2010Member": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "EquityCompensationPlan2010Member", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Compensation Plan 2010 [Member]", "documentation": "Equity Compensation Plan 2010 [Member]" } } }, "auth_ref": [] }, "nanx_EquityCompensationPlan2019Member": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "EquityCompensationPlan2019Member", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Compensation Plan 2019 [Member]", "documentation": "Equity Compensation Plan 2019 [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r151", "r174", "r175", "r176", "r192", "r193", "r194", "r197", "r204", "r206", "r221", "r263", "r269", "r324", "r392", "r393", "r394", "r413", "r414", "r431", "r432", "r433", "r434", "r435", "r437", "r447", "r458", "r459", "r460", "r461", "r462", "r463", "r492", "r540", "r541", "r542", "r559", "r623" ] }, "nanx_ExpirationOfNolCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "ExpirationOfNolCredits", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Expiration of NOL & credits", "documentation": "The element represents expiration of nol credits." } } }, "auth_ref": [] }, "nanx_Expiring2023To2037Member": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "Expiring2023To2037Member", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expiring2023 To2037 [Member]", "documentation": "The element represents expiring2023 to2037 member." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r8", "r14" ] }, "nanx_FinanceLeaseCostComponentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanophase.com/20231231", "localname": "FinanceLeaseCostComponentsAbstract", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Finance lease cost components:", "documentation": "The element represents finance lease cost components abstract." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsFinance", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Interest on finance lease liabilities", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r473", "r478", "r683" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payment on finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r474", "r483" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsFinance", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of finance lease assets", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r473", "r478", "r683" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralBusinessMember", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "General Business Tax Credit Carryforward [Member]", "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit." } } }, "auth_ref": [ "r64" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r97", "r188", "r228", "r236", "r241", "r244", "r259", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r453", "r671", "r751" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Long Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r109" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision (benefit) for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r95", "r128", "r228", "r236", "r241", "r244", "r516", "r527", "r671" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r189", "r397", "r403", "r404", "r411", "r415", "r417", "r418", "r419", "r558" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/IncomeTaxesDetailsNarrative", "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Provision (benefit) for income taxes", "totalLabel": "", "verboseLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r134", "r144", "r205", "r206", "r233", "r401", "r416", "r530" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r173", "r399", "r400", "r404", "r405", "r410", "r412", "r552" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r784" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Effect of change in deferred tax rate", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r398", "r402" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Income tax credit at statutory rates", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r402" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Expiration of stock options", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r784" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r784" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "State income tax, net of federal benefits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r784" ] }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCredits", "crdr": "credit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Record Tax Credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r784" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r658" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities related to operations:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net changes in right-of-use assets and lease liabilities \u2013 operating", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r725", "r733" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average additional shares assuming conversion of in-the-money stock options to common shares", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r211", "r212", "r213", "r218", "r360" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r69", "r130", "r177", "r231", "r467", "r608", "r695", "r813" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r180", "r182", "r183" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued interest expense, related parties", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r71", "r806" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/Inventories" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r271" ] }, "nanx_InventoryFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "InventoryFacilityMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Facility [Member]", "documentation": "Inventory Facility." } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r729" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Inventories, net", "totalLabel": "Total Inventories, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r169", "r663", "r684" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r135", "r157", "r168", "r271", "r272", "r273", "r501", "r668" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r730" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory reserve", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r46", "r731" ] }, "nanx_JanuaryThroughMayMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "JanuaryThroughMayMember", "presentation": [ "http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details" ], "lang": { "en-us": { "role": { "label": "January - May [Member]", "documentation": "January - May [Member]" } } }, "auth_ref": [] }, "nanx_JuneThroughDecemberMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "JuneThroughDecemberMember", "presentation": [ "http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details" ], "lang": { "en-us": { "role": { "label": "June - December [Member]", "documentation": "June - December [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r477", "r683" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Components of lease cost" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "label": "Quantitative information regarding the Company\u2019s leases is as follows:", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r792" ] }, "nanx_LeaseCostsFinance": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "LeaseCostsFinance", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total finance lease costs", "documentation": "Total finance lease costs.", "label": "Lease Costs Finance" } } }, "auth_ref": [] }, "nanx_LeaseCostsOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "LeaseCostsOperating", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease costs", "documentation": "Total operating lease costs.", "label": "Lease Costs Operating" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r108" ] }, "nanx_LeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20231231", "localname": "LeasesTextBlock", "presentation": [ "http://nanophase.com/role/LeaseCommitments" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease Commitments", "documentation": "The element represents leases text block.", "label": "Leases [Text Block]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r476" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r476" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "label": "The future maturities of the Company\u2019s operating leases as of December 31, 2023 are as follows:", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r793" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r486" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r486" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r486" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r486" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r486" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r486" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r486" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less amounts representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r486" ] }, "nanx_LesseeOperatingLeasePaymentsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "LesseeOperatingLeasePaymentsNet", "crdr": "credit", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease payment net", "documentation": "Net operating lease payments." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312023And2022Details" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term-operating leases (in years)", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r791" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "label": "The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance.", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r794" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "presentation": [ "http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r487" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "presentation": [ "http://nanophase.com/role/FutureUndiscountedLeasePaymentsAssociatedWithThisArrangementAreProvidedBelowAndOnlyIncludePeriodForWhichEnforceableRightsAndObligationsExistAsOfDateOfFinancialStatementIssuance.Details" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r487" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r90", "r127", "r523", "r684", "r736", "r743", "r790" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r23", "r156", "r188", "r259", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r425", "r426", "r427", "r453", "r684", "r751", "r796", "r797" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r15", "r74", "r75", "r76", "r80", "r188", "r259", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r425", "r426", "r427", "r453", "r751", "r796", "r797" ] }, "nanx_LibertyvilleBankAndTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "LibertyvilleBankAndTrustMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Libertyville Bank and Trust [Member]", "documentation": "The element represents libertyville bank and trust member." } } }, "auth_ref": [] }, "nanx_LibertyvilleBankAndTrustOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "LibertyvilleBankAndTrustOneMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Libertyville Bank and Trust One [Member]", "documentation": "The element represents libertyville bank and trust one member." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Available", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r20" ] }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Expiration Date", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": [ "r20" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r735" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r20" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r20", "r735" ] }, "nanx_LineOfCreditPercentageOfEligibleInventory": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20231231", "localname": "LineOfCreditPercentageOfEligibleInventory", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Percentage of Eligible inventory", "documentation": "The element represents line of credit percentage of eligible inventory." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Line of credit \u2013 accounts receivable, related party", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r78", "r124" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermLineOfCredit", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term line of credit \u2013 inventory, related party", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r25", "r49", "r50" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r250", "r677", "r756", "r808", "r809" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r280", "r281", "r282", "r283", "r355", "r500", "r537", "r574", "r575", "r629", "r631", "r633", "r634", "r636", "r656", "r657", "r672", "r674", "r680", "r686", "r753", "r798", "r799", "r800", "r801", "r802", "r803" ] }, "nanx_MedicalDiagnosticsApplicationCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "MedicalDiagnosticsApplicationCustomerMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Medical Diagnostics Application Customer [Member]", "documentation": "The element represents medical diagnostics application customer." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r280", "r281", "r282", "r283", "r355", "r500", "r537", "r574", "r575", "r629", "r631", "r633", "r634", "r636", "r656", "r657", "r672", "r674", "r680", "r686", "r753", "r798", "r799", "r800", "r801", "r802", "r803" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "auth_ref": [ "r250", "r677", "r756", "r808", "r809" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://nanophase.com/role/DescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Description of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r136", "r146" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r181" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r181" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r101", "r102", "r103" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net loss:", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r96", "r103", "r129", "r154", "r171", "r172", "r176", "r188", "r196", "r199", "r200", "r201", "r202", "r205", "r206", "r215", "r228", "r236", "r241", "r244", "r259", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r449", "r453", "r528", "r604", "r621", "r622", "r671", "r695", "r751" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Numerator: (in Thousands)" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Adopted Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r816", "r817", "r818", "r819" ] }, "nanx_NondeductibleExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "NondeductibleExpenses", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Nondeductible Expenses", "documentation": "The element represents nondeductible expenses." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expense:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r228", "r236", "r241", "r244", "r671" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsOperating", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r479", "r683" ] }, "nanx_OperatingLeaseCostComponentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanophase.com/20231231", "localname": "OperatingLeaseCostComponentsAbstract", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease cost components:", "documentation": "The element represents operating lease cost components abstract." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312023AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Total minimum payments required", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r472" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r472" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-term portion of operating lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r472" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312023And2022Details" ], "lang": { "en-us": { "role": { "label": "Operating cash outflow from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r475", "r483" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating leases, right of use", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r471" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312023And2022Details" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate-operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r485", "r683" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r65" ] }, "nanx_OperatingLossCarryforwardsExpirationYearEnd": { "xbrltype": "stringItemType", "nsuri": "http://nanophase.com/20231231", "localname": "OperatingLossCarryforwardsExpirationYearEnd", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards expiration period end", "documentation": "The element represents operating loss carryforwards expiration year end." } } }, "auth_ref": [] }, "nanx_OperatingLossCarryforwardsExpirationYearStart": { "xbrltype": "stringItemType", "nsuri": "http://nanophase.com/20231231", "localname": "OperatingLossCarryforwardsExpirationYearStart", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards expiration period start", "documentation": "The element represents operating loss carryforwards expiration year start." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r64" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r22" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets, net", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r161" ] }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Capitalized Property Plant and Equipment [Member]", "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized." } } }, "auth_ref": [ "r108" ] }, "us-gaap_OtherLongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebtCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of debt, related party", "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r78", "r79", "r582" ] }, "us-gaap_OtherLongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term debt, related party", "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer." } } }, "auth_ref": [ "r25", "r582" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r711" ] }, "nanx_OtherRevenuePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20231231", "localname": "OtherRevenuePolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Other Revenue", "documentation": "The element represents other revenue policy text block." } } }, "auth_ref": [] }, "nanx_OverunderAccrualOfIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "OverunderAccrualOfIncomeTaxes", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312023And2022IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Over/Under Accrual of Income Taxes", "documentation": "The element represents overunder accrual of income taxes." } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "crdr": "credit", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312023And2022Details" ], "lang": { "en-us": { "role": { "label": "Lease liabilities arising from obtaining right-of-use assets", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of equipment and leasehold improvements", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r100" ] }, "nanx_PaymentsToTermLoansRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "PaymentsToTermLoansRelatedParty", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments to term loans, related party", "documentation": "The element represents payments to term loans related party.", "label": "Payments to Term Loans Related Party" } } }, "auth_ref": [] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/KProfit-sharingPlan" ], "lang": { "en-us": { "role": { "label": "401(k) Profit-Sharing Plan", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r679" ] }, "nanx_PercentageOfPrepayments": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20231231", "localname": "PercentageOfPrepayments", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of prepayments", "documentation": "The element represents percentage of prepayments." } } }, "auth_ref": [] }, "nanx_PersonalCareIngredientCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "PersonalCareIngredientCustomerMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Personal Care Ingredient Customer [Member]", "documentation": "The element represents personal care ingredient customer member." } } }, "auth_ref": [] }, "nanx_PersonalCareIngredientsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "PersonalCareIngredientsMember", "presentation": [ "http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Personal Care ingredients [Member]", "documentation": "The element represents personal care ingredients member." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r705" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r706" ] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r309" ] }, "nanx_PreferredStockConvertibleInterestRateForUnpaidRedemption": { "xbrltype": "pureItemType", "nsuri": "http://nanophase.com/20231231", "localname": "PreferredStockConvertibleInterestRateForUnpaidRedemption", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "If the Company fails to fully pay any Redemption within five days of receiving notice, all unpaid amounts will bear interest at specified rate per annum." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liquidation preference", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r54", "r55", "r84", "r734", "r754" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r687", "r688", "r691", "r692", "r693", "r694", "r811", "r814" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r84", "r307" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, authorized", "verboseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r84", "r584" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r84", "r307" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r84", "r584", "r602", "r814", "r815" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r84", "r520", "r684" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r732" ] }, "nanx_PriorToEquityCompensationPlan2019Member": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "PriorToEquityCompensationPlan2019Member", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prior to Equity Compensation Plan 2019 [Member]", "documentation": "Prior to Equity Compensation Plan 2019 [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consideration from sale of shares", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from line of credit \u2013 inventory, related party", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r28" ] }, "nanx_ProceedsFromRelatedPartyTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "ProceedsFromRelatedPartyTermLoan", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from term loans, related party", "documentation": "The element represents proceeds from related party term loan." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "(Payments) proceeds to line of credit \u2013 accounts receivable, related party", "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details", "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of stock options", "verboseLabel": "Cash received", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r13" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r757" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r675" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r246", "r502", "r531", "r532", "r533", "r534", "r535", "r536", "r660", "r675", "r685", "r726", "r749", "r750", "r756", "r808" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails" ], "auth_ref": [ "r246", "r502", "r531", "r532", "r533", "r534", "r535", "r536", "r660", "r675", "r685", "r726", "r749", "r750", "r756", "r808" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovements" ], "lang": { "en-us": { "role": { "label": "Equipment and Leasehold Improvements", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r107", "r139", "r142", "r143" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Property plant and equipment,gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r108", "r159", "r526" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Equipment and leasehold improvements, net", "totalLabel": "Property, Plant and Equipment, Net, Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r517", "r526", "r684" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Equipment and Leasehold Improvements", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r7", "r139", "r142", "r524" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables" ], "lang": { "en-us": { "role": { "label": "Equipment and leasehold improvements consist of the following:", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r108" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment leasehold improvements and leased assets useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r280", "r281", "r282", "r283", "r342", "r355", "r384", "r385", "r386", "r499", "r500", "r537", "r574", "r575", "r629", "r631", "r633", "r634", "r636", "r656", "r657", "r672", "r674", "r680", "r686", "r689", "r747", "r753", "r799", "r800", "r801", "r802", "r803" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r280", "r281", "r282", "r283", "r342", "r355", "r384", "r385", "r386", "r499", "r500", "r537", "r574", "r575", "r629", "r631", "r633", "r634", "r636", "r656", "r657", "r672", "r674", "r680", "r686", "r689", "r747", "r753", "r799", "r800", "r801", "r802", "r803" ] }, "nanx_RecentlyIssuedPronouncementsPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20231231", "localname": "RecentlyIssuedPronouncementsPoliciesTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Pronouncements", "documentation": "The element represents recently issued pronouncements policies text block." } } }, "auth_ref": [] }, "nanx_ReductionInLeaseLiabilityDueToRemeasurement": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "ReductionInLeaseLiabilityDueToRemeasurement", "crdr": "debit", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312023And2022Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Reduction in lease liability due to remeasurement", "documentation": "The element represents reduction in lease liability due to remeasurement.", "label": "Reduction in Lease Liability Due To Remeasurement" } } }, "auth_ref": [] }, "nanx_ReductionInRightOfUseAssetDueToRemeasurement": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "ReductionInRightOfUseAssetDueToRemeasurement", "crdr": "credit", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312023And2022Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Reduction in right of use asset due to remeasurement", "documentation": "The element represents reduction in right of use asset due to remeasurement.", "label": "Reduction in Right of Use Asset Due To Remeasurement" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r346", "r493", "r494", "r577", "r578", "r579", "r580", "r581", "r601", "r603", "r628" ] }, "nanx_RelatedPartyInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "RelatedPartyInterestExpense", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense related party", "documentation": "The element represents related party interest expense." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding balances associated with related partie", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r70", "r493" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r346", "r493", "r494", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r577", "r578", "r579", "r580", "r581", "r601", "r603", "r628", "r795" ] }, "nanx_ReplacementPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "ReplacementPromissoryNoteMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Replacement Promissory Note [Member]", "documentation": "Replacement Promissory Note [Member]" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "auth_ref": [ "r190", "r191", "r295", "r310", "r495", "r666", "r667" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r73", "r396", "r804" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r395" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r87", "r116", "r522", "r544", "r549", "r557", "r585", "r684" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r151", "r192", "r193", "r194", "r197", "r204", "r206", "r263", "r269", "r392", "r393", "r394", "r413", "r414", "r431", "r433", "r434", "r437", "r447", "r540", "r542", "r559", "r814" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total revenue", "verboseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r229", "r230", "r235", "r239", "r240", "r246", "r248", "r250", "r337", "r338", "r502" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r147", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r659" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Product Revenue", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r606", "r659", "r669" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r178", "r188", "r229", "r230", "r235", "r239", "r240", "r246", "r248", "r250", "r259", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r453", "r516", "r751" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-use asset obtained in exchange for a lease liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r484", "r683" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://nanophase.com/role/WeHadThreeSignificantCustomersForYearEndedDecember312023.Details" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r250", "r722" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://nanophase.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Accrued expenses consist of the following:", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Activity in the asset retirement obligation account for the years ended December 31, is as follows:", "documentation": "Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation." } } }, "auth_ref": [ "r746" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://nanophase.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r121" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r742" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://nanophase.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows:", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customers by Products and Services [Table]", "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://nanophase.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "Inventories consist of the following:", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r17", "r91", "r92", "r93" ] }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": [ "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditTables" ], "lang": { "en-us": { "role": { "label": "Notes and lines of credit consist of the following:", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Parties", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r45", "r94" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r357", "r359", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023:", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r59" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r119" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r51", "r52", "r53", "r54", "r55", "r56", "r57", "r113", "r115", "r116", "r163", "r164", "r165", "r222", "r307", "r308", "r310", "r312", "r315", "r321", "r323", "r553", "r554", "r555", "r556", "r674", "r719", "r734" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://nanophase.com/role/SignificantCustomersTables" ], "lang": { "en-us": { "role": { "label": "We had three significant customers for the year ended December 31, 2023.", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r36", "r37", "r39", "r40", "r67", "r122" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r699" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r703" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r702" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r707" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "auth_ref": [ "r248", "r249", "r571", "r572", "r573", "r630", "r632", "r635", "r637", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r661", "r676", "r689", "r756", "r808" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution" ], "lang": { "en-us": { "role": { "label": "Business Segmentation and Geographical Distribution", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r224", "r225", "r226", "r227", "r228", "r234", "r238", "r242", "r243", "r244", "r245", "r246", "r247", "r250" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r99" ] }, "nanx_SeriesXPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "SeriesXPreferredStockMember", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series X Preferred Stock [Member]", "documentation": "Series X Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "nanx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://nanophase.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Contractual life (years) of shares granted in period", "documentation": "The element represents share based compensation arrangement by share based payment award award contractual life." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Vesting period (years) of shares granted in period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r681" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r385" ] }, "nanx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Estimated forfeitures", "documentation": "The element represents share based compensation arrangement by share based payment award fair value assumptions fortfeiture rate." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average risk-free interest rates", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r386" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average expected stock price volatility", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r384" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r357", "r359", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "label": "Shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "periodEndLabel": "Shares Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r367" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "periodEndLabel": "Shares Exercisable, (per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r367" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details" ], "lang": { "en-us": { "role": { "label": "Total intrinsic value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r380" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited or expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r764" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "label": "Forfeited or expired (per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r764" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "label": "Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r369" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average fair value of the options granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r379" ] }, "nanx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValu1": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValu1", "crdr": "debit", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "label": "Shares Outstanding (Intrinsic value)", "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding intrinsic valu1." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares Outstanding (Intrinsic value)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares Outstanding, Beginning", "periodEndLabel": "Shares Outstanding, Beginning", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r365", "r366" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares Outstanding Beginning, (per share)", "periodEndLabel": "Shares Outstanding Beginning, (per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r365", "r366" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest.", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r118" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "label": "Exercised (per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r370" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "label": "Granted (per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r369" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details" ], "lang": { "en-us": { "role": { "label": "Closing stock share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares based compensation payment award expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r682" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average expected life (years) of the option", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r383" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "label": "Shares Exercisable (Intrinsic value)", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r58" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "label": "Shares Exercisable (years)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r58" ] }, "nanx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://nanophase.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Term, Outstanding, end", "documentation": "The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Remaining Contractual Term, Outstanding, end", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r117" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Letter of credit and related promissory note", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r77", "r124", "r684", "r807" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsOperating", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r480", "r683" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r104", "r185" ] }, "nanx_SolesenceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "SolesenceMember", "presentation": [ "http://nanophase.com/role/RevenuesFor2023And2022ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Solesence [Member]", "documentation": "The element represents solesence member." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r708" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r148", "r163", "r164", "r165", "r188", "r210", "r214", "r216", "r218", "r222", "r223", "r259", "r284", "r286", "r287", "r288", "r291", "r292", "r307", "r308", "r312", "r315", "r323", "r453", "r553", "r554", "r555", "r556", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r584", "r605", "r623", "r638", "r639", "r640", "r641", "r642", "r719", "r734", "r741" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r10", "r27", "r151", "r174", "r175", "r176", "r192", "r193", "r194", "r197", "r204", "r206", "r221", "r263", "r269", "r324", "r392", "r393", "r394", "r413", "r414", "r431", "r432", "r433", "r434", "r435", "r437", "r447", "r458", "r459", "r460", "r461", "r462", "r463", "r492", "r540", "r541", "r542", "r559", "r623" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r248", "r249", "r571", "r572", "r573", "r630", "r632", "r635", "r637", "r644", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r661", "r676", "r689", "r756", "r808" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r192", "r193", "r194", "r221", "r502", "r551", "r570", "r576", "r577", "r578", "r579", "r580", "r581", "r584", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r603", "r606", "r607", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r623", "r690" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r192", "r193", "r194", "r221", "r502", "r551", "r570", "r576", "r577", "r578", "r579", "r580", "r581", "r584", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r603", "r606", "r607", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r623", "r690" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuances of shares and stock option exercises (in shares)", "verboseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r10", "r84", "r85", "r116", "r553", "r623", "r639" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf0.60Details", "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312023Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised", "label": "Shares exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r10", "r84", "r85", "r116", "r370" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuances of shares and stock option exercises", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r10", "r84", "r85", "r116", "r559", "r623", "r639", "r696" ] }, "us-gaap_StockOptionPlanExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionPlanExpense", "crdr": "debit", "presentation": [ "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Share-based compensation expense", "documentation": "Amount of noncash expense for option under share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "nanx_StockOptionsRecognizedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20231231", "localname": "StockOptionsRecognizedTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "The aggregate intrinsic value in the table above is based on our closing stock price of $0.60", "documentation": "The element represents stock options recognized table text block." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r85", "r88", "r89", "r106", "r586", "r602", "r624", "r625", "r684", "r697", "r736", "r743", "r790", "r814" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/CapitalStock" ], "lang": { "en-us": { "role": { "label": "Capital Stock", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r112", "r187", "r306", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r319", "r320", "r322", "r324", "r438", "r626", "r627", "r643" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Cumulative effect of accounting changes related to expected credit losses", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "nanx_StrandlerLLCAndBeachcorpLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "StrandlerLLCAndBeachcorpLLCMember", "presentation": [ "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Strandler, LLC and Beachcorp, LLC [Member]", "documentation": "Strandler, LLC and Beachcorp, LLC [Member]" } } }, "auth_ref": [] }, "nanx_StrandlerLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "StrandlerLLCMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Strandler, LLC [Member]", "documentation": "The element represents strandler l l c member." } } }, "auth_ref": [] }, "nanx_StrandlerLLCOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "StrandlerLLCOneMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Strandler LLC One [Member]", "documentation": "The element represents strandler l l c one member." } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsOperating", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Sub-lease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r482", "r683" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r464", "r497" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r464", "r497" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r464", "r497" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r464", "r497" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r464", "r497" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://nanophase.com/role/SubsequentEvent" ], "lang": { "en-us": { "role": { "label": "Subsequent Event", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r496", "r498" ] }, "nanx_SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20231231", "localname": "SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022:", "documentation": "The element represents summary of supplemental cash flow information related to leases table text block." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentArrangementMember", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r81", "r126" ] }, "us-gaap_SupplyCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentAxis", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Axis]", "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer." } } }, "auth_ref": [ "r81", "r126" ] }, "us-gaap_SupplyCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentLineItems", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentMember", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Member]", "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments." } } }, "auth_ref": [ "r81", "r126" ] }, "us-gaap_SupplyCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentTable", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Table]", "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has committed resources to supply goods or services to a customer. May include identification of the goods or services to be furnished, identity of the purchasing party, pricing, effects on pricing for failing to deliver the [minimum] quantities required to be furnished, cancellation rights, and termination provisions." } } }, "auth_ref": [ "r81", "r126" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Carryforwards", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r65" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TaxCreditCarryforwardValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardValuationAllowance", "crdr": "credit", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Valuation allowance, net operating loss carryforwards and credits", "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r63" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodAxis", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information about the period subject to enacted tax laws." } } }, "auth_ref": [] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodDomain", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identified tax period." } } }, "auth_ref": [] }, "us-gaap_TaxYear2018Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxYear2018Member", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Year 2018 [Member]", "documentation": "Identified as tax year 2018." } } }, "auth_ref": [ "r785" ] }, "us-gaap_TaxYear2023Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxYear2023Member", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Year 2023 [Member]", "documentation": "Identified as tax year 2023." } } }, "auth_ref": [ "r785" ] }, "us-gaap_TenantImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TenantImprovements", "crdr": "debit", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tenant improvement allowances", "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants." } } }, "auth_ref": [ "r805" ] }, "nanx_TenantSecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "TenantSecurityDeposit", "crdr": "credit", "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Tenant security deposit / advance rent", "documentation": "The element represents tenant security deposit." } } }, "auth_ref": [] }, "nanx_TermLoanAndTheRevolverFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "TermLoanAndTheRevolverFacilityMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan and the Revolver Facility [Member]", "documentation": "The element represents term loan and the revolver facility member." } } }, "auth_ref": [] }, "nanx_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20231231", "localname": "TermLoanMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan [Member]", "documentation": "The element represents term loan member." } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r678", "r756" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r678", "r756" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Trade Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r131", "r132", "r133", "r253", "r254", "r256" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferredOverTimeMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r678" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditDetailsNarrative", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r423" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates and Risks and Uncertainties", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r41", "r42", "r43", "r137", "r138", "r140", "r141" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase (decrease) in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r406" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsOperating", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r481", "r683" ] }, "nanx_VolumeRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20231231", "localname": "VolumeRebates", "crdr": "debit", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Volume Rebates", "documentation": "Volume rebates recognized as a reduction in revenue." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of diluted common shares outstanding", "totalLabel": "Weighted average number of diluted common shares outstanding", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r209", "r218" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of basic common shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r208", "r218" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r717" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(ee)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-13" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-14" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//410-20/tableOfContent" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481879/410-20-45-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r719": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481174/470-10-25-2" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481879/410-20-45-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 87 0001999371-24-004138-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001999371-24-004138-xbrl.zip M4$L#!!0 ( />)?%A9HDIFMP( "U776^; M,!1]CY3_<(?4:I-"@73K0R!($$C#Q@ !K=:GR2%.@LK7P&F[_?H9"!F5VFU9 M:1=I2R((ON;ZG&/CRY%F_D=3[O>DF:YH] SE1_(-W]1EB:O/-,IMPY)J:U?@ M^5>F/F:6:4)&(/ 9 3^,<0$6O@4WC5$RJ!L&X.$\7#+EC:]8%J8ACA8C<#<1 M9AVTPL"RLK0(;Z @7R,\9F*4K\)D!+P(M^&"K,OD_!%SKT\Y*%N$WS -9D2$ M>9HO<,Z2-!N!&J'@&H843Y%&X6(7G*>$I'$3%YHX(Q\G\R(3)8[FE[?'%D[N M'M!^C[+(VC!^A[L(.U*T*T^Y3&W+WU]!"<$ZQ\LQDZ#DCA7XZ\_"\)3^3M8D M9F1+L6QGIG@Z^/ID9MFF?6[H'DQLU[%=Q3=LBP["?I X1&F6 .@IZXI1(Z)3 M)W3V)=>51 V.+;^.X(A \!UA412N:%,>KM;DSR=1E?5/,T,U_'YO*)P($J?* MAXSW)10-<$)P_A1)O0O5,S1#<:_Z/7L*OWX6GE_VIY(Z:'"J_!H5_5ZZ! T' M.)[C'$Z% 0SYX>F;@Y?VX27M*ZJIPT0W3<]1)H9U/F9XIKIV%$UKKO>FT2IB MNUH4I%&$LH*6K^9?51Y]MTE_@W,2!BAJ"-/*)L(^I;:NX%J3;P?B:)\TW?LB>.ABE2YD"\58XB[D>ZOS)]C>O2"V]YL\+!9A0,(TJ?'0!VN:YC$J M6QY"30_N\RZ90U@F_RB&_Y/;"08OC8XQ"C8$BP5. CRH(9CFY._BTG"$;E&. M'YIRKJI"OT-V_DS>I6OZH=$8B[?]E4TI,TXI@9^6N58S*O!ZN-C41+E&T M*<.UBZHDUXS+!E(]4&W@SDI'MVUH3-M9R^4]:N1^,&SA;LL@<73(BD$U?MOE MM0U>\Z5[+C6ZM?,M#?)W4$L#!!0 ( />)?%A7KE"[:0, 'L, * M97@R,RTQ+FAT;=576V_B1A1^1^(_G"*UVDHXOH%)P+$$"2FH!!"XN]VG:K ' M&,6><>UAL]E?WS.^L.8AN\F6=EN$?)DY<\[WGL^%.QL-;O(/Z MN?[4GXT]5R_N.*N7T^YHUO[[V?BZM15<]L$T$@D^BVD&<_H(*Q$3WBX& MVK"F*=NV<"$N_4'3X([1*.S#ZA!1;4EV%#3--], ;P MR$*Y5^J-'ULG,LJLEK%/%"<3.8"-2$.::E(D?1A%)'@ "Q%E(F+A<7(CI!1Q M-6]6\RWO)[[)DH&KHWZOO-9PZB= 1RMYC[K_>A2V"? MTNUUBQ/^43.-AS],R\;_Q5[&+6\^G"^6D^%Z#/[X9C)?S!:_3,=KN%FLEHO5 MT)\NYFA$^]75"=)4 /"6G(M1Y<1EH7#Y6G+G?GL01][X]\ET-/6;#0R=Z>HC[_O@U;8D9M%3_VNJZ]6&ZE_HY(V(PM]&\ P?06QARD.:4+S@ZXKN6(8"-&PVEH=-Q (8!H$X M<,GX#FLYC?]EG%\NB.]B]!NJ\!V%H'2X%"#W%!@/1)J(E$@F.&R> #DMS[9M MK6MW.MTV*%/JM=\;G5].\ZCA.N]DX#G2-GE.3-R][3N>J#82'QS&KV[6[ MO3+=?P9D=8?F8:U=_J-L$$*S\8PSX4T%[LJP+:=.T+&L3NV]8W0<\Y2/Z=BV M8]>)V%"RPZJ:$RZ2/#FPEN&1UC 2(0'SY'3L\:A9AMC1Y*$DE2ISC.. M93#D_("Z5@6>BI$-3L,VZ'J MF0ZK]3W\MH;9;/E?1GK/HD=R>*"T#>]8IK*"\7.J/TG#2O'_]4RM-:*J!1W@ M\C\/:K/%90-X2Z*#>BHZT[QMOYV^K> 4Z(NFV%%=IH,@>;VZ]WSO6FN0R"KCX>BJ\)]='Q%U!+ P04 " #WB7Q818 + MR*P( ":-0 "@ &5X,S$M,2YH=&WM6VUOXK@:_8[$?_"MM"LJ02E]F7O5 M,I4HI%-FNH" SIW]=&42 [X-,1,GM.ROW_/8":0MW:'==K94'74"B=^.[?,\ MS[%QJN?]WRY.\KGJN5-KX)/1OVJ_V;]P3JIE^XG4]_N\7SL>M MH0JB(U;9G4:L+R="LY:X9ETUX4'1/BBRG@CE<(L*_JM48F=2^-X1Z\:^*'7X M2+!2Z:3JR1G3T=P7'[:C1DI9_""1.HV,V M4*$GPE*DID?LU.?N%=L#'JU\Z2T2!RJ*U"1-KZ3I6R>_!@,]/:Z64?])J[>[G7:WUF^V6VBD]*5:YN@F M <#']+EZE YBQU;8>6SGGFN(4AQ)_YX)SC&+Q$U4XKXN)\ M.V^>-OOYW'YEIU(MGYZ\9KP_8T1=$40B7 &Q-.03Z<^/?E1WUB&@?C/*=:?; M;YXUZX;Z^5S[C/7/'58_;SIGS/GFU"_[S:\.:Y\AB]/-SL)IEWS5=_4/RA6N-Z]I4[5Y>.+U\KK)?*U4."K5M5FLU6.6PD=Q= MMAI.UXRK\ZU^7FM]+^=QGH36K[;#//+A2U_I*%M'/ M,)+#.8O&/#IZB1%^94-X>Y;_'VOJ??)0!IZ@2G=W#@YE\&3@E1T+??UK,Y\; M\YE@H9A)<2T\S(;4C =!S'T\G*HP8BI@9RJ*"F8ZX%ZPMW'"A? MC210U56([#R2*MC$L=O82=][]*2?8NZ\? [S.IFSJT!=^\(;B:*=^V32/84V M Q4Q%T"X#,").8N#*(P%M!6/Q 38B0T<'8:_DN#+D+MX%#(UD1&+E,UW+T,@ M7#@#'L[S.>29\"N!AC.5:CSS@ 9M^A3HJ1'*X,K0C2?(%J \H$ #L^NQ=,=, MQW19EK\6H4@JH1Y,I/8%]V0P@@"/QNBAG@HW,LU3Q5. 4QXZ.D,YCPWFV8'8 M1$9L+)7WGY'*@@TEEA4N\6[)C2)X[#&%Y#"3+H,A')QQ7?CN^K$''H!_&1X4 M05X9^G,V!7V(^F02OK_@=CZ7T$K?:1OVXTFJN4C$BWUD *$52&?:TP:0R_68 M#7U$QI3MH1A)'84<+7%Z:($#9C'#69VBH3&XC7<3IW]C>7OP:-[VQX(8D\[Q MKZ'^'JMCG3 SD4;DL=1P*'%;T-N& $W&0V$\&*@C![X@2C !@@]\J<=4@K)- MX+'):].])[7K*QVC'/GR4/F&<_G<-%2N\/!N7''/!@)5H._ MIOT"S2K[O%0Y+ @+HW+HV3M[*TFQ!I;LU C5YJQ 4M) I-IR##VX9:&:4L% M;]O>;YN^WC4.Y"$%<[2!M'D1OA_N?#@D_/1_YT &/Z$?!;Z]/O,;0@,)3;\) MVP^PDRW)621)X?(8CIZM683$QT" :+:I1"RH.$0%\)PSJ"J,:,(%Y0J2F'T;BQSRGNH&,&Q5*PH(35/UG=AF\#01D1 M&5!>>&^ 7V_&3@9/MY.U7>P] +'>C(&XCS 0 M9\;]F!OI2^01PR'4MYQAUO4*%;U06&M$#WN;".L[ZP 315 0CE];^3Y0#]EZH]LVGPINAM+<6I1N6)??7 M<6;?)='()F4EJ1_AXTGH*->-0R)51E3BWX%2D/*X>-]C!2WFS)I_N-#Y)W9;0PZTLXXE"L=K[<0TDM%K[W0:(G M"P 4 6,ATXM6_VB,BHXGF!#YAS"]2:+>RKW98R!Y=\ROIQ\_7,_6 D3Q80BO M5@25A''&(*/Y429A;=&&?AG,E#\3%/\#/DI^7 H3_RTF4U_-!5*OQ\IZ;,ZR M-@$._X4Z(DFU)N%W-G]25I.K7SN]<%C=N;CH=6KU9NO3QZW=+7/?J34:Z?VC M^YHYT+8XE^8JW^=3+8Y8^LTMWT^IG%(ZA#M-AB-34GC)9]]B=/,)A MA*<-:0-[M[!XM1[C?^ 5AW9OJ58,"EN^'S_3H']C5@ M>/G)33S*(3F4US#("9[]7^Z=NQW?D+X#)/.N M#KVEI#+@0^;E MH@??'UH.1::#V3=BJF4T:<":]K,O%V7?*S*]*=.[5?9E*WHGZT]02P,$% M @ ]XE\6+,^X=3+" ?C8 H !E>#,Q+3(N:'1M[5MM;^*X&OV.Q'_P MK;2K5H)2^G97+8-$(9TRTP4$S+Y\NC*) =^&F(D36O;7[WGL!-*6[M)..U.J M3D>0Q&_GL<_S^-@XE8O^KY?5?*YRX=0:^&;TK])O]B^=:J5DOY%:2I(K9^W& MGZS7__/2^; U5$%TPLI[TXCUY41HUA+7K*LF/"C8!P76$Z$<;J$@BOZG6&3G M4OC>">O&OBAV^$BP8K%:\>2,Z6CNBP];$QZ.9'#"]D[9M?2B,56_]]/6K3S4 M;%'+OP02I]$I&ZC0$V$Q4M,3=N9S]XKM Y%6OO06B0,516J2II?3]*WJS\% M3T\K)=1?33XS.$NW@!HKIED8ZUA_RA9&(>L>;#EOM_J/[\,*9^-0##]L!3RX M*9;WKOY7WC_ _]UQ--FJMFJM=N>BUG-8WZE?M-J7[8]-I\?J[6ZGW:WUF^T6 M&BE^KI0XS"0 ^)H^ET5I)W9LA9W'&O=<793B2.Q[)CBG+!(W49'[-^O&/?*Y]CGK7SBL?M%TSMEY$QY5 M;]8N6?L<69QN=EC.NA0*GQ-*YTNW]Z6&^OKMM'^?GP7F\WCW8/W>73,RG56[ M7RZ=7CY7/J@5RX?;M1U6:S58^:B1W'UI-9RNZ5WGC_I%K?718;5Z?Y-L?)G0 M\BU=WBSDM=#7_VSFQ< MA1,S)S,U9"T>J.F8:\'ZPAT'RE^\$:B8,<^&71/HYE"(2+2,##>3Z'/!-^)=!PIE*-9Q[0H$V?)G]J MA#*X,G3C";(%* \HD,KL>BS=,=,Q?2S+7XM0))60!1.I?<$]&8R@TZ,Q+-13 MX4:F>:IX"G#*@Z$SE//88)[MB$UDQ,92^> 9J2S84&+UX1+OEMPH@,<>4T@. M,^DR&"+ F="%:]>//? _,OPH #RRM"?LRGH0]0GE_#]!;?SN816^D[;\!]/ M4LT%(E[L(P,(K4 ZTYXV@%RNQVSH8V9,V1Z*D=11R-$2IX<6.& 6,IS5*1KJ M@]MX-W'X-Y:WAX_F;7\LB#'I&/\3 %T0))D#P@2_UF$I0M@DB-D5MNO>D=GVE8Y2C6!XJWW NGYN&RA4> MGFNV#8YY J2UO'=NW#$/1H+5$*]I6T&S\@$OEH^VA851/O+LG;V5)%<#2W9J M@%$HS?B I22!R31D&/MP2\.TI6UOQ][O&%OO.@?RD((YV4#:O C?CW:/CY+5 M*>#)X#O8L+G3&J*RD8&B,!41$N1I5K)S@JA\+DA<*(9E@PL)#,&)4H$=X QVW6H MA9 .M/0D#R59(*VT,?-40#7%&FH#LQ&&11+V8(25@5EU1NN!H(R8GY >>&] 9:]&6\9?*NWK!UN[SG-^H%ZE>^ MJ7>.BEE(4723Z0OHSFI'-6M4LN;-AM MB&N=+YL57; 4^F;NNTE,FL98?VKT/"DSUU6A9Q 8R3\2 ?26#P="BIB2:U(6 MK&>LD\"%Y123SQN@UYMQ$_?1;N+,N!]S(X:)0F(XA!Z7,XR]7J&K%YIKC9G$ MWB92^\[*P,PH*(A)0%M!/U!Q] \0UIGL^"*WH/7*\-\7JFQ 2R':K"%/S^>$ M[0S:C:':-Y\0;X;8WB.(W;! D"\9W<"7*7-A-I+RFXO?6X8V&- MN5ZH,A]ZB1NO$IZ9WDR/)#//G/GR2N#+;"RE!9C-7_CF3GIWI!^[7CKZCLML MLRONI=Y76$97BO99_B_C+#%X)9?RN97:[-Y28@&/8SD1J5 OU)!Y@#HG$QE% MPOC*BF(#!:U%:9X$.%/!-CP$TP;< VZ+"UK1I)XMOL82X(T3QX%+)NR\+Z,W M:AE=\TD0 Y($?6D[A/967"G M42U+%:SUX)?D0JQ MGH$"/NS89]NAOY((57 MSAEFW8EP'(K5(9A[**G%(@(_2/=D28 BX"V$>\%J(8V^T?$$PR+_$L::9.Y; MN7-["B3OX?GUV/&$=6XMP.P^#!'M"B"7,$$:]#0_XB0\+EA)((.9\F>"=$' M1\F/46$2U\5DZJNY0.KU6-E(SEG62\#J?U!-)+76=('=S1^FU73KU\XN'59W M+B][G5J]V?KX86MOR]QW:HU&>O]H6S/GY!;'W5SE^WRJQ0E+K^@,7J7?3:N? MT30-U9AV0Z2F]F#*NN?Y[#'!QA-.+CRM2QO@ZHEM]E<>NF.V_TN![>_M'RYZ MN=_X ;#NC/0KP8"/[H:/]^OLV-> X>4'-XDH1Q107D,G)W@.?KIWG'=P^SCO M=X!;TJ5UL![^]S6 _>3T>A9A;9=]JK4^MW_O?6ZNP/\>+]X*!CH1N!SR]&3@ M^^3P)C%T0BPW2;$6;-OUL11#YMP(-Z8-R[TW9OTJ)WA^S+Y31>V=_ U!+ P04 " #W MB7Q8D4Y&@-8$ "]&P " &5X,S(N:'1M[5EM4^)($/Y.%?^ACZJUM"J\ MJ[<+D2J$N*(L4!#W:C]=#VCRUO_1;^9QY:K6[> ?]9]H]NV^US')R1VDY%9O'P^XWF-C?^M91819R MU8!J)5)@LX!*&- ;&(U5L=/R5-!H35H#X:C MT_;$ MOJG Z&_>'GGC6!SG \&H[;=F\XP$&*YV:9H)H: -ZBE](H,^(HZ7#T M5.5>RD09CE0_#>=?@VF"HK>J2'PVQT>"S3WU?!<>MZQ;CTV9RN?J-;-\W-K MNF5H[['FBR-T*%=4W .Q.",!\Y>-?^I[/1E@_[&-.];8[IWT.C'M\[G1Q7AR MT<;N[2%4/\)%:5+JE&!B=9*HJ!]4,DU?VQ\/:OMH^NP2F<\1-XP4=2%:"+D@ M7($*L8FC6,CA4^40PADHC\*$B"GA5!:'MSY=0MM16E*K5&I[6Z_JJW#OH'2H M@?X,]J^%5&RV3!\R[E+=?:6T?\#XLU7H\7S."3E/'7/#E(=N81((YPOB@Z!1 M*&*7# @/(X]("C9U/![ZX9QASYU08 L2O[VK';KCNU>+L-D)@XCPY8Z(?^T! MBD]"$<3Y'>-!Q,Y?4B+R.%LQAQ$FG(XU=5 /@GM(F.# M]'?1O"/1S,TXF VM7!HB^=RS8\1 .5&&?B]8PB4/;]!<<]IXTYQ\!V%5+25* MO-35]F@^EU 79@O?7X*#G/-U'*QB0]"K!1,T0/Q2\T.F1*K6=PG&GX#JP:Z[ MM^+4722MHB@E5O53?;^I>?^F7? .6%1[#18QCMDW2!(V9GY%&,<,RY*LF5&, M,($M(?N)YG=/NY;T+'Z_D-/A\5*H7X]ZC=[6:_GZSF MVEYSM65T0M\GD<2%9?9-[V-->YQU?ZVG)(?XF1EP YJL1Q^[)TZVVMUG+ 2? M9](NR9-9DD"/4.ICTX'_XQ.>_= M@_]7OG@O&/1^]<[EV:;UU^3P+C&L3B*,9.P'SB*,M8.*D]5Z/!7>1XURO$I] M@E0UYG2!]E\=+A6>WJPO'1GOC6CK!=,S#(.&8.-QU^O/:V7G9)_LZS+;TD] M3I?M_@902P,$% @ ]XE\6#FPOU+!$P( A044 !, !N86YX+3$P:U\Q M,C,Q,C,N:'1M['U9=]M(DNX[?@6N9GK&/I>426JWJWP/K<6E*EM22W)5=[_X M@$"21!D$6%@DL7[]C24SD0!!+18IDQ+F])1M$DSD$AGK%Q$__;^;46!?B3CQ MH_#G_VVOM_[7%J$;>7XX^/E_NQ?[Q\?_^__>6S\-4W@,'@V3G]>&:3I^^^;- M]?7U^O7&>A0/WK3W]O;>W. S:_S0VYO*YSJM5OO-OSY_NG"'8N0T_3!)G= 5 M^D>!'WZ;/3Y^JQ_MQ8%?>!0_42_9>#,U-'SKY3\P']Y^PU\6'DTK']WB1U/U MJ)]$FYWVSFWSX"?T#VYF/=O&.<,*Q;\^G'_*'T^KG\\??9/&3ICTHWCDI'"$ M.-)6L]5I=K:-09J)< L#P;_7!]'5G>/L-C?::IRIPRFN%+_N.8G><4^4MEN] M$[Z 7W0VU(.QZ,\<=OL-?*L>S)+FP''&^N&^D_3H0?E%853X+(X"D50^3=\4 M'O?2N)E.QB*IG@I\_0:_QM]TFJT-8UO<* O3>%*]5OEEX55)G$Y/"CXL/!0Z M84XJ\(]H/(2]77>C$3W6AO^MX;44CO?>LO'_?DK]-!#O?WK#?UH_C43JV#A" M4_R5^5<_K^U'82K"M'D)"UFS7?[7SVNIN$G?T-U] []ZPT/^]'^:3?O(%X'W MUKX0Z3O[Q!F)M_:-=_/./CZ@OWQM=?:_?KGX1^?@8[=[!G_@Q.QF\YX_WMCX MBHO\6EC<5[6X^X^SV:4?M=JM]G?\>FOOJP""A-G#_[HC$7KP_^E1X R^]IT@ M$0\8:<,8Z2!R,QK(3UPG^+=PXB/X)/GZL"W:ZLX<\DS$?N3QH$?_?L"0;6/( M_2R."Y,\#+T#)Q5?^>M/%ZV;SW[K[\___/GG![RA8[SA, 1JG.S#2V(G. X] M9KPT0.&Z'R]&#JQ@-/\2F*(QTCHLP<,A/^"ITZ M>F/?9;YSDYXCUS^*HQ%>B6:K#?]+(_I[NT/<-81UP7N$_[9P+==LW_MYS;^Y M:K;;K0XP0;JF/[TIO&0NKYUQAXL3Z*R]QU\O_OW&A2_.8&/M_=&_%_'^6=RA M^/K-M?=-_NTBYE#)/XH3V%I[G_.3V7,XBAT7%1LYN%09WIZF0Q%_BL+!I8A' M!Z*7RE6O%2;;34[[)/GE!/']<-$Z/EZO5FL/Q'86^OPL7%T0XB#!_0!D:YP) M%*MW3>- ] 6\USL75R+,Q$D4NK?,8Z-Z'NWVWF/GL1^-1GZ*5)=T0P\5!K # MP![P1?*@F71VGWHF,\ZFW7GTGIS%\G NTLC]]KL39.)!>[&Q^50SF+4'&UN/ MG0&]>!@%P-^30] FTTGE!-H\@:_R9U^+$_\L1CT1EV?7V7@TK; ,/H1.',&(R8_);[05-GH]QH1N_-0^RZ7I_9@FSP,NHZWD^/@.: M@.-[Q^&^,_93)Z"QT>P&%CD:BS AZ_T<+;[$3P6H;E>^*WC=Y\*-!B&-4L%# MYK3P1U/_G]J/OYXE(CT.P^L6G*%G(-=Q^M.A] MS!3O)IWM1POFQ\QO!J7-FNOV$RD1WW72.ZVG42*^;W+;\U(B"KM'MDOEF6_H M,]_XGOGN=N9_U-\SV;LOT.ZC+:_YS/1A5VGWT6SI^]6RQY+&#]0H9T_]GA)K M[T=JE(_<^+V5U2@?N_#5U"@?P]7V5E.C?.S]W&@]^G[>:]WY'<;_8I1X/TK2 M1=S:C=:C.?T3KNA.PMQH/5I??<+EW)?H=A:O@S^2BMJ/5FX?,\6[R:+]!);@ MG'2OC?8"=-O;W,$//.G'&UGW,F.^:W*=SAQ4D",_Q O]28#@.0,-RO7'>' 3 M8@FWG7PQ1%2:VO=;+!A0?JO>?QEA&.A3Y(3)N0B<5'AG3EP^WUEV]=2D]AXY MJ3ARA? 2?)\Y&S7%[YW5HWGXN3\8IJ?]+XGH)HE(3WO,9X_#PQMWZ(0#<13% MIV,1.QBRH8/^Y#L]/YBZ*?>=\V;G_G.^)=9X]WLV=M;*\LHE" \LY +ODQ-[ MR9>Q!V=Q>)."RN3W EAX^6GV&N?%DG$!* M/^)VW32-_5Z6.G#JEQ%]]@'U9\D^NG&,U/\H3K:UN3<')KN@^=^Y]5M;K3G, M_A-PD]/^/D@C/SUR7&(0.=Q"WBTT?%4)W :BAEKV%N90[AE M#8\^!U-9*DG=[BB*4_]O8I3?RVQV'Q\?-F=X#'. "Y]*!O_=L_K^P"_I3307 M,ACEY+Y_(H^_2"))RLI0KFQ^$.?"%?Z5\"ZO(T18W0JR483X:Q:*RV$<98/A M ?P<2:^: />^'_M"&WDIX(_T0KA9#'?D0(RCQ'\0(&EO\[O=\S2!DRCTA)?! MYR"P)%5]IV3:>WSXB@W42^<&G6$A,A2Z?/ !,YGOGMD\U)6JF5$@PW"X?.\] MV-O][KVC8U3@-IB@,@1\,%$+EX)XV@- 3>W6XUUKQKSH]8GZ@/?S 91.2-1Y MSP;LOS%*G+, ;B%(&_0UC$M"L-K];[RB3.D_I7G;P77.:&[Q43\NXARVS,06HK?_.&GPWV2L")FL8QF4KEP5>>T$3"RA[S$%ZVU"N74PCDT)_A%WU?Q#8M0E2FK.T?_U9$?)=_K%_VINIM\EUC"FM-32%)G3A%D/O[?"5J MG/R[\J\$ ^/?YRO.W^V9OU ?FV]7G\FMG+F]FK):V\V-UNIL*6=BIN_SN>OQ MY3?SVYQ-3,T#P;**FR/GOKC-6;G+6*"^Z\MYVIX_PL!( M%()6$:=OY2).8XDGZ=[XR=K[/+/%6.)/;RI'-.;RIG(RSTS0WP/Z7-/%D]#% M:O(+L,CEGI(#Z 602>6*:V[R(&Y24TW-:Z:TXGNE3*X@C>10+M@O_#GCN! ' M&X64]&&4/G(I]%_S_^\I];\4@[[=BCE\S_X6]?_4HA@ M!F[Z^9]^]<*?^;&OCBOG*3?G7FF>S_]&+)'BLS@GYXPCKQ6?%W38M>*S?(K/ MDQ-!K?@L@^+S]-&L6LK_6"F_Q'ZP[ZCQ\OSIY8=J":M,++66L21:QBH34:VE M_# M9?G)YH&%!IX_T2R5;K.4D>&'%'YX_O2R/+K-BA%+K=LLHVZS8D14ZS;+ MH=LL%]D\I&;-\R>5'ZW1/"4JO]9(EBET7,L M")838F%SGRLONA>5<2&IFLH60F7FYKX4*J/Z(%A5]G@TCJ,KKL+WXOG:+;M2 M\[BGI+X7R>]^!/6]1-Y'^7?2O/7_%M[,0WKQ_/"!.U7SR!]-I2^2;RX+E;XD M7BHKC7T6GN\ZP8'O#,(H27TWZ8YQO5004I4A6UURY&/],XK54J37C(KO/6#M M+X0:SF"#T(&\[\3B.!Q@Z3J8^3,G@_LL^MF=_YVA]B?@2-G-U MSU\)&EB%'PY.^VIQI_V/4>3-*/LP?WLET0$>M6UM/@. M:5'3S$N6&?7IORS)\4$X[M"-XO&G3_O/^."GEUG+AEMD0TT5SYO[U^?[$OG[ M\Y;ME2NMN?P]N7Q-&R^!U]>G_/PY_D4:.Z$7B/AYR_;I9=:\_A9>7U/%\^;R M]?F^1/[^O.5YY4IK+G]/+E_3QG/A]>W-9FNGF'V2IHB\X=U9_5.^&$9Q>BGB MT8'HI55I)=/+_3%'K4YB86R?7X!LOS[T'WOH)N]7I_(0WE\FE:<0.DI--^-XXQ M#0:',7U)L[?H3M*:BX)3/("YO)-*8T094$<\!JJG5I"Y?O^O&IMU!=O_A?OOF]=OA(B2RH82X898KJ'@BE# MQ+5X7!)S[;9C6=*;^I)$9*?5;.TU6[NU)KJ25VV5!>)B@K*2GA<'P&FAT[ZS M45^8^L(\DPM#]+PX1!._H/.PJU,K=TMZ@6KEKCK^*ZG\0?'?TM6;OW+7;K8V MFYUV+:M6\JK5LJHLJR0]+TY6\0M:#[LZM:Q:T@M4RZIJ626I_$&RJG3UY@]K M^ZZK5TNMI;MTM=1:]@OW<.6PQD#]\&OU(C%0JZ;ZU1>COABU=)'0BUJ)6]U+ M52MQ)?FCZ'EQ<26J4-VI ['UA7D6%T;1\^(4-G[!SL.N3NVK6](+5/OJJI4[ M2>4/4NY*5V]!O2\>>O5JJ;5TEZZ66BMRX38(!MC1?ZOA1_6%>RX73M+V@RZ< MO 7+Y!P_#J_@LRB>U/?K!VN1,T[B^5^KIW27/\;ZJJ]*?56620(ME\J7EWB[ MKZ(G'SD7X\!QZ8LSN*1^DL#!GD2IJ*_7#[I>=YS(\[]FQ6IYILJVB,J9WV$C MU5>GOCK+>766V$:Z2P6\,Z8;:W3HNMD]//DS,;QY7 MPGBN/O5:QWJ R*@IN*;@Y>;!,ZR$V/<&8EIQ>2%EXLO+?PHM86E*T_] !;NF MNI=%=4O,%R6M;C9;G69GC_^&M7D?8 R:>]L-O8IB3RJR=I'U$O%7!B,<7NEA M5IG&?Z1)^ "*KSR5N2HCI9.=+CY=>?0_[ Y*YT:IH0#>' M.UC?LB6]90L4,TA-#Q4S"RJP;KI J!9_W6EU&1P,#RS W_EA]/%"5.,E4E.7 MBSY*?9R40OD9KA.P_W@"O/?PK\P?Y]Q_E>GC+(Y@D]+)60 6J;FT#Y-IS>J6 M/?AQEO73-/6KR6"9R6!QO?]F<(/3?M]WQ4LE@,K5OQ0.4!_]LAS]D]_ZHRP. M_32+!>S2D7^#?TM>V/G/WH*70/N1?G3!SXLGE,(ZRP?"S,UE]$B V#T>;QHZ;9DZ T"_#G3QCQ<_UXI?/ M.PN%7/J!<&F)S__$9ZWYV9WYG=V]+YV;?PLGQF]6_]AA,6>T246N/K7&'QAN M7KY^WF6&<'@S]F,_'. WEU&GM;'S[ B#F,"L=;X\'G 0C422^BXA..)G(/"/ M0Q>6!(?>S=)A%$\52JA<<,T4;K,3/XI0Q$Z@@$2K3R- '0PPV'?B>-*/XFLG M+LF-RC4_._8PX\"UT&SO/HO#OE4Q4&M\*8=[D0*W &/X4^0ZP:]9[">>3T;O MZA_U7;S_CJ4_.PJX4_K7M+ ,M+#$&L',Y(=;$Q8T)A'>*))_G<6B+V(0N!=I MY'Y;?=):$)3_05- ZL45[ =. GR>=M:$2<[>^1]&V932&U)A6Q'HS%LIH.2"\,23W7'4MM^]% M0R^,>&JJ62S5M%X6U;1JJGF(E7DX&@?11 @2VJ?CYV%?=M%G.*TJS5QK32RW MI['5Q+(,Q+(2.6TUB;PH9Z54/O;I#Q&?AJHHC(:OR6_VH] 5B/O 73KWDV^E MYRZ<0"3G DS83)R(%4Z!P93[S\Z?4:Q6GAA:R]0^S=50G]KC2BC=[0>RZ E] M$*$['#GQMY(7H^KX:[%\K^SR^O+5E^\97;[E4G/N*_DNKZ/Z\MWC\NE]JB_? M,EZ^U91\]>6K+]\SN'PK*OF&L:@5SWM=OWRGZ@NXC!=P1:5??0'K"_@\+N!J M2L#D5*>MU7?QOG>Q>M/J:[F,UW(UY6)]+>MK^:ROY7))R^JLU2FG^[.].?:F3*7?AL3_;^#M'G=6?KDWVV=S97VI[OV3Y ,7UF][8^ MW>=T=_/$MO$X0##[R$]Q':M[PGE66G%%Y9RUJO4^N[M\)_C^) J_K'#)#KS. M.CGPHX@&L3,>^JX3%$_;6&7MP;H?T+XFC)?I0[DKXG 1!2(1H;OB.L!9''F9 MFY[&%R*^\MU"2[+B"FN&<;\&4S5=U/RB*AT=5.PH=()])Q;'X0#K:HF5+B=^ M!Y7_&6FDYJ M?O+0 D^K2!P+KMZT&$?8?*LF9:'/9_WEXJ!\A"/A)%DLWOM)M-EI[[R%1]10 MZJO"^#A6]> 70Y#:R:SQY2[1,]_Y IC:6?5+//\*R&9J0_&7)]E(Q$X:3>-1 M[K_V\O0JQC3>>"#":.2'=[SSSOTHO[1B6/6UN?R[M_$,7G'[*8WAK_Q" BLDPS]L=T'H7,N^@F('\=-X6YO[6ROV6DD/XNB-(Q2 9]O;[37WMQW MB-WO'N+&N^GX..?6UFYK+J-L/GHYN[-V9._^0\S:D?L/L==Y_! S%K*Y:9O_ MW-NX_X@SUO7=(VZW9ISZ(T:="(]SJ9!XUXKY-YT(CW.YG. T:\W\D\8,3._4[F(2/>[V0>,N+]3N8A(U:? MS,[&UOV'J#Z*APRQ4;WW^1!O:(PDRF)7)/ )?3 4CH=*Z4]O0!5X;UG63V,[ M22^.%;N[7V M_JL?:^__Y[_:VZUWO"WRO\:BWA16]?A= M2\9.:([0[#LC/YB\O6L,GGD/YHWCJC-YS!3AT=8[VSPQQ%JC63>7 MJ6_*J7\Y.;X\/+ N+KN7AQ7QX<75O?DP#[\U_XOW9./A_;^ MZ>?/QQ<7QZZ%NA0K,N== M24Y'I^>?+1X1#3 P)[[NM;:^"D_XS>9!Y&8CZ9#XZJ)+L-5NM;]^Q;^UX7]? M_QX<;H]ZVY/]F]"!X8#=AU%()JCOVM+Y>7+-#![TP\,*WYOO6 M:#[^S14\UMGIK+UOMYJ_D43)7Y&3^0I1_"I22T=22YE0-DN$T@W#S G.Q3B* MTVJ"\^[":8?Q2,G1>)(W_:B*!!.F,:9J*(D?.E^LL\/ST[/+^VS+^<77[HGE_;EJ0T\^!(8K=W>L$_/[?;6 M*^^U?7ID7_YR:.?L.6?-W?U+_+J]M[&Y4I3:64%*I=MU%,56.A1VWT]<)[ G MPHEM$7K"L^\B8&XS=,@N[&H*3@_.M@[^W3_^>_#G7"C80P 4_&[H.1.5?$2;TEQM#E3',F3ZKV_/.^> M7!R3 'JYLFD5B;>5Z]P6GH=QD&>'Y\>G!_;1^>GGK_A_<)+T9WTF3W0FN?EL M'1U_.K1/OGS^<'@^I2\H5G-(L=,C/Q!P3;$,0"6+^13\]>6O _?\_/>-.5A' MY7<6&<@V!:R;G<[&QFSIWUO)XUFM.7(@WMK+T_Z9Z7%_NDY M2)KN);F7GHD-_NKPQG%3"S?(COIVK#?&=A([&0L7D1Z>[<,9IHGM#IT8)O!Z MM8AQ]@5*G5X@X%U! )^Z?CCX>:VU1O\>.YZG_OW@=1DN;NT?=Z,@<,8)3$?] M;>T]3"!^^.A7(DXQ041M51J-)5S@I]3[[LENX5P7+F'*[&"OP ZPUV4,:B$% M8"@I1G:WWH^\&=QAX_+&O_KH'?WGWYUY*+#-1+@(^$K%.(ZN\%84+=%[S+/( M37;1+@V<:P<1&W?SC-1;U9,\*)SDI7-S+'%B+NW2;1K"3?#WV?7AWJ^3P?PT MA!D3*![.WMK[C>WFQO;NSN[V;?J">3SPGW@Y+NZ"!0/1-N*EQ<8]6YK[7U[H[UG?7;BOS*1IL(^B/VK61*U,66Q[E2M=1_^ M>AI?1M?A#!_WOW[[>]S;'M]T=^:]TOS5Q76VU][#>8KHR@^"^Z]NMVIUQ+Y/ MXS-08^".S]">1F+8SGX??/R2?/\2'ZP]54^PN!&@S!T'@1]&?C)C&Z9V8;]J M%\XBF$[P'W\\6X/<_7;8NK[X[?PZ'LS[F MO+RX0-)WMUN;F]HS5Y>B2532U M7LGU6V!1CF,X77_L!+:X$6Z6PK4%0Q/$KTA>VZ_^]L>PR9YXO5H+7,5#R7T> M__-?NYWVSKO$2D4@QL,H%'9(VG$#U8$@0\/7!H/%H:-Y:U<(CP_RLB$CZ\*3 MLZ_7\+2CWYON*%VH3R&Y[H_7ZONQ"K>!3!!K;&6[";2;*G]^$ M^-7_-MZ(YR'URN\LKF1K[?W.3KNYO=/:?39NIE6\,!? KF(_]45BL5M,Q,*S MQUF<9.@?2R/X)9E"=KOSJO<:W6<8;^^Z*5V9$SC>^J"6[J &A8-:Q>56L.,- MR-9($GY(?HNX+/U+3^\\S=\Y85\XS&] ML)K*G7_^MBTNOGSN>IMST^MG3*!(\AA BF:I(1INMTKD\8Q(VN]74',8I?#) M7YF/<@/$1=\/\!$$J"359__TGTY\YL^-E$LO+I+P;DW"#Y8D?V9)ZOH](1^ X8K47:!J@V$+"[6>]/6 $^3X_"CW 6U=_GWWV?_.4^.LODYDZK?7[RP>VOO_RUFNLKDC;5/(EOC MZU;^(CSW&SU#^4)R!TH?^6D*=T,$0/%Q%&+8*9C8XDK$$_L855K')5?;@9,Z M]A'+L\*MS\=0 LZ"+TQ=[5P,,LZ%M"^:E_8KW/"==YV-SKI6YGR"A(P1$O)8 M%F#=P0)XOOIFB^3UNJ;K\OUMEU %>CMP-^1UJKZ_P8?SC=VKSB!MST_25K^_ M<'_W6G??WTV\O\^ W%_HO26C*8!)"]MQ7;BWL8.7#TD9+::P\E/03,-FY1?) M""X\O"564L%RHQ&L;-) V0W#@<###1K8@SBZ3H>V_'H=EB-H;F2A$10[PB14'[+AV?,53VI;,AVI]?L*(U$J2&L M<+_:IP, D^SUVV= 6C56;<9DAWXJFKA^F!O8X;$SUBOH8#[Y_([@$UX$FND4 MK<\5K;4QWVF7];O'3?'IMKN;;S+-=Q4W>GF@0Q4'-U%*M9D5N[S=QUKL\W15SPQUP)3>B&U>^O I]4)A=40EKH]>C(&]-4KP]E_ 1 M%+I*UW^N81M6$6A^4VK"LFWL[>@I6LJ'+/%#D]V-OD3G? M%?,I$GGGKI3O)^%HH%?@6WY>ZSQ895DL=G!I;\NAU)%I@D4]>=GO2M$<5POY M2&O8YR7,".$$O_ZQO2EZP\VY@/MG9J?>,K'BY=FX*T'UZ6"HMUHB"\2F/I5Q MW;=F&[&(4V+;V[[+"X[N,G*2@?*.89XTLK.$#6"8/]=#2'52LG)( =&0/1U, M\.77/KP:7FN',/T(;=HK/R%C('1"UW<"-!$P 00?QD*PGA-[B8T82-^;A438 M>.6\KK9E:Q?MDB[DX8Y:&7N1ZHT-YXY>#R=-!:)DD0Z )#"Q#B;A#"A&H!'8'D-4@SUZPRV)T\:+G9 MVC1 2Q=.W'-@V.;I32 F2(?VJ_:6_67] BM1[72V$>'T&F];ODI$V5CCK!< M-S8N0-^/1QS4&<.['73?PITA:(!',W8RST_EO&IJ7\*% .]-\G@?G*#]0/S; M3/YL7I6<1!/5_BJ18UBFWY00J8PDX9_)J%X_H& ??.1&<2QG K]'L1''&.>+ MD *O_"A+@HDBP*JW3@< ]TK%-([\\"(=I86_]976I]_E8XO.+H*ZM<;6( M)>N(&LHD-Z)P(8B>8)+X=/DP$R-$$=/L.:CBH!(DPH1DE851/?B*L +Z[:;, MT[*K#/6/$S,\&(-"=H5W6T]!JETF;Y'1QLW6>KMUT&P#@UFW%BDK5I$>ERFT ME0Q%$"@%W7Y5 0&<&;YY70!,33'C3M'5@N^YW6H\$:>AV$WF7%UOAM5HSJ?( M;+>>'$1%_]W86]_-K?"72L&7H$4X@P%0*6HA2+TBE;CCV6SK*I(F7 04#^=* MG(Y"L'U4.V"D9/K7-G/*;!RQ@A(@M(BU6]"/$R= / 3PP%O>ZQ)"6KX7_O)K M%@I[H\55[ @)\=_E2]$J7(HSTL*/@LA)O_K'\EIL;[2^_NV=#:-A+XZRRT!? MAB-"(\![RK1L#+-6N"I=U8NYM=W$"MCF]0BSD1>EGG#]D1.LV?(O"44CL0\% M#8"-30J78WOM?6>CL=GN-+9WMM0E41/3M\2A_2;,!U8(7%\M&ES1>R.3P6CG MJ?V)'64IN37PZ L@GXP?CLF8K;%:>X38>H-\S8!C.N)#N9E%\^AA4T>[%POC5[ M D0DS-()KIU)LHCWF@>^K&?];)%\?&QS*#RW/6=8UAPC^CS!W;U9]=0<>QBC M8O=?H1-&[=8WI]5JSUDI.>N>7]K'!;W#F5>=N-*R8G\P7*3?8+YXDL?2WUS= M9:D8T3S:Z_.COVKZZLQSWA]%*&(GF!]E+92<.B^ DA9-/AOSG*ST>MH?0,,8 MQ%$6>C4EO1A*VIPK%#0*_N>_.AL;[Q)4?.T/PLG2B7WA^OQ/"62LJ>N1U*5H M8N[$L#W/_3L3<1(AHF4?8YC'X2 6GD\AS" M_=D!?=MW@IH"EI\"=N8K%ZB-*J'FNE>.'S@]/_!3@AZ<.];-3MY+#VUY]H7&BUBD?J$?"/M)74&8D6(::LFID<3TUR]OY^=,.L[ M;LK R=.QX"+]JZ+KU/3T>'J:J[<7Z] $")K/P+8^BR,@J'1"D@__$?L"J\'9 MYT@'-8V]'!J;NTN8!.""5>CYS7B[)J%'D]!@PQ^<:R+ MT^\'_@AQO?N$(:\I[<50VES]B[(EE%@5:5<3T.,):*Z1"@Q\!M%@1(@[#!*/8>:KHT[51/9X(INKA_LW,;'W MLP0V3\2K(NAJ(GH\$3;_:1XP)1K0I7>EF4]&&!E#171_F7 M,!9)%&"E"Q!T_;Z-6:(K).Q>%EGM+Y"LYNL;G_1 !9?=TFI26CY2ZBR0DN;J M(I?!.W]E/)^8,TJX.[1]EL7NT$D$54#CW]IY0]45X7?MUDNBU^T%TNM<(W,7 MJKG!D2YLC4TF:Z):0J+:61Q1;+L+I+NYA@1S'I=#7XC^+K+Q.*!_8_+,*HG>%T5H M>PLDM/D&"2FC =OZJ)QT9Q +27#4B*K+K78<:I<2JG\B*@M_8*B!FAO6%+F, M%+E(F3O7:"-H==A8*E&I@J[P5BA2\,*H:H$@FXVY!A]/J9/(ZJ'_VB\A"R>G MI_W%D=-=D:@1TEDLKC#EXCA,QK)E M4DV RT. =>RS#C L17"J@F\M*/99!S^?-7TMYZQJ.IDW'+FU0 5\KI'. Q][ M148Q/'*HVS6>JG:-:.OM1_$XBK'. M=DP&*<*\*@7H22E!-=>X%$-]=P94YI M^T9GT54AJI> .LR):H%P^,VJ<.7]1I/ B8E]>AT"HQKZ8PPP[L...GYH?Q"A M Z&_D_^GAA9'L^4@28% MFKN,'6!ZKJQHQ"Y^EL/V<>@)8(F>6!TQVWD)!8US.EP@N']SKN'*L]@/77\, M7- (#QT)(6.6(KX"+6]EF%U=YG;U9U4;FLM](K%E0ZT7+26@+A.1OSA79 MW66X_ M19OEARZ9!V[AP-.+GGH9:U[&%JC%O[,O)V-88S=V>K[[SCYQ1H(WZ"3"9;<+ M39;5KZA5^(MH OU4N8J+I/]YS[DGA_2]G]>*C8]Y-:C>6\5H]BHM;ZYSGK/E M5+7Q';WQ)"O;Z[9NZSOO$ZAWFQKH\IQE]UO+['[[TC:\>"7_S)+4[T_DASYZ MLF'0UOJ6'\YS(2=P&&/,I[4NA3L,HR :^"+1T6I,/WN%>6N=UCO]:(,^:+^S MY1?R\,H?7T\]&&6Q_BB*U:=9(C][W;"<( H'#,U'Z^)Z& 7!Q(ZN0P$*7M9+ M?,\''1"64^AQV[ _?=JW7\'P:LQ2#]P>]\!-9 _^03!TB:/5B[1Q8/#03'@XI^,&EZL7\E0GLHG F[F*G55!<,D9( M.FX<)8F: OXZ\/M"S\4%BVD0Q;#I#6L<1RGJ2S"#Y!N\N1]'(UN$5WX5\[9'PJ,HU+&L01D [;K)N7^ H,5#MAN->K!"SW*S M.(:7P'Z/G&_"SL9V.A0VO,Y)X9,_HUCVBL1M[JEJVS@J+9\^[G-I6_A1= VO MQ(1O6!V<%YVHXW%"(TR *,9'@Q.?T \-H4YT(HC0C,'8N"XL&&J;^E(]RUU MQN, ED';NVY?#CG^CV&G9[ M;W>/YM\3+FAJMF,=B,"YQM-S#?+WN&64_FE[;V]GW3Z%U;J+V_B70,VBQL9XB14?PNF8QZ46"?=$_^M6[_(>RA [OGY?WR M+#K8?(UVX/1P,DPD?(Z%;E:N,W91W![^"'M[P&"#J)'O!BS3 M67\&#.S9<.)/0 &Q Y,86(X--),BF!_OFP^ZV8#)>0S_#5/)A,9&HZG48-YP MVX""\=H*?,;+7)7ME(4^V!SV6,24*(#L)XV P0SIKR+TFB[03(;%S66NLF4P MCVL1!$VZL$2V4;\/!)U$V1@LD&:8P4ODVX#P&HIWP7J$B,WKVT N,9*-:$RZ M9]+N^Z&?#(6G!K,*3\!T\=:)F-Q-Q6M >P+Z ^TA70KJ;PL[PM=5W%"=OT00 MN]3<1,V1A@B"Z#JQLX3V!1;H(KPFF%ANY##- ; #&T;E1IZ0 J@ M, J;^)D2=PFP74&5,#*>@&-?.7AZQ%)'LG,J?)[D++N!O(R;]%C&+Y,L3.!X M!DQ,U M+,ER5 M(2%)JJT@6Z&V 6S'T W&/J9IWB30">(4E+XF' M5 '3<5F2.[!;0T%B%+:+)&")?/F][I#7%@M7^%@*MQ=',*[CNF*+ M)5D$'!3KKBO!=V+%043U.DF@X01KE?5Z_8_OA2D7P&4*/X.W$1G ' MI(C7-124GU6S1^0F1!C"@>V6T]>/?Q.P97Q5"F,3T>$:Y&'=!7YL)T1Y ML??NV8C"9[.0LRB8P%5!\VI_R%@FABMIIGRV?ZYY:/_T]^.#9GM/6S3 <=#J '&)JJV+ M]9&0>I$S2B7>X >2_10L$]@%)/XRG\9?>D*,9\E3]7-\/6LAGLF[:0P1HB.\ MH(C@-9" +]P'^>#(F>"B809P>X\!EMN#P.%^XYO!7^,K@'#F9YS1LX5K9'8$_ZV-$C?3U+.ZQW0O*)2@] M"#"6O(K>P9=8\SD8I=/JM%$==,(0- N\*$I!C 4:P60!X324V:_\#.O6'X5[ MSH26"+2^QZA[>?Q;UESP53UX>TD!:>@MHU.HLDGD[A2X)=K3R;IUJ94XWGIZ M >E^R3"ZQCH4R%*PJRM; ]=R9;FF#1NHC7P%M)8,6#+%%$A(N5C@;T,<,,1] M#Z-KRV,.Y^ ^] ..,$WQ^X8B/5<5F9)#]T%;R2?%$Q(\G8A-**:% N^' TS4 M!IA\ZQG<\&>SD-QY:X$] /.!4;0<+7M3@8[ DHY3POR3?.O%I.H#84GSK&$8 MWT+1*Y%4@3\9!A@1F#)D;%2Y$ST!9FT3XG.D<>!UZ$=NQMHO^]K(2ZD]C\V& M,7BSH3PB^.JFX3(H^ $LX,)W>D2(H)6#S/Z#]'&X"]<^B'!3AY"7@]DPZA.Y M-)U*+')R++TU/K M,;46&%@K1;R3L; ,AP,QZXR/L9<1RQXY-_X(B(>^,]@^=G+)8A*QDR12.!6AH>6@ M[N2F58Y('AS8, 4:(]*$-VW,>Z*29;3O2G;8!)G")31A:SURC8L;;#Y"3EU[ M(IP8?[\A1ZTULR5=R"6Z=V]21B'!N*5X^#@ MXJ^,*1)=[-?D2J''AAFL-U<2E"VW*8.L$[ UM'('2B@&E/V_*;B1CT_S3\AV M)FH'FS8EGZN:D-;/-*-":P?C-F1/J24H%:*A?-"HB3 _[,.(O'FUXW3!"[DG MB+@PWUNPI1LUC!26W:EAI(NBQ&6[/]]?CX38/:B*[2TR7M$ &V#W!8S>2AB! M#%S#F"G0&^E%#H:X HS6QGT$K:2H4A'7?841QEP+>N>4BI(R%'?A\$LI6O&\*)!"-ODY?*PO4,R"1?"B 8G=Y4RF*80#V88 M#WD';UFO$5_%:*2E8@:\:5)G=1!, 'OJIMH1K,(D!>7;<$XTC(@S2;8W.8RN M$'A5'F@&AUE??F?!78"2*;09REK>K$#<^#V&*2! 0_H$<^'J>!%!^U&M!04" MB^OB!*5SB,9085.])C63I.RJ+:C01NATT# 1$\TQ:6BGD5:5R*T@ M0TTL[_$T$0O0R(T/J[/5LB]^^T);RK ']0)A>'C=*!EQ0-\T$G*/+JC?K)H7 M*,_ E\6HG\6R MRC$L5H:AK(]11-4[#,C,10H3<&(O!XFX'S^?Y2%$!^$QL$TN PIP]"_K%^OV M$0Y%]1;B;&!WO1%N7UK"BQX==/.1Z+ LCONI@'G B">AP@S2HWQM8D T+D([ M&^65F&4O=N% 9F!2K-PUB>[%*1I@]9'!#7#,Y-[R(G+.D8//H^(2P42JR@R4 M0M<;WN/8[V4FX*KP#!V.A0LISNBG)!N_YQ ,"!WX.]\E3>((-8@QMHA0(7H5 MT!1,!<9A&M!5H:'2F/!&OY$9:N?N;;!4$>CC$I5PV]E\3=%1)R 07B/PT)H\P M4'XW0_(.?$=[!QL M$,GHS[0GR&F<()X! M=H' =_!@EKZS&F:77.'L/CV5B.:X;!8A2I@OS:P9# M@GC?!XD7H5ELG\!KAG87;AG0T]0K<,6(CO:$)]UD^#NTL+J$^28R0O?;D0'O MQ _]'!EJ?^ O<130,ZYI*R[$."5P][T6S>K!_SBC,5AJD1^( ME)AS-\!?[FR],_;C,X)V+D#QIU0!D,%2:48'UU05B0QK(9#N.AKD2BMG0LHC'& H<1 MQ\0872GOJ+I0\.S,Q3L#1#<]] XUV-V5@L%7OD[ C_@>?40-_0@MME,_H/NT M"?>I7WV?R(W\(8BB415EJ1W+ Z_*H>;GY^&,808HS(';ENY8E:VF!/34ME@$ M=+R6YT#>:CYJKB!GGQS^Z]+8F@^":"4$&>.FABJ+UP !ZD3'US!/5!KXT#H= MK+W)V0^:HK#3!PX*-@E1&K)+Q&F5IZ?IL4HO@F?[*>^\8F#&0C;OQ2HLG@8O M#&CC2*D$\OR;9\J&V)? ,-0"HC1 ;J$8(/P)UJTODXO(#O*OC%P=9XM. U[ JI\-S9UAP,("?L?A5[Q8 4P* M+V[@L[=*1R2&#L8[Q+3I2N8^JZ2,+I."-2GEZ8$&RJ:M=#PH^YE,8P9,$+). MVD3:7LSQ(THAQIJ)Z[;:_[GMQA_",ETY4VMD=/L0[#<@8I*@(^1]+CP$] QA7>OE""RUI'^&LJK MI##G17, MSR+.@3+0 6F%#?>8X;NN@A7AV\'L:_"1&\LQIXNX W0SZY3.AF*>S*$Q%,%@ M>^E 8O@BB BK!*.DQV-9,YBACL5(4F(:N&3?4BJ74K"E8*8("%C+#'.@1%@) M!$<368UOKL'2.2P]':!@HQM,A?B;&021TRI@2&7F78[WICVJ\[9_)*/=,7"1 MA'(A:[I[Y?B!0N0 _9P[U[;FOS7;?1*"0DO>DE9_#/N?7Z5K!C&CHH06/"+? M\R1R=(+RZ06"_!0)QJ(Q2,&)]#%Z9S'>%P6BR<@F9'ZN+,)!R=L*UTW7'=2M M +'3F.D1QP[1 ]SVP+M&)58!J)6'K3A3F=XA)NH52NG%5&?R(R FF$.CV8)]8D,!+XXT)I=V1Y;#C@SH0"-P!UYN(> MJ05IHG3",GN01&BM+/G=*M5OF)A?G4O'B) M%G(!=[>:!S"2 4TEE0BK#US5K%#^LD(""^I?M_P:*%N&^^2/-3;2XBI &<7. M">2,MB!A:_#N4:Q*_Y4?V N2@%PKIW;%+:;2C" Q##.#"-9YP]0JX MR&-$'HF;,26!5"ULW3X0R1@#D_CB\PQ,5Y2SX17Q'GSSEV\Q7+1"!!Y;U6,5 M_I17H&/Q2N^2G -LZCCC^I,6:UKWVP<]'MX!L$ M;0CU/G8X&-ET62@G9DD.KGF.)AF*YVO*8GRL=KG'46 J^JC9XBH4O!S+#2 V M('14.A"6'T)T 'I99.$I] ;K&5EJH] ,&(,H&E&%*%#RT\F8ZU@1:)TX7(C@ MC"1AU#YBL>"DTZ%VA\N]AH,J7C)]82R]K.(-B$SZETECWX3.&,)5>518:V*F M.N6_P-B+5*4"CV0!Q;74:HH2P'X&G'/91,"^9:_O3&?_]$H<"7)G8>$Q"3(;="PCQ![&4$ MJ@?J[EDKY^Z,^4L,.U7 6YL&O#6O2-K+_"!59;O,X%0)LU(J*JC- M;$\DL+52"^6B5Y89P;S%44JH9?XQ;5.IF!C]]+Z%Q(K[I"L+&#.9*C7F!GG\ MJPPCC8 FP>8*%%M6.:?A_- KA8)PP%(%V?(M$8J-B@<-3S- ! M)1X=,M%UF&!>QXAUZY(@QU;GC&LL@,L9X3F8C)=8V=J;(J7MG00P3P# M,B^MPE%6=?41)E6F;*N$Y2;?&T'J:778'2/&8E4R-1I1?*:G@PO4H+]OJC A M$0F3(5\3(P=$ [4Y)=Q$$%)?* M>DLE6-6<-0(U>"WQEVTA?#[W 6W59[=L"SD.+;,L&X6VR0]4AD\A#_:H.F@> MYZ;Z-"(:P/T'E2BOM=VH+!,$+"9*18'#ZPQYBR0H^]Q4T$'%>;E&1AX>87W@ M0_?BJ+(X/WZ19UL1=EFBTW3!")DP640QF?*\#%>0.H0&+3@JB ^Z97%N2J1+ MOJTW029%21>HC''+VCZTEH;%:B4P?A<>%I2;(X*^[7!-#PJ<:;^C*L_O#M%[ M2: N6?>=RLL3'$P+6412($SYQD<)'4SL_][9LX&%!UR8#Q4BN7>LGP<32XVO M?>N$6Y E5P-!P;5FL594OGLJHE?.36-LN>Y[(-4ZK5RPH= P"43EJTJ=6*H/S#DDG#0XF/MYL5C)U=:IB="XO5>_86/>R MB9EI>0K+#%IM&/,SG+7H@&AR26P5V33@?]QH(3=G*/D(KZEZM!@-E>E$!( I MUGRFF&7A. P%GN980OUY#D[T&O30_.WG[ >5L$< 2Z5\98A<9JLL1EI4$Y0_O/K[K5^3]$PXAY/^F M: +_VH4_1M*JR?/#T&&*+1 M!CO%B)]4J8OMO;T]^S]([J<$;+W@<$H7M55. MESBB9&L= /%#XCB<8M&+LE2G^/ 4L,(E]BNRP2[XA.E]#!\0R,SJ /4R+825 MQELQFK6VN&P+(4"G"=!&Z5IH&S'5DJ50&K88(&7\)$I ]*IBA]0PG.2RDJ* MP(*&8&BFD45A4D-JY@-5%),6W)R5_'3Q5*%M=^A@^A0\FZC&!:K8.%GI#=6J M ,M#D2/,*K3P;KR,058"6*G M5'8W'ZA!"6"FZBO=1PHQ5+%56C\B-P>F=A3<+'0P5J[8J1MIG.5J%H;% M@ G37K.6:^8F4N\!B2QE0"J5A9Z:C%GT ].>M7/#3*7C6T7IU;)$N5ENN')4 M!!$@_,W%Q'V7,P85E+915>M%0VK!E 1D[![C>31%5X4O&X^:J.EZNB**!,N M,38]%S75665 N(;>=:GB?#GW'W0S 1064R5GRH;A.@X.576E$NTINK*$[M;B M*6Z/^>92UDU[2@4JY6J;X])^8V5!WIO)$7 6<4V$%N-!6*-JBK6/"V6'?^F3#P M%0W.[NG@[#EP%[R_')W-N4$=G'U2:+&L@4Q'P?:B855'5[+^#J8VV'T8G("R MN?MD"K(&U_Q^,0D40K-*WA2AO(6DZS^HIY>@DN[H'V=0VTB 2-2FM#;V09?Q M&)%FL&0SE\&0][HW#>@K8$[+WU)3*\Y70;B4DKZZ^K-6#S*C9X=BV!P"TH$? M4V?0T9]UB]IXY>6E9YU%0]OY9A&IA@95EW4W+:G,+ZA:;))7(@=U7??7X\Q" MXKI (Z\+W?I,FM#@:^E,>&=W7LL,;53OX,N>]OWEYAY6Z#:AJX:4L*0<*P%; M26,CFU#7R5)^31@):VY@Y0))765I)X4R!UDW7I?*VJJN1KIT>%EHJ0>*"K"! MDBB$J-G7KHQ1:I=-75<<@MB:=XRI-CM@BE_VEK#ZT:(BY5E8 M5@P[;VY 1]5C#L=)(7DT] J1D%/IU+ERK?*:+Z4EA >37D=-*BE-1ITWZXAT M?-S-F.VR)7DK8253KGKKO[=+1QM&6FH:(ZOJP#00L$_80(+<& 6*L4T+5OX= M8I$]R:HHA[KF0DL/VMVJ0;NP[,T:M+M*H-T?5$>FW=(7"T,3V& *.*355;IS M73KFAZ(-[H]D:MR_N+!$YE4V@68$7UN66;:TTE8L*:<>DA6)9?<@$\NI&[$J MMZAAF35USGNA%ZW1[!%K?IHUAW6'^V(!7:.,:)[R!-]^^;W[YLOO'QJ8X\_& M)[WJE\/?[5<]$ RO;2J$950REE#8XE;(XL(.:5:(N3#!LZB[Y>G^A!TST@(- M#!W\/HZ2)*_?J>L?TS!8LKK0OC70_;Q! Y,[BT 2)R6US3(:82;%;M AZ"B! M]FB27Y!JK4V]6$V2_:$XR40WIB/"!27NPT3VSE*@$C;W+&ITSP1GTI!1DZ;0 M/T*"I MMU@)]MMEPR^O8#O"^R]A-VXNV U(M(R3X<\D5DD%.PBERA2NJ'?(2^.B8[I> MH\44K8M\HQQ,05-=UNC,"XZKBT7Y MKAC5 ]/;:$/.X9L1#!@[ 2.'S*ZH2_-1(B$*YZ"'>Q[CLK>-NJ=6KJA MZ#.@[N=V36^)XC;*W0!L$@@Z#F+R:DT9E4[NF'QWYKD<& ?KB$^&]+9 MB:%S+IAAYCP@3 ?].;*I;T'F%R.IN18DGV5L.R;6WU*Z:6;O\'PXU7FW4D^* MQ544(&_AS"!RXUU'9C:&X>&UE#/]U=GO%UJ1/ N<9.2 V3Z&>5Q,0O2L^$71[],8UO-,RW4 M^F.O&:V;W98%3\B(*1TVI^:Y#-5&89B.X1"EA/TAC MQ9X?U//9;'6:C3FJ@(IMH*H[RLJ.5BJ+=E$L6:E)JD1CS4B7RUO0-O)^S4M] MJL,V)@1@ 3!+&SYP;393F.([8W<4CKMB$/"Q;F[0,K^);L M@D@07M]1V9Y4T[4?&08I-X[YKIX[N$NZA#R*M(D,SU7TT]&=[D\O]_,BY =1 M DNQL!:Y<0SZFTI*TT/L=-);AK3PVZ^''9G_'L:D,#^-^)49%+95V M0V65..\G*IJTAQGHP@+KSR5XX16U\<>PL?LJ<:<[ *,Q[_>0KQDADTDFM3TL M]C3FHFMR$\YI9I+H#S&0Z6BW8#=+AU'L_ZTMNGT]7W4]S@^[^[^H"[)N[RN^ MFAL.QM)SA#Z01I#!?W4FTGB!TXHY)G2.VO] M9XD6@I@' Y\BX&I&V-#.%4& R"4$N#HCZ4LH"EO5^**A8$T1&!(ZJY],-:KL MJFH8P(B)3OUB>G P(!U:Q7$-+Z71B!>,.$0BL&&C.JT0V,:H6F>Z:8TD+>0Z M1O%%P@"@4U/V^+-PFM3932&()$I-.KFI_IJ7]];U4XE[YMVBQ+7(\7!Z_ MV M+9MKD@8B.:'A5H6R&:&-,0/L3+G'B@9.M"<&W(%8GX69+YF7X@).BYF/\41N M.%;@Q"DF8#&F=F8"+A2B9+J^WXRF<":R>M:A:P.R@"!S#?QS1!%C) M/;+RACJ)>80+X91L7\-K7Q9?[F@#F)#$V/WL$Y; 9FHS#>"VC0X8F') M!LFZZ8O2*4DS$ZGT:M=<;(D6 G:!5"%'?BKAI([]"<7LA7^#7:=&SFQ"CF33 M1>I;-H8+3&FC _^*\GQ5I=,1T(34-?R8A;0JU8*9NQ+8:=@*"NB'G>B!*9!+ M7*7'J$Z/Z%E(,&B%%\>5=R6$NSPQ+0P,GW%.!*$\B!)!#< 6A,1B42%0EXUG MI/*5=7,B4KK4'6);A[D4@C>U (#?#R)4$IKVJ_9KKJS(W<(1;C_.6&7#I#N$ M:*)++E2E:>'<.) E6],5<4>O.J\-7NYPSSW:'9-[(R)2A@W1I8W*!UU:?@9' M)?367U*E+7&K&JB_!$#]=D=[4X[#%-MSPH5S NSWBMHKD_69$60]QZAUL@"O MRK*?Q8]BE*J(MR-CX=I$8&]^@\NGHE<8H>/C28P')#\%@0GL(#52[GSCD,G[ M3X<<.-U$H2Z1!BM*C%3%8K&#GBXEI0257&+/@N DTT_S=+^/ [5,5@V'*L M1H5_VGDLOX3\Q0G4.L,2+:2;*%N>;&OZ.TC,/I@/F!\!I!!=A_ L=WE6)XXG MNVNKB)?QU72B'%$1CK&U34F1L#AS&*OB=TKLR837C2WE > J)>CQ$VBZ&],HX[I$\%/IL02)M @+ M*DW9$J"AH-J5("77%.+#$J("MU5+'+*3:BCQ4 @3V)5.IQ&H!# MGJ]B42X*)&I[GJKWHQ0&[52E.1H%](]E60A=1Y6:<;'ZBU&2J3E'V/XQEI4> MI(R>>(=U-'3#'".;G\LQ1&$)WJDZC)G-#]G=44A>M#E"5DYYM9 7DCOK1%V-9&#RDNGH2RSP"2- M/+6W?(@EL$PY+2P?>ZKF@R6C>*[#2RSZ5QNS*L BSB_F2D8:9([=E!C)ETCW M>P$0K+?42M%WA.4ZK_P$B(0I[98J)TKERJ7(JG*!9\7.+)FD25?$8 U&CQQI MGO*=08L:R]6EY$2,J5N3\*JY"I.Q-&2KL%W)NJ7:?2F6R1%9M9/4GIY'Q4+-B'1'<'AZ#:;'T&* ;C_6N'.\Z]1\)DGKGMW+ MMY _A%6 @)L2P9ZR_DHA,6DL2@%!-9DK"LS8=Q:8L686F*FN&Z!<0V"E8.W) MV.-HFO;4&/$FSIJXDM*@ME67:"&ELK6F J<:F%;K9DI'T?K5W?EH2=9+?,]' M=S7JC8GY-HO41<>FCH8&B%D5?=>0LSZ:9CI%"A,!&!LT*U](<7FB=QU6R343 MZN@5!-C9"Y/I#94%)Z1PS[*ZKHE[UIY7,_D^[T%EJKO88RH1XEM>0"-/0N)B MK19W(]"W3_9ZP!^2_\M$Z3!W1X^87B08O$.8IBSOBO(-:U1Z?I]RN$#-35G- MY#1]]/ZJJOPJ&(8*WX#\LS$'GS7NE@\8N(0KN&0EQ\!N6*&D@]P4-2T6QRPT>-!J)XN6R1UIPRU(4A#+7NG7K,A]NJ1.K6*GY MD%6AYG+T/Y0T0X5HN>)/X9Y*);_08S#ASLK%4F-:MI0+_1>O::G.!K4@Q)3% MU$]THH]QK$8YG)(ZCL:?0SF79I(<.D/'@2&!+/;T%W9M8EHJA>3%!N#MT[=V"0@@GG7+>P$J2$/VEDN?1),&;%(\>*XK*(C"WDO\AY(C26 MF*7DRB9DE/T),O%79D(U5-,/BROYN!E-CIAP87P1$@R.\@VYN(WOPF!=M*4H<:(B!D!P061O.'). 83%_X$ MTO@F>[@$V!>7FHD:R@'9.Z",P!N+,X,MH1*F#(R1!&'H"]0<@01!400VJ1Y\ M+D%5#?R)6@ MT?(R5_I+2-V!+X#/"2P;@A3)Q2G[]B?$XFG6=.JZV5CAWW[)IWS!4YZ17G)Z M\8O.+UFW/@C70:%2"'OC71Y12PG8<6"Q\4!%W"F[E.PYUEW)RQ\+V;G=J%JK MF$%#X6.D(#!2]',,C66 [E27=T.'5UYK.":<)I>GQ+83M,YU$'3H#:'&T,1) M%5((&#G9%SJJ(<]2!EC(F<$:X]B@50DKQ *N=I MY$9!A5&@Q ,6I0LM@I-CT7#,Q]"6(F9'2&I3?5]*%1F+]A$S-_D/[ 8G&9[L M\"VQ&6RY$&Q3U&QIF19B>(;8N6-FS%$H*S_\HN)&.F#@J%IY7,,"L;B2X,NZ MF'*R%)D>AH$BDZ48UT4R1,3'5?DZ"1#/V5&NR)D?]?/&WT@'EF%<.*'6HQHR MLF9J6D39Z(57/C#NC4.-T1E6Y(/EB>4+\UU9MX^XX5NC7*E69S'(_ <5B>L# M5_$).\BL@M0"+$5NH:TKT3+2/6BBI1.0I7K=9]ZNGK$ MU;'/>DRI^&1M2SM*1A"(<803@VL:->AUKW=32782>GN7'4! L_C(!K6@:-U%;[TBT$5)E< MCK"-IOI'44TH+AR?P^F!_K5,X:)9#*[7F052AM&-\0C6:DA+OD#TPB)_LJ;, MG/NE9#XL[U9EW,JT4RITP5XMW?5+M>I2E9^U$N&)/EMJQ3JU3RFBMK MY!=3&Z9P0;H7EY_M8Y:ZO"!K7ZJ29(N<%%2IAO;,?KFP+[L?<0=QJ:VU*I4;JKA_G*4TA1I 107M#X)!1Q(X]=<*5:VM.^()9)$7XLI23E M@YGD!>?0[S?8;4_E![]3X^!A MV=LU#K[&P1=4B&U]ASX Q8/Z7<!,Z!O1R8#7%<&)V(J*( MF\^(#)?M%<1"<,<-#DW*JE/<9)DJ/NIR.68U&_B[B_U=+>)[C#'5/>@JZTMH MR(4PDRYG%D=M%-NE&!AY)=JI(H\AQFD#!M0.0X-?J*8RE<8VYFS6.I3UN";< MJ"Z/ZLI6+/I)#'"@NL6!46G;&F]OY,!Z>2Y1#P@"]YMBFOF,S'D@TA]S^;-1 M82+D\C-FPP@FHW089P0$$TL-I4U<]:*&@HBI!N*HNG#95^S&FP64E8 MG7*\ M+=JR.)31AD8OD!HR$K4"ZM MV53*8LH*1ET-NZPS?>$D6'V39&[)]C.U!O7#),!.+@%4F\X+7?32LS^*:! [ MXZ'$3>C^S;6<^!$EGM"I$_O, C'69Y2K3HQ#43(6\FU524 M?D/) 0HAUW68D+!/HE18[0T57<&6463OX 4^TL[U"^U\#KK@/Q MJKYJA9%CD/AVJL;3S!XL<25[S$,2^JGJ/;FDN-"FYQ=+OS@"9_^YLK7<^8^1U M>_W] CT"'VB[WW9%TZ MY.EY>)/[)%<=-Y5K+VCEA>ZGKSYT+XY>RWB,[*-7<23Z]00_E*$5K]C=SNYL M_:-AMW?P/_@W'!/_838L;*CQ<:>MPG;5(F&)%H(%56[-9\G[G.^FH^F&&!C056:,4Z]S>(@Z, M=UOJ=Z#UDB''+36F:9^[&8CE$68")G&5D"%-V%70TU/9;;&+9T1 MY>OX0<8X:R?E-']$M1HB*13#.P\2+-"SI/:'7%P%F M.8S$Q9I8LCN7KA!(W6\D>*2OVP[P,<(/T(4KP8=(^.26H0*'1;4 ;X#!T9.+H9IN4:91:4I<(M7 M-.^Q_1CBBV5E04?V>34B15.3YP09/4L+L98*21[%=IZ>PZE $J^<0Y.+]0\4 M#%J5;^PA[1BU&L%H0G!WDD2NKRV?7&86#JH63#_,5MG3M@IH9]=.[#4_11&5 MR,RMS-IP>2H/];5R%DO6SK6 5;"71;+AXY.Y.

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end XML 89 nanx-10k_123123_htm.xml IDEA: XBRL DOCUMENT 0000883107 2023-01-01 2023-12-31 0000883107 2023-06-30 0000883107 2024-03-28 0000883107 2023-12-31 0000883107 2022-12-31 0000883107 2022-01-01 2022-12-31 0000883107 us-gaap:ProductMember 2023-01-01 2023-12-31 0000883107 us-gaap:ProductMember 2022-01-01 2022-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-12-31 0000883107 us-gaap:PreferredStockMember 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-12-31 0000883107 2021-12-31 0000883107 us-gaap:PreferredStockMember 2022-12-31 0000883107 us-gaap:CommonStockMember 2022-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000883107 us-gaap:RetainedEarningsMember 2022-12-31 0000883107 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0000883107 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000883107 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000883107 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0000883107 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000883107 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000883107 us-gaap:PreferredStockMember 2023-12-31 0000883107 us-gaap:CommonStockMember 2023-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000883107 us-gaap:RetainedEarningsMember 2023-12-31 0000883107 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2022-12-31 0000883107 srt:MinimumMember us-gaap:EquipmentMember 2023-12-31 0000883107 srt:MaximumMember us-gaap:EquipmentMember 2023-12-31 0000883107 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2023-12-31 0000883107 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2023-12-31 0000883107 srt:MinimumMember us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2023-12-31 0000883107 srt:MaximumMember us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2023-12-31 0000883107 nanx:MedicalDiagnosticsApplicationCustomerMember 2023-12-31 0000883107 nanx:PersonalCareIngredientCustomerMember 2023-12-31 0000883107 us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000883107 us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2023-01-01 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2022-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-01-01 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2022-12-31 0000883107 nanx:BeachcorpLLCMember 2023-01-01 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2022-12-31 0000883107 nanx:BeachcorpLLCOneMember 2023-01-01 2023-12-31 0000883107 nanx:BeachcorpLLCOneMember 2023-12-31 0000883107 nanx:BeachcorpLLCOneMember 2022-12-31 0000883107 nanx:StrandlerLLCMember 2023-01-01 2023-12-31 0000883107 nanx:StrandlerLLCMember 2023-12-31 0000883107 nanx:StrandlerLLCMember 2022-12-31 0000883107 nanx:StrandlerLLCOneMember 2023-01-01 2023-12-31 0000883107 nanx:StrandlerLLCOneMember 2023-12-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-01 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2023-01-01 2023-12-31 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanMember nanx:BusinessLoanAgreementMember 2018-11-16 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanMember nanx:BusinessLoanAgreementMember 2018-11-15 2018-11-16 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2018-11-16 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2018-11-15 2018-11-16 0000883107 nanx:BeachcorpLLCMember srt:MinimumMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2018-11-16 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BusinessLoanAgreementMember 2018-11-15 2018-11-16 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2020-09-08 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2020-12-23 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BusinessLoanAgreementMember 2020-12-22 2020-12-23 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2021-04-21 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BusinessLoanAgreementMember 2021-04-20 2021-04-21 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2021-04-20 2021-04-21 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanMember nanx:BusinessLoanAgreementMember 2021-04-21 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanMember nanx:BusinessLoanAgreementMember 2021-04-20 2021-04-21 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2018-04-21 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BusinessLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2023-11-12 2023-11-13 0000883107 nanx:BeachcorpLLCMember nanx:InventoryFacilityMember nanx:BusinessLoanAgreementMember 2021-04-21 0000883107 nanx:BeachcorpLLCMember nanx:InventoryFacilityMember nanx:BusinessLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:ReplacementPromissoryNoteMember nanx:BusinessLoanAgreementMember 2023-11-13 0000883107 nanx:BeachcorpLLCMember nanx:ReplacementPromissoryNoteMember nanx:BusinessLoanAgreementMember 2023-11-12 2023-11-13 0000883107 nanx:TermLoanMember nanx:StrandlerLLCMember 2022-01-27 2022-01-28 0000883107 nanx:TermLoanMember nanx:StrandlerLLCMember 2023-11-12 2023-11-13 0000883107 nanx:StrandlerLLCMember nanx:BridgeNoteMember 2023-11-13 0000883107 nanx:StrandlerLLCMember nanx:BridgeNoteMember 2023-11-12 2023-11-13 0000883107 nanx:StrandlerLLCAndBeachcorpLLCMember us-gaap:SubsequentEventMember nanx:BusinessLoanAgreementMember 2024-02-29 2024-03-01 0000883107 nanx:StrandlerLLCAndBeachcorpLLCMember nanx:BusinessLoanAgreementMember 2023-12-30 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2022-01-01 2022-12-31 0000883107 nanx:StrandlerLLCMember 2022-01-01 2022-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000883107 us-gaap:OfficeEquipmentMember 2023-12-31 0000883107 us-gaap:OfficeEquipmentMember 2022-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000883107 us-gaap:ConstructionInProgressMember 2023-12-31 0000883107 us-gaap:ConstructionInProgressMember 2022-12-31 0000883107 nanx:JanuaryThroughMayMember 2023-12-31 0000883107 nanx:JuneThroughDecemberMember 2023-12-31 0000883107 us-gaap:TaxYear2023Member 2023-01-01 2023-12-31 0000883107 nanx:Expiring2023To2037Member 2023-12-31 0000883107 us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0000883107 us-gaap:GeneralBusinessMember 2023-12-31 0000883107 us-gaap:TaxYear2018Member 2023-12-31 0000883107 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0000883107 us-gaap:StateAndLocalJurisdictionMember 2023-01-01 2023-12-31 0000883107 nanx:SeriesXPreferredStockMember us-gaap:SubsequentEventMember 2024-02-29 2024-03-01 0000883107 nanx:SeriesXPreferredStockMember us-gaap:SubsequentEventMember 2024-03-01 0000883107 nanx:PriorToEquityCompensationPlan2019Member 2023-01-01 2023-12-31 0000883107 nanx:EquityCompensationPlan2019Member 2023-01-01 2023-12-31 0000883107 nanx:EquityCompensationPlan2010Member 2023-01-01 2023-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2023-12-31 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000883107 nanx:CustomerOneMember 2023-12-31 0000883107 nanx:CustomerOneMember 2022-12-31 0000883107 nanx:CustomerTwoMember 2023-12-31 0000883107 nanx:CustomerTwoMember 2022-12-31 0000883107 nanx:CustomerThreeMember 2023-12-31 0000883107 nanx:CustomerThreeMember 2022-12-31 0000883107 us-gaap:SupplyCommitmentMember 2023-12-31 0000883107 us-gaap:NonUsMember 2023-01-01 2023-12-31 0000883107 us-gaap:NonUsMember 2022-01-01 2022-12-31 0000883107 nanx:SolesenceMember 2023-01-01 2023-12-31 0000883107 nanx:SolesenceMember 2022-01-01 2022-12-31 0000883107 nanx:PersonalCareIngredientsMember 2023-01-01 2023-12-31 0000883107 nanx:PersonalCareIngredientsMember 2022-01-01 2022-12-31 0000883107 nanx:AdvancedMaterialsMember 2023-01-01 2023-12-31 0000883107 nanx:AdvancedMaterialsMember 2022-01-01 2022-12-31 0000883107 us-gaap:SubsequentEventMember 2024-03-01 iso4217:USD shares iso4217:USD shares pure false 2023 FY --12-31 0000883107 http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member 10-K true 2023-12-31 false 000-22333 NANOPHASE TECHNOLOGIES CORPORATION DE 36-3687863 1319 Marquette Drive Romeoville IL 60446 (630) 771-6708 Common Stock, par value $.01 per share No No Yes Yes Non-accelerated Filer true false false false 23412675 54801834 49 RSM US LLP Milwaukee, Wisconsin 1722000 2186000 3692000 4873000 225000 139000 3467000 4734000 10031000 8839000 1082000 866000 16302000 16625000 8668000 7949000 7907000 8978000 4000 6000 32881000 33558000 2810000 4282000 2000000 1297000 0 6260000 6363000 2353000 2167000 869000 1023000 15589000 13835000 9152000 9823000 5000000 3000000 1000000 1000000 21000 238000 230000 15390000 14074000 0.01 0.01 24088 24088 0 0 0 0 0.01 0.01 60000000 60000000 49627254 49627254 49320680 49320680 496000 493000 106069000 105226000 -104663000 -100070000 1902000 5649000 32881000 33558000 36641000 36731000 656000 586000 37297000 37317000 29472000 28957000 7825000 8360000 3837000 3037000 7534000 7581000 -3546000 -2258000 838000 382000 -4384000 -2640000 6000 -17000 -4390000 -2623000 -0.09 -0.05 49556305 49117000 -0.09 -0.05 49556305 49117000 48893573 489000 104423000 -97447000 7465000 427107 4000 178000 182000 625000 625000 -2623000 -2623000 49320680 493000 105226000 -100070000 5649000 5649000 203000 203000 306574 3000 151000 154000 773000 773000 81000 81000 -4390000 -4390000 49627254 496000 106069000 -104663000 1902000 1902000 -4390000 -2623000 742000 567000 773000 625000 -1064000 797000 1192000 2744000 216000 -44000 -503000 1826000 165000 744000 -146000 77000 1697000 631000 -2006000 -1650000 1051000 2823000 -1051000 -2823000 111000 -1472000 2931000 2000000 3000000 1346000 3338000 73000 182000 2593000 6002000 -464000 1529000 2186000 657000 1722000 2186000 752000 333000 400000 971000 182000 <p id="xdx_803_eus-gaap--NatureOfOperations_zHlZjxZQvhBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_z2Nyxz6nlKV5">Description of Business</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably COVID-19, has become a critical use of our technology.<span style="text-decoration: line-through"> </span> Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category.   </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> We target markets<span style="text-decoration: line-through">,</span> primarily related to skin health products and ingredients<span style="text-decoration: line-through">,</span> as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.    </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded a net loss and negative cash flow from operations in 2023.  In addition, the company outstanding debt increased which left little borrowing capacity available. In early March 2024 the company completed an equity financing providing an additional $6 million in funds. For additional information see Note 9. Management believes that current liquidity and available borrowing capacity are sufficient to fund operations and there is not substantial doubt regarding the Company's ability to continue as a going concern.</span></p> <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zYFvRwWEI2nd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td> <td id="xdx_823_zufAwwglaGi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S<span>ummary of Significant Accounting Policies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84B_eus-gaap--UseOfEstimates_zQTRXxEQWqT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zW9btUs3c97b">Use of Estimates and Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.</span></p> <p id="xdx_856_zNWzI1gMdzX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmgv4hxeMTef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cash balance on December 31, 2023 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.</span></p> <p id="xdx_859_zYkVuc5gyF1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z6mCd7aI6xKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b><span id="xdx_866_z6RGMeauVVBf">Trade Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are carried at original invoice amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2023, the Company adopted <span id="xdx_909_eus-gaap--AccountingStandardsUpdateExtensibleList_dxL_c20220101__20221231_zRE08FyHJkEg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23AccountingStandardsUpdate201613Member"><span style="-sec-ix-hidden: xdx2ixbrl0437">ASU 2016-13</span></span> “<i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of <span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20221231__srt--CumulativeEffectPeriodOfAdoptionAxis__srt--CumulativeEffectPeriodOfAdoptionAdjustmentMember_zq8br9Zixcpe" title="Retained earnings">$203</span>.</span></p> <p id="xdx_899_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zBy7OZ3JJwwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <span style="display: none; visibility: hidden"><span id="xdx_8B7_zNOozykbX5d6">Allowance for Credit Losses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_zjZbDBX31mVb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_z6xup5sec3u1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_pn3n3_z6dCNt4b0t4k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Balance, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_pn3n3_z8gUPs3HJOG7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Change in credit loss</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">86</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">139</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iE_pn3n3_ziwlTIMHx9w3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zUNG2W0TGbV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_853_zkp59k7FTJ39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zFe0ziwSQqnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zuvD3NL2NnVg">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.</span></p> <p id="xdx_855_zSlQWW1SAQga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zHYg8ZOXwetb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_ztEfqdZ0ktg5">Equipment and Leasehold Improvements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment is stated at cost and is being depreciated over its estimated useful life (<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zQyEx7Mqsmi4" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zwYcZvkIDZv6" title="Equipment leasehold improvements and leased assets useful life">20</span> years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zBJ9JdhdrlT7" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zDXfwrz2AHi7" title="Equipment leasehold improvements and leased assets useful life">7</span> years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zGoR4SYzF7Ff" title="Equipment leasehold improvements and leased assets useful life">7</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zRDeoNiCJzPc" title="Equipment leasehold improvements and leased assets useful life">10</span> years) using the straight-line method.</span></p> <p id="xdx_854_z9tRaaQGKTV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zTB8dJrFQEAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zEyX0Sj4T0Q">Long Lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, <i>Impairment or Disposal of Long-Lived Assets</i>. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented. </span></p> <p id="xdx_85E_z8eeu1GDxfZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zT1VYMI7pYmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z4YQv9KKVnUa">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $<span id="xdx_905_eus-gaap--DeferredIncome_iI_pn3n3_c20231231_zpPZOklwKQe8" title="Deferred revenue">2,353</span> in deferred revenue reported in 2023, <span id="xdx_90C_ecustom--PercentageOfPrepayments_iI_pid_dp_uPure_c20231231__srt--MajorCustomersAxis__custom--MedicalDiagnosticsApplicationCustomerMember_zF8lhpeodhKj" title="Percentage of prepayments">97</span>% related to prepayments received from certain customers per Company policy, and the remaining <span id="xdx_909_ecustom--PercentageOfPrepayments_iI_pid_dp_uPure_c20231231__srt--MajorCustomersAxis__custom--PersonalCareIngredientCustomerMember_zBMuhbNitrq6">3</span>% related to prepayments from a product development agreement with a personal care ingredient customer.</span></p> <p id="xdx_85E_zwM9Xasu6DI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p id="xdx_842_eus-gaap--AssetRetirementObligationsPolicy_zEbKr0V2UtMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z7CQZkfcGOc">Asset Retirement Obligations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, <i>Asset Retirement Obligations</i>, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfChangeInAssetRetirementObligationTableTextBlock_z5Z1XM1tyhz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_z3RbwJrU6Lie">Activity in the asset retirement obligation account for the years ended December 31, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zyJlh1EygNbg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20220101__20221231_z2SVZmWzKyga" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AssetRetirementObligationsNoncurrent_iS_zsuxyT0PhNW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Balance, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">230</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">222</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationAccretionExpense_zKfz1lbUXfS5" style="vertical-align: bottom"> <td style="padding-left: 10pt; text-align: left">Accretion of liability due to passage of time</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccretionExpenseIncludingAssetRetirementObligations_zkHEZFyxEDS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization of asset due to passage of time</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationsNoncurrent_iE_zK2YHpgWRio6" style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Balance, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">238</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z1WxcHFVh99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_853_zEu8MSBDwj5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrYoBLcsVTCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zRGxZMcgld8k">Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We follow ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments include cash, cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no financial instruments adjusted to fair value on December 31, 2023 and 2022.</span></p> <p id="xdx_858_zCrPbaKMZPIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zSdv7lHLhGpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zhaaRNBo3oU8">Product Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. </span>For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2023 no volume rebates were recorded because the customers did not meet required volumes. In 2022 the company recorded <span id="xdx_90A_ecustom--VolumeRebates_pn3n3_c20220101__20221231_z6TdJZwWldwf">$557</span> in volume rebates as a reduction in revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_895_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_z5IUxLNxY3M4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zjpPeqPu6Yl2">Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accounts Receivable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Assets</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20211231_zyWDLEJSApBe" style="width: 15%; text-align: right">3,937</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20211231_zNYKthBl6nR1" style="width: 15%; text-align: right" title="Contract assets">179</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zPoGDHa4okRl" style="width: 15%; text-align: right" title="Contract liabilities">1,444</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20221231_zWRyR2SgiNmi" style="text-align: right" title="Accounts receivable, net">4,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20221231_z0NUy7321Md4" style="text-align: right" title="Contract liabilities">2,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20231231_zxVkI3DDNGq3" style="text-align: right" title="Accounts receivable, net">3,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20231231_zVeKqKb67A3l" style="text-align: right" title="Contract liabilities">2,353</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zNHWdmDc26Uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $<span id="xdx_90A_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20230101__20231231_zT4QkL8aqwO7" title="Revenue recognized in the reporting period included in contract liability balance at beginning of period">2,084</span> and $<span id="xdx_908_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20220101__20221231_zGolzWSu4yy" title="Revenue recognized in the reporting period included in contract liability balance at beginning of period">667</span> for the years ended December 31, 2023, and 2022, respectively. </span></p> <p id="xdx_85C_zCJ3vFtInKle" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p id="xdx_845_ecustom--OtherRevenuePolicyTextBlock_zI2rs1a9mkfh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zCcc5fk5VhBd">Other Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zAdagoOCmeab" title="Revenue">656</span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zovuyi8MH6tb" title="Revenue">217</span> for the years ended December 31, 2023 and 2022, respectively.</span></p> <p id="xdx_851_zpi6YfeUZ7Jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTf5agfUFEo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zgscoWlBAVnh">Research and Development Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are recognized as expense when incurred.</span></p> <p id="xdx_85D_zAt2DLWdqskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_z0zBxSz5GrKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z1q7yTR9GSQ2">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2023, and 2022, we had no liability for unrecognized tax benefits.</span></p> <p id="xdx_85D_zsOKF7Rz0mn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z76URZTzRoU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zpJXvn9lGhp9">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options to purchase approximately <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zK2GJEOXQTWa" title="Anti-dilutive pptions excluded from computation of earnings per share">889,000</span> shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period.  Options to purchase approximately <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_za3bRLWfc4rk" title="Anti-dilutive pptions excluded from computation of earnings per share">2,051,000</span> shares of common stock that were outstanding as of December 31, 2022 were not included in the computation of earnings per share for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpiMFJjpDLta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zxHwuAm6ix6">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49B_20230101__20231231_zHAoTaFvxqu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_498_20220101__20221231_zmDW2m5FEqjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zp9eikKXh6C4" style="vertical-align: bottom"> <td><span style="text-decoration: underline">Numerator: (in Thousands)</span></td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_z4FJIYqw65nh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(4,390</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,623</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zJmAAQirDqbc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zi2UVoy8DbAc" style="vertical-align: bottom; background-color: White"> <td>Weighted average number of basic common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,556,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,117,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_z1QcHvJU9Fvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zGkdJ8JWTKf5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,556,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,117,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zfApUq7GkVLi" style="vertical-align: bottom; background-color: White"> <td><span style="text-decoration: underline">Basic earnings per common share:</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zuTHLgXtmuje" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net loss per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zYW19rH54tN7" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_z5QwblHXFZ81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net loss per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AE_zkkwmSU4q1bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_85E_zUQynOmJJnUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6XxY7y7q1n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zKMt8eH5YfLa">Recently Adopted Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2023, the Company adopted ASU 2016-13 “<i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.</span></p> <p id="xdx_856_zcywcPvxq55e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--RecentlyIssuedPronouncementsPoliciesTextBlock_zKh2Jn4Q20X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z6RFpvfFJwha">Recently Issued Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, <i>Improvements to Income Tax Disclosures</i>, applies to all entities subject to income taxes. This new requirement will be effective for Nanophase Technologies for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.</span></p> <p id="xdx_859_z1pOnmc4Qzca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_84B_eus-gaap--UseOfEstimates_zQTRXxEQWqT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zW9btUs3c97b">Use of Estimates and Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.</span></p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmgv4hxeMTef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cash balance on December 31, 2023 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.</span></p> <p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z6mCd7aI6xKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b><span id="xdx_866_z6RGMeauVVBf">Trade Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are carried at original invoice amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2023, the Company adopted <span id="xdx_909_eus-gaap--AccountingStandardsUpdateExtensibleList_dxL_c20220101__20221231_zRE08FyHJkEg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23AccountingStandardsUpdate201613Member"><span style="-sec-ix-hidden: xdx2ixbrl0437">ASU 2016-13</span></span> “<i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of <span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20221231__srt--CumulativeEffectPeriodOfAdoptionAxis__srt--CumulativeEffectPeriodOfAdoptionAdjustmentMember_zq8br9Zixcpe" title="Retained earnings">$203</span>.</span></p> <p id="xdx_899_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zBy7OZ3JJwwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <span style="display: none; visibility: hidden"><span id="xdx_8B7_zNOozykbX5d6">Allowance for Credit Losses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_zjZbDBX31mVb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_z6xup5sec3u1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_pn3n3_z6dCNt4b0t4k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Balance, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_pn3n3_z8gUPs3HJOG7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Change in credit loss</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">86</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">139</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iE_pn3n3_ziwlTIMHx9w3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zUNG2W0TGbV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> -203000 <p id="xdx_899_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zBy7OZ3JJwwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <span style="display: none; visibility: hidden"><span id="xdx_8B7_zNOozykbX5d6">Allowance for Credit Losses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_zjZbDBX31mVb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_z6xup5sec3u1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_pn3n3_z6dCNt4b0t4k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Balance, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_pn3n3_z8gUPs3HJOG7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Change in credit loss</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">86</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">139</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iE_pn3n3_ziwlTIMHx9w3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 139000 0 86000 139000 225000 139000 <p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zFe0ziwSQqnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zuvD3NL2NnVg">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.</span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zHYg8ZOXwetb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_ztEfqdZ0ktg5">Equipment and Leasehold Improvements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment is stated at cost and is being depreciated over its estimated useful life (<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zQyEx7Mqsmi4" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zwYcZvkIDZv6" title="Equipment leasehold improvements and leased assets useful life">20</span> years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zBJ9JdhdrlT7" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zDXfwrz2AHi7" title="Equipment leasehold improvements and leased assets useful life">7</span> years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zGoR4SYzF7Ff" title="Equipment leasehold improvements and leased assets useful life">7</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zRDeoNiCJzPc" title="Equipment leasehold improvements and leased assets useful life">10</span> years) using the straight-line method.</span></p> P3Y P20Y P3Y P7Y P7Y P10Y <p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zTB8dJrFQEAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zEyX0Sj4T0Q">Long Lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, <i>Impairment or Disposal of Long-Lived Assets</i>. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented. </span></p> <p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zT1VYMI7pYmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z4YQv9KKVnUa">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $<span id="xdx_905_eus-gaap--DeferredIncome_iI_pn3n3_c20231231_zpPZOklwKQe8" title="Deferred revenue">2,353</span> in deferred revenue reported in 2023, <span id="xdx_90C_ecustom--PercentageOfPrepayments_iI_pid_dp_uPure_c20231231__srt--MajorCustomersAxis__custom--MedicalDiagnosticsApplicationCustomerMember_zF8lhpeodhKj" title="Percentage of prepayments">97</span>% related to prepayments received from certain customers per Company policy, and the remaining <span id="xdx_909_ecustom--PercentageOfPrepayments_iI_pid_dp_uPure_c20231231__srt--MajorCustomersAxis__custom--PersonalCareIngredientCustomerMember_zBMuhbNitrq6">3</span>% related to prepayments from a product development agreement with a personal care ingredient customer.</span></p> 2353000 0.97 0.03 <p id="xdx_842_eus-gaap--AssetRetirementObligationsPolicy_zEbKr0V2UtMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z7CQZkfcGOc">Asset Retirement Obligations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, <i>Asset Retirement Obligations</i>, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfChangeInAssetRetirementObligationTableTextBlock_z5Z1XM1tyhz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_z3RbwJrU6Lie">Activity in the asset retirement obligation account for the years ended December 31, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zyJlh1EygNbg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20220101__20221231_z2SVZmWzKyga" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AssetRetirementObligationsNoncurrent_iS_zsuxyT0PhNW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Balance, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">230</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">222</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationAccretionExpense_zKfz1lbUXfS5" style="vertical-align: bottom"> <td style="padding-left: 10pt; text-align: left">Accretion of liability due to passage of time</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccretionExpenseIncludingAssetRetirementObligations_zkHEZFyxEDS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization of asset due to passage of time</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationsNoncurrent_iE_zK2YHpgWRio6" style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Balance, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">238</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z1WxcHFVh99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_896_eus-gaap--ScheduleOfChangeInAssetRetirementObligationTableTextBlock_z5Z1XM1tyhz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_z3RbwJrU6Lie">Activity in the asset retirement obligation account for the years ended December 31, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zyJlh1EygNbg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20220101__20221231_z2SVZmWzKyga" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AssetRetirementObligationsNoncurrent_iS_zsuxyT0PhNW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Balance, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">230</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">222</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationAccretionExpense_zKfz1lbUXfS5" style="vertical-align: bottom"> <td style="padding-left: 10pt; text-align: left">Accretion of liability due to passage of time</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccretionExpenseIncludingAssetRetirementObligations_zkHEZFyxEDS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization of asset due to passage of time</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationsNoncurrent_iE_zK2YHpgWRio6" style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Balance, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">238</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 230000 222000 8000 8000 238000 230000 <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrYoBLcsVTCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zRGxZMcgld8k">Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We follow ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments include cash, cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no financial instruments adjusted to fair value on December 31, 2023 and 2022.</span></p> <p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zSdv7lHLhGpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zhaaRNBo3oU8">Product Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. </span>For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2023 no volume rebates were recorded because the customers did not meet required volumes. In 2022 the company recorded <span id="xdx_90A_ecustom--VolumeRebates_pn3n3_c20220101__20221231_z6TdJZwWldwf">$557</span> in volume rebates as a reduction in revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_895_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_z5IUxLNxY3M4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zjpPeqPu6Yl2">Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accounts Receivable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Assets</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20211231_zyWDLEJSApBe" style="width: 15%; text-align: right">3,937</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20211231_zNYKthBl6nR1" style="width: 15%; text-align: right" title="Contract assets">179</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zPoGDHa4okRl" style="width: 15%; text-align: right" title="Contract liabilities">1,444</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20221231_zWRyR2SgiNmi" style="text-align: right" title="Accounts receivable, net">4,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20221231_z0NUy7321Md4" style="text-align: right" title="Contract liabilities">2,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20231231_zxVkI3DDNGq3" style="text-align: right" title="Accounts receivable, net">3,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20231231_zVeKqKb67A3l" style="text-align: right" title="Contract liabilities">2,353</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zNHWdmDc26Uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $<span id="xdx_90A_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20230101__20231231_zT4QkL8aqwO7" title="Revenue recognized in the reporting period included in contract liability balance at beginning of period">2,084</span> and $<span id="xdx_908_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20220101__20221231_zGolzWSu4yy" title="Revenue recognized in the reporting period included in contract liability balance at beginning of period">667</span> for the years ended December 31, 2023, and 2022, respectively. </span></p> 557000 <p id="xdx_895_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_z5IUxLNxY3M4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zjpPeqPu6Yl2">Contract balances for the years ended December 31, 2023, 2022, and 2021 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accounts Receivable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Assets</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20211231_zyWDLEJSApBe" style="width: 15%; text-align: right">3,937</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20211231_zNYKthBl6nR1" style="width: 15%; text-align: right" title="Contract assets">179</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zPoGDHa4okRl" style="width: 15%; text-align: right" title="Contract liabilities">1,444</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20221231_zWRyR2SgiNmi" style="text-align: right" title="Accounts receivable, net">4,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20221231_z0NUy7321Md4" style="text-align: right" title="Contract liabilities">2,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20231231_zxVkI3DDNGq3" style="text-align: right" title="Accounts receivable, net">3,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20231231_zVeKqKb67A3l" style="text-align: right" title="Contract liabilities">2,353</td><td style="text-align: left"> </td></tr> </table> 3937000 179000 1444000 4734000 2188000 3467000 2353000 2084000 667000 <p id="xdx_845_ecustom--OtherRevenuePolicyTextBlock_zI2rs1a9mkfh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zCcc5fk5VhBd">Other Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zAdagoOCmeab" title="Revenue">656</span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zovuyi8MH6tb" title="Revenue">217</span> for the years ended December 31, 2023 and 2022, respectively.</span></p> 656000 217000 <p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTf5agfUFEo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zgscoWlBAVnh">Research and Development Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are recognized as expense when incurred.</span></p> <p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_z0zBxSz5GrKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z1q7yTR9GSQ2">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2023, and 2022, we had no liability for unrecognized tax benefits.</span></p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z76URZTzRoU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zpJXvn9lGhp9">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options to purchase approximately <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zK2GJEOXQTWa" title="Anti-dilutive pptions excluded from computation of earnings per share">889,000</span> shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period.  Options to purchase approximately <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_za3bRLWfc4rk" title="Anti-dilutive pptions excluded from computation of earnings per share">2,051,000</span> shares of common stock that were outstanding as of December 31, 2022 were not included in the computation of earnings per share for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpiMFJjpDLta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zxHwuAm6ix6">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49B_20230101__20231231_zHAoTaFvxqu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_498_20220101__20221231_zmDW2m5FEqjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zp9eikKXh6C4" style="vertical-align: bottom"> <td><span style="text-decoration: underline">Numerator: (in Thousands)</span></td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_z4FJIYqw65nh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(4,390</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,623</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zJmAAQirDqbc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zi2UVoy8DbAc" style="vertical-align: bottom; background-color: White"> <td>Weighted average number of basic common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,556,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,117,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_z1QcHvJU9Fvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zGkdJ8JWTKf5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,556,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,117,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zfApUq7GkVLi" style="vertical-align: bottom; background-color: White"> <td><span style="text-decoration: underline">Basic earnings per common share:</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zuTHLgXtmuje" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net loss per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zYW19rH54tN7" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_z5QwblHXFZ81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net loss per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AE_zkkwmSU4q1bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> 889000 2051000 <p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpiMFJjpDLta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zxHwuAm6ix6">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49B_20230101__20231231_zHAoTaFvxqu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_498_20220101__20221231_zmDW2m5FEqjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zp9eikKXh6C4" style="vertical-align: bottom"> <td><span style="text-decoration: underline">Numerator: (in Thousands)</span></td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_z4FJIYqw65nh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(4,390</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,623</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zJmAAQirDqbc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zi2UVoy8DbAc" style="vertical-align: bottom; background-color: White"> <td>Weighted average number of basic common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,556,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,117,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_z1QcHvJU9Fvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zGkdJ8JWTKf5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,556,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,117,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zfApUq7GkVLi" style="vertical-align: bottom; background-color: White"> <td><span style="text-decoration: underline">Basic earnings per common share:</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zuTHLgXtmuje" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net loss per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zYW19rH54tN7" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_z5QwblHXFZ81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net loss per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -4390000 -2623000 49556305 49117000 49556305 49117000 -0.09 -0.05 -0.09 -0.05 <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6XxY7y7q1n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zKMt8eH5YfLa">Recently Adopted Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2023, the Company adopted ASU 2016-13 “<i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.</span></p> <p id="xdx_849_ecustom--RecentlyIssuedPronouncementsPoliciesTextBlock_zKh2Jn4Q20X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z6RFpvfFJwha">Recently Issued Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, <i>Improvements to Income Tax Disclosures</i>, applies to all entities subject to income taxes. This new requirement will be effective for Nanophase Technologies for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.</span></p> <p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zR5nEF8OLuD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zXEyfBCt2wTj">Related Party Notes and Lines of Credit</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_892_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_ziiCgQvtmjJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zCVN5Xymnmzd">Notes and lines of credit consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Available</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b> </span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Available</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b> </span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Libertyville Bank &amp; Trust <sup id="xdx_F4D_zojrDvtokiAc">(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_z47OtcHbnz3f" title="Line of Credit Facility, Commitment Fee Percentage">9.50</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_ztOYCdnHoMZb" style="width: 12%; text-align: right" title="Available">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zivPAkV8PJCf" style="width: 12%; text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0580">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_znr4BrhZOUvb" style="width: 12%; text-align: right" title="Available">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zOa64CC8gWab" style="width: 12%; text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0584">—</span>  </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Libertyville Bank &amp; Trust <sup id="xdx_F48_zEOQG68iuYTf">(2)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zx9mPX4cLEV4" title="Line of Credit Facility, Commitment Fee Percentage">9.50</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_z24LiQoaXaG6" style="text-align: right" title="Available">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_z6PIaSDRK5v3" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zIfrjDO4Ok3l" style="text-align: right" title="Available">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zH5Gf8NbZHx" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0594">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beachcorp, LLC <sup id="xdx_F4A_z7vWK3XT3Bzl">(3) (4)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zWvzRnclv8ri" title="Line of Credit Facility, Commitment Fee Percentage">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zy0RRZDJ3bH8" style="text-align: right" title="Available">3,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zZRK420E2xn" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">2,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zf7LTWhs0OI9" style="text-align: right" title="Available">4,392</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zH17vPWVk3B1" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">4,282</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beachcorp, LLC <sup id="xdx_F45_z0VikaBzfcxl">(3) (5)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_zQp2YaEYXKUj" title="Line of Credit Facility, Commitment Fee Percentage">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_zzzyfIjYm9vd" style="text-align: right" title="Available">5,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_zdUAJl8NZFQj" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_zRAwb9zCC1Ia" style="text-align: right" title="Available">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_z5q6gqnOTGy2" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strandler, LLC   <sup id="xdx_F4A_zo1sDLxMuG1e">(3) (6)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_zEU6RQUgaUTl" title="Line of Credit Facility, Commitment Fee Percentage">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_z0xw5CzkCzml" style="text-align: right" title="Available">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_zLgdOUmhcPq5" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_zCF3np5po5Ca" style="text-align: right" title="Available">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_zNK5GBiHX1Hl" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strandler, LLC <sup id="xdx_F43_zQBaTvNYlHkk"> (7)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDcp_zHfvZhXA9zWb" title="Line of Credit Facility, Commitment Fee Percentage">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDcp_zYd5yCI3R3X9" style="text-align: right" title="Available">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDcp_zbmvpgn4tCaj" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zgY5LBOU2pz6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zJ6vy1ZkkTrj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since July 2014, we have maintained a bank-issued letter of credit for up to $<span id="xdx_907_eus-gaap--ShortTermBorrowings_iI_c20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zPhBXCsiKGXf" title="Letter of credit and related promissory note">30</span> in borrowings, with interest at the <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zh9nhD0nrCif" title="Variable interest rate basis">prime rate</span> plus <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zrk7RLQfaNQ7" title="Basis spread variable interest rate">1</span>%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zA9mi1Idx0we" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zKnM9CDaMWJc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Interest on drawn balances was at the <span id="xdx_903_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zGckKQ4l1iVi" title="Variable interest rate basis">prime rate</span> plus <span id="xdx_909_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zWDgt7XSV4jl" title="Basis spread variable interest rate">1</span>%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2024. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F01_zqMHq2KZeaM6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zTO6hwnKB0Lb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z8KEQjrifsIb" title="Line of Credit Facility, Maximum Borrowing Capacity">500</span> to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z2TV1TcfKnOk" title="Debt Instrument, Interest Rate, Stated Percentage">8.25</span>%, payable quarterly, and with principal due on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zePION3UA3Gl" title="DebtInstrumentMaturityDate">December 31, 2020</span>; and an asset-based revolving loan facility for the Company of up to $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zIKoIxVQrW7g" title="Line of Credit Facility, Maximum Borrowing Capacity">2,000</span> (the “A/R Revolver Facility”), with floating interest accruing at the <span id="xdx_905_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1g8mei9eM9f" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zbVKDiuJMEud" title="Debt Instrument, Basis Spread on Variable Rate">3</span>% (<span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__srt--RangeAxis__srt--MinimumMember_zO31CBNXqp1f" title="Debt Instrument, Interest Rate, Stated Percentage">8.25</span>% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of <span id="xdx_909_eus-gaap--LineOfCreditFacilityExpirationDate1_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zQ7Zn29xpZme" title="Line of Credit Facility, Expiration Date">March 31, 2020</span>, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z3BM0vgrpwa5" title="Debt Instrument, Maturity Date">March 31, 2021</span>. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zB2AP5wiOLCg" title="Line of Credit Facility, Maximum Borrowing Capacity">2,000</span> to $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20200908__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zXvCLMWIQHc4" title="Line of Credit Facility, Maximum Borrowing Capacity">2,750</span>.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20200908__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zNY66tsLItU9" title="Line of Credit Facility, Maximum Borrowing Capacity">2,750</span> to $<span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20201223__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zu9YGW8YrvV5" title="Line of Credit Facility, Maximum Borrowing Capacity">4,000</span> and extended the maturities of both the Term Loan and the A/R Revolver Facility to <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_c20201222__20201223__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zASYKRrpy9Mk" title="Debt Instrument, Maturity Date">March 31, 2022</span>. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20201223__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zFmcQkZ8JDm9" title="Line of Credit Facility, Maximum Borrowing Capacity">4,000</span> to $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zTCxcChnKwr3" title="Line of Credit Facility, Maximum Borrowing Capacity">6,000</span>, changed the interest rate to fully floating and reduced the rate to the <span id="xdx_909_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zDUHutFIB211" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zo2RmTvoxHba" title="Debt Instrument, Basis Spread on Variable Rate">2</span>%, also extending the maturity of the A/R Revolver Facility to <span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationDate1_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z58Zk2Shk3k7" title="Line of Credit Facility, Expiration Date">March 31, 2023</span>. This amendment also increased the amount of the Term Loan from $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_znjRpWmOiP0a" title="Line of Credit Facility, Maximum Borrowing Capacity">500</span> to $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zKxycgOjWVK7" title="Line of Credit Facility, Maximum Borrowing Capacity">1,000</span>, changed the interest rate to fully floating and reduced the rate to the <span id="xdx_905_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zMpvhsZIp7S3" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zFhGV9s3tjfg" title="Debt Instrument, Basis Spread on Variable Rate">2</span>%. The maturity of the Term Loan remained <span id="xdx_907_eus-gaap--LineOfCreditFacilityExpirationDate1_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zA20qbKcJlH7" title="Line of Credit Facility, Expiration Date">March 31, 2022</span>. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F02_zglDbscu6Ld9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zljnEeqWHM7d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&amp;R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20180421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z97AXgXJXBk5" title="Line of Credit Facility, Maximum Borrowing Capacity">6,000</span> to $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zlTvhrNowgc" title="Line of Credit Facility, Maximum Borrowing Capacity">8,000</span>, reduce the interest rate to the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zV261eA8TMH9" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_90E_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zkfbvZqKRDr3" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and extend the maturity of the A/R Revolver Facility to <span id="xdx_904_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zCejIzc570Nl" title="Line of Credit Facility, Expiration Date">March 31, 2024</span>. On November 13, 2023 the Company entered into a First Amendment to the A&amp;R Loan Agreement extending the maturity of the A/R Revolver Facility to <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z31I8oUdoSIj" title="Line of Credit Facility, Expiration Date">March 31, 2025</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zYdO7E8bBRxg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zjb6U1Rpgcmh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 the Company entered into the A&amp;R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $<span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z5ZEveY9RJX" title="Line of Credit Facility, Maximum Borrowing Capacity">4,000</span>, with a borrowing base consisting of up to <span id="xdx_90C_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zfhwojvefgM4" title="Line of Credit Percentage of Eligible inventory">50</span>% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zNLrEEvGV3x8" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zGaR3zI4uMW1" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and it matures on <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zqpfB7CGAUh2" title="Line of Credit Facility, Expiration Date">March 31, 2024</span>. On November 13, 2023 the company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to <span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zv8gqNni00l8" title="Line of Credit Facility, Maximum Borrowing Capacity">$5,200</span>, with a borrowing base consisting of up to <span id="xdx_901_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zvggTnfh4rMl" title="Line of Credit Percentage of Eligible inventory">55</span>% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the <span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zqWSXjZo79Ya" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zYasj2wPZeQl" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and it now matures on <span id="xdx_903_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zbIj8JdeFGQ">March 31, 2025</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zk6xPcy05EQa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zmzUeLYCDov6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the <span id="xdx_90F_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StrandlerLLCMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember_zojVxi5CRr7l" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_90E_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--CreditFacilityAxis__custom--TermLoanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StrandlerLLCMember_z4iU3VL9BSV7" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and it matures on <span id="xdx_90C_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StrandlerLLCMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember_zdfO5cz0q8Gh" title="Line of Credit Facility, Expiration Date">March 31, 2024</span>. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On November 13, 2023 the Company entered into the First Amendment To the New Term Loan Agreement with Strandler, LLC, which extended the maturity of the New Term Loan Agreement to <span id="xdx_905_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StrandlerLLCMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember_zeGIeOKiOExl" title="Line of Credit Facility, Expiration Date">March 31, 2025</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zc6p9dgLgDrd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zZtTvQnPEKAc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 13, 2023 the Company entered into a new Promissory Note (“Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is <span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zyqjgxeLvFLk" title="Line of Credit Facility, Maximum Borrowing Capacity">$2,000</span>. The interest rate for the Bridge Note is at the <span id="xdx_900_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zbZNh5BcRK25">prime rate</span> plus <span id="xdx_90E_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zPtkaD5hurRa">0.75</span>%, and it matures on <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zNAgrpKPtY1k">May 13, 2024</span>.</span></td></tr></table> <p id="xdx_8A2_zs3WukiA5Wsi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the March 1, 2024 Securities Purchase Agreement the maturity dates of the Term Loan, A/R Revolver Facility and Inventory Facility were extended to <span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationDate1_c20240229__20240301__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__srt--CounterpartyNameAxis__custom--StrandlerLLCAndBeachcorpLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuvvmJ5dlLnh" title="Line of Credit Facility, Expiration Date">October 1, 2025</span> from <span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231230__20231231__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__srt--CounterpartyNameAxis__custom--StrandlerLLCAndBeachcorpLLCMember_zlZwx03xLtca" title="Line of Credit Facility, Expiration Date">March 31, 2025</span>. No other changes were made to the debt agreements. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0px 4.5pt; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The Company classifies the line of credit – accounts receivable as current because we are required to pay back the borrowings as cash is received from our customers. The company’s remaining debt is presented within the Consolidated Balance Sheet as of December 31, 2023, and 2022 in accordance with the maturity dates in the financing agreements. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank &amp; Trust. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z0XAHnpM9NT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party interest expense consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zJTFbBbc1iD7" style="display: none; visibility: hidden">Schedule of Related Parties</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyInterestExpense_c20230101__20231231_zJsKkOcCWHQk" style="width: 12%; text-align: right" title="Interest expense related party">770</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--RelatedPartyInterestExpense_c20220101__20221231_zNv92zcuOBpf" style="width: 12%; text-align: right" title="Interest expense related party">356</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued interest consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Accrued interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20231231_z4jTThjX4tNg" style="width: 12%; text-align: right" title="Accrued interest expense, related parties">81</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20221231_zeZafsdjQg8g" style="width: 12%; text-align: right" title="Accrued interest expense, related parties">49</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding balances associated with related parties are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Beachcorp, LLC</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_z9Cw86HX5DB9" style="width: 12%; text-align: right" title="Outstanding balances associated with related partie">7,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_z2pAnZ6gGlvk" style="width: 12%; text-align: right" title="Outstanding balances associated with related partie">7,282</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Strandler, LLC</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zkZuTxTMY2n9" style="text-align: right" title="Outstanding balances associated with related partie">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zi5R8v1Cbloh" style="text-align: right" title="Outstanding balances associated with related partie">1,000</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zYghMBo9d3xf" style="margin-top: 0; margin-bottom: 0"></p> <p id="xdx_892_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_ziiCgQvtmjJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zCVN5Xymnmzd">Notes and lines of credit consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Available</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b> </span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Available</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b> </span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Libertyville Bank &amp; Trust <sup id="xdx_F4D_zojrDvtokiAc">(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_z47OtcHbnz3f" title="Line of Credit Facility, Commitment Fee Percentage">9.50</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_ztOYCdnHoMZb" style="width: 12%; text-align: right" title="Available">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zivPAkV8PJCf" style="width: 12%; text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0580">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_znr4BrhZOUvb" style="width: 12%; text-align: right" title="Available">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zOa64CC8gWab" style="width: 12%; text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0584">—</span>  </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Libertyville Bank &amp; Trust <sup id="xdx_F48_zEOQG68iuYTf">(2)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zx9mPX4cLEV4" title="Line of Credit Facility, Commitment Fee Percentage">9.50</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_z24LiQoaXaG6" style="text-align: right" title="Available">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_z6PIaSDRK5v3" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zIfrjDO4Ok3l" style="text-align: right" title="Available">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zH5Gf8NbZHx" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0594">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beachcorp, LLC <sup id="xdx_F4A_z7vWK3XT3Bzl">(3) (4)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zWvzRnclv8ri" title="Line of Credit Facility, Commitment Fee Percentage">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zy0RRZDJ3bH8" style="text-align: right" title="Available">3,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zZRK420E2xn" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">2,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zf7LTWhs0OI9" style="text-align: right" title="Available">4,392</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMpKDQp_zH17vPWVk3B1" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">4,282</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beachcorp, LLC <sup id="xdx_F45_z0VikaBzfcxl">(3) (5)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_zQp2YaEYXKUj" title="Line of Credit Facility, Commitment Fee Percentage">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_zzzyfIjYm9vd" style="text-align: right" title="Available">5,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_zdUAJl8NZFQj" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_zRAwb9zCC1Ia" style="text-align: right" title="Available">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDMpKDUp_z5q6gqnOTGy2" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strandler, LLC   <sup id="xdx_F4A_zo1sDLxMuG1e">(3) (6)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_zEU6RQUgaUTl" title="Line of Credit Facility, Commitment Fee Percentage">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_z0xw5CzkCzml" style="text-align: right" title="Available">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_zLgdOUmhcPq5" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_zCF3np5po5Ca" style="text-align: right" title="Available">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMpKDYp_zNK5GBiHX1Hl" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strandler, LLC <sup id="xdx_F43_zQBaTvNYlHkk"> (7)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDcp_zHfvZhXA9zWb" title="Line of Credit Facility, Commitment Fee Percentage">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDcp_zYd5yCI3R3X9" style="text-align: right" title="Available">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDcp_zbmvpgn4tCaj" style="text-align: right" title="Line of Credit Facility, Maximum Borrowing Capacity">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zgY5LBOU2pz6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zJ6vy1ZkkTrj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since July 2014, we have maintained a bank-issued letter of credit for up to $<span id="xdx_907_eus-gaap--ShortTermBorrowings_iI_c20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zPhBXCsiKGXf" title="Letter of credit and related promissory note">30</span> in borrowings, with interest at the <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zh9nhD0nrCif" title="Variable interest rate basis">prime rate</span> plus <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zrk7RLQfaNQ7" title="Basis spread variable interest rate">1</span>%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zA9mi1Idx0we" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zKnM9CDaMWJc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Interest on drawn balances was at the <span id="xdx_903_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zGckKQ4l1iVi" title="Variable interest rate basis">prime rate</span> plus <span id="xdx_909_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zWDgt7XSV4jl" title="Basis spread variable interest rate">1</span>%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2024. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F01_zqMHq2KZeaM6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zTO6hwnKB0Lb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z8KEQjrifsIb" title="Line of Credit Facility, Maximum Borrowing Capacity">500</span> to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z2TV1TcfKnOk" title="Debt Instrument, Interest Rate, Stated Percentage">8.25</span>%, payable quarterly, and with principal due on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zePION3UA3Gl" title="DebtInstrumentMaturityDate">December 31, 2020</span>; and an asset-based revolving loan facility for the Company of up to $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zIKoIxVQrW7g" title="Line of Credit Facility, Maximum Borrowing Capacity">2,000</span> (the “A/R Revolver Facility”), with floating interest accruing at the <span id="xdx_905_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1g8mei9eM9f" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zbVKDiuJMEud" title="Debt Instrument, Basis Spread on Variable Rate">3</span>% (<span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__srt--RangeAxis__srt--MinimumMember_zO31CBNXqp1f" title="Debt Instrument, Interest Rate, Stated Percentage">8.25</span>% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of <span id="xdx_909_eus-gaap--LineOfCreditFacilityExpirationDate1_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zQ7Zn29xpZme" title="Line of Credit Facility, Expiration Date">March 31, 2020</span>, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z3BM0vgrpwa5" title="Debt Instrument, Maturity Date">March 31, 2021</span>. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zB2AP5wiOLCg" title="Line of Credit Facility, Maximum Borrowing Capacity">2,000</span> to $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20200908__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zXvCLMWIQHc4" title="Line of Credit Facility, Maximum Borrowing Capacity">2,750</span>.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20200908__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zNY66tsLItU9" title="Line of Credit Facility, Maximum Borrowing Capacity">2,750</span> to $<span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20201223__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zu9YGW8YrvV5" title="Line of Credit Facility, Maximum Borrowing Capacity">4,000</span> and extended the maturities of both the Term Loan and the A/R Revolver Facility to <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_c20201222__20201223__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zASYKRrpy9Mk" title="Debt Instrument, Maturity Date">March 31, 2022</span>. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20201223__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zFmcQkZ8JDm9" title="Line of Credit Facility, Maximum Borrowing Capacity">4,000</span> to $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zTCxcChnKwr3" title="Line of Credit Facility, Maximum Borrowing Capacity">6,000</span>, changed the interest rate to fully floating and reduced the rate to the <span id="xdx_909_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zDUHutFIB211" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zo2RmTvoxHba" title="Debt Instrument, Basis Spread on Variable Rate">2</span>%, also extending the maturity of the A/R Revolver Facility to <span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationDate1_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z58Zk2Shk3k7" title="Line of Credit Facility, Expiration Date">March 31, 2023</span>. This amendment also increased the amount of the Term Loan from $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_znjRpWmOiP0a" title="Line of Credit Facility, Maximum Borrowing Capacity">500</span> to $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zKxycgOjWVK7" title="Line of Credit Facility, Maximum Borrowing Capacity">1,000</span>, changed the interest rate to fully floating and reduced the rate to the <span id="xdx_905_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zMpvhsZIp7S3" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zFhGV9s3tjfg" title="Debt Instrument, Basis Spread on Variable Rate">2</span>%. The maturity of the Term Loan remained <span id="xdx_907_eus-gaap--LineOfCreditFacilityExpirationDate1_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zA20qbKcJlH7" title="Line of Credit Facility, Expiration Date">March 31, 2022</span>. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F02_zglDbscu6Ld9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zljnEeqWHM7d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&amp;R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20180421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z97AXgXJXBk5" title="Line of Credit Facility, Maximum Borrowing Capacity">6,000</span> to $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zlTvhrNowgc" title="Line of Credit Facility, Maximum Borrowing Capacity">8,000</span>, reduce the interest rate to the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zV261eA8TMH9" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_90E_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zkfbvZqKRDr3" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and extend the maturity of the A/R Revolver Facility to <span id="xdx_904_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zCejIzc570Nl" title="Line of Credit Facility, Expiration Date">March 31, 2024</span>. On November 13, 2023 the Company entered into a First Amendment to the A&amp;R Loan Agreement extending the maturity of the A/R Revolver Facility to <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z31I8oUdoSIj" title="Line of Credit Facility, Expiration Date">March 31, 2025</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zYdO7E8bBRxg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zjb6U1Rpgcmh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 the Company entered into the A&amp;R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $<span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210421__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z5ZEveY9RJX" title="Line of Credit Facility, Maximum Borrowing Capacity">4,000</span>, with a borrowing base consisting of up to <span id="xdx_90C_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zfhwojvefgM4" title="Line of Credit Percentage of Eligible inventory">50</span>% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zNLrEEvGV3x8" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zGaR3zI4uMW1" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and it matures on <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zqpfB7CGAUh2" title="Line of Credit Facility, Expiration Date">March 31, 2024</span>. On November 13, 2023 the company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to <span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zv8gqNni00l8" title="Line of Credit Facility, Maximum Borrowing Capacity">$5,200</span>, with a borrowing base consisting of up to <span id="xdx_901_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zvggTnfh4rMl" title="Line of Credit Percentage of Eligible inventory">55</span>% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the <span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zqWSXjZo79Ya" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zYasj2wPZeQl" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and it now matures on <span id="xdx_903_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zbIj8JdeFGQ">March 31, 2025</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zk6xPcy05EQa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zmzUeLYCDov6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the <span id="xdx_90F_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StrandlerLLCMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember_zojVxi5CRr7l" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_90E_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--CreditFacilityAxis__custom--TermLoanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StrandlerLLCMember_z4iU3VL9BSV7" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and it matures on <span id="xdx_90C_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StrandlerLLCMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember_zdfO5cz0q8Gh" title="Line of Credit Facility, Expiration Date">March 31, 2024</span>. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On November 13, 2023 the Company entered into the First Amendment To the New Term Loan Agreement with Strandler, LLC, which extended the maturity of the New Term Loan Agreement to <span id="xdx_905_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StrandlerLLCMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember_zeGIeOKiOExl" title="Line of Credit Facility, Expiration Date">March 31, 2025</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zc6p9dgLgDrd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zZtTvQnPEKAc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 13, 2023 the Company entered into a new Promissory Note (“Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is <span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zyqjgxeLvFLk" title="Line of Credit Facility, Maximum Borrowing Capacity">$2,000</span>. The interest rate for the Bridge Note is at the <span id="xdx_900_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zbZNh5BcRK25">prime rate</span> plus <span id="xdx_90E_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zPtkaD5hurRa">0.75</span>%, and it matures on <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zNAgrpKPtY1k">May 13, 2024</span>.</span></td></tr></table> 0.0950 30000 30000 0.0950 500000 500000 0.0925 3298000 2810000 4392000 4282000 0.0925 5200000 5000000 4000000 3000000 0.0925 1000000 1000000 1000000 1000000 0.0925 2000000 2000000 30000 prime rate 0.01 prime rate 0.01 500000 0.0825 2020-12-31 2000000 prime rate 0.03 0.0825 2020-03-31 2021-03-31 2000000 2750000 2750000 4000000 2022-03-31 4000000 6000000 prime rate 0.02 2023-03-31 500000 1000000 prime rate 0.02 2022-03-31 6000000 8000000 prime rate 0.0075 2024-03-31 2025-03-31 4000000 0.50 prime rate 0.0075 2024-03-31 5200000 0.55 prime rate 0.0075 2025-03-31 prime rate 0.0075 2024-03-31 2025-03-31 2000000 prime rate 0.0075 2024-05-13 2025-10-01 2025-03-31 <p id="xdx_891_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z0XAHnpM9NT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party interest expense consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zJTFbBbc1iD7" style="display: none; visibility: hidden">Schedule of Related Parties</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyInterestExpense_c20230101__20231231_zJsKkOcCWHQk" style="width: 12%; text-align: right" title="Interest expense related party">770</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--RelatedPartyInterestExpense_c20220101__20221231_zNv92zcuOBpf" style="width: 12%; text-align: right" title="Interest expense related party">356</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued interest consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Accrued interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20231231_z4jTThjX4tNg" style="width: 12%; text-align: right" title="Accrued interest expense, related parties">81</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20221231_zeZafsdjQg8g" style="width: 12%; text-align: right" title="Accrued interest expense, related parties">49</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding balances associated with related parties are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Beachcorp, LLC</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_z9Cw86HX5DB9" style="width: 12%; text-align: right" title="Outstanding balances associated with related partie">7,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_z2pAnZ6gGlvk" style="width: 12%; text-align: right" title="Outstanding balances associated with related partie">7,282</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Strandler, LLC</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zkZuTxTMY2n9" style="text-align: right" title="Outstanding balances associated with related partie">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zi5R8v1Cbloh" style="text-align: right" title="Outstanding balances associated with related partie">1,000</td><td style="text-align: left"> </td></tr> </table> 770000 356000 81000 49000 7810000 7282000 3000000 1000000 <p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zwXfweXjdZY" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(4)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zPwC25pt8BTe">Inventories</span>  </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p id="xdx_893_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zUzHbEs2uCFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zJuBXFFOqPy2">Inventories consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_497_20231231_zAjLBzCk3nS7" style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_490_20221231_zzBFPix3AKKi" style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>As of December 31,</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzWNM_z171gpuBsEhl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,524</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,298</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzWNM_z7T4M8zkzD23" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,041</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzWNM_zJnc8cVuSK5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Inventory reserve</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(677</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3n3_mtINzWNM_z5MH4mhSeSg1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">      Total Inventories, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,839</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_ziAexsD4MRHe" style="margin-top: 0; margin-bottom: 0"></p> <p id="xdx_893_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zUzHbEs2uCFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zJuBXFFOqPy2">Inventories consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_497_20231231_zAjLBzCk3nS7" style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_490_20221231_zzBFPix3AKKi" style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>As of December 31,</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzWNM_z171gpuBsEhl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,524</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,298</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzWNM_z7T4M8zkzD23" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,041</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzWNM_zJnc8cVuSK5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Inventory reserve</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(677</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3n3_mtINzWNM_z5MH4mhSeSg1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">      Total Inventories, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,839</td><td style="text-align: left"> </td></tr> </table> 8524000 7298000 2184000 2041000 677000 500000 10031000 8839000 <p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zYVRoAx0SBjc" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(5)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_zGfJ3eGQfaIj">Equipment and Leasehold Improvements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment and leasehold improvements consist of the following:  </span></p></td></tr> </table> <p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9NMPYxowphl" style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zywmXlRGaugf">Equipment and leasehold improvements consist of the following:  </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Machinery and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zb2siGSejoU5" style="width: 12%; text-align: right" title="Machinery and equipment">23,339</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zxR9E5wLdHTf" style="width: 12%; text-align: right" title="Machinery and equipment">19,899</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Office equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zWkRYQlKICkg" style="text-align: right" title="Office equipment">1,014</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNIg2rYftyz6" style="text-align: right" title="Office equipment">1,014</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z4ZlSWMyq8B2" style="text-align: right" title="Office furniture">126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ziEkKWCH0vtg" style="text-align: right" title="Office furniture">110</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zEqgTJbjeELa" style="text-align: right" title="Leasehold improvements">5,157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zZfJj2A8BKs5" style="text-align: right" title="Leasehold improvements">5,140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zmTx6MCHYD7b" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress">931</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zHDi2rirDbP3" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress">2,952</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20231231_zUngx9E6QsM9" style="text-align: right" title="Property plant and equipment,gross">30,567</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_zySEkihT6XEi" style="text-align: right" title="Property plant and equipment,gross">29,115</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20231231_zAD7LNp1f4Vb" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(21,899</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_zuF9FUcXQeI3" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(21,166</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20231231_zuTrZ7f7fbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total">8,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_c20221231_zSlaSst9P8o2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total">7,949</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_znVBNEUlViK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_90F_eus-gaap--Depreciation_pn3n3_c20230101__20231231_zWiKS7vdcPIe" title="Depreciation expense">732</span> and $<span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20220101__20221231_zYqQsqRBNKv6" title="Depreciation expense">557</span>, for the years ended December 31, 2023 and 2022, respectively.</span></p> <p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9NMPYxowphl" style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zywmXlRGaugf">Equipment and leasehold improvements consist of the following:  </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Machinery and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zb2siGSejoU5" style="width: 12%; text-align: right" title="Machinery and equipment">23,339</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zxR9E5wLdHTf" style="width: 12%; text-align: right" title="Machinery and equipment">19,899</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Office equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zWkRYQlKICkg" style="text-align: right" title="Office equipment">1,014</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNIg2rYftyz6" style="text-align: right" title="Office equipment">1,014</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z4ZlSWMyq8B2" style="text-align: right" title="Office furniture">126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ziEkKWCH0vtg" style="text-align: right" title="Office furniture">110</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zEqgTJbjeELa" style="text-align: right" title="Leasehold improvements">5,157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zZfJj2A8BKs5" style="text-align: right" title="Leasehold improvements">5,140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zmTx6MCHYD7b" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress">931</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zHDi2rirDbP3" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress">2,952</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20231231_zUngx9E6QsM9" style="text-align: right" title="Property plant and equipment,gross">30,567</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_zySEkihT6XEi" style="text-align: right" title="Property plant and equipment,gross">29,115</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20231231_zAD7LNp1f4Vb" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(21,899</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_zuF9FUcXQeI3" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(21,166</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20231231_zuTrZ7f7fbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total">8,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_c20221231_zSlaSst9P8o2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total">7,949</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 23339000 19899000 1014000 1014000 126000 110000 5157000 5140000 931000 2952000 30567000 29115000 21899000 21166000 8668000 7949000 732000 557000 <p id="xdx_800_ecustom--LeasesTextBlock_zRUcuQ3iytj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(6)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zD9pIjLmPtJi">Lease Commitments</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. During the first calendar year of our newly leased building, we have subleased a portion of the unused floorspace on a temporary basis. This sublease may convert to a month-to-month lease upon expiration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the right-of-use (ROU) asset had a balance of $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231_zqbLUKr0EDu1" title="Operating leases, right of use">7,907</span> which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $<span id="xdx_90F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20231231_zi1mNIr0qhng" title="Current portion of operating lease obligations">1,297</span> and $<span id="xdx_907_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20231231_zDm3LjcCGAyl" title="Long-term portion of operating lease obligations">9,152</span>, respectively. These amounts are included in the “Current portion of operating lease obligations” and “Long-term portion of operating lease obligations” line items of these consolidated financial statements. As of December 31, 2022, the ROU asset had a balance of $<span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231_zpWizF9wmTG3" title="Operating leases, right of use">8,978</span> which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of <span id="xdx_909_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20221231_zn5ypjl551c9" title="Current portion of operating lease obligations">$0</span> and <span id="xdx_900_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20221231_z5AwPV4r9vFd" title="Long-term portion of operating lease obligations">$9,823</span>, respectively.  The <span id="xdx_909_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20221231_z4fpY4bi8xdl" title="Current portion of operating lease obligations">$0</span> in current lease liability stems from expected payments from the lessor of the Bolingbrook facility reimbursing the Company for tenant improvement allowances in the amount of $<span id="xdx_90B_eus-gaap--TenantImprovements_iI_pn3n3_c20231231_z9CJquILUQhi" title="Tenant improvement allowances">1,957</span> over the subsequent twelve months. As a result, the total lease liability was reduced by the expected payment, and the net effect of reimbursements received, and cash paid for leases in 2023 results in net lease payments of $<span id="xdx_90A_ecustom--LesseeOperatingLeasePaymentsNet_pn3n3_c20230101__20231231_zVIhK2GVO5wa" title="Operating lease payment net">97</span>. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The office leases contain variable lease payments which consist primarily of taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to combine lease and non-lease components for building leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--LeaseCostTableTextBlock_zCwfTcpyOlo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z0u1SIqFjDed">Quantitative information regarding the Company’s leases is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_zDFp5gOKkue1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zibBsrBxE4O5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zEI6acCNNQaf" style="vertical-align: bottom"> <td style="text-align: left">Components of lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinanceLeaseCostComponentsAbstract_i01B_zi0hVDEnsy19" style="vertical-align: bottom"> <td style="text-align: left">Finance lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_pn3n3_maLCFzzmZ_maFLIEzlEp_maLCFzxlZ_zeINOG916Zte" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; text-align: left; padding-left: 12pt">Amortization of finance lease assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">33</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseInterestExpense_i02_pn3n3_maLCFzzmZ_maLCFzxlZ_zcFO5FWpH78c" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Interest on finance lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--LeaseCostsFinance_i02T_pn3n3_mtLCFzxlZ_maLCzWd6_zt3eas4q4yM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 24pt">Total finance lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingLeaseCostComponentsAbstract_i01B_pn3n3_zZBg21fklTZk" style="vertical-align: bottom"> <td style="text-align: left">Operating lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_i02_pn3n3_maOLEzNuA_zXIJta2mQh8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 12pt">Operating lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,068</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--VariableLeaseCost_i02_pn3n3_maOLEzNuA_zVEjOQlvv6Hl" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 12pt">Variable lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">581</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">536</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ShortTermLeaseCost_i02_pn3n3_maOLEzNuA_zvUsEMxErqeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 12pt">Short-term lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--SubleaseIncome_i02N_pn3n3_di_msOLEzNuA_z4Gi09539Ckd" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Sub-lease income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(786</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(689</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--LeaseCostsOperating_i02T_pn3n3_maLCzWd6_mtOLEzNuA_zfm36BYZc8W" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 24pt">Total operating lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,788</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,053</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzWd6_zjctmtLuLVi" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,788</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,090</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_z92CuQ8WcWe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_890_ecustom--SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zpKRDiYxXEQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zuRXOry7s6Dh">Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%; padding-left: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating cash outflow from operating leases</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--OperatingLeasePayments_pn3n3_c20230101__20231231_z8kxeTjjYpg4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: right" title="Operating cash outflow from operating leases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20221231_zqHl6k6UcR48" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: right" title="Operating cash outflow from operating leases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,433</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease liabilities arising from obtaining right-of-use assets</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--PaymentForContingentConsiderationLiabilityOperatingActivities_pn3n3_c20230101__20231231_zlXmNmf5H1D2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Lease liabilities arising from obtaining right-of-use assets"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">182</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--PaymentForContingentConsiderationLiabilityOperatingActivities_pn3n3_c20220101__20221231_zegeQ1VGK2Bi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Lease liabilities arising from obtaining right-of-use assets"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early termination of operating lease</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--EarlyTerminationOfOperatingLease_pn3n3_c20220101__20221231_zbmtoaOZmJb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Early termination of operating lease"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction in right of use asset due to remeasurement</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_ecustom--ReductionInRightOfUseAssetDueToRemeasurement_iN_pn3n3_di_c20220101__20221231_z2YRakg5fjWh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Reduction in right of use asset due to remeasurement"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,793</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction in lease liability due to remeasurement</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_ecustom--ReductionInLeaseLiabilityDueToRemeasurement_iN_pn3n3_di_c20220101__20221231_zeCvI4ViU2W9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Reduction in lease liability due to remeasurement"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,898</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term-operating leases (in years)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20231231_zJDyGkdAN3u3" title="Weighted-average remaining lease term-operating leases (in years)">7.9</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zSTungWLGjS4" title="Weighted-average remaining lease term-operating leases (in years)">9.6</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate-operating leases</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20231231_zrgFasZGcdxi" title="Weighted-average discount rate-operating leases">7.1</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20221231_zp30EMHgi5t3" title="Weighted-average discount rate-operating leases">7.6</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A1_zBN9zv93bjDl" style="margin-top: 0; margin-bottom: 0">  </p> <p style="margin-top: 0; margin-bottom: 0"></p> <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLE8gM9v9uRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zF3ypLFoeco2">The future maturities of the Company’s operating leases as of December 31, 2023 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 51%; text-align: left">2024</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLL_c20231231_zTcSXzzO9dOc" style="width: 15%; text-align: right" title="2024">1,968</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">2025</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLL_c20231231_zu4765dvp0Ch" style="text-align: right" title="2025">1,483</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLL_c20231231_zbnQlAs1rmUf" style="text-align: right" title="2026">1,481</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">2027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLL_c20231231_zHUaWLbz76ch" style="text-align: right" title="2027">1,520</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLL_c20231231_zFWpxfWRqb4a" style="text-align: right" title="2028">1,549</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLL_c20231231_zfiHRaiuXcTb" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">5,613</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLL_c20231231_zasDuGPzX5p3" style="text-align: right" title="Total payments">13,614</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20231231_zXBjjFBYjO9f" style="text-align: right" title="Less amounts representing interest">(3,165</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20231231_zZUIUJNeyWsb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total minimum payments required">10,449</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_z7guQvZCcTu7" style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Nanophase Technologies subleases a portion of a leased industrial building that is used primarily for the storage of furniture, equipment and displays used for retail sales. The arrangement is not with a related party.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payments received by the Company for this sublease are comprised of two components, which include base rent and Common Area Maintenance (CAM) charges. While the base rent is fixed, the CAM charges are indexed directly to the Master Lease and are expected to be adjusted periodically as actual costs are incurred. However, the executed sublease agreement specifically itemizes these costs with a provision that informs the sublessee that the CAM charges will be adjusted (up or down) based on actual amounts once this information becomes known. As such, the nature of the charges is more closely representative of a fixed payment (an “in-substance fixed” charge) with the adjustments occurring simply to “true up” the listed CAM charges once actual charges from the head lessor become known. As sublessor, Nanophase Technologies has elected the practical expedient to not separate lease and nonlease components in disclosing future undiscounted cashflows and treats the combined components as a single lease component.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The sublease arrangement automatically renews following expiration of the initial term on May 31, 2025, with a one-year notice required to terminate the lease. As of the issuance of these financial statements the sublessee has not yet provided notice of their intent to renew or terminate said arrangement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p id="xdx_895_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_zjYdzrmsPm24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Months</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_483_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_iI_pn3n3_zeTBNpYN29F6" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_48E_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedTwoYears_iI_pn3n3_zvhp6RF9a9Uk" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>For the Year</b></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Months</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_91A_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_zcyMFHwRaeqa">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_915_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedTwoYears_zO1QDoRG1BLk">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_410_20231231__us-gaap--LeaseContractualTermAxis__custom--JanuaryThroughMayMember_z5NXHYhA3XHa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-size: 10pt">January - May</span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">124,015</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">128,640</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_414_20231231__us-gaap--LeaseContractualTermAxis__custom--JuneThroughDecemberMember_zlEx34eZkQcd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">June - December</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">173,621</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_411_20231231_zvCuOEtJrWO6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">297,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,640</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zVewZ96eof71" style="margin-top: 0; margin-bottom: 0"> </p> 7907000 1297000 9152000 8978000 0 9823000 0 1957000 97000 <p id="xdx_892_eus-gaap--LeaseCostTableTextBlock_zCwfTcpyOlo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z0u1SIqFjDed">Quantitative information regarding the Company’s leases is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_zDFp5gOKkue1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zibBsrBxE4O5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zEI6acCNNQaf" style="vertical-align: bottom"> <td style="text-align: left">Components of lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinanceLeaseCostComponentsAbstract_i01B_zi0hVDEnsy19" style="vertical-align: bottom"> <td style="text-align: left">Finance lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_pn3n3_maLCFzzmZ_maFLIEzlEp_maLCFzxlZ_zeINOG916Zte" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; text-align: left; padding-left: 12pt">Amortization of finance lease assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">33</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseInterestExpense_i02_pn3n3_maLCFzzmZ_maLCFzxlZ_zcFO5FWpH78c" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Interest on finance lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--LeaseCostsFinance_i02T_pn3n3_mtLCFzxlZ_maLCzWd6_zt3eas4q4yM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 24pt">Total finance lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingLeaseCostComponentsAbstract_i01B_pn3n3_zZBg21fklTZk" style="vertical-align: bottom"> <td style="text-align: left">Operating lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_i02_pn3n3_maOLEzNuA_zXIJta2mQh8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 12pt">Operating lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,068</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--VariableLeaseCost_i02_pn3n3_maOLEzNuA_zVEjOQlvv6Hl" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 12pt">Variable lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">581</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">536</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ShortTermLeaseCost_i02_pn3n3_maOLEzNuA_zvUsEMxErqeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 12pt">Short-term lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--SubleaseIncome_i02N_pn3n3_di_msOLEzNuA_z4Gi09539Ckd" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Sub-lease income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(786</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(689</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--LeaseCostsOperating_i02T_pn3n3_maLCzWd6_mtOLEzNuA_zfm36BYZc8W" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 24pt">Total operating lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,788</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,053</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzWd6_zjctmtLuLVi" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,788</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,090</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 33000 4000 37000 1881000 2068000 581000 536000 112000 138000 786000 689000 1788000 2053000 1788000 2090000 <p id="xdx_890_ecustom--SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zpKRDiYxXEQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zuRXOry7s6Dh">Supplemental cash flow information related to leases is as follows for the years ended December 31, 2023 and 2022:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%; padding-left: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating cash outflow from operating leases</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--OperatingLeasePayments_pn3n3_c20230101__20231231_z8kxeTjjYpg4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: right" title="Operating cash outflow from operating leases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20221231_zqHl6k6UcR48" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: right" title="Operating cash outflow from operating leases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,433</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease liabilities arising from obtaining right-of-use assets</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--PaymentForContingentConsiderationLiabilityOperatingActivities_pn3n3_c20230101__20231231_zlXmNmf5H1D2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Lease liabilities arising from obtaining right-of-use assets"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">182</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--PaymentForContingentConsiderationLiabilityOperatingActivities_pn3n3_c20220101__20221231_zegeQ1VGK2Bi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Lease liabilities arising from obtaining right-of-use assets"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early termination of operating lease</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--EarlyTerminationOfOperatingLease_pn3n3_c20220101__20221231_zbmtoaOZmJb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Early termination of operating lease"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction in right of use asset due to remeasurement</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_ecustom--ReductionInRightOfUseAssetDueToRemeasurement_iN_pn3n3_di_c20220101__20221231_z2YRakg5fjWh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Reduction in right of use asset due to remeasurement"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,793</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction in lease liability due to remeasurement</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_ecustom--ReductionInLeaseLiabilityDueToRemeasurement_iN_pn3n3_di_c20220101__20221231_zeCvI4ViU2W9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Reduction in lease liability due to remeasurement"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,898</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term-operating leases (in years)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20231231_zJDyGkdAN3u3" title="Weighted-average remaining lease term-operating leases (in years)">7.9</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zSTungWLGjS4" title="Weighted-average remaining lease term-operating leases (in years)">9.6</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate-operating leases</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20231231_zrgFasZGcdxi" title="Weighted-average discount rate-operating leases">7.1</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20221231_zp30EMHgi5t3" title="Weighted-average discount rate-operating leases">7.6</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 172000 1433000 182000 12000 73000 1793000 1898000 P7Y10M24D P9Y7M6D 0.071 0.076 <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLE8gM9v9uRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zF3ypLFoeco2">The future maturities of the Company’s operating leases as of December 31, 2023 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 51%; text-align: left">2024</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLL_c20231231_zTcSXzzO9dOc" style="width: 15%; text-align: right" title="2024">1,968</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">2025</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLL_c20231231_zu4765dvp0Ch" style="text-align: right" title="2025">1,483</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLL_c20231231_zbnQlAs1rmUf" style="text-align: right" title="2026">1,481</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">2027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLL_c20231231_zHUaWLbz76ch" style="text-align: right" title="2027">1,520</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLL_c20231231_zFWpxfWRqb4a" style="text-align: right" title="2028">1,549</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLL_c20231231_zfiHRaiuXcTb" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">5,613</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLL_c20231231_zasDuGPzX5p3" style="text-align: right" title="Total payments">13,614</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20231231_zXBjjFBYjO9f" style="text-align: right" title="Less amounts representing interest">(3,165</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20231231_zZUIUJNeyWsb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total minimum payments required">10,449</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1968000 1483000 1481000 1520000 1549000 5613000 13614000 3165000 10449000 <p id="xdx_895_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_zjYdzrmsPm24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The future undiscounted lease payments associated with this arrangement are provided below, and only include the period for which enforceable rights and obligations exist as of the date of financial statement issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Months</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_483_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_iI_pn3n3_zeTBNpYN29F6" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_48E_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedTwoYears_iI_pn3n3_zvhp6RF9a9Uk" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>For the Year</b></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Months</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_91A_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_zcyMFHwRaeqa">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_915_eus-gaap--LessorOperatingLeasePaymentsToBeReceivedTwoYears_zO1QDoRG1BLk">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_410_20231231__us-gaap--LeaseContractualTermAxis__custom--JanuaryThroughMayMember_z5NXHYhA3XHa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><span style="font-size: 10pt">January - May</span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">124,015</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">128,640</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_414_20231231__us-gaap--LeaseContractualTermAxis__custom--JuneThroughDecemberMember_zlEx34eZkQcd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">June - December</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">173,621</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_411_20231231_zvCuOEtJrWO6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">297,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,640</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 124015000 128640000 173621000 297636000 128640000 <p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zuZe0gT5PPM6" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(7)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zWMrEwkvuJb1">Accrued Expenses</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zh94QCgeAt1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zkjCKuqv88k3">Accrued expenses consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td id="xdx_49E_20231231_zbKROtC7xduh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="4" id="xdx_49D_20221231_z62yWliWxdYf" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of December 31,</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzPuI_zHk0vPCZODs8" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 75%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued payroll and related expenses</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">255</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">288</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--CustomerNetVolumeRebatePayable_iI_maALCzPuI_zVXNASzmFPF3" style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued accounts payable</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">403</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_ecustom--TenantSecurityDeposit_iI_maALCzPuI_zblVkGVImSni" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant security deposit / advance rent</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0943">—</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzPuI_zcfo8ngQR2Tc" style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">486</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">271</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzPuI_z1f679iH33D5" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">869</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zfqEGC8RbMxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zh94QCgeAt1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zkjCKuqv88k3">Accrued expenses consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td id="xdx_49E_20231231_zbKROtC7xduh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="4" id="xdx_49D_20221231_z62yWliWxdYf" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of December 31,</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzPuI_zHk0vPCZODs8" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 75%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued payroll and related expenses</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">255</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">288</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--CustomerNetVolumeRebatePayable_iI_maALCzPuI_zVXNASzmFPF3" style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued accounts payable</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">403</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_ecustom--TenantSecurityDeposit_iI_maALCzPuI_zblVkGVImSni" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant security deposit / advance rent</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0943">—</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzPuI_zcfo8ngQR2Tc" style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">486</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">271</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzPuI_z1f679iH33D5" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">869</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 255000 288000 128000 403000 61000 486000 271000 869000 1023000 <p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_z5Op01OUFsQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(8)</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82D_zuIbQKaBF46b">Income Taxes</span></b></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our net income tax provision, including both current and deferred, related to U.S. federal and state income taxes, is $<span id="xdx_90C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20230101__20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2023Member_zZs6GXO0PAS7" title="Income tax provision">6</span>. Our current federal and deferred tax expenses are zero.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zNYigvDagHL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zK7Tgs8l9cE5">A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231_zmrRK2KGjLwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zgtFWQCNJCB5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBz3M7_zhCmkm6gWjCd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Income tax credit at statutory rates</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(921</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(551</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--OverunderAccrualOfIncomeTaxes_maITEBz3M7_zl7CmivbGXlj" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Over/Under Accrual of Income Taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(17</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NondeductibleExpenses_maITEBz3M7_zQwAiujZRFb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Nondeductible Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_di_msITEBz3M7_zkrfgQO19MO3" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Record Tax Credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(118</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBz3M7_zzxJ6obbwzJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Permanent tax deduction stock options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(63</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(273</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBz3M7_zuSBguStXBG9" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">State income tax, net of federal benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(165</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(124</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ExpirationOfNolCredits_maITEBz3M7_zfowcIyOyhj8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Expiration of NOL &amp; credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,492</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,149</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBz3M7_zNXvJml4WZA3" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Effect of change in deferred tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBz3M7_zFDZ1ud1rknl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Expiration of stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBz3M7_zlBHoAUCJzFb" style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0986">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz3M7_z7WJK0siGO3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(344</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(347</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz3M7_zToRqI1Pm87l" style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A7_zGTlkTeOmoU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ze2kON7LiBFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zScEO46ACgb4">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20231231_z0UHp1yA4Alc" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20221231_z0tNB4VAEpF3" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zDk65EGOH4sf" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Deferred tax liabilities:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_maDTLzzT5_zdkYApHhTCzl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">  Excess tax depreciation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(477</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">(253</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesOperatingLeaseAsset_iNI_pn3n3_di_maDTLzzT5_zzd1c4dgLbsi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">ASC 892 Operating Lease Asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,975</td><td style="padding-bottom: 1pt; text-align: left">) </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDTLzzT5_msDTANzkIN_zvcScLHTTIlc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">     Total deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,452</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(253</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zwSOcMAYF2wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzqfm_zeYmwFiBCBij" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  Net operating loss carryforwards</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,416</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOtherTaxCarryforwards_iI_pn3n3_maDTAGzqfm_z5ToFdecau84" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">  179 Carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_maDTAGzqfm_z2wN3JQHNYm9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  163(j) Business interest limitation carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_maDTAGzqfm_zwH5j9tjkm4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">  Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzqfm_z1brl3odYXfg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  Inventory and other allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">177</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pn3n3_maDTAGzqfm_zSpXXHgQntXa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">  Excess (tax) book depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzqfm_zdkauNzw1bs7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  Excess (tax) book amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzqfm_zslagyspp6W6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">  174 research &amp; experimental expenditures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">902</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzqfm_zGIKlOsUUoU6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">394</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTAGzqfm_zuvg4H1KQjK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">  Tax Credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1040">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiability_iI_pn3n3_maDTAGzqfm_z5Lx6ZdaIIxb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">ASC 892 Operating Lease Liability </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,610</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_maDTAGzqfm_zaBLfCnzJNxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Other accrued costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">238</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzqfm_maDTANzkIN_z8mmHEXXE6lf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">     Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,039</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzkIN_ztUJ2r0yhfa1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Less: Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,587</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,928</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTANzkIN_znYofaVGm6ad" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Deferred income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zeUzcKpicSXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The valuation allowance decreased approximately $<span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20230101__20231231_zZ6NesrrLg1k" title="Increase (decrease) in valuation allowance">0.3</span> million and $<span id="xdx_90A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20220101__20221231_zcXQ01ql1Hs9" title="Increase (decrease) in valuation allowance">0.3</span> million for the years ended December 31, 2023 and 2022, respectively (net of approximately $<span id="xdx_90A_eus-gaap--TaxCreditCarryforwardValuationAllowance_iI_pn5n6_c20231231_zIMSvJShc6g3" title="Valuation allowance, net operating loss carryforwards and credits">7.1</span> million and $<span id="xdx_907_eus-gaap--TaxCreditCarryforwardValuationAllowance_iI_pn5n6_c20221231_zCKn102dZl95">5.5</span> million for the years ended December 31, 2023 and 2022, respectively, for expiring net operating loss carryforwards and credits) due principally to the change in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and our public offering of common stock, may subject us to annual limitations on the utilization of our net operating loss carryforward. As of December 31, 2023, it has been determined that we are not subject to annual limitations on the utilization of our net operating loss carryforward.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have federal net operating loss carryforwards for tax purposes of approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20231231_zpb0QT6tgp55" title="Net operating loss carryforwards">50</span> million on December 31, 2023. $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20231231__us-gaap--TaxPeriodAxis__custom--Expiring2023To2037Member_zgJ2v53F88Jh" title="Net operating loss carryforwards">44</span> million expire between <span id="xdx_90A_ecustom--OperatingLossCarryforwardsExpirationYearStart_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIKNbatDVSBh" title="Operating loss carryforwards expiration period start">2024</span> and <span id="xdx_90C_ecustom--OperatingLossCarryforwardsExpirationYearEnd_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zB8BUPozKgB7" title="Operating loss carryforwards expiration period end">2037</span>. We have section 179 carryforwards of approximately $<span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20231231__us-gaap--TaxCreditCarryforwardAxis__us-gaap--GeneralBusinessMember_zIWuXCyjNFt5" title="Carryforwards">0.2</span>M at December 31, 2023. All net operating loss carryforwards generated after January 1, 2018 do not expire. Therefore, $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2018Member_zfklNzSRUFia">5.6</span> million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zJBRZdKvyO95">21.3</span> million on December 31, 2023. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between <span id="xdx_90C_ecustom--OperatingLossCarryforwardsExpirationYearStart_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zIM7xdyKdYrl">2029</span> and <span id="xdx_909_ecustom--OperatingLossCarryforwardsExpirationYearEnd_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zQOxcHrkGqcj" title="Operating loss carryforwards expiration period end">2039</span>.</span></p> 6000 <p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zNYigvDagHL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zK7Tgs8l9cE5">A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2023 and 2022 is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231_zmrRK2KGjLwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zgtFWQCNJCB5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBz3M7_zhCmkm6gWjCd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Income tax credit at statutory rates</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(921</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(551</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--OverunderAccrualOfIncomeTaxes_maITEBz3M7_zl7CmivbGXlj" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Over/Under Accrual of Income Taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(17</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NondeductibleExpenses_maITEBz3M7_zQwAiujZRFb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Nondeductible Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_di_msITEBz3M7_zkrfgQO19MO3" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Record Tax Credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(118</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBz3M7_zzxJ6obbwzJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Permanent tax deduction stock options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(63</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(273</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBz3M7_zuSBguStXBG9" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">State income tax, net of federal benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(165</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(124</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ExpirationOfNolCredits_maITEBz3M7_zfowcIyOyhj8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Expiration of NOL &amp; credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,492</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,149</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBz3M7_zNXvJml4WZA3" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Effect of change in deferred tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBz3M7_zFDZ1ud1rknl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Expiration of stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBz3M7_zlBHoAUCJzFb" style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0986">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz3M7_z7WJK0siGO3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(344</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(347</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz3M7_zToRqI1Pm87l" style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -921000 -551000 -3000 -17000 23000 118000 -63000 -273000 -165000 -124000 1492000 1149000 45000 69000 60000 75000 2000 -344000 -347000 6000 -17000 <p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ze2kON7LiBFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zScEO46ACgb4">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20231231_z0UHp1yA4Alc" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20221231_z0tNB4VAEpF3" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zDk65EGOH4sf" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Deferred tax liabilities:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_maDTLzzT5_zdkYApHhTCzl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">  Excess tax depreciation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(477</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">(253</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesOperatingLeaseAsset_iNI_pn3n3_di_maDTLzzT5_zzd1c4dgLbsi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">ASC 892 Operating Lease Asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,975</td><td style="padding-bottom: 1pt; text-align: left">) </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDTLzzT5_msDTANzkIN_zvcScLHTTIlc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">     Total deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,452</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(253</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zwSOcMAYF2wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzqfm_zeYmwFiBCBij" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  Net operating loss carryforwards</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,416</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOtherTaxCarryforwards_iI_pn3n3_maDTAGzqfm_z5ToFdecau84" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">  179 Carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_maDTAGzqfm_z2wN3JQHNYm9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  163(j) Business interest limitation carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_maDTAGzqfm_zwH5j9tjkm4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">  Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzqfm_z1brl3odYXfg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  Inventory and other allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">177</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pn3n3_maDTAGzqfm_zSpXXHgQntXa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">  Excess (tax) book depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzqfm_zdkauNzw1bs7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  Excess (tax) book amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzqfm_zslagyspp6W6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">  174 research &amp; experimental expenditures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">902</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzqfm_zGIKlOsUUoU6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">  Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">394</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTAGzqfm_zuvg4H1KQjK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">  Tax Credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1040">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiability_iI_pn3n3_maDTAGzqfm_z5Lx6ZdaIIxb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">ASC 892 Operating Lease Liability </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,610</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_maDTAGzqfm_zaBLfCnzJNxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Other accrued costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">238</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzqfm_maDTANzkIN_z8mmHEXXE6lf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">     Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,039</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzkIN_ztUJ2r0yhfa1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Less: Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,587</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,928</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTANzkIN_znYofaVGm6ad" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Deferred income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 477000 253000 1975000 2452000 253000 12020000 13416000 245000 117000 302000 98000 202000 239000 177000 60000 59000 902000 480000 530000 394000 118000 2610000 13000 238000 17039000 15181000 14587000 14928000 -300000 -300000 7100000 5500000 50000000 44000000 2024 2037 200000 5600000 21300000 2029 2039 <p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1KJYyVoi2Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b> </span></p></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_zKFfZe4LUHrk">Capital Stock</span></b> </span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, and 2022, we had <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20221231_z0eRQMcvTsOi" title="Preferred stock, shares authorized"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20231231_zHRghH8uDSv5" title="Preferred stock, shares authorized">24,088</span></span> authorized but unissued shares of preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Securities Purchase Agreement executed on March 1, 2024, the Company issued to Strandler <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20240229__20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_z2gGX1taZApj" title="Number of shares issued">15,000</span> shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”)at a purchase price per share of <span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pip0_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zMWQPuDsy1t5" title="Price per share">$400</span>, for total consideration of <span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pp0p0_c20240229__20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_z3TGQcUIwdoc" title="Consideration from sale of shares">$6,000,000</span>, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”).</span></p> 24088 24088 15000 400 6000000 <p id="xdx_80A_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z8thnNqYhQe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zRuYfbMLCwDj">Stock Options and Stock Grants</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have entered into stock option agreements with certain officers, employees and directors. The stock options granted prior to the adoption of the 2019 Equity Compensation Plan (the “2019 Plan”) on November 19, 2019 generally expire <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20230101__20231231__us-gaap--PlanNameAxis__custom--PriorToEquityCompensationPlan2019Member_zsXASpnepebj" title="Shares based compensation payment award expiration period">ten years</span> from the date of grant. Future options to be granted under the 2019 Plan will expire <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityCompensationPlan2019Member_z4qVSZaQCCjg" title="Shares based compensation payment award expiration period">seven years</span> from the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Employee Stock Options</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zvyUzMidRs1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0G3nqISsAm9">We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td id="xdx_49E_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlTqv3JvLfk8" style="border-bottom: Black 1pt solid; text-align: center"> </td> <td colspan="4" id="xdx_49A_20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztgrZrsoyEEi" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended </b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b> </span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--StockOptionPlanExpense_z4e1Bc4xcdqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Share-based compensation expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">773</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">625</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_zdoenjCrAd7i" style="vertical-align: bottom"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Remaining unrecognized compensation expense</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,732</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Remaining weighted average-period, expense recognition (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlmiOqDi1Sxl" title="Remaining weighted average-period, expense recognition (years)">1.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT3ruQBrfCi4" title="Remaining weighted average-period, expense recognition (years)">2.5</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p id="xdx_8A5_zcAQEBZiu4L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use the Black-Scholes option pricing model to determine the fair value of stock-based compensation. The Black-Scholes model requires us to make several assumptions, including the estimated length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of our common stock price over the expected term, and estimated forfeitures. Expected price volatility is based on the daily market rate changes of our stock. The active shares granted prior to fiscal 2020 had a contractual life of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityCompensationPlan2010Member_zbK0RDzJtc9c" title="Shares based compensation payment award expiration period">10</span> years as dictated by the 2010 Plan. The Black-Scholes model also requires a risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of the grant, and the dividend yield on our common stock, which is assumed to be zero since we do not pay dividends and have no current plans to do so in the future. Changes in these assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related expense recognized on the statement of operations. We recognize stock-based compensation expense on a straight-line basis over the requisite service period. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_zV02VMCmmZ5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zSTaJSjrjOic">The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Weighted-average risk-free interest rates:</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_uPure_c20230101__20231231_z5Zwc0PARz86" title="Weighted-average risk-free interest rates">3.8</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_uPure_c20220101__20221231_zj5FSqhzfNa7" title="Weighted-average risk-free interest rates">3.5</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20230101__20231231_zsDDOyrkUXre" title="Dividend yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20220101__20221231_znsVrxHntOrg" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average expected life (years) of the option:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z857Iedn4aS9" title="Weighted-average expected life (years) of the option">4</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zkEU8FPeQjcb" title="Weighted-average expected life (years) of the option">5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average expected stock price volatility:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20230101__20231231_zQyuvnUAlHPj" title="Weighted-average expected stock price volatility">93</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20220101__20221231_zVZBK9v3xvBd" title="Weighted-average expected stock price volatility">116</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average fair value of the options granted:</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zvuTvBs95SD3" style="text-align: right" title="Weighted-average fair value of the options granted">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zCsZStohKN79" style="text-align: right" title="Weighted-average fair value of the options granted">0.97</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zIbxW1Q7vN4f" style="margin-top: 0; margin-bottom: 0">  </p> <p style="margin-top: 0; margin-bottom: 0"></p> <p id="xdx_89D_ecustom--AdditionalDisclosuresForOptionsGrantedTableTextBlock_zZD0RLfReTG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_z0suIRj3wzM9">Additional disclosures for options granted for all years presented:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Vesting period (years) of shares granted in period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3D4dKuhV49j" style="width: 12%; text-align: right" title="Vesting period (years) of shares granted in period">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zonzzjzK22Mf" style="width: 12%; text-align: right" title="Vesting period (years) of shares granted in period">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual life (years) of shares granted in period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFMOXE35m3d2" style="text-align: right" title="Contractual life (years) of shares granted in period">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQgeyZyNTKdd" style="text-align: right" title="Contractual life (years) of shares granted in period">7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Estimated forfeitures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUWCbBgmzBS7" style="text-align: right" title="Estimated forfeitures">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqnXXRayRU4l" style="text-align: right" title="Estimated forfeitures">4</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AD_zXmq9JJhsVGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvnifkds58F8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zkjjoQYYPfxd">The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Rounded)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term (Years)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(000s)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding on January 1, 2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20231231_zlZAyF3njMS6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right" title="Shares Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,443,661</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231_z1ceCesHvMp" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right" title="Shares Outstanding Beginning, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zNlFCsqU21q2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right" title="Weighted Average Remaining Contractual Term, Outstanding, end"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValu1_iI_c20231231_zqEGNnOkMt03" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right" title="Shares Outstanding (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,230</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231_zwhQDASYHaKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">668,200</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231_z8Ahff9GhcNc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Granted (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.68</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20230101__20231231_zagRXe6reOD9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(294,074</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231_zGKDHs3cQgMg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercised (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited or expired</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20230101__20231231_z8E4oAjZxnu5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(291,821</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231_z6cfvoNoNIv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Forfeited or expired (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.92</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding on December 31, 2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20231231_zOxJBCoJYAtk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,525,966</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zSyajzTc8KI3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Outstanding Beginning, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zwakkWpDBryf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Weighted Average Remaining Contractual Term, Outstanding, end"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231_zYOLSlm4uQUl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Outstanding (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable on December 31, 2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20230101__20231231_zU1HPdzUEpMd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,334,458</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zimum0qd6XKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Exercisable, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zeSGkfU2O4Vc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Exercisable (years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231_zNwmCXlHJGEe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Exercisable (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares available for grant</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20231231_zkeJukNzZfBc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares available for grant"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">450,900</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A2_zwWCy0sv2CIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_890_ecustom--StockOptionsRecognizedTableTextBlock_zyk8vKU1yC41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zvKZd0Yhknkk">The aggregate intrinsic value in the table above is based on our closing stock price of $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z82yptkRBbTf" title="Closing stock share price">0.60 </span>on the last business day for the year ended December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td id="xdx_497_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzGuaGXZryJd" style="border-bottom: Black 1pt solid; text-align: center"> </td> <td colspan="4" id="xdx_496_20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zg57L1aP8aL7" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended </b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b> </span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_zpinQIizuUM9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Shares exercised</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">294,074</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">414,455</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_zLkDRmBJr7wk" style="vertical-align: bottom"> <td>Total intrinsic value</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">942</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_zIDxKMf7Ndt7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash received</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">182</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zQPPWSFk826j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on our election of the “with and without” approach, no realized tax benefits from stock options were recognized for the years ended December 31, 2023 and 2022.</span></p> P10Y P7Y <p id="xdx_896_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zvyUzMidRs1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0G3nqISsAm9">We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td id="xdx_49E_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlTqv3JvLfk8" style="border-bottom: Black 1pt solid; text-align: center"> </td> <td colspan="4" id="xdx_49A_20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztgrZrsoyEEi" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended </b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b> </span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--StockOptionPlanExpense_z4e1Bc4xcdqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Share-based compensation expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">773</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">625</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_zdoenjCrAd7i" style="vertical-align: bottom"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Remaining unrecognized compensation expense</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,732</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Remaining weighted average-period, expense recognition (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlmiOqDi1Sxl" title="Remaining weighted average-period, expense recognition (years)">1.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT3ruQBrfCi4" title="Remaining weighted average-period, expense recognition (years)">2.5</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> 773000 625000 1118000 1732000 P1Y9M18D P2Y6M P10Y <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_zV02VMCmmZ5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zSTaJSjrjOic">The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Weighted-average risk-free interest rates:</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_uPure_c20230101__20231231_z5Zwc0PARz86" title="Weighted-average risk-free interest rates">3.8</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_uPure_c20220101__20221231_zj5FSqhzfNa7" title="Weighted-average risk-free interest rates">3.5</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20230101__20231231_zsDDOyrkUXre" title="Dividend yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20220101__20221231_znsVrxHntOrg" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average expected life (years) of the option:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z857Iedn4aS9" title="Weighted-average expected life (years) of the option">4</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zkEU8FPeQjcb" title="Weighted-average expected life (years) of the option">5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average expected stock price volatility:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20230101__20231231_zQyuvnUAlHPj" title="Weighted-average expected stock price volatility">93</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20220101__20221231_zVZBK9v3xvBd" title="Weighted-average expected stock price volatility">116</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average fair value of the options granted:</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zvuTvBs95SD3" style="text-align: right" title="Weighted-average fair value of the options granted">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zCsZStohKN79" style="text-align: right" title="Weighted-average fair value of the options granted">0.97</td><td style="text-align: left"> </td></tr> </table> 0.038 0.035 0 0 P4Y P5Y 0.93 1.16 0.50 0.97 <p id="xdx_89D_ecustom--AdditionalDisclosuresForOptionsGrantedTableTextBlock_zZD0RLfReTG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_z0suIRj3wzM9">Additional disclosures for options granted for all years presented:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Vesting period (years) of shares granted in period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3D4dKuhV49j" style="width: 12%; text-align: right" title="Vesting period (years) of shares granted in period">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zonzzjzK22Mf" style="width: 12%; text-align: right" title="Vesting period (years) of shares granted in period">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual life (years) of shares granted in period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFMOXE35m3d2" style="text-align: right" title="Contractual life (years) of shares granted in period">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQgeyZyNTKdd" style="text-align: right" title="Contractual life (years) of shares granted in period">7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Estimated forfeitures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUWCbBgmzBS7" style="text-align: right" title="Estimated forfeitures">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqnXXRayRU4l" style="text-align: right" title="Estimated forfeitures">4</td><td style="text-align: left">%</td></tr> </table> P3Y P3Y P7Y P7Y 0.08 0.04 <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvnifkds58F8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zkjjoQYYPfxd">The following table summarizes the option activity for our employees and directors during the year ended December 31, 2023:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Rounded)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term (Years)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(000s)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding on January 1, 2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20231231_zlZAyF3njMS6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right" title="Shares Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,443,661</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231_z1ceCesHvMp" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right" title="Shares Outstanding Beginning, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zNlFCsqU21q2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right" title="Weighted Average Remaining Contractual Term, Outstanding, end"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValu1_iI_c20231231_zqEGNnOkMt03" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right" title="Shares Outstanding (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,230</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231_zwhQDASYHaKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">668,200</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231_z8Ahff9GhcNc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Granted (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.68</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20230101__20231231_zagRXe6reOD9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(294,074</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231_zGKDHs3cQgMg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercised (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited or expired</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20230101__20231231_z8E4oAjZxnu5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(291,821</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231_z6cfvoNoNIv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Forfeited or expired (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.92</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding on December 31, 2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20231231_zOxJBCoJYAtk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,525,966</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zSyajzTc8KI3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Outstanding Beginning, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zwakkWpDBryf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Weighted Average Remaining Contractual Term, Outstanding, end"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231_zYOLSlm4uQUl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Outstanding (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable on December 31, 2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20230101__20231231_zU1HPdzUEpMd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,334,458</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zimum0qd6XKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Exercisable, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zeSGkfU2O4Vc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Exercisable (years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231_zNwmCXlHJGEe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares Exercisable (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares available for grant</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20231231_zkeJukNzZfBc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Shares available for grant"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">450,900</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 3443661 1.33 P4Y10M24D 1230000 668200 0.68 294074 0.50 291821 1.92 3525966 1.22 P4Y2M12D 160000 2334458 1.15 P3Y2M12D 160000 450900 <p id="xdx_890_ecustom--StockOptionsRecognizedTableTextBlock_zyk8vKU1yC41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zvKZd0Yhknkk">The aggregate intrinsic value in the table above is based on our closing stock price of $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z82yptkRBbTf" title="Closing stock share price">0.60 </span>on the last business day for the year ended December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td id="xdx_497_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzGuaGXZryJd" style="border-bottom: Black 1pt solid; text-align: center"> </td> <td colspan="4" id="xdx_496_20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zg57L1aP8aL7" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended </b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b> </span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_zpinQIizuUM9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Shares exercised</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">294,074</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">414,455</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_zLkDRmBJr7wk" style="vertical-align: bottom"> <td>Total intrinsic value</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">942</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_zIDxKMf7Ndt7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash received</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">182</td><td style="text-align: left"> </td></tr> </table> 0.60 294074 414455 195000 942000 154000 182000 <p id="xdx_80C_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zZTNarjDq5Wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(11)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zWCm4eZZHpEk">401(k) Profit-Sharing Plan</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. Contributions made in 2023 and 2022 aggregated to $<span id="xdx_90B_eus-gaap--DefinedContributionPlanCostRecognized_pn3n3_c20230101__20231231_zEsdnFVmFZo8" title="Defined contribution plan, cost">191</span> and $<span id="xdx_908_eus-gaap--DefinedContributionPlanCostRecognized_pn3n3_c20220101__20221231_zwRBmticUWje" title="Defined contribution plan, cost">153</span>, respectively.</span></p> 191000 153000 <p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_z2sltxqXJsfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(12)</b></span></td> <td id="xdx_82C_zrDAViZh2NGg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S<span>ignificant Customers </span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_890_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zgan7yAikb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zbRZoeqgEBS1">We had three significant customers for the year ended December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the years ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 12%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 16%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z827W5EkCvCc" title="Revenue from customers">25</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zXZoPtbFWXuc" title="Revenue from customers">30</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zz4pDS9NorHe" title="Revenue from customers">17</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYWkx3SAEh32" title="Revenue from customers">17</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zATDlve9hNy5" title="Revenue from customers">15</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z6tharj4pxwk" title="Revenue from customers">15</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.5in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zZeB8xQBgZe7" title="Revenue from customers">57</span></td><td style="vertical-align: bottom; text-align: center">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zwB0Vzi5bzl6" title="Revenue from customers">62</span></td><td style="vertical-align: bottom; text-align: center">%</td></tr> </table> <p id="xdx_8AF_zop3ZYw8H2pk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_ecustom--ContractWithCustomerAccountReceivablesTableTextBlock_zRXsj8SG8QNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zuq1ApBFnima">Accounts receivable balances for these three customers were approximately:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 12%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 16%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerOneMember_z5Efk0zTqexh" style="width: 12%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1229">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20221231__srt--MajorCustomersAxis__custom--CustomerOneMember_zIAqEZxS0gy4" style="width: 12%; text-align: right" title="Total">1,082</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zSfqqDIm7zPg" style="text-align: right" title="Total">1,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zXa1C3wVd75f" style="text-align: right" title="Total">438</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zSvb5hI3QaKf" style="text-align: right" title="Total">864</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zqoPbYhaBbC4" style="text-align: right" title="Total">683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.5in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231_zSD73xK4n1ul" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,152</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20221231_znNNp16f9wq5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,202</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zfIzX9kbHvJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either <span id="xdx_908_ecustom--EquipmentSaleNetBookValueEquipment_iI_pid_dp_uPure_c20231231__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_zqZfMVI7K2md" title="Equipment sale - net book value">115</span>% of the equipment’s net book value or the greater of <span id="xdx_908_ecustom--EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades_iI_pid_dp_uPure_c20231231__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_zERvgQE0VxP" title="Equipment sale- original book value">30</span>% of the original book value of such equipment, and any associated upgrades to it, or <span id="xdx_908_ecustom--EquipmentSaleNetBookValueEquipment_iI_pid_dp_uPure_c20231231__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_z1l02EJEtom3" title="Equipment sale - net book value">115</span>% of the equipment’s net book value, depending on the equipment and related products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a triggering event were to occur and BASF elected to proceed with the equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.</span></p> <p id="xdx_890_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zgan7yAikb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zbRZoeqgEBS1">We had three significant customers for the year ended December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the years ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 12%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 16%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z827W5EkCvCc" title="Revenue from customers">25</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zXZoPtbFWXuc" title="Revenue from customers">30</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zz4pDS9NorHe" title="Revenue from customers">17</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYWkx3SAEh32" title="Revenue from customers">17</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zATDlve9hNy5" title="Revenue from customers">15</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z6tharj4pxwk" title="Revenue from customers">15</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.5in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zZeB8xQBgZe7" title="Revenue from customers">57</span></td><td style="vertical-align: bottom; text-align: center">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zwB0Vzi5bzl6" title="Revenue from customers">62</span></td><td style="vertical-align: bottom; text-align: center">%</td></tr> </table> 0.25 0.30 0.17 0.17 0.15 0.15 0.57 0.62 <p id="xdx_895_ecustom--ContractWithCustomerAccountReceivablesTableTextBlock_zRXsj8SG8QNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zuq1ApBFnima">Accounts receivable balances for these three customers were approximately:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 12%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 16%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerOneMember_z5Efk0zTqexh" style="width: 12%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1229">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20221231__srt--MajorCustomersAxis__custom--CustomerOneMember_zIAqEZxS0gy4" style="width: 12%; text-align: right" title="Total">1,082</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zSfqqDIm7zPg" style="text-align: right" title="Total">1,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zXa1C3wVd75f" style="text-align: right" title="Total">438</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zSvb5hI3QaKf" style="text-align: right" title="Total">864</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zqoPbYhaBbC4" style="text-align: right" title="Total">683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.5in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231_zSD73xK4n1ul" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,152</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20221231_znNNp16f9wq5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,202</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1082000 1288000 438000 864000 683000 2152000 2202000 1.15 0.30 1.15 <p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_zoQP41LGtPn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(13)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zvUolSFvy719">Business Segmentation and Geographical Distribution</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from international sources approximated $<span id="xdx_90B_eus-gaap--Revenues_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zauKHHxyIsa5" title="Revenues">2,918</span> and $<span id="xdx_90B_eus-gaap--Revenues_pn3n3_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvavS6XY4fI8" title="Revenues">1,971</span> for the years ended December 31, 2023 and 2022, respectively. As part of our revenue from international sources, we recognized approximately $<span id="xdx_904_eus-gaap--Revenues_pn3n3_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--ProductMember_ziZx3GTXysa8" title="Revenues">1,664</span> and $<span id="xdx_907_eus-gaap--Revenues_pn3n3_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zyIdE9T8i4be" title="Revenues">1,236</span> in product revenue from German companies, in the aggregate, for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zOm0VME26W29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. <span id="xdx_8B7_z00vkpF7Rack">The revenues for 2023 and 2022 by category are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended </b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31</b> </span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Solésence</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--SolesenceMember_zOW7g35ZZOrg" style="width: 12%; text-align: right" title="Total revenue">25,211</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--SolesenceMember_zYef4fRqMFKj" style="width: 12%; text-align: right" title="Total revenue">23,111</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_z3YzPOAGo1M1" style="text-align: right" title="Total revenue">9,277</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_z0uMdFrPfdtb" style="text-align: right" title="Total revenue">11,121</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zkNFQzm03h1k" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">2,809</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zfVy3s08YQSf" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">3,085</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zJVnLwIEOJEl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">37,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zJCgxLjvsBC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">37,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zbPq5V6NeD03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 2918000 1971000 1664000 1236000 <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zOm0VME26W29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. <span id="xdx_8B7_z00vkpF7Rack">The revenues for 2023 and 2022 by category are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended </b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31</b> </span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Solésence</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--SolesenceMember_zOW7g35ZZOrg" style="width: 12%; text-align: right" title="Total revenue">25,211</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--SolesenceMember_zYef4fRqMFKj" style="width: 12%; text-align: right" title="Total revenue">23,111</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_z3YzPOAGo1M1" style="text-align: right" title="Total revenue">9,277</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_z0uMdFrPfdtb" style="text-align: right" title="Total revenue">11,121</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zkNFQzm03h1k" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">2,809</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zfVy3s08YQSf" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">3,085</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zJVnLwIEOJEl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">37,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zJCgxLjvsBC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">37,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 25211000 23111000 9277000 11121000 2809000 3085000 37297000 37317000 <p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z89rfOqzHYx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(14)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_82D_zGS5ZGkBvmIk">Commitments and Contingencies</span></span></b> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 9, 2022, BASF filed a complaint against Nanophase in New Jersey state court (the “New Jersey Complaint”), alleging that Nanophase had breached the 1999 Zinc Oxide Supply Agreement (the “Agreement”). BASF alleges several issues, the one having the biggest potential impact on Nanophase being a claim that our sales through Solésence violate the exclusivity provision of the Agreement. BASF seeks an unspecified amount of damages, a permanent injunction enjoining sales to any party (other than BASF) of a broad range of zinc oxide products that BASF contends are within the scope of the exclusivity provision, counsel fees and litigation expenses. On September 7, 2022, Nanophase filed a Complaint for Declaratory Judgement in Illinois state court (the “Illinois Complaint”), asking for a declaration that contrary to BASF’s allegation, the exclusivity provision of the Agreement does not apply to all products containing zinc oxide as an ingredient for uses designated under the Agreement, nor does the exclusivity provision prohibit Nanophase’s sales of Solésence products containing zinc oxide as an ingredient. Both companies filed Motions to Dismiss (MTD) the other’s respective complaint. Nanophase’s MTD BASF’s New Jersey Complaint was denied on procedural grounds on February 10, 2023, with the New Jersey court superficially noting that it did not consider whether BASF could prove its claims. On February 28, 2023, Nanophase filed its answer to BASF’s New Jersey Complaint, denying all wrongdoing and, as mandated by New Jersey procedural requirements, counterclaims including a request for a declaration similar to that Nanophase sought in its Illinois Complaint and a claim alleging that BASF had breached its obligations under the Agreement to buy from Nanophase at least 70% of BASF’s zinc oxide requirements for use in the Field under the Agreement. BASF subsequently moved to dismiss Nanophase’s counterclaims, arguing that the declaratory judgment claim duplicated BASF’s claim for Nanophase’s alleged breach of contract and Nanophase’s claim for BASF’s breach of the zinc oxide purchase requirement was procedurally insufficient. On October 6, 2023, the New Jersey court: denied BASF’s motion to dismiss Nanophase’s declaratory judgment claim, finding that it did not duplicate BASF’s breach of contract claim and that litigating that claim would not provide Nanophase with complete relief as to the exclusivity issues raised in the counterclaim; and granted BASF’s motion to dismiss Nanophase’s claim for BASF’s breach of its zinc oxide purchase requirement on procedural grounds. On March 16, 2023, the Illinois court granted BASF’s MTD Nanophase’s Illinois Complaint, finding it duplicative of the New Jersey litigation. Discovery in the New Jersy litigation is ongoing. Management believes at this time that the allegations of BASF’s complaint are without merit and are unsupported by the terms of the Agreement and governing law. Per ASC 450 for the period ending December 31, 2023, an estimated contingent loss was not recorded, and an estimated range of loss is not disclosed as the outcome is not probable at this time and nor is a range of loss estimable. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zkWaOCIlG1kl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(15)</b></span></td> <td id="xdx_82F_zxCwU8YTo7Bb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent Event </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 1, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”), between the Company and Strandler, LLC (“Strandler”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Purchase Agreement, the Company issued to Strandler <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20240229__20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zVDKqOUyxzQl" title="Number of shares issued">15,000</span> shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”) at a purchase price per share of <span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pip0_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zUerdxkWy7vc" title="Price per share">$400</span>, for total consideration of <span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pp0p0_c20240229__20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zOXxx6GFkyc2" title="Consideration from sale of shares">$6,000,000</span>, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Purchase Agreement, the Company granted Strandler customary registration rights with respect to shares of the Company’s common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkeIsucF9Ond" title="Common stock, par value (in dollars per share)">0.01</span> per share (the “Common Stock”), it may receive in connection with any conversion of Series X Preferred Stock into Common Stock, as described below. For so long as any amount of Preferred Stock is outstanding, the Purchase Agreement also (i) prevents the Company from paying any dividend on any shares of the Company’s capital stock (other than dividends consisting solely of Common Stock or rights to purchase Common Stock), (ii) prevents the Company from repurchasing any Common Stock, and (iii) subject to certain permitted exceptions, restricts the Company’s ability to permit any lien or other encumbrance on Company assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At any time and from time to time, in whole or in part, following the Company properly filing an amendment (the “Certificate Amendment”) to its Certificate of Incorporation to increase the number of authorized shares of its Common Stock from <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvUdWXThgrzk" title="Common stock, authorized">60,000,000</span> to <span id="xdx_904_ecustom--CommonStockSharesAuthorizedForConversionOfPreferredStock_iI_pip0_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zLmCahePpiog" title="Common stock, authorized for conversion of preferred stock">95,000,000</span>, each share of Series X Preferred Stock is convertible, at the option of the holder, into <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_uShares_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zTbpIwz8o2ze" title="Shares issued upon conversion per share">1,000</span> shares of Common Stock at no additional cost. If the Company has not properly filed, upon shareholder approval, the Certificate Amendment on or before August 1, 2024, then each share of Series X Preferred Stock will be redeemable at the holder’s option, in whole or in part, without penalty or premium, at a redemption price equal to $<span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pip0_uUSDPShares_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zFcWvURlsqM5" title="Conversion price">420</span> per share (each, a “Redemption”). If the Company fails to fully pay any Redemption within five days of receiving notice, all unpaid amounts will bear interest at a rate of <span id="xdx_900_ecustom--PreferredStockConvertibleInterestRateForUnpaidRedemption_iI_pid_dp_uPure_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zhGYuqVG7cH" title="Interest rate">10</span>% per annum. In addition, in the event of a Change in Control (as defined in the Certificate of Designations) of the Company, each share of the Series X Preferred Stock is redeemable at the option of the holder, without penalty or premium, at a redemption price equal to <span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pip0_uUSDPShares_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zgh7PJUkU8K" title="Conversion price">$420</span> per share. Upon any conversion of Preferred Stock into Common Stock by Strandler, Strandler is required to hold the Common Stock received in the conversion for a period of 12 months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of Series X Preferred Stock (i) are not entitled to receive dividends, subject to customary anti-dilution protections, (ii) have no voting rights, and (iii)receive a liquidation preference of <span id="xdx_90E_eus-gaap--PreferredStockLiquidationPreference_iI_pip0_uUSDPShares_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_z5VJqIKiMOv4" title="Liquidation preference">$400</span> per share. The Series X Preferred Stock ranks senior in right of payment to all securities designated as junior securities, including Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Company’s entry into the Purchase Agreement, the Company also entered into (i) a Second Amendment to Business Loan Agreement (the “Term Loan Agreement Amendment”) with Strandler, LLC, (ii) a Second Amendment to Business Loan Agreement (the “A&amp;R Loan Agreement Amendment”) with Beachcorp, LLC, which is also an affiliate of our controlling shareholder, Bradford T. Whitmore (“Beachcorp”), and (iii) a Second Amendment to Business Loan Agreement with Beachcorp (the “Revolving Loan Agreement Amendment” and together with the Term Loan Agreement Amendment and the A&amp;R Term Loan Agreement Amendment, the “Loan Agreement Amendments”). The Loan Agreement Amendments extend the maturity date under each respective loan agreement from <span id="xdx_904_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231230__20231231__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__srt--CounterpartyNameAxis__custom--StrandlerLLCAndBeachcorpLLCMember_zcxEXK7QAgMl" title="Line of Credit Facility, Expiration Date">March 31, 2025</span> to <span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationDate1_c20240229__20240301__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__srt--CounterpartyNameAxis__custom--StrandlerLLCAndBeachcorpLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zn9mLUz0uY8i" title="Line of Credit Facility, Expiration Date">October 1, 2025</span>.</span></p> 15000 400 6000000 0.01 60000000 95000000 1000 420 0.10 420 400 2025-03-31 2025-10-01 Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet. The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Interest on drawn balances was at the prime rate plus 1%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2024. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC. On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000 to $2,750.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750 to $4,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000 to $6,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500 to $1,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility. On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On November 13, 2023 the Company entered into a First Amendment to the A&R Loan Agreement extending the maturity of the A/R Revolver Facility to March 31, 2025. On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024. On November 13, 2023 the company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%, and it now matures on March 31, 2025. On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On November 13, 2023 the Company entered into the First Amendment To the New Term Loan Agreement with Strandler, LLC, which extended the maturity of the New Term Loan Agreement to March 31, 2025. On November 13, 2023 the Company entered into a new Promissory Note (“Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is $2,000. The interest rate for the Bridge Note is at the prime rate plus 0.75%, and it matures on May 13, 2024.

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